

McGill University, Faculty of Medicine

Curriculum Vitae

Date of Last Revision: May 2, 2021

A. IDENTIFICATION

Name: Brett D. Thombs, Ph.D.
Address: Jewish General Hospital, 4333 Cote Ste. Catherine Road, Montreal, QC, H3T 1E4
Telephone: (514) 340-8222 ext. 25112
E-mail: brett.thombs@mcgill.ca

Thombs Research Team: <https://www.thombsresearchteam.ca/>

SPIN: <https://www.spinsclero.com/>

DEPRESSD Project: <https://www.depressd.ca/>

COVID-19 Mental Health Living Systematic Review: <https://www.depressd.ca/covid-19-mental-health>

Canadian Task Force on Preventive Health Care: <https://canadiantaskforce.ca/>

B. OVERVIEW

Dr. Thombs completed his Ph.D. in clinical psychology at Fordham University in 2004, including clinical internship training at the Weill Cornell Medical College in New York, then was a postdoctoral fellow and instructor at the Johns Hopkins University School of Medicine. He began his career at McGill in 2006, when he was appointed as Assistant Professor in the Department of Psychiatry. He was promoted to Associate Professor with tenure in 2011 and to Full Professor in 2015. In addition to the Department of Psychiatry, he holds Associate Memberships in the Departments of Epidemiology, Biostatistics, and Occupational Health; Medicine; Psychology; Educational and Counselling Psychology, and the Biomedical Ethics Unit. He is a Senior Investigator at the Lady Davis Institute for Medical Research of the Jewish General Hospital. In 2020, Dr. Thombs was named a Canada Research Chair (Tier 1). Since 2006, Dr. Thombs has published 319 peer-reviewed articles, including many in the world's leading general medical journals (e.g., *JAMA*, *BMJ*, *JAMA Intern Med*, *CMAJ*). He has been awarded over \$36 million in grant funding, including \$18.8 million as Principal Investigator and \$17.4 million as Co-investigator. He has been awarded 31 CIHR team or operating grants as Principal Investigator. He founded and directs the Scleroderma Patient-Intervention Network (SPIN), a collaboration of over 150 investigators, health care providers, patients, and patient advocates from 9 countries and 50 scleroderma expert centers. He also founded and directs the DEPRESion Screening Data (DEPRESSD) Project, which currently includes more than 350 investigators from >50 countries, who have contributed >300 primary datasets for use in a shared database to conduct individual participant data meta-analyses. He is the Chair of the Canadian Task Force on Preventive Health Care, the first non-physician ever in this role. Dr. Thombs was one of two inaugural recipients of the McGill Principal's Prize for Outstanding Emerging Researchers and has been awarded lifetime research awards from the Association of Rheumatology Health Professionals and the Academy of Psychosomatic Medicine. He is a Fellow of the Canadian Academy of Health Sciences and a member of the College of New Scholars, Artists and Scientists of the Royal Society of Canada.

C. EDUCATION

Post-doctoral fellowship, Clinical Health Psychology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supervisor: Dr. James A. Fauerbach. 2004-2005.

MA, PhD, Clinical Psychology, Fordham University, Bronx, New York, USA. Doctoral Thesis: *Measurement invariance of the Childhood Trauma Questionnaire across gender and race/ethnicity: applications of structural equation modeling and item response theory*. Supervisors: Dr. Charles Lewis and Dr. David P. Bernstein. Predoctoral Internship: Weill Cornell Medical College (2003-2004; Supervisor, Dr. Susan Evans). 1999-2004.

MA, Special Education, University of Arizona, Tucson, Arizona, USA. Supervisor: Dr. Aldine Von Isser. 1994-1995.

BA, Economics and the Honors Program in Mathematical Methods in the Social Sciences, Northwestern University, Evanston, Illinois, USA. Supervisor: Dr. Michael F. Dacey. 1985-1989.

D. APPOINTMENTS

University

Professor with Tenure, Department of Psychiatry, McGill University, Montreal, Quebec, Canada. 2015-present.

Associate Professor with Tenure (early), Department of Psychiatry, McGill University, Montreal, Quebec, Canada. 2011-2015.

Assistant Professor, Department of Psychiatry, McGill University, Montreal, Quebec, Canada. 2006-2011.

Associate Member, Biomedical Ethics Unit (Faculty of Medicine), McGill University, Montreal, Quebec, Canada. 2017-present.

Associate Member, Department of Psychology, McGill University, Montreal, Quebec, Canada. 2013-present.

Associate Member, Department of Educational and Counselling Psychology, McGill University, Montreal, Quebec, Canada. 2011-present.

Associate Member, School of Nursing, McGill University, Montreal, Quebec, Canada. 2011-2016.

Associate Member, Department of Medicine, Division of Rheumatology, McGill University, Montreal, Quebec, Canada. 2009-present.

Associate Member, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada. 2008-present.

Instructor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2005-2006.

Hospital

Senior Investigator, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. 2011-present.

Investigator, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada. 2006-2011.

E. SPECIAL HONORS, AWARDS, RECOGNITION

- **Paper of the Month**. Lady Davis Institute for Medical Research, Jewish General Hospital (for Levis et al., *JAMA*, 2020;323:2290-2300). 2020.
- **Canada Research Chair (Tier 1)**. Canadian Institutes of Health Research. 2020-2027.
- **Research Scholar Award, Distinguished**. Fonds de la Recherche en Santé Quebec (2020-2024; declined). *For investigators with 12-13 years since first academic appointment*.

- **Member, College of New Scholars, Artists and Scientists of the Royal Society of Canada.** *Canada's first national system of multidisciplinary recognition for the emerging generation of Canadian intellectual leadership; members can be nominated within 15 years of their degree.* 2019-2026
- **Psychology Alumni Award**, Department of Psychiatry, Weill Cornell Medicine – New York Presbyterian Hospital. *In recognition of commitment and excellence in training the next generation of psychologists.* 2019.
- **Paper of the Month.** Lady Davis Institute for Medical Research, Jewish General Hospital (for Azar et al., *JAMA Intern Med*, 2019;179:624-632). 2019.
- **Fellow, Canadian Academy of Health Sciences.** *Fellows are recognized nationally and internationally for their contributions to the promotion of health science and for demonstrated leadership, creativity, distinctive competencies and a commitment to advance academic health science.* 2017.
- **Research Scholar Award, Senior.** Fonds de la Recherche en Santé Quebec. *For investigators with 9 to 11 years since first academic appointment.* 2017-2019.
- **Principal's Prize for Outstanding Emerging Researchers (Inaugural Recipient)**, McGill University. *Awarded to a faculty member up to 10 years beyond highest degree distinguished for exceptional contributions to research.* 2014.
- **Bill Silverman Prize**, Cochrane Collaboration (for Roseman et al., *BMJ* 2012;345:e5155). *Awarded to authors of a high-quality publication that constructively criticizes the work of Cochrane and will positively impact the scientific quality, relevance, and use of Cochrane Reviews.* 2013.
- **Investigator Salary Award (2013 – 2017).** The Arthritis Society. *Recognizes an investigator up to 10 years into career with outstanding contributions and demonstrated leadership in arthritis research.* 2013.
- **Research Award.** Academy of Psychosomatic Medicine. *Career award for an investigator with record of exceptional clinical research on psychopathology in the medically ill.* 2013.
- **Distinguished Scholar Award.** Association of Rheumatology Health Professionals. *Career award for a scholar with exceptional achievements in activities pertinent to arthritis and the rheumatic diseases.* 2013.
- **Research Scholar Award, Junior 2.** Fonds de la Recherche en Santé Quebec (2013 – 2015; declined). *For investigators with 4 to 7 years since first academic appointment.* 2013.
- **Paper of the Month.** Lady Davis Institute for Medical Research, Jewish General Hospital (for Roseman et al., *BMJ* 2012;345:e5155). 2012.
- **William Dawson Scholar Award.** McGill University (2012 – 2017). *For a scholar developing into an outstanding and original researcher of world-class caliber who is poised to become a leader in his or her field, Equivalent to Tier II Canada Research Chair.* 2012.
- **Award for Excellence in Clinical Research.** Jewish General Hospital. *Presented to a researcher whose insights and initiatives have resulted in unique and significant contribution to patient treatment and care.* 2010.
- **Early Career Award.** Canadian Psychological Association, Health Psychology Section. *Awarded to an individual within 10 years of doctoral degree who has made a significant contribution to the field of health psychology.* 2010.
- **Partnership Award.** Canadian Institutes of Health Research, to Canadian Scleroderma Research Group and Scleroderma Society of Canada (\$25,000). *To recognize a partnership that exemplifies excellence.* 2009.
- **Finalist (top 8)– Research Paper of the Year.** BMJ Group Awards (for Thombs et al., *JAMA*, 2008;300:2161-2171). *Recognizes original research with the potential to contribute significantly to improving health and health care.* 2009.

- **President's New Researcher Award.** Canadian Psychological Association. *Recognizes the exceptional quality of the contribution of new researchers to psychological knowledge in Canada.* 2009.
- **Investigator Award.** Rheumatology Research Foundation. *To support exceptional early- to mid-career investigators.* 2009.
- **Research Scholar Award Junior 1.** Fonds de la Recherche en Santé Quebec, (2008 – 2012; declined). *For investigators with 0 to 3 years since first academic appointment.* 2008.
- **New Investigator Salary Award.** Canadian Institutes of Health Research (2008 – 2013). *For outstanding new investigators.* 2008.
- **Carolyn Thomas Award.** Arthritis Health Professionals Association. *For Best Scientific Abstract, 2008 Canadian Rheumatology Association Annual Meeting.* 2008.
- **Outstanding Dissertation Award.** Fordham University, Department of Psychology. 2004.
- **Student Travel Award.** American Psychological Association. 2001, 2002.
- **Bennett Prestigious Fellowship.** Fordham University, Graduate School of Arts and Sciences. 1999-2003.
- **Merit-Based Tuition Scholarship.** University of Arizona, Department of Special Education. 1994-1995.
- **Graduated with "Highest Distinction," Departmental Honours.** Northwestern University. 1989.
- **President, Mortar Board Senior Honorary Society.** Northwestern University. 1988-1989.
- **Phi Beta Kappa Honor Society.** Northwestern University. 1988.

F. TEACHING

F.1. McGill University Courses

- Advances in the Biology and Management of COVID-19, McGill Summer Institute in Infectious Diseases and Global Health. 1 class hour, 2021-present.
- PSYC-752 Psychotherapy & Behaviour Change, lecture (*Consultation in Psychology: The Canadian Task Force on Preventive Health Care*), 1.5 class hours, 2016-present.
- Diploma Course in Psychiatry, lecture (*Meta-analysis in psychiatry*) 2.5 class hours, 2012-present.
- NUR2-515 Applied Statistics for Nursing, Coordinator/Instructor, 39 class hours, 2008-2015.
- PSYT-713 Psychiatric Epidemiology, 2 lectures (*Reliability, validity, and evaluation of diagnostic instruments; Systematic reviews and meta-analyses*), 4 class hours, 2008-present.
- EPIB-628 Measurement in Epidemiology, lecture (*Measurement equivalence and differential item functioning in epidemiological research*), 2 class hours, 2008 – present.
- EPIB-619 Systematic Reviews and Meta-Analyses, lecture (*Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments*, 2011; *Systematic Reviews of Observational Studies*, 2012-present), 1.5 class hours, 2011 – present.
- EPIB-677 Knowledge Synthesis, lecture (*Systematic Reviews of Observational Studies*), 1.5 class hours, 2013 – 2016.
- EDPC-677 Internship Research Seminar: Quantitative Studies, lecture (*Systematic reviews and meta-analyses*), 2 class hours, 2013 – present.
- EPIB-600 Clinical Epidemiology, lecture (*Reporting of Conflicts of Interest in Meta-analyses and Systematic Reviews*), 1.5 class hours, 2012.
- PSYC-729 Theory of Assessment, lecture (*Issues in testing individuals from diverse populations*), 2 class hours, 2008 – 2010.
- PSYC-305 Psychological Statistics, Course coordinator/Instructor, 39 class hours, 2008 – 2009.
- Quantitative Methods for Cross-Cultural Research, Summer Program in Social and Cultural Psychiatry, Workshop Co-Coordinator/Instructor, 15 class hours, 2007 – 2009.

F.2. Other University Courses

- PSMU-2030 Introduction to Research Methods and Statistics (Part II), Department of Psychology, Marymount College of Fordham University, Tarrytown, NY, USA, Coordinator/Instructor, 45 class hours, 2004.
- PSMU-2020 Introduction to Research Methods and Statistics (Part II), Department of Psychology, Marymount College of Fordham University, Tarrytown, NY, USA, Coordinator/Instructor, 45 class hours, 2003.
- PSRU-2000 Statistics, Department of Psychology, Fordham University, New York, NY, USA, Coordinator/Instructor, 45 class hours, 2003.
- PSRU-3600 Multicultural Issues, Department of Psychology, Fordham University, New York, NY, USA, Coordinator/Instructor, 45 class hours, 2003.
- PSRU-3200 Psychological Testing, Department of Psychology, Fordham University, New York, NY, USA, Coordinator/Instructor, 45 class hours, 2002.

F.3. Clinical Instruction

- Supervision in cognitive-behavioural therapy, PGY3 residents in psychiatry, Anxiety Disorders Clinic, Johns Hopkins Hospital (3-4 hours weekly), 2004-2006.

F.4. Supervision of McGill University Students (with Awards)

F.4.1. Postdoctoral Fellows

- **Henry, Richard.** 2020- present.
 - MITACS Accelerate Postdoctoral Fellowship (\$50,000 per year).
 - Strategy for Patient-oriented Research Evidence Alliance. Seed Grant (2020; \$10,000)
- **Negeri, Zelalem.** 2019-present. Co-supervisor with Dr. Andrea Benedetti.
 - MITACS Accelerate Postdoctoral Fellowship (\$55,000 per year).
- **Horwood, Linda.** 2019.
 - MITACS Accelerate Postdoctoral Fellowship (\$50,000 per year).
- **Gholizadeh, Shadi.** 2018-2019. Currently, Assistant Professor, Alliant International University, Los Angeles, California, United States.
- **Wu, Yin.** 2018-present. Co-supervisor with Dr. Andrea Benedetti.
 - Utting Postdoctoral Fellowship for Studies in Depression, Department of Psychiatry, Jewish General Hospital (2018-2019, 2019-2020 (declined); \$45,000 per year + \$5,000 per year research allowance).
 - FRQ-S Postdoctoral Training Award (2019-2021; \$45,000 per year).
- **Kwakkenbos, Linda.** 2012-2017. Currently, Assistant Professor, Radboud University, Nijmegen, the Netherlands.
 - CIHR Banting Postdoctoral Fellowship Award (2015-2017; \$70,000 per year).
 - European League Against Rheumatism Abstract Award (2015; €1000).
 - CIHR Institute of Musculoskeletal Health and Arthritis Travel Award (2013; \$1,000).
 - FRQ-S Postdoctoral Training Award (2013-2015; \$30,000 per year).
 - Nationale Vereniging voor Lupus, APS, Sclerodermie en MCTD (Dutch patient organization for systemic autoimmune diseases) Award for Young Investigators in Systemic Sclerosis (2013; €2500).
- **El-Baalbaki, Ghassan.** 2009-2010. Currently, Assistant Professor, Department of Psychology, Université du Québec à Montréal.
 - CIHR Institute of Musculoskeletal Health and Arthritis Travel Award (2010; \$1,000).
- **Ruiz Casares, Monica.** 2007-2008. Co-supervisor with Dr. Cécile Rousseau. Currently Assistant Professor, Department of Psychiatry, McGill University.
- **Benoit, Maryse.** 2007-2008. Co-supervisor with Dr. Cécile Rousseau. Currently Assistant Professor, Department of Psychology, Sherbrooke University.

F.4.2. Doctoral Students

- **Rice, Danielle.** 2015-present. Department of Psychology (Clinical).
 - Rare Disease Foundation. Microgrant Program. *Illuminating the experience of caring for a patient with scleroderma through focus groups* (2015; \$3,467).
 - FRS-Q Masters Training Award (2015-2017; \$15,000 per year).
 - CIHR Vanier Canada Graduate Scholarship (2017-2021 with fellowship break 2018-2019; \$50,000 per year).
 - CIHR Doctoral Research Award (2017-2020; \$30,000 per year + \$5,000 per year research allowance; declined).
 - FRS-Q Doctoral Training Award (2017-2020; \$20,000 per year, declined).
 - Graduate Mobility Award, McGill University (2018; \$4,000).
 - Association of Rheumatology Health Professionals Outstanding Student in Rheumatology Award (2018; \$500).
 - CIHR Health System Impact Fellowship (2018-2019; \$45,000 + \$5,000 research allowance).
 - Poster presentation award. *18th National Scleroderma Conference, Scleroderma Canada*, Calgary, Alberta, Canada. September 2018.
 - CIHR Institute of Health Policy and Services Research Travel Award (2019; \$1,500).
- **Levis, Brooke.** 2014-2019. Department of Epidemiology, Biostatistics, and Occupational Health. Co-supervisor with Dr. Andrea Benedetti. Currently postdoctoral fellow, Centre for Prognosis Research School of Primary, Community and Social Care, Keele University, United Kingdom.
 - Paper of the Month (September 2020). For Levis et al., *JAMA*, 2020;323:2290-2300. Lady Davis Institute for Medical Research, Jewish General Hospital (2020).
 - McGill MedStar Award for Levis et al., *BMJ*, 2019 (2019; \$500).
 - Trainee Paper of the Year Award for Levis et al., *BMJ*, 2019, Lady Davis Institute for Medical Research, Jewish General Hospital (2019; \$500).
 - Graduate Mobility Award, McGill University (2018; \$1,000).
 - CIHR Institute of Health Policy and Services Research Travel Award (2018; \$1,500).
 - Graduate Mobility Award, McGill University (2017; \$3,050).
 - CIHR Institute of Health Policy and Services Research Travel Award (2017; \$1,500).
 - Graduate Mobility Award, McGill University (2016; \$2,010).
 - CIHR Doctoral Research Award (2016-2019; \$30,000 per year + \$5,000 per year research allowance).
 - CIHR Institute of Health Policy and Services Research Travel Award (2016; \$1,500).
 - FRS-Q Doctoral Training Award (2014-2017; \$20,000 per year, accepted 2014-2016).
 - GREAT Travel Awards, McGill University (2015 = \$975; 2017 = \$1,000; 2018 = \$500).
 - Best Oral Presentation - PhD Category. McGill Epidemiology, Biostatistics and Occupational Health 11th Annual Student Research Day (2015; \$100).
 - Emerging Leaders in Assessment Award, American Psychological Association Divisions 5 (Quantitative and Qualitative Methods), 12 (Society for Clinical Psychology), and 40 (Society for Clinical Neuropsychology) and the Association of Test Publishers (2015; \$250).
 - Student Travel Award, Lady Davis Institute for Medical Research, Jewish General Hospital (2015; \$1,000).
- **Coroiu, Adina.** 2013-2019. Department of Educational and Counseling Psychology. Co-supervisor with Dr. Annett Koerner.
 - Graduate Excellence Fellowship, Faculty of Education, McGill University (2013; \$7,500).
 - FRS-Q Masters Training Award (2012-2014; \$15,000 per year).
 - Psychosocial Oncology Research Training Doctoral Fellowship, CIHR (2013-2016; \$6,000 per year).
 - FRS-Q Doctoral Training Award (2014 – 2017; \$20,000 per year, accepted 2014-2015).
 - GREAT Travel Award, McGill University (2014; \$280).
 - Graduate Research Mobility Award, McGill University (2014; \$1,900).

- CIHR Doctoral Research Award (2015-2018; \$30,000 per year + \$5,000 per year research allowance).
 - CIHR Institute of Health Policy and Services Research Travel Award (2016; \$1,500).
- **Jewett, Lisa.** 2012-2018. Department of Educational and Counseling Psychology.
- McGill MedStar Award for excellent research carried out in the McGill Faculty of Medicine (2018; \$500).
 - Poster presentation award. *17th Annual National Scleroderma Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
 - Rare Disease Foundation. Microgrant Program. *Testing the Feasibility of the Changing Faces Practitioner Training Program for Scleroderma Patients* (2014; \$3,500).
 - FRS-Q Doctoral Training Award (2012-2015; \$20,000 per year; accepted 2012-2013).
 - The Arthritis Society/Canadian Arthritis Network Graduate PhD Student Award (2012-2015; \$10,500 per year; declined).
 - CIHR Institute of Musculoskeletal Health and Arthritis Travel Award (2013; \$1,000).
 - CIHR Doctoral Research Award (2013-2016; \$30,000 per year + \$5,000 per year research allowance).
 - CIHR Canada Graduate Scholarships – Michael Smith Foreign Study Supplement. 3-month research internship to study body image concerns at the University of the West of England, UK with Drs. Nichola Rumsey and Diana Harcourt (2014; \$5,987).
 - American College of Rheumatology Research and Education Foundation / Abbott Health Professional Graduate Student Preceptorship (2014, \$3,500).
 - CIHR Institute of Health Services and Policy Research Travel Award (2013; \$1,500).
- **Milette, Katherine.** 2012-2018. Department of Educational and Counseling Psychology.
- Poster presentation award. *17th Annual National Scleroderma Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
 - FRS-Q Doctoral Training Award (2015-2018; \$20,000 per year).
 - Association of Rheumatology Health Professionals Graduate Student Recognition Award (2013; \$500).
 - Graduate Excellence Fellowship, Faculty of Education, McGill University (2012, \$6,000).
 - CIHR Doctoral Research Award (2012-2015; \$30,000 per year + \$5,000 per year research allowance).
 - FRS-Q Doctoral Training Award (2012-2015; \$20,000 per year; declined).
 - American College of Rheumatology Research and Education Foundation / Abbott Health Professional Graduate Student Preceptorship (2012, \$3,500).
- **Delisle, Vanessa.** 2011-2018. Department of Educational and Counseling Psychology.
- Association of Rheumatology Health Professionals Outstanding Student in Rheumatology Award (2017; \$500).
 - The Arthritis Society PhD Salary Award (2016-2017; \$10,500).
 - Rare Disease Foundation. Microgrant Program. *Illuminating the scleroderma support group experience through qualitative interviews* (2015; \$3,420).
 - FRS-Q Masters Training Award (2011-2013; \$15,000 per year).
 - CIHR Doctoral Research Award (2013-2016; \$30,000 per year + \$5,000 per year research allowance).
 - FRS-Q Doctoral Training Award (2013 – 2016; \$20,000 per year; declined).
 - American College of Rheumatology Research and Education Foundation / Abbott Health Professional Graduate Student Preceptorship (2014, \$3,500).
- **Gumuchian, Stephanie.** 2016-2017. Department of Educational and Counseling Psychology.
- FRS-Q Masters Training Award (2015-2017; \$15,000 per year; accepted for 2016-2017).
 - Graduate Excellence Fellowship, McGill University (2016-2018; \$37,000; accepted \$27,000).
 - Ruth Hoyt Award, McGill University (2016-2017; \$3,000).

- Tomlinson Doctoral Fellowship, McGill University (2016-2017; \$22,000).
 - FRS-Q Doctoral Training Award (2017-2020; \$20,000 per year).
 - Best poster award. *48th Laurentian Conference of Rheumatology*, Estérel, Québec, Canada. May 2017.
- **Razykov, Ilya.** 2013-2015. Department of Educational and Counseling Psychology. Withdrew due to medical illness. Currently research assistant at Jewish General Hospital, Montreal, Quebec, Canada.
- Graduate Excellence Fellowship, Faculty of Education, McGill University (2013; \$7,500).
 - CIHR Doctoral Research Award (2013-2016; \$30,000 per year + \$5,000 per year research allowance).
 - FRS-Q Doctoral Training Award (2013-2016; \$20,000 per year; declined).
- **Meijer, Anna.** 2007-2012. Co-supervisor with Dr. Peter de Jonge. Interdisciplinary Center for Psychiatric Epidemiology, University Medical Center Groningen/University of Groningen, The Netherlands.

F.4.3. Master's Students

- **Nassar, Elsa-Lynn.** 2021-present. Department of Psychiatry.
- SSHRC Canadian Graduate Scholarships – Master's Award (2021-2022; \$17,500).
 - FRS-Q Masters Training Award (2021-2023; \$17,500 per year; accepted for 2022-2023).
- **Carboni-Jiménez, Andrea.** 2019-present. Department of Psychiatry.
- CIHR Canadian Graduate Scholarships – Master's Award (2019-2020; \$17,500).
 - McGill University Delta Upsilon Scholarship (2020-2021, \$5,000).
 - McGill University, Faculty of Medicine, Solvay Fellowship (2020-2021; \$10,000).
- **Bhandari, Parash Mani.** 2018-2020. Department of Epidemiology, Biostatistics, and Occupational Health. Co-supervisor with Dr. Andrea Benedetti.
- Research Institute of McGill University Health Centre Studentship (2019; \$10,000).
- **Neupane, Dipika.** 2018-2020. Department of Epidemiology, Biostatistics, and Occupational Health. Co-supervisor with Dr. Andrea Benedetti.
- McGill University, Faculty of Medicine, G. R. Caverhill Fellowship (2019-2020; \$10,000).
- **Turner, Kimberly.** 2018-2020. Department of Psychiatry.
- FRS-Q Masters Training Award (2018-2020; \$17,500 per year).
 - CIHR Institute of Health Policy and Services Research Travel Award (2019; \$1,500).
- **Harb, Sami.** 2018-2020. Department of Psychiatry. Co-supervisor with Dr. Ian Shrier.
- Graduate Excellence Fellowship, Department of Psychiatry, McGill University (2018-2019; \$10,000).
 - CIHR Canadian Graduate Scholarships – Master's Award (2019-2020; \$17,500).
- **Azar, Marleine.** 2015-2018. Department of Epidemiology, Biostatistics, and Occupational Health.
- CIHR. Frederick Banting and Charles Best Canadian Graduate Scholarships – Master's Award (2015-2016; \$17,500).
 - FRS-Q Masters Training Award (2016-2018; \$15,000 per year).
 - CIHR Institute of Health Policy and Services Research Travel Award (2016; \$1,500).
 - GREAT Travel Award, McGill University (2016; \$1000).
 - Lady Davis Institute, Jewish General Hospital Student Travel Award (2016, \$1,000).
- **Gumuchian, Stephanie.** 2015-2016. Department of Psychiatry.
- CIHR. Frederick Banting and Charles Best Canadian Graduate Scholarships – Master's Award (2015-2016; \$17,500).
 - FRS-Q Masters Training Award (2015-2017; \$15,000 per year; accepted for 2016-2017).
 - GREAT Travel Award, McGill University (2015; \$700).
 - CIHR Institute of Health Services and Policy Research Travel Award (2015; \$1,500).
- **Rice, Danielle.** 2014-2015. Department of Psychiatry.

- CIHR. Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2014-2015; \$17,500).
 - FRS-Q Masters Training Award (2015-2017; \$15,000 per year).
- **Coronado-Montoya, Stephanie.** 2013-2015. Department of Psychiatry.
- FRS-Q Masters Training Award (2014-2016; \$15,000 per year).
 - CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2013-2014; \$17,500).
 - Graduate Excellence Entry Award, Faculty of Medicine, McGill University (2013; \$1,000).
 - 2014 Cochrane Canada Symposia Graduate Student Poster Award (1st prize).
- **Levis, Brooke.** 2012-2014. Department of Epidemiology, Biostatistics, and Occupational Health. Currently, supervised PhD student.
- CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2013-2014; \$17,500).
 - FRS-Q Masters Training Award (2012 – 2014; \$15,000 per year).
 - Association of Rheumatology Health Professionals Graduate Student Recognition Award (2012; \$500).
 - GREAT Travel Award, McGill University (2013 = \$750).
- **Razykov, Ilya.** 2011-2013. Department of Psychiatry. Currently, supervised PhD student.
- Canadian Scleroderma Research Group Studentship (2011-2013; \$17,500 per year, *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
 - Alexander McFee Fellowship, McGill University Faculty of Medicine (2011-2012, \$10,000).
 - American College of Rheumatology Research and Education Foundation / Abbott Health Professional Graduate Student Preceptorship (2011, \$3,500).
- **Delisle, Vanessa.** 2010-2011. Department of Psychiatry. Currently, supervised PhD student.
- CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2010-2011; \$17,500).
- **Milette, Katherine.** 2010-2012. Department of Educational and Counseling Psychology. Currently, supervised PhD student.
- Maysie McSporran Graduate Studentship, Faculty of Medicine, McGill University (2011; \$2,500)
 - CIBC Fellowship, Faculty of Education, McGill University (2011; \$2,500).
 - Graduate Studies Fellowship, Faculty of Education, McGill University (2011; \$5000)
 - CIHR Canada Graduate Scholarships – Michael Smith Foreign Study Supplement. 3-month research internship to study depression screening in cardiovascular care settings at the University of Groningen, the Netherlands with Dr. Peter de Jonge (2011; \$6,000).
 - CIHR Institute of Musculoskeletal Health and Arthritis Travel Awards (2010, 2011; \$1,000).
 - CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2010; \$17,500).
 - Canadian Scleroderma Research Group Studentship (2010-2012; \$8,925 per year, *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
 - FRS-Q Masters Training Award (2010-2012; \$15,000 per year, delayed 1st year).
 - McGill Provost’s Graduate Fellowship, Faculty of Education, McGill University (2010; \$1,500).
- **Roseman, Michelle.** 2010-2012. Department of Psychiatry, Currently, Doctor of Medicine and Master of Surgery program, McGill University.
- CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2010-2011; \$17,500).
 - FRS-Q Masters Training Award (2010-2012; \$15,000 per year).
 - Birmingham – Dennis Award (2011; \$1,000) – Top presentation at Student Research Day for a graduate student, Department of Psychiatry, McGill University.
 - CIHR Institute of Health Services and Research Policy Travel Award (2011; \$1,500).

- McGill MedStar Award for excellent research carried out in the McGill Faculty of Medicine (2012; \$1,000).
- FRS-Q, Étudiants-chercheurs étoiles du mois (March 2012; \$1,000).
- **Ma, Denise.** 2009-2011. Co-supervisor with Dr. David Dunkley. Department of Psychiatry. Currently, PhD program in clinical psychiatry, Concordia University.
 - SSHRC. Joseph-Armand Bombardier Canada Graduate Scholarships Program – Master’s Scholarship (2010-2011; \$17,500).
- **Jewett, Lisa.** 2009-2011. Department of Psychiatry. Currently, supervised PhD student.
 - CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2009-2010; \$17,500).
 - FRS-Q Masters Training Award (2009 – 2011; \$15,000).
 - Canadian Scleroderma Research Group Studentship (2009 – 2011; \$8,925, *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
 - FRS-Q Programme de Formation de maîtrise ou de doctorat – Stages internationaux. 3-month research internship to study and research couples relationships in chronic illness at the University of Groningen, the Netherlands with Dr. Mariet Hagedoorn (2009; \$7,500).
 - Association of Rheumatology Health Professionals Graduate Student Recognition Award (2010; \$500).
 - CIHR Institute of Musculoskeletal Health and Arthritis Travel Award (2011; \$1,000).
- **Knafo, Ruby.** 2009-2011. Department of Psychiatry. Currently, graduate program in occupational therapy, University of Toronto.
 - CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2009-2010; \$17,500).
 - FRS-Q Masters Training Award (2009 – 2011; \$15,000).
 - Canadian Scleroderma Research Group Studentship (2009 – 2011; \$8,925, *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
 - FRS-Q Programme de Formation de maîtrise ou de doctorat – Stages internationaux. 3-month research internship to study and research couples relationships in chronic illness at the University of Groningen, the Netherlands with Dr. Mariet Hagedoorn (2009; \$7,500).
 - Association of Rheumatology Health Professionals Graduate Student Recognition Award (2009; \$500).
- **Zhao, Yue.** 2008-2010. Department of Psychiatry. Currently, PhD program in clinical psychology, Concordia University.
 - FRSC – Masters Training Award (2009-2010; \$15,000).
 - SSHRC. Joseph-Armand Bombardier Canada Graduate Scholarships Program – Master’s Scholarship (2008-2009; \$17,500).
 - FRS-Q – Programme de Formation de maîtrise ou de doctorat – Stages internationaux. 3-month research internship to study expression of psychological symptoms at Xiangya Hospital, an affiliated hospital of Central South University, Changsha, China with Dr. Zhu Xiongzhao (2010; \$7,500).
- **Newton, Evan.** 2008-2010. Department of Psychiatry, 2008-2010. Currently, research coordinator.
 - Canadian Scleroderma Research Group Studentship (2008-2010; \$8,925, *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
- **Adeponle, Ademola.** 2007-2010. Co-supervisor with Dr. Laurence Kirmayer. Department of Psychiatry, Currently PhD student, Department of Psychiatry, McGill University.
 - Culture and Mental Health Services Studentship (2007-2010; \$17,500, *CIHR Strategic Training Initiative in Health Research grant, PI: L Kirmayer*).
- **Nath, Yogini.** 2007-2009. Co-supervisor with Dr. Laurence Kirmayer. Department of Psychiatry, Currently PhD student, Department of Educational and Counselling Psychology, McGill University.

- Culture and Mental Health Services Studentship (2007-2009; \$17,500, *CIHR Strategic Training Initiative in Health Research grant, PI: L Kirmayer*).
- **Schieir, Orit**. 2007-2009. Department of Epidemiology, Biostatistics, and Occupational Health. Currently, PhD program, epidemiology, University of Toronto.
 - FRS-Q Masters Training Award (2008 -2009; \$15,000).
 - CIHR Frederick Banting and Charles Best Canadian Graduate Scholarships – Master’s Award (2007-2008; \$17,500).
 - Canadian Scleroderma Research Group Studentship (2007-2009; \$8,925, *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
 - Association of Rheumatology Health Professionals Graduate Student Recognition Award (2008; \$500).

F.4.4. McGill University Medical Student Research

- **Roseman, Michelle**. 2013-2014.
 - Mach-Gaensslen Foundation of Canada Student Grant, Summer 2013, (\$3,125).
 - Murray R. Stalker Primary Care Research Bursary, Fall 2013 (\$2,000).

F.4.5. Undergraduate Thesis and Summer Students/Interns

- **Razek, Layla**. 2021. Summer internship.
 - McGill University Schull Yang International Experience Award (\$7,000).
- **Provencher, Sabrina**. 2021. Department of Psychology (thesis).
- **Jizhou Tian**. 2021. Mitacs Globalink Research Internship (Beijing Normal University, Beijing, China; co-supervisor with Dr. Andrea Benedetti).
- **Yi Liu**. 2021. Mitacs Globalink Research Internship (Sichuan University, Chengdu, Sichuan, China; co-supervisor with Dr. Andrea Benedetti).
- **Neyer, Marieke**. 2021. Mitacs Globalink Research Internship (University of Lübeck, Germany).
- **Yao, Anneke**. 2020-2021. Department of Psychology (thesis).
- **Dal Santo, Tiffany**. 2020-2021. Department of Psychology (thesis).
- **Tasleem, Amina**. 2020-2021. Department of Psychology (thesis).
- **Bonardi, Olivia**. 2020-2021. Department of Anatomy & Cell Biology (thesis).
- **Discepolo, Marie-Nicole**. 2020-2021. Department of Psychology (thesis).
- **Abdulkareem, Dalal**. 2020-2021. Department of Psychology (thesis).
- **Allen-Flanagan, Erin**. 2020-2021. Department of Psychology (thesis).
- Jin, Yaqi**. 2020. Mitacs Globalink Research Internship (University of Hong Kong, Hong Kong). Cancelled due to COVID-19.
- **Wang, Yutong**. 2020. Mitacs Globalink Research Internship (Southeast University, Nanjing, China). Cancelled due to COVID-19.
- **Cai, Yuxi**. 2020. Mitacs Globalink Research Internship (University of Hong Kong, Hong Kong). Cancelled due to COVID-19.
- **Brehaut, Eliana**. 2019-2020, 2020-2021. Department of Psychology (thesis, summer student).
 - McGill University Arts Research Internship Award (\$4,500).
- **Chmoulevitch, Denis**. 2019-2020. Department of Psychology (thesis, summer student).
 - McGill University Arts Research Internship Award (\$4,500).

- **Ostbo, Nora.** 2019-2020. Department of Psychology (thesis).
- **López Malo Vázquez de Lara, Aurelio.** 2019. Mitacs Globalink Research Internship (Universidad de las Américas, Puebla, Mexico; co-supervisor with Dr. Andrea Benedetti).
- **Lyubenova, Anita.** 2019. Mitacs Globalink Research Internship (University of Bonn, Germany).
- **Dehtiarova, Yulia.** 2018. Mitacs Globalink Research Internship (Taras Shevchenko National University of Kiev, Ukraine).
- **Carboni-Jiménez, Andrea.** 2017-2018. Department of Psychology (thesis, summer student).
 - CIHR Institute of Musculoskeletal Health and Arthritis, Summer Studentship Award, 2018 (\$5,000).
 - Carol Yeadon Prize for Best Presentation of Clinical Research Results, Laurentian Conference of Rheumatology, 2018.
 - Best Abstract by an Undergraduate Student, *2019 Canadian Rheumatology Association Annual Scientific Meeting* (\$1,000).
- **Cañedo-Ayala, Mara.** 2017-2018. Department of Psychology (thesis, summer student).
 - McGill University Faculty of Science Undergraduate Society Ambassador Fund, 2017 (\$1,286 travel award to present research).
 - Canadian Psychological Association Certificate of Academic Excellence for best honours thesis in McGill's Department of Psychology (2018).
- **Pépin, Mia.** 2016-2017. Department of Psychology, University of Montreal (summer student).
 - Poster presentation award. *17th Annual National Scleroderma Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
- **Bacalao, Carolina.** 2014-2015. Department of Psychology (thesis).
- **Molnar, Jacqueline.** 2014-2015. Department of Psychology (thesis).
- **Azar, Marleine.** 2015. Department of Psychology (thesis, summer student).
 - McGill University Faculty of Science Undergraduate Research Award, 2015 (\$5,600).
 - Poster presentation award. *16th Annual National Scleroderma Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
- **Riehm, Kira.** 2014, 2015. Department of Psychology (thesis, summer student).
 - CIHR Institute of Musculoskeletal Health and Arthritis, Studentship in Mobility, Musculoskeletal, Health and Arthritis, 2015 (\$5,000).
 - Poster prize, 4th Systemic Sclerosis World Congress (€500).
- **Levis, Alexander.** 2013-2015. Department of Pharmacology (summer student).
 - CIHR Institute of Musculoskeletal Health and Arthritis, Studentship in Mobility, Musculoskeletal, Health and Arthritis, 2014, 2015 (\$5,000 per year).
- **Lallitto, Bianca.** 2013-2014. Department of Psychology (thesis).
- **Syamchandra, Achyuth.** 2012. Department of Psychology (summer student).
 - Canadian Scleroderma Research Group Summer Studentship, 2012 (\$3,950; *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
- **Lober, Janie.** 2009-2010. Department of Psychology (thesis).
- **Levis, Brooke.** 2010-2011. Department of Psychology (thesis).
 - CIHR Institute of Musculoskeletal Health and Arthritis, Studentship in Mobility, Musculoskeletal, Oral, and Skin Health and Arthritis Across the Lifespan, 2010, 2011 (\$4,950 per year).
 - Canadian Scleroderma Research Group Summer Studentship, 2010, 2011 (declined; *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
 - CIHR Institute of Musculoskeletal Health and Arthritis Travel Award (2011; \$1,000).
- **Razykov, Ilya.** 2008-2011. Department of Psychology (thesis x 2).

- CIHR Institute of Musculoskeletal Health and Arthritis Travel Award (2010; \$1,000).
 - CIHR Institute of Musculoskeletal Health and Arthritis, Studentship in Mobility, Musculoskeletal, Oral, and Skin Health and Arthritis Across the Lifespan, 2009, 2010 (\$4,950 per year).
 - Canadian Scleroderma Research Group Summer Studentship, 2009, 2010 (declined; *CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
- **Bassel, Marielle**. 2007. Department of Psychology (summer student).
- Canadian Scleroderma Research Group Summer Studentship, 2007. (*CIHR Strategic Training Initiative in Health Research grant, PI: M Baron*).
- **Fuss, Samantha**. 2006-2008. Department of Psychology (thesis x 2).

F.4.6. Doctoral and Master's Dissertation Committees

- **Marbaniang, Ivan**. 2019 – present. PhD candidate. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (committee member; supervisors, Drs. Joseph Cox and Erica Moodie).
- **Oliviero, Lisa**. 2018 – present. MSc candidate, Department of Experimental Medicine, McGill University (committee member; supervisor, Dr. Jonathan Kimmelman).
- **Chen, Liying**. 2017-2018. MSc candidate, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (committee member; supervisor, Dr. Andrea Benedetti).
- **Federico, Carole**. 2015-present. PhD candidate. Department of Experimental Medicine, McGill University (committee member; supervisor, Dr. Jonathan Kimmelman).
- **Schwartzman, Deborah**. 2013-2017. PhD candidate. Department of Educational and Counseling Psychology, McGill University (committee member; supervisor, Dr. Martin Drapeau).
- **Brosseau, Danielle**. 2010-present. PhD candidate. Department of Educational and Counseling Psychology, McGill University (committee member; supervisor, Dr. Annett Koerner).
- **Nath, Yogini**. 2010-2018. PhD candidate. Department of Educational and Counseling Psychology, McGill University (committee member; supervisors, Drs. Nancy Heath and Laurence Kirmayer).
- **Gariepy, Genevieve**. 2010-2015. PhD candidate, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (committee member; supervisor, Dr. Norbert Schmitz).
- **Simoneau, Gabrielle**. 2014-2015. MSc candidate, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (committee member; supervisor, Dr. Andrea Benedetti).
- **Graham, Eva**. 2013-2015. MSc candidate, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (committee member; supervisor, Dr. Norbert Schmitz).
- **Au, Bonnie**. 2013-2014. MSc candidate, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (committee member; supervisor, Dr. Norbert Schmitz).
- **Farthing, Dasa**. 2009-2011. MSc candidate, Department of Psychiatry, McGill University (committee member; supervisor, Dr. Anne Crocker).
- **Persson, Tonje**. 2008-2010. MSc candidate, Department of Psychiatry, McGill University (committee member; supervisor, Dr. Cécile Rousseau).
- **Pierre, Andrena**. 2006-2008. MSc candidate, Department of Psychiatry, McGill University (committee member; supervisor, Dr. Karl Looper).

F.4.7. Internal/External Examiner - Doctoral Dissertations and Master's Theses

- **Carlisle, Benjamin**. 2019. Doctoral Thesis - – Internal Examiner. Department of Experimental Medicine, McGill University (supervisor, Dr. Jonathan Kimmelman).

- **Syrowatka, Anna.** 2017. Doctoral Thesis – Internal Examiner. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (supervisors, Dr. Robyn Tamblyn and R. Ari Meguerditchian).
- **Schwartzman, Deborah.** 2016. Doctoral Thesis – Internal Examiner. Department of Educational and Counseling (supervisor, Dr. Martin Drapeau).
- **Powell, Guido.** 2015. Masters Thesis – External Examiner. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (supervisors, Drs. Eric Latimer and Nancy Mayo).
- **Lipscombe, Carla.** 2015. Masters Thesis – External Examiner. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University (supervisor, Dr. Norbert Schmitz).
- **Singla, Daisy.** 2015. Doctoral Thesis – External Examiner. Department of Psychology, McGill University (supervisor, Dr. Frances Aboud).
- **Clyde, Matthew.** 2013. Masters Thesis – External Examiner. Department of Psychiatry, McGill University (supervisor, Dr. Norbert Schmitz).
- **Kwakkenbos, Linda.** 2012. Doctoral Examination Board. Radboud University Nijmegen, Nijmegen, The Netherlands (supervisors Drs. Eni S. Becker, Cornelia H.M. van den Ende, and Frank van den Hoogen).

F.4.8. McGill Masters in Public Health Practicum Supervision

- **Gagarine, Maria.** 2020.
- **He, Chen.** 2018.

F.4.9. Visiting Graduate Students

- **Xia Qiu.** Sichuan University, China, 2021-2022.
- **Franziska Kolorz.** Radboud University, Netherlands, 2015-2016.
- **Meijer, Anna.** University of Groningen, Netherlands, 2012-2013.

F.5. Invited Talks

F.5.1. International Scientific Community

1. Use of individual participant data meta-analysis to address problematic research on mental health assessment. *Meta-Research Innovation Center at Stanford (METRICS)*, Stanford University, Palo Alto, California, USA. April 8, 2021 (presented via videoconference due to COVID-19).
2. Mental health in systemic sclerosis during the COVID-19 pandemic. *Annual Meeting of the Groupe Francophone de Recherche sur la Sclérodémie*. Paris, France. March 11, 2021 (presented via videoconference due to COVID-19).
3. Supporting mental health during COVID-19 among people vulnerable due to a pre-existing medical condition: the SPIN-CHAT Trial. *Weill Cornell Medicine, Department of Psychiatry, Psychology Grand Rounds*. New York, New York, USA, January 21, 2021 (presented via videoconference due to COVID-19).
4. Mental health during the COVID-19 pandemic: A living systematic review of changes in mental health and interventions. Royal College of Psychiatrists South West Division Biannual Conference. United Kingdom. November 13, 2020 (presented via videoconference due to COVID-19).
5. A “big data” approach to evidence on depression screening: the DEPRESSD and DEPRESSD-KIDS Projects. *24th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions*. Singapore, July 20-23, 2020 (not presented due to COVID-19).
6. To screen or not to screen: a Canadian perspective on depression screening. Johns Hopkins University School of Medicine, Department of Psychiatry, Baltimore, USA, May 18, 2020 (not presented due to COVID-19).
7. The Scleroderma Patient-centered Intervention Network (SPIN): partnering with patients to develop, test, and deliver psychosocial, educational, and rehabilitation interventions. Johns Hopkins University School of Medicine, Department of Rheumatology, Baltimore, USA, May 18, 2020 (not presented due to COVID-19).

8. Patient support programs from the Scleroderma Patient-centered Intervention Network (SPIN). *World Scleroderma Congress for Patients*. Prague, Czech Republic, March 6, 2020 (not presented due to COVID-19).
9. Use and misuse of depression screening tools: advancing the evidence base via individual participant data meta-analysis. Charite – Universitätsmedizin, Department for Psychosomatic Medicine, Berlin, Germany, February 27, 2020.
10. Development of reporting guidelines for randomized controlled trials using cohorts and routinely collected health data. *40th Annual Meeting of the Society for Clinical Trials*. New Orleans, Louisiana, USA, May 20, 2019.
11. CONSORT reporting guidelines for RCTs using cohorts and routinely collected health data. *Trials Using Cohorts and Routinely Collected Health Data: International Symposium on their Efficacy and Analysis*. London, UK, May 15, 2019.
12. The Scleroderma Patient-centered Intervention Network – Support Group Leader Education Program (SPIN-SSLED). *Scleroderma Foundation (USA) Monthly Chapter Meeting*. Teleconference. October 4, 2018.
13. Addressing psychological concerns of newly diagnoses patients: Scleroderma Patient-centered Intervention Network programs. *World Scleroderma Congress, Round-table Networking Meeting for Leaders of Patient Associations*. Bordeaux, France, February 17, 2018.
14. Making tough healthcare decisions to optimize your health and well-being: A toolkit. *Scleroderma Foundation Annual Patient Conference*. New Orleans, Louisiana, USA. July 31, 2016.
15. Challenges in rare disease research. *iSPIN: Combining Forces*. Vrije Universiteit, Amsterdam, the Netherlands, October 2, 2015.
16. Improving behavioral science research through identifying and reducing the impact of reporting biases. Radboud University, Behavioral Science Institute, Nijmegen, the Netherlands, June 15, 2015.
17. Empirically supported therapies: Time for a 20-year tune-up. *Association of Psychological Science 2015 Annual Convention*, New York, New York, May 21-25, 2015.
18. The cmRCT design in a rare disease context: The Scleroderma Patient-centered Intervention Network. *Trials within Cohorts Symposium*, London School of Hygiene & Tropical Medicine, November 10-11, 2014.
19. A hydrid cohort-trial design for internet-based outcome data collection: The Scleroderma Patient-centered Intervention Network. *Lupus 2014*, Quebec City, Quebec, Canada, September 19, 2014.
20. Leveraging an innovative trial design for a rare disease context: The cohort multiple RCT (cmRCT) design. In symposium (Geenen R and Redmond A, Chairs). The Scleroderma Patient-centered Intervention Network (SPIN): Meeting the challenges of research into a rare disease. *European League Against Rheumatism Congress 2014*, Paris, France, June 14, 2014.
21. Coping with the emotional aspects of living with scleroderma. 3rd Systemic Sclerosis World Congress, Patient Congress. Rome, Italy. February 8, 2014.
22. The Scleroderma Patient-centered Intervention Network (SPIN). Spanish Society for Rheumatology, Madrid, Spain. November 21, 2013.
23. The Scleroderma Patient-centered Intervention Network (SPIN): an international partnership to develop, test, and deliver psychosocial, educational, and rehabilitation interventions. Annual Meeting of the Groupe Francophone de Recherche sur la Sclérodémie, Paris, France. November 20, 2013.
24. Improving depression care in medical settings: is screening the answer? Research Award Plenary Lecture, *Academy of Psychosomatic Medicine, 60th Annual Meeting*. Tucson, Arizona, USA. November 14, 2013.
25. The Scleroderma Patient-centered Intervention Network (SPIN): An international patient-researcher partnership. *2013 National Patient Education Conference*, Scleroderma Foundation, Atlanta, Georgia, USA. July 27, 2013.
26. The Scleroderma Patient-centered Intervention Network (SPIN): an international partnership to develop, test, and deliver psychosocial and rehabilitation services. Mexican College of Rheumatology, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico. July 3, 2013.
27. Improving depression care in medical settings: is screening the answer? Oregon Health & Science University, Department of Medicine Grand Rounds, Portland, Oregon, USA. April 30, 2013.

28. Systematic reviews and meta-analyses: a user's guide. Oregon Health & Science University, Department of Psychiatry, Evidence-based psychiatry course, Portland, Oregon, USA. April 30, 2013.
29. Improving depression care in medical settings: is screening the answer? San Diego State University / University of California San Diego Joint Doctoral Program in Clinical Psychology, Department of Psychology, San Diego State University and Department of Psychiatry, University of California San Diego. San Diego, California, USA. April 29, 2013.
30. The Scleroderma Patient-centered Intervention Network (SPIN): an international partnership to develop, test, and deliver psychosocial and rehabilitation services in a rare disease context. Institut Cochin, Institute de Recherche biomédicale, Paris, France. January 18, 2013.
31. Rethinking depression screening: is there evidence to support current recommendations? VU University, Faculty of Psychology and Education, Amsterdam, The Netherlands. January 17, 2013.
32. The Scleroderma Patient-centered Intervention Network (SPIN): an international partnership to develop, test, and deliver psychosocial and rehabilitation services in a rare disease context. Radboud University Nijmegen, Institute of Behavioral Sciences, Nijmegen, The Netherlands. January 16, 2013.
33. Using mental health outcome measures in research and practice: considerations for individual- and population-level applications. Sint Maartenskliniek, Department of Rheumatology, Nijmegen, The Netherlands. January 15, 2013.
34. Using the cmRCT model in a rare disease context: the Scleroderma Patient-centered Intervention Network. *Cohort Multiple Randomised Controlled Trial (cmRCT) Design Workshop*. The University of Sheffield, School of Health and Related Research, Public Health Section, Sheffield, United Kingdom. July 6, 2012.
35. Rethinking depression screening: a look at the evidence. The University of York, Department of Health Sciences, York, United Kingdom. July 5, 2012.
36. Should physicians screen for depression? a look at the evidence. Department of Psychological Medicine, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth, Exeter, United Kingdom, July 2, 2012.
37. An overview of assessment research in the Canadian Scleroderma Research Group. In symposium (**BD Thombs**, Chair), Measure by measure: assessing psychological health and well-being in scleroderma. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*. Atlanta, Georgia, USA. November 2010.
38. Screening for depression in cardiac patients. In symposium (P de Jonge, Chair), Should we apply routine screening for depression? evidence against screening in several populations, *XIII Annual Scientific Meeting, European Association for Consultation-Liaison Psychiatry and Psychosomatics/XXVIII European Conference on Psychosomatic Research*. Innsbruck, Austria. July 2010.
39. Does depression screening benefit patients? should we expect benefits in the absence of evidence? Plenary Session, *XIII Annual Scientific Meeting, European Association for Consultation-Liaison Psychiatry and Psychosomatics/XXVIII European Conference on Psychosomatic Research*. Innsbruck, Austria. July 2010.
40. To screen or not to screen: depression screening in cardiovascular disease. *American Psychosomatic Society, Psychosomatic Interest Groups 2010 Online Interactive Seminars*. March 2010.
41. Improving health-related quality of life of patients with scleroderma. *Scleroderma World Congress*. Florence, Italy. February 2010.
42. Health and well-being in scleroderma: a behavioral health research and practice agenda. In symposium (**BD Thombs**, Chair), The psychology of improving health and well-being in scleroderma: Assessment and intervention approaches. *American College of Rheumatology / Association for Rheumatology Health Professionals Annual Scientific Meeting*. Philadelphia, Pennsylvania, USA. October 2009.
43. Will recommendations for depression screening benefit patients with cardiovascular disease? In invited session, Whooley MA (Chair), The pros and cons of depression screening in patients with coronary heart disease. *American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2009*. Washington, DC, USA. April 2009.
44. Depression screening and patient outcomes in cardiovascular care: a systematic review. *Author in the Room™ teleconference*. JAMA and the Institute for Healthcare Improvement. December 2008.

45. Why cardiologists don't care about depression: should they? University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center for Psychiatric Epidemiology, Groningen, Netherlands. September 2008.

F.5.2. National Scientific Community

1. An update on SPIN patient programs. *Scleroderma Manitoba*. May 15, 2021 (presented via videoconference due to COVID-19).
2. Patients Supporting Patients: The SPIN – Scleroderma Support group Leader Education (SPIN-SSLED). *19th Bi-Annual National Scleroderma Conference*. October 5, 2020 (presented via videoconference due to COVID-19).
3. The Scleroderma Patient-centered Intervention Network (SPIN): A Patient-Researcher Partnership to Support Better Living with Scleroderma. *19th Bi-Annual National Scleroderma Conference*. Niagara Falls, Ontario, Canada. September 19, 2020 (presented via videoconference due to COVID-19).
4. The Scleroderma Patient-centered Intervention Network (SPIN). *Health and Wellness Lab, University of Calgary*, Alberta. September 2, 2020 (presented via videoconference due to COVID-19).
5. The Scleroderma Patient-centered Intervention Network (SPIN). *Conferences of Medical Researchers and Meetings with the Presidents of the Provincial Associations of Scleroderma*. Montreal, Quebec, Canada. September 5, 2019.
6. The Scleroderma Patient-centered Intervention Network (SPIN). *Scleroderma Patient Forum and Education Day*. Winnipeg, Manitoba, Canada. May 25, 2019.
7. Approaches to reducing and managing COI in CPG development – best practices and experiences: The Canadian Task Force on Preventive Health Care: *Best Brains Exchange - Reducing and managing conflicts of interest in clinical practice guideline development: do we need Pan-Canadian standards?* Ottawa, Ontario, Canada. January 23, 2019.
8. The SPIN-SHARE Program. *Scleroderma Canada Living with Scleroderma Patient Forum*. Halifax, Nova Scotia, Canada. November 24, 2018.
9. The SPIN-SHARE Program. *Scleroderma Canada Living with Scleroderma Patient Forum*. London, Ontario, Canada. November 11, 2018.
10. Supporting Support Group Leaders: The SPIN Scleroderma Support Group Leader Education (SSLED) Program. *18th Bi-Annual National Scleroderma Conference*. Calgary, Alberta, Canada. September 21, 2018.
11. The SPIN-SHARE Program. *18th Bi-Annual National Scleroderma Conference*. Calgary, Alberta, Canada. September 21, 2018.
12. Making tough health care decisions. *18th Bi-Annual National Scleroderma Conference*. Calgary, Alberta, Canada. September 21, 2018.
13. Patient-focused research in scleroderma: The Scleroderma Patient-centered Intervention Network. *5th Annual Skin Research Group of Canada Conference*, Montreal, Quebec, Canada. June 23, 2018.
14. Who needs the Canadian Task Force on Preventive Health Care? *University of Toronto Department of Family and Community Medicine City Wide Research Rounds*. Toronto, Ontario, Canada. November 30, 2017.
15. Making tough healthcare decisions to optimize your health and well-being: A toolkit. *Scleroderma Society of Canada, 16th Annual National Scleroderma Conference*. Montreal, Quebec, Canada. September 17, 2016.
16. Supporting patients with rare diseases. The Scleroderma Patient-centered Intervention Network. *Canadian Organization for Rare Diseases, Rare Disease Day Conference 2016*. Ottawa, Ontario, Canada. March 9, 2016.
17. When less may be more: Why depression screening may not be as good as advertised. The Hospital for Sick Children, Mental Health Grand Rounds. Toronto, Ontario, Canada. November 26, 2015.
18. Research 101. *Scleroderma Society of Canada, 15th Annual National Scleroderma Conference*. Hamilton, Ontario, Canada. September 19, 2015.
19. When less may be more: Why health screening isn't always a good idea. *McGill University Cutting Edge Lecture Series*. Montreal, Quebec, Canada. March 12, 2015.

20. Empowering patients with rare diseases: The Scleroderma Patient-centered Intervention Network. *Canadian Organization for Rare Diseases, Rare Disease Day Conference 2015*. Toronto, Ontario, Canada. March 7, 2015.
21. Progress in supporting patients with rare diseases: The Scleroderma Patient-Centered Intervention Network. *Canadian Organization for Rare Disorders 6th Rare Disease Day Conference*. Ottawa, Ontario, Canada. March 3, 2014.
22. The Scleroderma Patient-centered Intervention Network. *Scleroderma Society of Canada, 14th Annual Conference*. Hamilton, Ontario, Canada. September 28, 2013.
23. How can direct patient collaboration increase relevance and value of research projects: the Scleroderma Patient-Centered Intervention Network. *Canadian Organization for Rare Disorders 5th Rare Disease Day Conference*. Toronto, Ontario, Canada. February 28, 2013.
24. Scleroderma Patient-centered Intervention Network (SPIN). *Scleroderma Society of Canada, 13th Annual Conference*. Vancouver, British Columbia, Canada. September 28, 2012.
25. "SPIN" – Managing depression and body image. *Scleroderma Society of Canada, 13th Annual Conference*. Vancouver, British Columbia, Canada. September 29, 2012.
26. Challenges in evaluating evidence on depression screening: the DEPRESSD Registry. *Mental Health Commission of Canada, Systems Performance Initiative Project Team Meeting*. Montreal, Quebec, Canada. September 26, 2012.
27. The Scleroderma Patient-centered Intervention Network. *43rd Laurentian Conference of Rheumatology*. Mt. Tremblant, Quebec, Canada. May 11, 2012.
28. The Scleroderma Patient-centered Intervention Network. *2012 Rare Disease Day Conference: Innovations in Research, Therapies and Policy for Rare Disorders*. Canadian Organization for Rare Disorders. Ottawa, Ontario, Canada. March 1, 2012.
29. The Scleroderma Patient-centered Intervention Network. *5th Annual Scientific Meeting of the Canadian Scleroderma Research Group*. Quebec City, Quebec, Canada. October 2011.
30. New directions for patient-centered care in scleroderma: the Scleroderma Patient-centered Intervention Network. *Tipping Point for Rare Disorders in Canada*. Canadian Organization for Rare Disorders. Toronto, Ontario, Canada. September 2011.
31. Living well with scleroderma: a patient's toolbox – self-management. *Scleroderma Society of Canada Annual General Meeting*. Halifax, Nova Scotia, Canada. November 2010.
32. Behavioral health in systemic sclerosis: a(nother) progress report. *3rd Annual Scientific Meeting of the Canadian Scleroderma Research Group*. Winnipeg, Manitoba, Canada. October 2009.
33. Smoke screens: do recommendations for depression screening in cardiovascular care benefit patients? In Lee CM (Chair), Canadian Psychological Association President's New Investigator Award Symposium. *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada. June 2009.
34. Psychological well-being in scleroderma: should rheumatologists care? *Canadian Scleroderma Research Group Annual Clinical Researcher's Meeting*. Web conference. April 2009.
35. Detection, assessment, and treatment of mental health issues in the general healthcare setting. University of New Brunswick, Department of Psychology. Fredericton, New Brunswick, Canada. October 2008.
36. The Canadian Scleroderma Research Group – Scleroderma Society of Canada National Survey. *Scleroderma Society of Canada Annual General Meeting*. Ottawa, Ontario, Canada. September 2008.
37. Behavioral health in systemic sclerosis: a progress report. *2nd Annual Scientific Meeting of the Canadian Scleroderma Research Group*. Ottawa, Ontario, Canada. September 2008.
38. Patient reported outcome assessment in scleroderma: quality of life, depression, fatigue, pain, body image distress. *Canadian Scleroderma Research Group Annual Clinical Researcher's Meeting*. Web conference. April 2008.
39. Things we know and things we need to know about living with scleroderma: developing collaborative approaches to improving quality of life. *1st Annual Scientific Meeting of the Canadian Scleroderma Research Group*. Calgary, Alberta, Canada. September 2007.
40. Cultural sensitivity in screening for history of childhood abuse among adults. Western Washington University, Department of Psychology, Bellingham, Washington, USA. January 2006.

F.5.3. Local Scientific Community

1. Using cohorts and other routinely collected data in randomized controlled trials: Examples from the Scleroderma Patient-centered Intervention Network. McGill University, Faculty of Medicine, Department of Epidemiology, Biostatistics, and Occupational Health. Montreal, Quebec, Canada. March 29, 2021 (presented via videoconference due to COVID-19).
2. Mental health in COVID-19: a living systematic review. *Living in a Covidian world: the McGill response*. McGill University, Montreal, Quebec, Canada. March 19, 2021 (presented via videoconference due to COVID-19).
3. Mental health in COVID-19: a living systematic review. Medical Grand Rounds. Jewish General Hospital. Montreal, Quebec, Canada. February 22, 2021 (presented via videoconference due to COVID-19).
4. Mental Health in COVID-19: Beyond Shock and Awe. Shoptalk. McGill University, Faculty of Medicine. Montreal, Quebec, Canada. February 19, 2021 (presented via videoconference due to COVID-19).
5. Changing the World One Semester at a Time: Examples of Student Health Research and Advocacy at McGill. Marianopolis College. Montreal, Quebec, Canada. February 18, 2021 (presented via videoconference due to COVID-19).
6. Ways of doing bioethics: meta-research and research integrity. McGill University, Faculty of Medicine, Biomedical Ethics Unit. Montreal, Quebec, Canada. February 11, 2021 (presented via videoconference due to COVID-19).
7. Improving access to effective psychological services through better evidence. *1st Annual McGill Applied Psychology Conference*. McGill University, Montreal, Quebec, Canada. April 21, 2020 (not presented due to COVID-19).
8. The Scleroderma Patient-centered Intervention Network: A Patient-Researcher Partnership to Improve the Lives of People Living with Scleroderma. Lethbridge-Layton-Mackay Rehabilitation Centre, Montreal, Quebec, Canada. January 14, 2020.
9. Integrating shared decision-making into prevention activities: examples from the Canadian Task Force on Preventive Health Care. McGill University, Faculty of Medicine, Office of Continuing Professional Development. Montreal, Quebec, Canada, October 17, 2019.
10. The Scleroderma Patient-centered Intervention Network. McGill Rare Disease Interest Group. *rareDIG Rare Disease Day*. Montreal, Quebec, Canada, February 28, 2019.
11. Depression in the rheumatology clinic: How common is it and what can you do about it. *49th Laurentian Conference of Rheumatology*, Esterel, Quebec, Canada, May 11, 2018.
12. The DEPRESSion Screening Data (DEPRESSD) Project: Using individual participant data meta-analysis to assess diagnostic accuracy and develop individualized depression risk estimates. Jewish General Hospital, Lady Davis Institute for Medical Research, Centre for Clinical Epidemiology and Community Studies. Montreal, Quebec, Canada, March 20, 2018.
13. Who Needs the Canadian Task Force on Preventive Health Care? Why Task Force Guidance Matters. *Herzl Family Practice Centre, Jewish General Hospital*. Montreal, Quebec, Canada, March 13, 2018.
14. Would routine depression screening improve the mental health of Canadians? A look at the evidence. Grand Rounds, Department of Psychiatry, McGill University Health Centre. Montreal, Quebec, Canada. October 25, 2016.
15. Should depression screening be part of routine care? A look at the evidence. St. Mary's Research Centre Seminar Series. Montreal, Quebec, Canada. October 25, 2016.
16. Detecting excess journal self-citation in impact factor years: Application in general medicine, psychiatry, and cardiology journals. Lady Davis Institute, Jewish General Hospital, 7th Annual Scientific Retreat, Montreal, Quebec, Canada. June 3, 2016.
17. A method for identifying journal-generated self-citation: Application to general medicine and psychiatry journals. McGill University, Faculty of Medicine, Department of Epidemiology, Biostatistics, and Occupational Health, 2015-2016 Seminar Series. Montreal, Quebec, Canada. November 2, 2015.

18. Identifying excessive rates of journal-generated self-citation: Application to general medicine, cardiology, and psychiatry journals. McGill University, Faculty of Medicine, Studies of Translation, Ethics, and Medicine (STREAM) Group, Montreal, Quebec, Canada. October 30, 2015.
19. Individual patient data meta-analyses to address reporting biases in studies of the diagnostic accuracy of depression screening tools. Jewish General Hospital, Lady Davis Institute for Medical Research, Centre for Clinical Epidemiology and Community Studies. Montreal, Quebec, Canada, January 20, 2015.
20. Individual patient data meta-analyses: The diagnostic accuracy of depression screening tools. McGill University Biostatistics Reading Group, Montreal, Quebec, Canada. November 26, 2014.
21. Using the cohort multiple randomized controlled trial (cmRCT) design for pragmatic intervention trials in a rare disease context: The Scleroderma Patient-centered Intervention Network. Royal Victoria Hospital, Division of Clinical Epidemiology, Montreal, Quebec, Canada. September 18, 2014.
22. Should physicians screen for depression in medical settings? Evidence on depression screening and its components. McGill University, Faculty of Medicine, Department of Epidemiology, Biostatistics, and Occupational Health, 2013-2014 Seminar Series. Montreal, Quebec, Canada. January 20, 2014.
23. Using the cohort multiple randomized controlled trial (cmRCT) design for pragmatic intervention trials: An example from a rare disease context. Réseau de recherche en interventions en sciences infirmières du Québec, Montreal, Quebec, Canada. January 15, 2014.
24. Meta(analyze) this: a user's guide to identifying credible evidence syntheses. Jewish General Hospital, Combined Rounds, Departments of Obstetrics and Gynecology and Surgery, Montreal, Quebec, Canada. May 23, 2013.
25. Delivering patient-centered care in a rare disease context: the Scleroderma Patient-centered Intervention Network. Jewish General Hospital, Department of Psychiatry Research Day, Montreal, Quebec, Canada. April 26, 2013.
26. The Scleroderma Patient-centered Intervention Network (SPIN): an international partnership to develop, test, and deliver psychosocial and rehabilitation services in a rare disease context. Lady Davis Institute for Medical Research, Principal Investigator Talk Series, Montreal, Quebec. April 10, 2013.
27. Using the cohort multiple randomized controlled trial (cmRCT) design in a rare disease context: the Scleroderma Patient-centered Intervention Network. Jewish General Hospital, Lady Davis Institute for Medical Research, Centre for Clinical Epidemiology and Community Studies. Montreal, Quebec, Canada. April 9, 2013.
28. Myths and measures: the ins and outs of depression and its measurement. McGill Doctoral Nursing Colloquium, McGill University, Montreal, Quebec, Canada. March 20, 2013.
29. A user's guide to systematic reviews and meta-analyses. Hôpital du Sacré-Coeur de Montréal, Department of Psychiatry, Montreal, Quebec, Canada. February 14, 2013.
30. An introduction to systematic reviews and meta-analyses. Academic Grand Rounds, Department of Psychiatry, Jewish General Hospital, Montreal, Quebec, Canada. February 7, 2013.
31. Using a cohort trial design in a rare disease context: the Scleroderma Patient-centered Intervention Network. Montreal Chest Institute. Respiratory Epidemiology and Clinical Research Unit. Montreal, Quebec, Canada. February 1, 2013.
32. Systematic reviews and meta-analyses: a "user's guide." Jewish General Hospital, Lady Davis Institute for Medical Research, Psychosocial Axis Seminar Series, Montreal, Quebec, Canada. January 9, 2013.
33. Rethinking recommendations for depression screening: a look at the evidence. Department of Psychology, McGill University, Montreal, Quebec, Canada. November 7, 2012.
34. The reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. Royal Victoria Hospital, Division of Clinical Epidemiology, Montreal, Quebec, Canada. May 24, 2012.
35. Systematic reviews and meta-analyses: a user's guide. Department of Educational and Counselling Psychology, McGill University, Montreal, Quebec, Canada. May 1, 2012.
36. Rethinking recommendations for depression screening. Montreal Chest Institute. Respiratory Epidemiology and Clinical Research Unit. Montreal, Quebec, Canada. February 2012.
37. Propaganda-based medicine: the case of depression screening. Lady Davis Institute, Jewish General Hospital, Second Annual Scientific Retreat, Montreal, Quebec, Canada. May 2011.

38. Screening for depression in medical settings: a series of studies. Lady Davis Institute, Jewish General Hospital, Principal Investigator Meetings, Montreal, Quebec, Canada. May 2011.
39. The reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. Jewish General Hospital, Lady Davis Institute for Medical Research, Centre for Clinical Epidemiology and Community Studies, Montreal, Quebec, Canada. February 2011.
40. Does depression screening benefit patients? should we expect benefits in the absence of evidence? Jewish General Hospital, Medical Grand Rounds. Montreal, Quebec, Canada. February 2010.
41. Smoke screens: will recommendations for depression screening benefit patients in medical care? McGill University, Faculty of Medicine, Department of Epidemiology, Biostatistics, and Occupational Health, 2009-2010 Seminar Series. Montreal, Quebec, Canada. January 2010.
42. Does depression screening benefit patients? should we expect benefits in the absence of evidence? Douglas Hospital Research Centre, Clinical Research Division, Montreal, Quebec, Canada. December 2009.
43. Does screening for depression help patients? Can it harm them? Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. March 2009.
44. Does screening for depression improve outcomes for patients in cardiovascular care? A systematic review of the evidence. Jewish General Hospital, Lady Davis Institute for Medical Research, Psychosocial Axis Seminar Series, Montreal, Quebec, Canada. December 2008.
45. Should we screen for depression in specialty medicine? A systematic review of the evidence from cardiovascular care. Concordia University, Department of Psychology, Clinical Health Science Research Group, Montreal, Quebec, Canada. December 2008.
46. Smoke screens: do recommendations for depression screening really benefit patients? Jewish General Hospital, Lady Davis Institute, Centre for Clinical Epidemiology and Community Studies, Montreal, Quebec, Canada. November 2008.
47. Behavioral health research in the Canadian Scleroderma Research Group. *Improving Health and Well-Being in Scleroderma: Establishing a Collaborative Behavioural Health Research Agenda*. Hosted conference. Montreal, Quebec, Canada. November 2008.
48. Depression in scleroderma. *Improving Health and Well-Being in Scleroderma: Establishing a Collaborative Behavioural Health Research Agenda*. Hosted conference. Montreal, Quebec, Canada. November 2008.
49. Fatigue in scleroderma. *Improving Health and Well-Being in Scleroderma: Establishing a Collaborative Behavioural Health Research Agenda*. Hosted conference. Montreal, Quebec, Canada. November 2008.
50. "I think my patients are depressed – should I ask them? Screening for depression in specialty medicine. Jewish General Hospital, Department of Psychiatry Research Day, Montreal, Quebec, Canada. April 2008.
51. Depression in cardiovascular disease: should cardiologists care? Jewish General Hospital, Division of Cardiology, Montreal, Quebec, Canada. April 2008.
52. Assessing and controlling for somatic symptom bias in measurement of depressive symptoms among patients with medical illness. Concordia University, Department of Psychology, Clinical Health Science Research Group, Montreal, Quebec, Canada. February 2008.
53. Is depression an independent predictor of post-acute myocardial infarction outcomes? A structural equation modeling approach. McGill University, Faculty of Medicine, Department of Epidemiology, Biostatistics, and Occupational Health, 2007-2008 Seminar Series. Montreal, Quebec, Canada. January 2008.
54. Do patient responses to research questionnaires mean what we think they do? The mysterious case of post-myocardial infarction depression and the missing somatic symptoms. Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. January 2008.
55. Does overreporting of somatic symptoms account for high rates of depressive symptoms among hospitalized post-acute myocardial infarction patients? Detecting differential item functioning using MIMIC modeling. Jewish General Hospital, Lady Davis Institute for Medical Research, Centre for Clinical Epidemiology and Community Studies, Montreal, Quebec, Canada. December 2008.
56. Can we measure symptoms of depression in patients with post-acute myocardial infarction well enough to talk about an *independent* risk factor? A structural equation modeling approach to

controlling for somatic symptom overlap. McGill University, Faculty of Medicine, Department of Psychiatry Research Day, Montreal, Quebec, Canada. October 2007.

57. Culture and confounding: what does multiple regression really tell us? Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. July 2007.
58. Cross-cultural considerations in clinical assessment: screening for history of childhood maltreatment. Jewish General Hospital, Department of Psychiatry, Research Section, Montreal, Quebec, Canada. March 2007.
59. Getting to the heart of measurement in transcultural psychiatry. Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. February 2007.
60. Screening for depression among patients with acute myocardial infarction: disentangling the heart from mind-body depression. Jewish General Hospital, Department of Psychiatry, Montreal, Quebec, Canada. January 2006.
61. Assessing depression in patients with acute myocardial infarction: disentangling the heart from mind-body depression. Center for Mind-Body Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. November 2005.
62. What do culturally sensitive mental health services mean? Fifteen years later. The 8th Student Alliance for Multicultural and Mental Health Issues Conference, Bronx, New York, USA. April 2003.

F.5.4. Supervised Invited Talks by Trainees – International and National

1. **Rice DB.** Coping strategies during COVID-19: prioritizing mental health and well-being. *Scleroderma SASK and Scleroderma Alberta Education and Support Group*. December 6, 2020 (presented via videoconference due to COVID-19).
2. **Rice DB.** Identifying the needs and priorities of informal caregivers for people living with systemic sclerosis. *19th Bi-Annual National Scleroderma Conference*. October 5, 2020 (presented via videoconference due to COVID-19).
3. **Levis B.** depressionscreening100.com/phq: a practice-based perspective to using the Patient Health Questionnaire-9 to screen for depression. North American Systematic Review Methods Virtual Research Day. October 30, 2020 (presented via videoconference due to COVID-19).
4. **Levis B.** Using individual participant data meta-analysis to address and overcome challenges in evaluating depression screening tool accuracy. *Centre for Biostatistics Seminar Series*. University of Manchester, Manchester, UK. September 14, 2020 (presented via videoconference due to COVID-19).
5. **Rice DB.** Identifying the Needs and Priorities of Informal Caregivers for People Living with Systemic Sclerosis. *Scleroderma Foundation - Michigan Chapter*. July 23, 2020 (presented via videoconference due to COVID-19).
6. **Wu Y.** The DEPRESSD Project: Methods. *24th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions*. Singapore, July 20-23, 2020 (not presented due to COVID-19).
7. **Levis B.** DEPRESSD-Youth: A Proposal. *24th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions*. Singapore, July 20-23, 2020 (not presented due to COVID-19).
8. **Levis B.** Use of individual participant data meta-analysis to address and overcome challenges in evaluating depression screening tool accuracy. Leicester Biostatistics Research Group. June 25, 2020. (presented via videoconference due to COVID-19).
9. **Levis B.** The DEPRESSion Screening Data (DEPRESSD) Project: Using individual participant data meta-analysis to address challenges in evaluating depression screening tool accuracy. Mental Health and Addiction Research Group, Department of Health Sciences and Hull York Medical School, University of York, Heslington, UK. May 4, 2020 (not presented due to COVID-19).
10. **Levis B.** Using individual participant data meta-analysis to evaluate the diagnostic accuracy of the Patient Health Questionnaire-9 depression screening tool. *Primary Care Seminar Series*. Keele University, Staffordshire, UK. February 26, 2020.
11. **Levis B.** Improving depression screening and assessment via individual participant data metaanalysis. Population Health Research Institute Seminar Series, St Georges, University of London, London, UK. February 11, 2020.

12. **Wu Y.** Individual participant meta-analysis: Theory and practice. *Department of Psychology Seminar Series*, Department of Psychology and Children Behavior and Development Center, Sun Yat-sen University, Guangzhou, China. December 27, 2019.
13. **Fedoruk C.** The who, why, and how of getting involved in scleroderma research. *Scleroderma Foundation Annual Patient Education Conference*. Chicago, Illinois, USA, July 21, 2019.
14. **Gholizadeh S.** The SPIN Scleroderma Support Group Leader Education (SSLED) Program. *Scleroderma Foundation of Southern California Annual Board Meeting*. Marina Del Rey, California, USA. December 8, 2018.
15. **Fedoruk C.** The SPIN-SHARE Program. *The Scleroderma Society of Ontario Patient Information Session*. Ottawa, Ontario, Canada. November 27, 2018.
16. **Rice DB.** SPIN-CARE: Caring for caregivers. *Scleroderma Canada Living with Scleroderma Patient Forum*. London, Ontario, Canada. November 11, 2018.
17. **Rice DB.** SPIN-CARE: Caring for caregivers. *18th Bi-Annual National Scleroderma Conference*. Calgary, Alberta, Canada. September 21, 2018.
18. **Levis B.** Improving depression screening and assessment: Using individual patient data meta-analysis to generate personalized risk estimates. *Cognitive Processes in Psychopathology and Treatment (CogPT) Seminar*, Behavioural Science Institute, Clinical Psychology, Radboud University, Nijmegen, the Netherlands. June 29, 2018.
19. **Kwakkenbos L.** Managing fatigue. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. Sept 17, 2016.
20. **Jewett LR.** Body image distress. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. Sept 17, 2016.
21. **Delisle VC, Gumuchian S.** Support groups. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. Sept 17, 2016.
22. **Jewett LR, Gholizadeh S.** Body image distress in scleroderma. *Scleroderma Foundation Annual Patient Conference*. New Orleans, Louisiana, USA. July 30, 2016.
23. **Delisle VC.** The Scleroderma Support Group Survey: Understanding people's experiences with scleroderma support groups. *Scleroderma Foundation Annual Patient Conference*. New Orleans, Louisiana, USA. July 31, 2016.
24. **Delisle VC.** Do support groups help? *3rd Systemic Sclerosis World Congress*. Lisbon, Portugal. February 2016.
25. **Kwakkenbos L.** Coping with the everyday challenges of scleroderma. *3rd Systemic Sclerosis World Congress*. Lisbon, Portugal. February 2016.
26. **Delisle VC, Gumuchian ST.** The Scleroderma Support Group Survey: Understanding people's experiences with scleroderma. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 19, 2015.
27. Gholizadeh S, **Jewett LR.** Body image distress in scleroderma. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 19, 2015.
28. **Kwakkenbos L.** Overcoming barriers to evaluating psychological interventions: the cohort multiple randomized controlled trial (cmRCT) design. *Appearance Matters: An International Conference about the Impact of Appearance in our Society*, Kristianstad, Sweden, December 10, 2014.
29. **Kwakkenbos L.** Ethical considerations in pre-consent randomization models. *Trials within Cohorts Symposium*, London School of Hygiene & Tropical Medicine, November 10-11, 2014.
30. **Jewett LR.** Visible differences from medical illness: Body image concerns in scleroderma. *Changing Faces*, London, England, August 12, 2014.
31. **Kwakkenbos L.** The Scleroderma Patient-centered Intervention Network (SPIN). *Scleroderma Society UK Annual General Meeting*, London, United Kingdom, June 29, 2013.
32. **Kwakkenbos L.** A Novel Approach for Pragmatic Evaluations of Psychological Interventions: the Cohort Multiple Randomized Controlled Trial (cmRCT) Design. *Center for Appearance Research*, University of the West of England, Bristol, United Kingdom, June 28, 2013.
33. **Jewett LR.** Let's talk about scleroderma and sexuality: keeping ourselves and relationships healthy. *Scleroderma Society of Ontario*, Mississauga, Ontario, Canada. April 20, 2013.

34. **Jewett LR.** The Scleroderma Patient-centered Intervention Network: internet-based management of body image distress. *Scleroderma Educational Forum*. Scleroderma Society of Ontario / Scleroderma Foundation. Niagara Falls, New York, USA. October 20, 2012.
35. **Jewett LR.** "SPIN" – Managing depression and body image. *Scleroderma Society of Canada, 13th Annual Conference*. Vancouver, British Columbia, Canada. September 29, 2012.
36. **Bassel M.** Psychological health and well-being in scleroderma. *Scleroderma Patient Education Bilingual Conference*. Scleroderma Society of Canada. Quebec City, Quebec, Canada. October 2011.
37. **Milette K.** Measuring depression in systemic sclerosis. In symposium (**BD Thombs**, Chair), Measure by measure: Assessing psychological health and well-being in scleroderma. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*. Atlanta, Georgia, USA. November 2010.
38. **El-Baalbaki G.** Measuring pain in systemic sclerosis: the Short-Form McGill Pain Questionnaire or a single-item measure of pain? In symposium (**BD Thombs**, Chair), Measure by measure: Assessing psychological health and well-being in scleroderma. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*. Atlanta, Georgia, USA. November 2010.
39. **Milette K.** Clinical Correlates of Sleep Problems in Systemic Sclerosis: the Prominent Role of Pain. *3rd Annual Scientific Meeting of the Canadian Scleroderma Research Group*. Halifax, New Brunswick, Canada. November 2010.

F.5.5. Supervised Invited Talks by Trainees – Local

1. **Levis B.** Selective cutoff reporting in studies of diagnostic accuracy of depression screening tools: Comparing traditional meta-analysis to individual patient data meta analysis. McGill Epidemiology, Biostatistics and Occupational Health 50th Anniversary Conference and Alumni Reunion, Montreal, Quebec, Canada. April 30, 2015.
2. **Levis B.** Using individual patient data meta-analysis to address reporting biases in studies of the diagnostic accuracy of depression screening tools. Montreal Chest Institute. Respiratory Epidemiology and Clinical Research Unit. Montreal, Quebec, Canada. February 12, 2015.
3. **Razykov I.** The utility of the Patient Health Questionnaire - 9 to assess suicide risk in medical patients. Jewish General Hospital, Department of Psychiatry Student Research Day, Montreal, Quebec, Canada. June 12, 2013.
4. **Roseman M.** Reporting of conflicts of interest from drug trials in systematic reviews and meta-analyses. Jewish General Hospital, Department of Psychiatry Student Research Day, Montreal, Quebec, Canada. June 13, 2012.
5. **Roseman M.** Reporting of conflicts of interest in Cochrane reviews of trials of pharmacological treatments. Montreal Chest Institute. Respiratory Epidemiology and Clinical Research Unit. Montreal, Quebec, Canada. April 2012.
6. **Delisle VC.** Revisiting the role of somatic symptoms among depressed men and women: much ado about nothing? Jewish General Hospital, Department of Psychiatry Student Research Day, Montreal, Quebec, Canada. June 2011.
7. **Roseman M.** Unreported conflicts of interest when pharmacological treatment trials are synthesized in meta-analyses. Jewish General Hospital, Lady Davis Institute for Medical Research, Psychosocial Axis Seminar Series, Montreal, Quebec, Canada. January 2011.
8. **Milette K.** Outcome reporting and trial registration standards: a neglected necessity for quality research. McGill University, Department of Educational and Counselling Psychology, Montreal, Quebec, Canada. October 2010.
9. **Roseman M.** Hidden conflicts of interest in meta-analyses of pharmacological treatments. Montreal Chest Institute. Respiratory Epidemiology and Clinical Research Unit. Montreal, Quebec, Canada. October 2010.
10. **Adeponle AB.** Use of cultural consultation to resolve uncertainty of psychosis diagnosis. Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. June 2010.
11. **Newton EG.** The experience of women living with scleroderma; a qualitative approach. 2nd Jewish General Hospital Department of Psychiatry Student Research Day, Montreal, Quebec, Canada. June 2010.

12. **Milette K.** Transparency of outcome reporting in behavioral health research: a systematic review. Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. June 2010.
13. **Roseman M.** Hidden conflicts of interest in meta-analyses of pharmacological treatments. Lady Davis Institute, Jewish General Hospital, First Annual Scientific Retreat, Montreal, Quebec, Canada. May 2010.
14. **Roseman M.** Hidden conflicts of interest in meta-analyses of pharmacological treatments. McGill University, Faculty of Medicine, Department of Epidemiology, Biostatistics, and Occupational Health, 2009-2010 Seminar Series. Montreal, Quebec, Canada. May 2010.
15. **Roseman M.** How transparent is evidence reporting in meta-analyses? An assessment of hidden conflicts of interests in meta-analyses of pharmacological treatments. Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. April 2010.
16. **Newton EG.** The experience of women living with scleroderma: a qualitative approach. Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. March 2010.
17. **Zhao Y.** Risk for suicide ideation and attempt among adolescents reporting “unsure” sexual identity or heterosexual identity plus same-sex attraction or behavior: forgotten groups? Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. January 2010.
18. **Zhao Y.** Risk of mental health problems among non-heterosexual identified adolescents: what about adolescents who are unsure of their sexual identity? Jewish General Hospital, Department of Psychiatry, Student Research Day, Montreal, Quebec, Canada. June 2009.
19. **Schieir O.** Clinical signs and symptoms associated with pain in patients with systemic sclerosis. Jewish General Hospital, Lady Davis Institute, Centre for Clinical Epidemiology and Community Studies, Montreal, Quebec, Canada. April 2009.
20. **Schieir O.** Where does it hurt? An examination of clinical signs and symptoms associated with pain in patients with systemic sclerosis. McGill University Hospital Center, Division of Clinical Epidemiology, Montreal, Quebec, Canada. January 2009.
21. **Adeponle AB.** Family participation in treatment and post-discharge appointment and medication adherence at a Nigerian psychiatric hospital. Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. August 2008.
22. **Ruiz Casares M.** Promoting child and adolescent mental health in the context of HIV/AIDS: measuring Depression in Namibia. Jewish General Hospital, Culture and Mental Health Research Unit, Montreal, Quebec, Canada. April 2008.
23. **Schieir O.** Baseline depression predicts depression and pain at 6-month follow-up when controlling for objective disease severity. Jewish General Hospital, Lady Davis Institute, Centre for Clinical Epidemiology and Community Studies, Montreal, Quebec, Canada. January 2008.

G. OTHER CONTRIBUTIONS

G.1. Academic Journals and Scientific Meetings

G.1.1. Editorial Appointments

- *Contemporary Clinical Trials*, Editorial Board, 2020-present.
- *Journal of Scleroderma and Related Disorders*, Editorial Board, 2015-present.
- *Research Synthesis Methods*, Editorial Board. 2015-present.
- *Cochrane Collaboration: Common Mental Disorders Group*, Methods Editor. 2013-present; Content Editor. 2019 – present.
- *Cochrane Collaboration: Diagnostic Test Accuracy Working Group*, Contact Editor. 2014-present.
- *Canadian Journal of Psychiatry*, Editorial Board. 2008-present.
- *Journal of Psychosomatic Research*, Editorial Board. 2009-2010. Associate Editor. 2010-2017.
- *PLOS ONE*, Academic Editor. 2013-2015. Section Editor 2015-2017.
- *Arthritis Care & Research*, Editorial Board. 2010-2016.
- *Transcultural Psychiatry*, Statistical Editor. 2006-2013.
- *Burns*, Editorial Board. 2006-2010.
- *Journal of Burns and Wounds*, Editorial Board. 2005-2007.

G.1.2. Journal Peer Review Activities Since 2006 (543 Total Reviews; 698 including supervised trainee reviews)

2020 – 2021 (19 Total Reviews; 25 including supervised trainee reviews): Australian and New Zealand Journal of Psychiatry (1); BMJ (1); BMJ Open (1); Comprehensive Psychiatry (1); Contemporary Clinical Trials (1); JAMA (1); JAMA Open (12). J Psychosom Res (1).

2019 – 2020 (27 Total Reviews; 33 including supervised trainee reviews): Arthritis Care & Research (1); BMJ (1); BMJ Open (1); Cochrane Reviews (1); Epidemiology and Infection (1); JAMA (1); JAMA Open (14); Journal of Psychosomatic Research (2); Journal of Rheumatology (1); Pediatrics (1); Physiotherapy Theory and Practice (1); Psychotherapy and Psychosomatics (1); Scandinavian Journal of Rheumatology (1).

2018 – 2019 (23 Total Reviews; 27 including supervised trainee reviews): American Heart Journal (2); BMJ (2); BMJ Open (3); Contemporary Clinical Trials (1); JAMA (1); JAMA Open (10); Journal of the American College of Cardiology (1); Psycho-Oncology (3).

2017 – 2018 (19 Total Reviews; 21 including supervised trainee reviews): American Heart Journal (1); Arthritis Care & Research (1); Arthritis & Rheumatism (1); BMJ (3); BMJ Open (3); Canadian Family Physician (1); Depression and Anxiety (1); JAMA Open (3); Journal of Psychosomatic Research (3); Journal of Scleroderma and Related Disorders (1); Medical Principles and Practice (1).

2016 – 2017 (24 Total Reviews; 46 including supervised trainee reviews): Australian and New Zealand Journal of Psychiatry (1); BMJ (2); BMJ Open (1); British Journal of Psychiatry (1); Journal of the American College of Cardiology (1); Journal of Hand Therapy (1); Journal of Psychosomatic Research (9); Journal of Scleroderma and Related Disorders (2); Journal of Women's Health (1); PLOS Medicine (2); Research Integrity and Peer Review (2).

2015 – 2016 (43 Total Reviews; 86 including supervised trainee reviews): Annals of Internal Medicine (2); Arthritis & Rheumatism (1); BMJ (3); BMJ Open (4); CMAJ (1); Canadian Journal of Psychiatry (3); Cochrane Reviews (4); Epidemiology (1); European Journal of General Practice (1); JAMA (2); Journal of Consulting and Clinical Psychology (2); Journal of the American College of Cardiology (1); Journal of Clinical Rheumatology (1); Journal of Psychosomatic Research (13); Journal of Scleroderma and Related Disorders (1); Pediatrics (1); Research Synthesis Methods (1); Systematic Reviews (1).

2014 – 2015 (42 Total Reviews; 74 including supervised trainee reviews): Arthritis Care & Research (2); BMJ (1); Canadian Journal of Psychiatry (1); Cochrane Reviews (3); JAMA (7); Journal of Consulting and Clinical Psychology (1); Journal of Psychosomatic Research (21); Journal of Rheumatology (2); Nature Reviews: Disease Primers (1); PLOS Medicine (1); Psychotherapy and Psychosomatics (1); Trials (1).

2013 – 2014 (37 Total Reviews; 55 including supervised trainee reviews): Arthritis Care & Research (4); BMC Public Health (1); BMJ (2); Canadian Journal of Community Mental Health (1); Canadian Journal of Psychiatry (3); Cochrane Reviews (2); Depression and Anxiety (1); Health and Quality of Life Outcomes (1); JAMA (2); Journal of Psychiatric Research (1); Journal of Psychosomatic Research (16); PLOS ONE (2); Psychotherapy and Psychosomatics (1).

2006 – 2013 (308 Total Reviews; 329 including supervised trainee reviews): Acta Psychiatrica Scandinavica (2); Addiction (1); American Journal of Cardiology (1); American Journal of Managed Care (1); American Journal of Psychiatry (1); Annals of Behavioral Medicine (2); Annals of Internal Medicine (2); Annals of Oncology (1); Annals of the Rheumatic Diseases (2); Archives of General Psychiatry (6); Arthritis Care & Research (16); Arthritis & Rheumatism (1); Biological Psychiatry (1); BMC Health Services Research (1); BMJ (4); Brain Research Bulletin (1); British Journal of Psychiatry (1); Burns (24); Canadian Journal of Psychiatry (26); Circulation (2); CMAJ (1); Contemporary Clinical Trials (2); Critical Care Medicine (1); Diabetes Care (3); European Journal of Cardiovascular Prevention and Rehabilitation (1); European Journal of Heart Failure (1); European Journal of Psychiatry (1); General Hospital Psychiatry (2); Harvard Review of Psychiatry (1); Health Psychology (2); Health and Quality of Life Outcomes (2); Heart (2); JAMA (3); Journal of Affective Disorders (1); Journal of the American College of Cardiology (13); Journal of Burn Care & Research (2); Journal of Burns and Wounds (3); Journal of Consulting and

Clinical Psychology (1); *Journal of General Internal Medicine* (3); *Journal of Health Psychology* (1); *Journal of Psychosomatic Research* (77); *Journal of Rheumatology* (2); *Medicine* (1); *PLOS ONE* (7); *Psychiatry Research* (2); *Psychological Bulletin* (1); *Psychological Medicine* (1); *Psychology, Health, & Medicine* (1); *Psychosomatic Medicine* (6); *Rheumatology* (3); *Scandinavian Journal of Rheumatology* (2); *Transcultural Psychiatry* (64).

G.1.3. Supervised Journal Peer Review Activities by Trainees (155 Total Reviews)

2020-2021 (6 Total Reviews): **Olivia Bonardi:** *Res Integr Peer Rev* (2); **Andrea Carboni-Jiménez:** *Ann Behav Med* (1); **Richard Henry:** *J Homosex* (1); *Nature Commun* (1); **Zelalem Negeri:** *BMJ Open Respir Res* (1).

2019-2020 (8 Total Reviews): **Zelalem Negeri:** *J Am Geriatr Soc* (1); *JAMA Open* (1); *Journal of Clinical Epidemiology* (1); **Yin Wu:** *BMC Pregnancy and Childbirth* (1); *Canadian Journal of Psychiatry* (1); *Journal of Psychosomatic Research* (1); *PLoS ONE* (1); *Psychotherapy and Psychosomatics* (1).

2018-2019 (4 Total Reviews): **Claire Fedoruk:** *BMJ Open* (1); **Sami Harb:** *Arthritis Care & Research* (1); **Danielle Rice:** *CMAJ* (1); **Yin Wu:** *Systematic Reviews* (1).

2017-2018 (1 Total Review): **Yin Wu:** *Systematic Reviews* (1).

2016-2017 (22 Total Reviews): **Marleine Azar:** *Journal of Clinical Psychiatry* (1); *Research Integrity and Peer Review* (2); **Linda Kwakkenbos:** *Journal of Psychosomatic Research* (1); *Arthritis Care and Research* (2); **Brooke Levis:** *CMAJ* (1); *PLOS Medicine* (1); *PLOS ONE* (2); **Kira Riehm:** *Obesity* (2); *Research Integrity and Peer Review* (2); **Danielle Rice:** *CMAJ* (1); *Disability and Rehabilitation* (4); *Neurosciences Journal* (1); *PLOS ONE* (2).

2015-2016 (43 Total Reviews): **Marleine Azar:** *Journal of Clinical Psychiatry* (1); *Journal of Consulting and Clinical Psychology* (2); **Vanessa Delisle:** *Stigma and Health* (2); **Stephanie Gumuchian:** *Journal of Clinical Rheumatology* (1); *Journal of Psychosomatic Research* (1); **Lisa Jewett:** *Trials* (2); **Linda Kwakkenbos:** *Seminars in Arthritis and Rheumatism* (1); *Journal of Clinical Psychology in Medical Settings* (1); *Journal of Clinical Rheumatology* (1); *Clinical and Experimental Rheumatology* (1); *Journal of Psychosomatic Research* (9); *Arthritis Care and Research* (3); *Rheumatology International (Clinical and Experimental Investigations)* (2); **Alex Levis:** *Journal of Psychosomatic Research* (2); **Brooke Levis:** *International Journal of Geriatric Psychiatry* (1); *Journal of Psychosomatic Research* (1); *PLOS ONE* (1); **Danielle Rice:** *Journal of Affective Disorders* (1); *Journal of Psychiatric Research* (1); *Journal of Psychosomatic Research* (1); *PLOS ONE* (4); **Kira Riehm:** *Journal of Consulting and Clinical Psychology* (2); *Journal of Psychosomatic Research* (1); *PLOS ONE* (1).

2014-2015 (32 Total Reviews): **Marleine Azar:** *Journal of Consulting and Clinical Psychology* (1); **Adina Coroiu:** *PLOS ONE* (2); **Vanessa Delisle:** *Stigma and Health* (1); **Linda Kwakkenbos:** *Arthritis Care and Research* (4); *BMC Musculoskeletal Disorders* (1); *BMC Psychiatry* (1); *Journal of Psychosomatic Research* (8); *PLOS ONE* (3); *Rheumatology International (Clinical and Experimental Investigations)* (2); **Alex Levis:** *Journal of Psychosomatic Research* (1); **Brooke Levis:** *Journal of Psychosomatic Research* (2); **Kira Riehm:** *Journal of Consulting and Clinical Psychology* (1); *PLOS ONE* (1); **Michelle Roseman:** *American Journal of Preventive Medicine* (1); **Danielle Rice:** *Circulation: Heart Failure* (1); *Journal of Psychosomatic Research* (1); *PLOS ONE* (1).

2013 – 2014 (18 Total Reviews): **Vanessa Delisle:** *Journal of Psychosomatic Research* (1); **Linda Kwakkenbos:** *Arthritis Care & Research* (2); *Health and Quality of Life Outcomes* (1); *Journal of Depression and Anxiety* (1); *Journal of Psychosomatic Research* (1); *PLOS ONE* (5); *Rheumatology International: Clinical and Experimental Investigations* (2); **Lisa Jewett:** *Journal of Burn Care & Research* (1); **Brooke Levis:** *American Journal of Managed Care* (2); **Michelle Roseman:** *JAMA* (1); *Journal of Psychosomatic Research* (1).

2006- June 2013 (21 Total Reviews) **Vanessa Delisle:** *Journal of Psychosomatic Research* (2); *PLOS ONE* (1); **Ghassan El-Baalbaki:** *Journal of Psychosomatic Research* (1); *Transcultural Psychiatry* (1); **Lisa Jewett:** *Arthritis Care & Research* (1); *Burns* (2); *Journal of Psychosomatic Research* (1); **Linda Kwakkenbos:** *Journal of Psychosomatic Research* (2); *Journal of Rheumatology* (1); *PLOS ONE* (1); **Brooke Levis:** *Clinical Rheumatology* (1); *PLOS ONE* (1); **Katherine Milette:** *Arthritis Care & Research*

(2); *Journal of Psychosomatic Research* (1); **Michelle Roseman**: *BMJ* (1); *Journal of Clinical Epidemiology* (1); *Psycho-oncology* (1).

G.1.4. Peer-Review for Scientific Meetings

- Trials Using Cohorts & Routine Health Data: International Symposium on their Efficiency and Analysis. Queen Mary University of London. 2019.
- International Congress on Peer Review and Scientific Publication. 2017.
- Canadian Psychological Association. Annual Convention. 2011-2013.
- Society for Behavioral Medicine, Annual Meeting and Scientific Sessions. 2009-2011.

G.1.5. Conferences/Meetings Organized/Hosted

- Trials Using Cohorts & Routine Health Data: International Symposium on their Efficiency and Analysis. Queen Mary University of London, May 15, 2019, 75 attendees, Scientific Organizing Committee Member.
- CONSORT Extension for Trials Conducted Using Cohorts and Routinely Collected Health Data Reporting Guideline Development Meeting. London, UK, May 13-14, 2019, 27 attendees, CIHR-funded (PI Thombs).
- SPIN-SHARE Organizational Partners Meeting. Bordeaux, France, February 15-17, 2018, 30 attendees, CIHR-funded (PI Thombs).
- Scleroderma Patient-centered Intervention Network (SPIN) Project Teams Meeting. Anaheim, California, USA, September 27-28, 2013, 40 attendees. CIHR-funded (PI Thombs).
- Scleroderma Patient-centered Intervention Network (SPIN) Project Development Meeting. Hamilton, Ontario, Canada, September 27-28, 2013, 45 attendees. CIHR-funded (PI Thombs).
- Scleroderma Patient-centered Intervention Network (SPIN) Planning Meeting. Montreal, Quebec, Canada, July 14-15, 2011, 40 attendees. CIHR-funded (PI Thombs).
- Initial Organizational Meeting of the International Consortium for Behavioral, Educational, and Psychological Trials to Improve Health in Scleroderma. Montreal, Quebec, Canada, October 14-15, 2010, 35 attendees. CIHR-funded (PI Thombs).
- Evidence-based Perspectives on Detection and Clinical Care for Depression in Medical Settings. Montreal, Quebec, Canada, October 22-23, 2009, 15 attendees. CIHR-funded (PI Thombs).
- Joint Patient – Researcher Meeting to Interpret and Plan for Dissemination of Patient Survey Results. Montreal, Quebec, Canada, September 17-18, 2009, 18 attendees. CIHR-funded (PI Thombs).
- Improving Health and Well-Being in Scleroderma: establishing a Collaborative Behavioural Health Research Agenda. Montreal, Quebec, Canada, November 13-14, 2008, 15 attendees. CIHR-funded (PI Thombs).

G.1.6. Session Organizer/Chair/Moderator

1. Symposium Organizer/Chair, Improving evidence-based psychological services by identifying and reducing reporting biases. *Canadian Psychological Association Convention*, Ottawa, Ontario, Canada. June 2015.
2. Small Group Session Co-Chair, Access to healthcare and support services. *Canadian Organization for Rare Disorders 2013 Fall Conference*, Ottawa, Ontario, Canada. September 30, 2013.
3. Symposium Organizer/Chair, Psychological measurement in hospital and health centers. *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada. June 2013.
4. Symposium Organizer/Chair, Myths and measures: mental health assessment in medical settings. *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
5. Session Chair, What a pain rheumatic disease can be! *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*. Atlanta, Georgia, USA. November 2010.
6. Symposium Organizer/Chair, Measure by measure: assessing psychological health and well-being in scleroderma. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*. Atlanta, Georgia, USA. November 2010.

7. Symposium Organizer/Chair, Current controversies in the definition, identification, and care of depression. *Canadian Psychiatric Association Annual Conference*, Toronto, Ontario, Canada. September 2010.
8. Symposium Chair, Cognitive and somatic depression in cardiac patients, *XIII Annual Scientific Meeting, European Association for Consultation-Liaison Psychiatry and Psychosomatics/XXVIII European Conference on Psychosomatic Research*. Innsbruck, Austria. July 2010.
9. Session Chair, *1st Annual Lady Davis Institute for Medical Research Scientific Retreat*. Montreal, Quebec, Canada. June 2010.
10. Symposium Organizer/Chair, The psychology of improving health and well-being in scleroderma: assessment and intervention approaches. *American College of Rheumatology / Association for Rheumatology Health Professionals Annual Scientific Meeting*. Philadelphia, Pennsylvania, USA. October 2009.
11. Symposium Organizer/Chair, Clinical psychology in medical settings: does one size fit all? *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada. June 2009.

G.2. Grant and Guideline Reviews

G.2.1. Grant Review Committee Member

- CIHR, College of Reviewers. 2017-present.
- CIHR, Project Scheme. 2016.
- European Commission Horizon 2020, Personalizing Health and Care. 1 committee. 2014.
- CIHR, Knowledge Synthesis Grant Program. 4 committees, 2012-2014.
- CIHR, Pfizer Operating Grant in Disease Prevention and Management. 3 committees, 2010-2012.
- CIHR, Team Grant: Chronic Disease Risk and Intervention Strategies. 2 committees, 2011.
- CIHR, Meetings, Planning, and Dissemination Grants. 3 committees, 2010-2011.
- The Arthritis Society / Canadian Arthritis Network Training Competition. 1 committee, 2012.
- Heart and Stroke Foundation of Canada – Grants-in-Aid. 2 committees, 2010-2011.

G.2.2. External Grant Reviewer

- Agency for Health Quality and Assessment of Catalonia, 2020.
- Scar Free Foundation (United Kingdom), 2018.
- Scleroderma & Raynaud's UK, 2018.
- Health & Social Care Research & Development Division, Public Health Agency, Northern Ireland, 2017.
- Manitoba Medical Service Foundation, 2015.
- Dutch Cancer Society, 2013.
- Fondation des pompiers du Québec pour les grands brûlés, 2013.
- Preventing Violence Across the Lifespan Research Network - CIHR Centre, 2013.
- Rheumafonds – Dutch Arthritis Association, 2012.
- European League Against Rheumatism (EULAR), 2011.
- Ireland Health Research Board – Health Research Awards, 2010, 2013.
- The Netherlands Organisation for Health Research and Development, 2010.
- Douglas Mental Health University Research Center – Bombardier Fellowship, 2010.
- Yale University School of Medicine – Donaghue Women's Health Investigator Program, 2009.
- Dutch Burns Foundation, 2009.

G.2.3. External Reviewer for Tenure/Promotion

- 2 reviews, 2012, 2013 (both USA)
- 1 review, 2015 (USA)
- 1 review, 2017 (UK)
- 1 review, 2020 (Canada)

G.2.4. Guideline Reviewer

- Canadian Paediatric Society, *Early Detection for Autism Spectrum Disorder: Surveillance and Screening in Children Aged Four and Under*, 2018.
- Canadian Task Force on Preventive Health Care, *Screening for Depression in Adults*, 2012.

G.3. Administrative Responsibilities

G.3.1. Institutional Administrative Appointments and Responsibilities

McGill University

- Promotions Committee, Faculty of Medicine, Ingram School of Nursing (ad hoc), 2020.
- Promotions Committee, Faculty of Medicine, 2019-present.
- Internal Evaluation Committee, McGill Nominees for Networks for Centres of Excellence – Knowledge Mobilization Centres, 2018.
- Search Committee, Quantitative Psychology Faculty Hire, Department of Psychology, 2015.
- Preliminary Selection Committee, Nominees for CIHR Banting Postdoctoral Fellows, 2015-present.
- Selection Committee, Principal's Prize for Outstanding Emerging Researchers, 2015-2016, 2018-.
- Task Force, Institute of Public and Population Health, Faculty of Medicine, 2014-2016.
- University Tenure Committee, Faculty of Medicine, 2014-2016.
- Evaluator, Undergraduate Theses, Department of Psychology (3 theses), 2014-present.
- Internal Pre-Submission Grant Peer-Reviewer (including MUHC, 3 proposals), 2010-present.
- MSc in Epidemiology Admissions Committee, 2010-2014.
- MSc in Public Health Admissions Committee, 2015-present.

Lady Davis Institute for Medical Research, Jewish General Hospital

- 6-year Reappointment Review Committee, 2013-2014.
- Annual Scientific Retreat Organizing Committee, 2012-2017.
- Internal Studentship Review Committee, 2011-present.
- Internal Pre-Submission Grant Peer-Reviewer (51 proposals), 2010-present.
- Clinical Research Pilot Project Funding Initiative Review Committee, 2012-2014.
- Chair, Seminar Series, Psychosocial Axis, 2010-2014.
- Research Ethics Committee/Science Review Committee, 2007-present.
- Research Day Program Committee, Department of Psychiatry, 2007.

G.3.2. Policy, Advisory, and Organizational Committees

- Steering Committee, SPIRIT Extension for Protocols of Trials Conducted Using Cohorts and Routinely Collected Health Data, 2020-present.
- Chair, Steering Committee, CONSORT Extension for Trials Conducted Using Cohorts and Routinely Collected Health Data, 2017-present.
- Panel on Expert Groups, World Health Organization Science Division. Geneva, Switzerland, 2019.
- Scientific Organizing Committee, *Trials Using Cohorts and Routinely Collected Health Data: International Symposium on their Efficacy and Analysis*. London, UK. 2019.
- International Advisory Committee, Strategy for Patient-oriented Research (SPOR) Evidence Alliance, 2018-present.
- Steering Committee, Patient Educational Materials for Prostate Cancer Screening (Funded by Ontario Institute for Cancer Research, Principal Investigator S Strauss), 2017-2018.
- Chair, Canadian Task Force on Preventive Health Care, 2017-present.
- Chair-Elect, Canadian Task Force on Preventive Health Care, 2016-2017.
- Member, Canadian Task Force on Preventive Health Care, 2013-present (Working Group Chair - Child and Adolescent Smoking Prevention and Cessation Guideline; Adult Smoking Cessation Guideline; Methods; Topics. Working Group Member – Antenatal Bacteriuria Screening Guideline; Breast Cancer Screening Guideline; Chlamydia & Gonorrhea Screening Guideline; Cognitive Impairment Screening Guideline; Depression Screening Guideline; Developmental Delay Screening Guideline; Esophageal Cancer Screening Guideline; Fragility Fracture Screening Guideline, Hepatitis C Screening Guideline; Hypertension Screening Guideline, Methods; Periodic Health Exam Statement; Pelvic Exam Guideline; Thyroid Dysfunction Screening Guideline, Visual Acuity Screening Guideline).
- Steering Committee, National Plan for Rare Disorders, Canadian Organization for Rare Disorders, 2013-present.

- Expert Work Group on Depression Monitoring Tools, National Committee for Quality Assurance (United States), 2015
- Nominating Committee for Editor-in-Chief, Canadian Journal of Psychiatry, 2012.
- Member, Research Committee, Association of Rheumatology Health Professionals, 2009-2011.
- Clinical Research Committee, Canadian Scleroderma Research Group, 2007-present.
- Knowledge Transfer Committee, Canadian Scleroderma Research Group, 2007-present.
- Chair, Joint National Patient Survey Committee, Canadian Scleroderma Society and Canadian Scleroderma Research Group, 2007-2009
- Research Committee, American Burn Association, 2005-2008.

H. RESEARCH

H.1. Personal Support Awards

- Tier 1 Canada Research Chair (\$1,400,000, 2020-2027).
- FRS-Q Chercheur-Boursier, Distinguished (\$400,000, 2020-2024; declined \$220,000 due to overlap with Canada Research Chair and accepted \$180,000 in research funding).
- FRS-Q Chercheur-Boursier, Senior (\$151,708, 2017-2019).
- Arthritis Society Investigator Salary Award (\$350,000, 2013-2017).
- FRS-Q Chercheur-Boursier, Junior 2 (\$133,783; declined, 2013-2015).
- McGill University William Dawson Scholar Award (\$125,000, 2012-2017).
- CIHR New Investigator Award (\$300,000, 2008-2013).
- FRS-Q Chercheur-Boursier, Junior 1 (\$225,075; declined, 2008-2012).

H.2. Research Grants

H.2.1. Current Grants as Principal Investigator¹

- CIHR. Project Grant. *The DEPRESSion Screening Data (DEPRESSD) Project: continuous updating of databases for individual participant data meta-analyses of depression screening test accuracy.* (PI: Thombs BD, Benedetti A; \$100,000; 2021-2022).
- CIHR. Project Grant. *Statistical methodology for prediction modelling to improve depression screening with individualized risk estimates in the context of individual participant data meta-analysis.* (PI: Benedetti A, Thombs BD; \$100,000; 2021-2022).
- CIHR. COVID-19 Operating Grant. *Identifying effective mental health interventions and populations in need: A COVID-19 living systematic review* (PI: Thombs BD, Benedetti A; \$199,836; 2020-2021).
- CIHR. COVID-19 Operating Grant. *Identification of Factors to Improve Effectiveness and Implementation of a Multi-faceted COVID-19 Mental Health Intervention: Follow-up to the SPIN-CHAT Trial* (PI: Thombs BD, Benedetti A, Culos-Reed N, Kwakkenbos L; \$89,901; 2020-2021).
- MITACS and Scleroderma Canada. Accelerate Postdoctoral Fellowship Grant. *The Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Cohort and COVID-19 Home-isolation Activities Together (SPIN-CHAT) Trial* (PI: Thombs BD; \$60,000; 2020-2021).
- CIHR. COVID-19 Operating Grant. *Partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to reduce anxiety among vulnerable persons with a pre-existing medical condition* (PI Thombs BD, Benedetti A, Kwakkenbos L; \$156,353; 2020-2021).
- CIHR. COVID-19 Operating Grant: Knowledge Synthesis: COVID-19 in Mental Health & Substance Use. *Mental health during the COVID-19 pandemic: a living systematic review of mental health burden, factors associated with mental health outcomes, and intervention effectiveness in the general population and vulnerable populations* (PI Thombs BD, Benedetti A; \$50,000; 2020).
- McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund. *Mental health during the COVID-19 pandemic: a living systematic review of symptom levels, factors associated with symptoms, and intervention effectiveness* (PI Thombs BD; \$65,400; 2020).

¹ Nominated PIs underlined.

- McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund. *Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention* (PI Thombs BD; \$100,000; 2020).
- Scleroderma Canada (made possible by an educational grant for patient support programming from Boehringer Ingelheim). *Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention* (PI Thombs BD; \$65,000; 2020).
- Scleroderma Australia, Scleroderma New South Wales, Scleroderma Victoria, and Scleroderma Queensland. *Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention* (PI Thombs BD; \$13,400; 2020).
- Scleroderma Atlantic. *Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention* (PI Thombs BD; \$5,000; 2020).
- Scleroderma Manitoba. *Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention* (PI Thombs BD; \$5,000; 2020).
- Scleroderma Saskatchewan. *Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention* (PI Thombs BD; \$1,500; 2020).
- Scleroderma Association of British Columbia. *Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention* (PI Thombs BD; \$1,000; 2020).
- Sclérodermie Québec. *Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention* (PI Thombs BD; \$500; 2020).
- MITACS and Scleroderma Society of Ontario. Accelerate Postdoctoral Fellowship Grant. *The Scleroderma Support group Leader EDucation (SSLED) Program* (PI: Thombs BD; \$165,000; 2019-2022).
- CIHR. Operating Grant. *Depression Trajectories in Pregnant and Postpartum Women: An Individual Participant Data Meta-Analysis* (PIs: Benedetti A, Thombs BD; \$74,545; 2020-2021).
- Scleroderma Society of Ontario. *Scleroderma Patient-centered Intervention Network (SPIN)* (PI: Thombs BD; \$25,000; 2019-2020).
- CIHR. Operating Grant. *Artificial intelligence in systematic reviews: evaluation of emerging electronic tools for researchers in knowledge synthesis* (PIs Hutton B, Rodin R, Thombs BD; \$100,000, 2019-2020).
- MITACS and Scleroderma Society of Ontario. Research Internship. *The Scleroderma Patient-centered Intervention Network – Decision Aids* (PI: Thombs BD; \$30,000; 2020).
- CIHR. Catalyst Grant: SPOR Innovative Clinical Trials. *Feasibility Trial of the Scleroderma Patient-centered Intervention Network COping with Appearance CHanges (SPIN-COACH) Program: Delivering Accessible and Tailored Mental Health Services to People Living with a Rare Disease*. (PI: Thombs BD; \$100,000; 2019-2020).
- CIHR. Project Scheme Grant. *Diagnostic Accuracy of the Patient Health Questionnaire-9 for Detecting Major Depression: An Updated Systematic Review and Independent Participant Data Meta-analysis*. (PIs: Benedetti A, Thombs BD; \$210,375; 2019-2021).
- CIHR. Project Scheme Grant. *The Scleroderma Support group Leader EDucation (SSLED) Program: A Randomized Controlled Trial* (PI: Thombs BD; \$348,074; 2019-2022).
- Jewish General Hospital Foundation. *SPIN-SHARE*. (PI: Thombs BD; \$250,000; 2018-2021).
- CIHR. Patient-Oriented Research Collaboration Grants. *Developing a Program to Enhance Physical Activity in Scleroderma: The SPIN-PACE Study* (PIs: Shrier I, Thombs BD, Sauve M, Pelaez S; \$40,000; 2018-2019).
- Scleroderma Society of Ontario. *The Scleroderma Patient-centered Intervention Network Physical Activity Enhancement (SPIN-PACE) Program* (PI: Thombs BD; \$40,000; 2018-2019).
- Sclérodermie Québec. *The SPIN-SHARE Program* (PI: Thombs BD; \$50,000; 2018-2023).

- CIHR. *Personalized Health Catalyst Grant. Using Individual Patient Data Meta-Analyses to Develop Individual Prediction Models for Depression Screening* (PIs: Benedetti A, Thombs BD; \$200,000; 2018-2020).
- CIHR. Project Scheme Grant. *CONSORT Extension for Trials Conducted in Existing Data Structures, Including Researcher-generated Cohorts, Registries, Electronic Health Records, and Administrative Databases* (PIs Thombs BD, Frobert O, Juszczak E, Kwakkenbos L, Relton C; \$133,876; 2018-2020).
- CIHR. Project Scheme Grant. *Improving Depression Screening in Geriatric Patients by Reducing Bias and Generating Individualized Accuracy Estimates: An Individual Patient Data Meta-Analysis of the Geriatric Depression Scale (GDS)* (PIs: Benedetti A, Thombs BD; \$120,000; 2018-2020).
- Public Health Agency of Canada. *Contribution Agreement – Canadian Task Force on Preventive Health Care* (PI Thombs BD; \$7,905,691; 2018-2021).

H.2.2. Current Operating Grants as Co-investigator or Knowledge User

- CIHR. Project Grant. *Coping strategies and mental health: quantitative and qualitative insight into the COVID-19 experience in young adults* (PIs Sylvestre MP, Bélanger M, O’Laughlin JE; \$457,422; 2021-2023).
- Strategy for Patient-oriented Research Evidence Alliance. Seed Grant. *Incorporation of recommendations for gender-diverse people in clinical practice guidelines: A review of traditionally sex-binary guidelines and recommendations* (PI Henry RS, \$10,000, 2020).
- CIHR. Operating Grant. *COVID-19 Knowledge Synthesis Network* (PIs Lavis JN, Grimshaw JM, Santesso NA, Tricco AC, \$1,000,000, 2020-2021).
- Health Research Board of Ireland. *Developing Reporting Guidelines for Clinical Trial Protocols for Trials conducted using Routinely Collected Health Data: the SPIRIT-Routinely Collected Health Data (SPIRIT-RCHD) extension* (PI Kearney P, €9,889, 2020-2021).
- CIHR. Catalyst Grant. *Vaping safety: a knowledge synthesis* (PI Eisenberg M, \$99,984, 2020-2021).
- CIHR. Operating Grant. *Youth and e-cigarettes: a knowledge synthesis* (PI Eisenberg M, \$114,750, 2020-2021).
- CIHR. Operating Grant. *Cannabis and impaired driving: a knowledge synthesis* (PI Eisenberg M, \$114,750, 2019-2020).
- CIHR. Operating Grant. *Interventions for the opioid crisis: a systematic review examining approaches in the Canadian context and vulnerable sub-populations* (PI Eisenberg M, \$99,997, 2019-2020).
- CIHR. Operating Grant: Strategy for Patient-Oriented Research (SPOR) – Guidelines and Systematic Reviews. *The REACH Network* (PI Tricco A, \$4,997,000, matched funds = \$10,829,000, 2017-2022).

H.2.3. Current Team, Centre, and Training Grants as Co-investigator

None

H.2.4. Past Grants as Principal Investigator

- Scleroderma Society of Nova Scotia. *SPIN: Understanding Patient Decision-making Needs* (PI Thombs BD; \$8,500; 2018-2019).
- Scleroderma Society of Saskatchewan. *The SPIN-SHARE Program* (PI Thombs BD; \$4,000; 2018-2019).
- Scleroderma Manitoba. *The SPIN-SHARE Program*. (PI: Thombs BD; \$3,000; 2018-2019).
- CIHR. Project Scheme Grant. *The Scleroderma Support group Leader Education (SSLED) Program: A Randomized Controlled Trial* (PI: Thombs BD; \$100,000; 2018-2019).
- Public Health Agency of Canada. *Contribution Agreement (subaward) – Canadian Task Force on Preventive Health Care* (PI Thombs BD; \$67,193, 2017-2018).
- CIHR. Project Scheme Grant. *Development and Implementation of a Reporting Guideline for Systematic Reviews and Meta-analyses of Diagnostic Accuracy Studies: The PRISMA-DTA Initiative* (PIs McInnes M, Moher D, Thombs BD; \$100,000; 2017-2019).
- Scleroderma Society of Nova Scotia. *The SPIN-SHARE Program* (PI Thombs BD; \$5,000; 2017-2018).
- Scleroderma Society of British Columbia. *The SPIN-SHARE Program* (PI Thombs BD; \$10,000; 2017-2018).
- Canadian Institute for Outcomes in Rheumatology Care. *The Scleroderma Support Group Leader*

- Education (SSLED) Program Feasibility Trial: A Scleroderma Patient-centered Intervention Network (SPIN) Project* (PI Thombs BD; \$75,000; 2017-2018).
- CIHR. Project Scheme Grant. *Improving Depression Screening in Geriatric Patients by Reducing Bias and Generating Individualized Accuracy Estimates: An Individual Patient Data Meta-Analysis of the Geriatric Depression Scale (GDS)* (PIs Thombs BD, Benedetti A, Wilchesky M; \$75,000; 2017-2018).
 - CIHR. Catalyst Grant – Musculoskeletal Health and Arthritis. *Scleroderma Patient-centered Intervention Network Teletherapy for Appearance Anxiety (SPIN-TAPA) Feasibility Study* (PIs Thombs BD El-Baalbaki G; \$100,000; 2017-2018).
 - Arthritis Society. Strategic Operating Grant. *Randomized Controlled Trial of an Internet-based Exercise Program to Improve Hand Function in Patients with Scleroderma: A Scleroderma Patient-centered Intervention Network (SPIN) Study* (PI Thombs BD; \$359,686; 2016-2019).
 - CIHR. Project Scheme Grant. *Randomized Controlled Trial of an Internet-based Scleroderma Self-Management Program: A Scleroderma Patient-Centered Intervention Network (SPIN) Study* (PI Thombs BD; \$569,909; 2016-2019).
 - CIHR. Project Scheme Grant. *Randomized Controlled Trial of an Internet-based Exercise Program to Improve Hand Function in Patients with Scleroderma: A Scleroderma Patient-Centered Intervention Network (SPIN) Study* (PIs Thombs BD, Mouthon L, Poiraudau S; \$100,000; 2016-2017).
 - CIHR. Knowledge Synthesis and Exchange Grant. *Improving Depression Screening in Medically Ill Patients by Reducing Bias and Including Individual Patient Characteristics in Accuracy Estimates: An Independent Patient Data Meta-Analysis of the Hospital Anxiety and Depression Scale (HADS)* (PIs Thombs BD, Benedetti A, Loiselle C; \$100,000; 2016-2017).
 - CIHR. Emerging Team Grant: Rare Diseases. *Emerging team: The Scleroderma Patient-centered Intervention Network* (PI Thombs BD; \$1,499,765 + \$200,000 partner funding; 2012-2017).
 - CIHR. Knowledge Synthesis and Exchange Grant. *Improving Depression Screening by Reducing Bias in Accuracy Estimates: An Independent Patient Data Meta-Analysis of the Edinburgh Postnatal Depression Scale (EPDS)* (PIs Thombs BD, Benedetti A; \$100,000; 2015-2016).
 - CIHR. Knowledge Synthesis and Exchange Grant. *Improving Depression Screening by Reducing Bias in Accuracy Estimates: An Independent Patient Data Meta-Analysis of the PHQ-9* (PIs Thombs BD, Joffres MR; \$100,000; 2014-2015).
 - Scleroderma Society of Ontario. *Scleroderma Support Group Leader Training Program* (PI Thombs BD; \$30,000; 2014-2015).
 - SSHRC. Insight Development Grant. *Searching for identity in the dark: The experiences of women living with a rare disease* (PI Thombs BD; \$74,888; 2012-2014).
 - CIHR. Knowledge Synthesis and Exchange Grant. *Depression screening and mental health outcomes in children and adolescents: A systematic review* (PI Thombs BD; \$99,977; 2012-2013).
 - Scleroderma Society of Ontario. *Coordinator for the Scleroderma Patient-centered Intervention Network* (PI Thombs BD; \$25,000; 2011-2012).
 - Scleroderma Society of Canada. *Coordinator for the Scleroderma Patient-centered Intervention Network* (PI Thombs BD; \$12,500; 2011-2012).
 - CIHR. Knowledge Synthesis and Exchange Grant. *Will routine depression screening benefit patients in cardiovascular care settings? An updated systematic review* (PI Thombs BD; \$92,989; 2011-2012).
 - CIHR. Knowledge Synthesis and Exchange Grant. *Will screening for distress improve patient well-being in cancer? A systematic review* (PI Thombs BD; \$88,489; 2010-2011).
 - CIHR. Knowledge Synthesis and Exchange Grant. *Depression screening and patient outcomes in pregnancy and postpartum: A systematic review* (PI Thombs BD; \$97,766 – funding for full project to complement bridge funding – accepted non-overlapping funds of \$91,588; 2010-2011).
 - CIHR. Operating Grant – Priority Announcement Knowledge Translation. *Depression screening and patient outcomes in pregnancy and postpartum: A systematic review* (PI Thombs BD; \$60,000; 2010-2011).
 - American College of Rheumatology Research and Education Foundation. Health Professional Investigator Award. *Improving depression screening in rheumatology clinics: Detection of persistent versus acute depression in systemic sclerosis* (PI Thombs BD; US\$100,000; 2009-2010).
 - FRQ-S. Operating Grant. *Development and validation of an integrated system to evaluate fatigue in systemic sclerosis* (PI Thombs BD; \$217,160; 2008-2011).

- FRQ-S. Startup Funding. *Patient-reported outcomes in scleroderma* (PI Thombs BD; \$45,000; 2008-2011).
- Canadian Breast Cancer Research Alliance. Developmental and Exploratory Grant. *Depression screening in cancer: systematic review and recommendations for research and practice* (PI Thombs BD; \$50,000; 2009-2010).
- CIHR. Operating Grant. *Evaluation of a self-management program for scleroderma: Predictors of participation, attrition and beneficial health outcomes* (PI Thombs BD; \$78,317; 2008-2009).

H.2.5. Past Grants as Co-Investigator

- World Scleroderma Foundation. Research Grant Programme. *Patient decision aides for stem cell transplants in systemic sclerosis* (PI Kwakkenbos L, €29,887, 2018-2019).
- CIHR. Personalized Health Catalyst Grant. *Postpartum depression Action toward Causes and Treatment (PACT) - Canada: Predictive Analytic Models of Postpartum Depression Risk* (PI Vigod S, \$200,000, 2017-2019).
- CIHR. Catalyst Grant. Population Health Intervention Research on Legalization of Cannabis. *Legalization of Recreational Cannabis Use in Canada: a Knowledge Synthesis*. (PI Eisenberg M, \$99,998, 2017-2018).
- Canadian Institute for Outcomes in Rheumatology Care. *Bringing Patients and Therapies Together Sooner: Building Clinical Trial Capacity in Myositis to Facilitate Early Access to Treatments and Improved Outcomes* (PI Hudson M, \$120,000, 2017-2019).
- Edith Strauss Grants. McGill University School of Physical & Occupational Therapy. *Scoping Reviews to Inform Telehealth Rehabilitation of Scleroderma Hands* (PIs Kwakkenbos L & Ahmed S, \$10,000, 2017-2018).
- Rare Disease Foundation. Microgrant Program. *Illuminating the experience of caring for a patient with scleroderma through focus groups* (PI Rice DB; \$3,467, 2016).
- Rare Disease Foundation. Microgrant Program. *Illuminating the scleroderma support group experience through qualitative interviews* (PI Delisle VC; \$3,420, 2015).
- CIHR. Operating Grant. *Secondary prevention of melanoma through early detection via skin self-examination: A mixed-methods study of psychosocial barriers and facilitators of long-term adherence to medical advice* (PI Körner A; \$92,478, 2014-2016).
- CIHR. Knowledge Synthesis and Exchange Grant. *The Clinical, Regulatory, and Ethical Implications of Electronic Cigarettes: A Knowledge Synthesis Grant* (PI Eisenberg M; \$100,000, 2014-2015).
- Rare Disease Foundation. Microgrant Program. *Testing the Feasibility of the Changing Faces Practitioner Training Program for Scleroderma Patients* (PI Jewett LR; \$3,500, 2014).
- Children & Violence Evaluation Challenge Fund. *Families First Home Visiting Program* (PI Ruiz-Casares M; €128,530, 2013-2015).
- FRQ-S. Operating Grant. *Réduction de la mortalité liée aux melanomes chez les patients à risque: les facteurs facilitant et réduisant l'adhérence à un protocole d'auto-examen de la peau* (PI Koerner A; \$172,547, 2011-2014).
- CIHR. Operating Grant. *Assessment of a Drama Workshop Program for Immigrant and Refugee Adolescents* (PI Rousseau C; \$389,781, 2011-2014).
- US NIH. Research Project Grant Program (R01). *Mechanisms of Platelet Activation in Depression and Acute Coronary Syndromes* (PI Williams M; US\$2,050,000, 2010-2015).
- CIHR. Centre for Research Development Grant. *Centre for research development in gender, mental health and violence across the lifespan* (PIs MacMillan HL, Stewart D, Wathen CN, Coben J, Herrman H; \$2,000,000, 2009-2014).
- CIHR. Emerging Team Grant. *CIHR team in perinatal mental health* (PIs Gold IJ, Groleau D, Zelkowitz P; \$947,600, 2009-2013).
- CIHR. Strategic Training in Health Research Initiative. *Strategic training initiative: The Canadian Scleroderma Research Group* (PIs Baron M, Leask AC, Mort JS, Philip A, Pope JE; \$1,800,000, 2007-2013).
- CIHR. Emerging Team Grant. *New and emerging team: The Canadian Scleroderma Research Group* (PIs Baron M, Philip A, Pope JE; \$895,865, 2007-2012).

- FRQ-S. Team Grant. *Écoles, culture et santé mentale: une articulation à repenser dans une société en transformation* (PI Rousseau C; \$405,000, 2009-2012).
- Ride to Conquer Cancer Research Fund, Jewish General Hospital Foundation. *Understanding psychological core issues and coping patterns in reaction to melanoma and skin self-examination: a mixed-methods approach* (PI Koerner, A; \$22,324, 2011-2012).
- CIHR. Operating Grant. *Parents, daughters, and the HPV vaccine: Factors affecting parental decision-making in a universal immunization program* (PI Rosberger Z; \$100,000, 2009-2010).
- Max Bell Foundation. *Creativity and prevention of mental health problems in multiethnic schools* (PI Rousseau, C; \$100,000, 2007-2009).

H.2.6. Meetings and Travel Grants as Principal Investigator

- CIHR. Planning and Dissemination Grant. *Establishing next steps for SPIN-SHARE: an international collaboration to disseminate eHealth disease-management tools for people living with scleroderma* (\$10,000, 2019-2020).
- CIHR. Planning and Dissemination Grant. *Dissemination of the CONSolidated Standards of Reporting Trials (CONSORT) statement for randomized controlled trials (RCTs) using cohorts and routinely collected health data* (\$10,000, 2018-2019).
- CIHR. Planning and Dissemination Grant. *Establishing an international collaboration to disseminate eHealth disease-management tools for people living with scleroderma* (\$10,000, 2017-2018).
- CIHR. Planning Grant. *Supporting peer supporters: planning the development and testing of a training program for peer facilitators of scleroderma support groups* (2015, \$10,000).
- CIHR. Planning Grant. *The Scleroderma Patient-centered Intervention Network (SPIN) feasibility trial planning meeting* (2013, \$25,000).
- CIHR. Planning Grant. *Scleroderma Patient-centered Intervention Network (SPIN) Planning Meeting - II* (2013, \$25,000).
- CIHR. Meetings, Planning, and Dissemination Grant. *Scleroderma Patient-centered Intervention Network (SPIN) Planning Meeting* (2011, \$24,994).
- CIHR. Meetings, Planning, and Dissemination Grant. *Consortium for clinical trials of behavioral, psychological, and educational interventions in scleroderma; Initial planning meeting* (2010, \$18,880).
- Sclérodermie Québec. Research Support Program. *Consortium for clinical trials of behavioral, psychological, and educational interventions in scleroderma; Initial planning meeting* (2010, \$8,000).
- CIHR. Meetings, Planning, and Dissemination Grant. *Joint Patient – Researcher Meeting to Interpret and Plan for Dissemination of Patient Survey Results* (2009, \$11,240).
- CIHR. Meetings, Planning, and Dissemination Grant. *Evaluating evidence for detection and treatment of mental health problems in medical settings: Developing a “user’s guide” for behavioral health professionals and a collaborative behavioral health research agenda* (2009, \$14,497).
- CIHR. Institute of Health Services and Policy Research, Institute Community Support Program, New Investigator Travel Award. *Symposium on screening for major depressive disorder in cardiovascular care* (2009, \$2,150).
- CIHR. Meetings, Planning, and Dissemination Grant. *Improving health and well-being in scleroderma: Developing a collaborative behavioural health research agenda* (2008, \$18,454).

H.3. Publications²

H.3.1. Articles in Peer-Reviewed Journals: Submitted or in Revision

1. Sun Y, Wu Y, Bonardi O, Krishnan A, He C, Boruff JT, Rice DB, Wang Y, Jiang X, Li K, Markham S, Levis B, Azar M, Thombs-Vite I, Dal Santo T, Tasleem A, Yao A, Agic B, Fahim C, Martin MS, Sockalingam S, Turecki G, Benedetti A, **Thombs BD***. Comparison of mental health symptoms prior to and during COVID-19: evidence from a living systematic review and meta-analysis. *BMJ*.

² Names of supervised trainees are underlined and in bold and highly-trained research staff are underlined (not bold) in this and subsequent sections. Publications as corresponding or supervising author or principal investigator are indicated by *.

2. Effects of COVID-19 mental health interventions among community-based children, adolescents, and adults: a living systematic review of randomised controlled trials. *Lancet Public Health*.
3. **Bonardi O**, Wang Y, Li K, Jiang X, Krishnan A, He C, Sun Y, **Wu Y**, Boruff JT, Markham S, **Rice DB**, Thombs-Vite I, **Tasleem A**, **Dal Santo T**, **Yao A**, Azar M, Agic B, Fahim C, Martin MS, Sockalingam S, Turecki G, Benedetti A, **Thombs BD***. Effects of COVID-19 mental health interventions among community-based children, adolescents, and adults: a living systematic review of randomised controlled trials. *Lancet Public Health*.
4. Ferreira RC, Torres TS, Ceccato MDGB, Bezerra DRB, **Thombs BD**, Luz PM, Harel D. Development and evaluation of short-form measures of the HIV/AIDS Knowledge Assessment tool among sexual minorities in Brazil. *HIV Behav*.
5. Le Ralle MF, Daste C, Rannou F, Kwakkenbos L, **Carrier ME**, Lefèvre-Colau MM, Roren A, **Thombs BD**, Mouthon L, Nguyen C. Patient acceptable symptom state for burden from appearance changes in people with systemic sclerosis: a cross-sectional survey. *Semin Arthritis Rheum*.
6. **López Malo Vázquez de Lara A**, **Bhandari PM**, **Wu Y**, **Levis B**, **Thombs BD***, Benedetti A, DEPRESSsion Screening Data (DEPRESSD) PHQ-9 Collaboration. Prediction regions as a visual representation of heterogeneity: Illustration in an individual participant data meta-analysis of the screening accuracy of the PHQ-9 to detect major depression. *BMC Med Res Methodol*.
7. Kwakkenbos L, **Carrier ME**, Welling J, **Turner KA**, **Cumin J**, **Pépin M**, van den Ende C, Schouffoer AA, Hudson M, van Breda W, Sauve M, Nguyen C, Boutron I, Rannou F, **Thombs BD***, Mouthon L, **SPIN Investigators**. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND). *PeerJ*.
8. Kwakkenbos L, **Østbo N**, **Carrier ME**, Nielson WR, **Fedoruk C**, Nielsen K, **Milette K**, **Levis B**, **Henry RS**, Pope J, Frech T, Gholizadeh S, Hummers LK, Johnson SR, Piotrowski P, **Jewett L**, Gordon J, Chung L, Bilsker D, **Tao L**, **Turner KA**, **Cumin J**, Welling J, Fortune C, Leite C, Gottesman K, Sauve M, Rodriguez Reyna TS, Hudson M, Larche M, van Breda W, Suarez-Almazor M, Bartlett SJ, Malcarne VL, Mayes MD, Boutron I, Mouthon L, Benedetti A, **Thombs BD***, **SPIN Investigators**. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. *Pilot Feasibility Stud*.
9. Cuijpers P, Miguel C, Ciharova M, Karyotaki E, Noma H, **Thombs BD**, Furukawa TA. Response and remission in care-as-usual, waiting lists and pill placebo conditions in psychotherapy trials for depression: A meta-analysis. *Psychol Med*.
10. Kirren Q, Daste C, Foissac F, Abdoul H, Papelard A, Alami S, Kwakkenbos L, **Carrier ME**, Roren A, Lefèvre-Colau MM, Poiraudreau S, Rannou F, **Thombs BD**, Mouthon L, Nguyen C. Disability perception in systemic sclerosis: a mirror International Classification of Functioning, Disability and Health (ICF)-based survey of 109 patients and 105 health care providers. *J Am Acad Dermatol*.
11. Torres TS, Luz PM, Bezerra DRB, Almeida-Brasil CC, Marins LMS, Veloso VG, Grinsztejn B, Harel D, **Thombs BD**. Translation and validation in Brazilian Portuguese of the Reactions to Homosexuality Scale. *Psychol Health Med*.
12. **Negeri ZF**, **Levis B**, Sun Y, He C, Krishnan A, **Wu Y**, **Bhandari PM**, **Neupane D**, **Brehaut E**, Benedetti A, **Thombs BD***, **DEPRESSD PHQ Group**. Accuracy of the Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: an updated systematic review and individual participant meta-analysis. *BMJ*.
13. Becetti K, Nguyen J, Kwakkenbos L, **Carrier ME**, **Tao L**, Gordon JK, Mancuso C, Welling J, Mouthon L, Bartlett SJ, Malcarne V, **Thombs BD***, Spiera R, **SPIN Investigators**. Mental health care utilization and associated factors in systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study. *ACR Open Rheumatol*.
14. **Østbo N**, Yakes Jimenez E, **Harb S**, Bourgeault A, **Carrier ME**, **Thombs BD***, Scleroderma Patient centered Intervention Network (SPIN) Diet and Nutrition Education Patient Advisory Team. Nutrition information resources used by people with systemic sclerosis and perceived advantages and disadvantages: a nominal group technique study. *ACR Open Rheumatol*. Revision requested.
15. **Tao L**, **Carboni-Jiménez A**, **Turner K**, **Østbo N**, **Aguila K**, Boruff J, Krishnan A, Ahmed S, **Thombs BD***, Kwakkenbos L. Perceived barriers and facilitators of using synchronous telerehabilitation of physical and occupational therapy in musculoskeletal disorders. *Disabil Rehabil*. Revision requested.

16. **Carboni-Jiménez A, Rice DB, Levis B, Cañedo-Ayala M, Imran M, Chiovitte M, Benedetti A, Thombs BD***. Intensity of care and perceived burden among informal caregivers to persons with chronic medical conditions: a systematic review and meta-analysis. *Disabil Rehabil*. Revision requested.
17. Wojeck RK, Silva SG, Bailey DE, Knisely MR, Kwakkenbos L, **Carrier ME**, Nielson WR, Bartlett SJ, Pope J, **Thombs BD***, and the **SPIN Investigators**. Pain and self-efficacy among patients with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *Nurs Res*. Revision submitted.
18. Mc Cord KA, Imran M, **Rice DB**, McCall S, Kwakkenbos L, Sampson M, Fröbert O, Gale C, Langan SM, Moher D, Relton C, Zwarenstein M, Juszczak E, **Thombs BD***, Hemkens LG, **CONSORT Extension for Trials Conducted in Cohorts and Routinely Collected Health Data Group**. Reporting of randomized trials using registries was often inadequate and hindered interpretation of results. *J Clin Epidemiol*. Revision submitted.
19. **Thombs BD**, Markham S, **Rice DB**, Ziegelstein RC. Does depression screening improve mental health outcomes? *BMJ*. Revision submitted.
20. Imran M, Mc Cord KA, McCall S, Kwakkenbos L, Sampson M, Fröbert O, Gale C, Hemkens LG, Langan SM, Moher D, Relton C, Zwarenstein M, Juszczak E, **Thombs BD***, **CONSORT Extension for Trials Conducted in Cohorts and Routinely Collected Health Data Group**. Trials conducted using administrative databases do not adequately report elements related to use of databases. *J Clin Epidemiol*. Revision submitted.
21. Ruiz-Casares M, **Thombs BD**, Mayo N, Andrina M, Scott S, Platt RW. The Families First program to prevent child abuse: results of a cluster randomized controlled trial in West Java, Indonesia. *Prev Sci*. Revision submitted.
22. McCall S, Imran M, Hemkens LG, Mc Cord KA, Kwakkenbos L, Sampson M, Jawad S, Zwarenstein M, Relton C, Langan SM, Moher D, Fröbert O, **Thombs BD***, Gale C, Juszczak E, **CONSORT Extension for Trials Conducted in Cohorts and Routinely Collected Health Data Group**. Completeness and transparency of reporting of randomised controlled trials conducted using electronic health records – room for improvement. *J Clin Epidemiol*. Revision submitted.

H.3.2. Articles in Peer-Reviewed Journals: Published or Accepted for Publication³

In press

1. Luz PM, Jalil EM, Castilho J, Velasque L, Ramos M, Ferreira ACG, Ferreira AL, Wilson EC, Veloso VG, **Thombs BD**, Moodie EM, Grinsztejn B. Role of discrimination, violence and resilience on depression symptoms among transgender women in Rio de Janeiro, Brazil. *Transgend Health*. [IF=N/A].
2. **Discepolo MN, Carboni-Jiménez A**, Kwakkenbos L, **Henry RS**, Boruff J, Krishnan A, Boström C, Culos-Reed SN, Hudson M, Leader DM, Mattsson M, Mouthon L, Wojeck R, Yakes Jimenez E, Sauve M, Welling J, Guillot G, Benedetti A, **Thombs BD***. Effects of Nonpharmacological and Nonsurgical Interventions on Health Outcomes in Systemic Sclerosis: Protocol for A Living Systematic Review. *BMJ Open*. [IF=2.5].
3. **Wu Y, Levis B**, Sun Y, Krishnan A, **Neupane D, Bhandari PM, Negeri Z**, Benedetti A, **Thombs BD***, **DEPRESSD HADS Group**. Accuracy of the Hospital Anxiety and Depression Scale Depression Subscale (HADS-D) to screen for major depression: systematic review and individual participant meta-analysis. *BMJ*. [IF=30.2].
4. **Neupane D, Levis B, Bhandari PM, Thombs BD***, Benedetti A, **DEPRESSsion Screening Data (DEPRESSD) Collaboration**. Selective cutoff reporting in studies of the accuracy of the PHQ-9 and EPDS depression screening tools: comparison of results based on published cutoffs versus all cutoffs using individual participant data meta-analysis. *Int J Methods Psychiatr Res*. [IF=2.3].
5. **Thombs BD***, Kwakkenbos L, **Levis B**, Bourgeault A, **Henry RS, Levis AW, Harb S, Tao L, Carrier ME**, Bustamante L, Duchek D, Dyas L, El-Baalbaki G, Ellis K, **Rice DB**, Wurz A, **Nordlund J**,

³ Impact factors are the most recent published impact factor prior to the year of publication in this and subsequent sections (e.g., 2008 impact factor for articles published in 2008-2009).

- Gagarine M, Turner KA, Østbø N**, Culos-Reed N, Hebblethwaite S, Patten S, Bartlett SJ, Varga J, Mouthon L, Markham S, Martin MS, Benedetti A, and the SPIN-CHAT Patient Advisory Team and Program Facilitators on behalf of the Scleroderma Patient-centered Intervention Network Investigators. Effects of a multi-faceted education and support program on anxiety symptoms among people with systemic sclerosis with at least mild anxiety during COVID-19: a two-arm parallel partially nested randomised controlled trial. *Lancet Rheumatol*. [IF=N/A]. [Link](#)
6. **Bhandari PM, Levis B, Neupane D**, Patten SB, Shrier I, **Thombs BD***, Benedetti A, **DEPRESSsion Screening Data (DEPRESSD) EPDS Collaboration**. Data-driven methods distort optimal cutoffs and accuracy estimates of depression screening tools: a simulation study using individual participant data. *J Clin Epidemiol*. [IF=5.0]. [Link](#)
 7. **Harb S**, Peláez S, **Carrier ME**, Kwakkenbos L, Bartlett SJ, Hudson M, Mouthon L, Sauvé M, Welling J, Shrier I, **Thombs BD***, SPIN Physical Activity Enhancement Patient Advisory Team, SPIN Investigators. Barriers and facilitators to physical activity for people with scleroderma: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *Arthritis Care Res*. [IF=4.1]. [Link](#)
 8. Fischer F, **Levis B**, Falk C, **Sun Y**, Ioannidis JPA, Cuijpers P, Shrier I, Benedetti A, **Thombs BD***, **Depression Screening Data (DEPRESSD) PHQ Collaboration**. Comparison of different scoring methods based on latent variable models of the PHQ-9: an individual participant data meta-analysis. *Psychol Med*. [IF=5.6]. [Link](#)
 9. **Coroiu A**, Moran C, Kwakkenbos L, **Thombs BD**, Körner A. Validation of the Knowledge about Melanoma Early Detection Scale in a sample of melanoma survivors. *Curr Psychol*. [IF=2.1]. [Link](#)
 10. **Harb S**, Cumin J, **Rice DB**, Peláez S, Hudson M, Bartlett SJ, Roren A, Furst DE, Frech TM, Nguyen C, Nielson WR, **Thombs BD***, Shrier I, SPIN-PACE Patient Advisory Team. Identifying barriers and facilitators to physical activity for people with scleroderma: A nominal group technique study. *Disabil Rehabil*. [IF=2.2]. [Link](#)
 11. McGrath S, Zhao X, Steele R, **Thombs BD***, Benedetti A, **DEPRESSsion Screening Data (DEPRESSD) Collaboration**. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. *Stat Methods Med Res*. [IF=2.3]. [Link](#)
 12. **Kwakkenbos L, Carboni-Jiménez A, Carrier ME, Pépin M, Peláez S, Malcarne VL, El-Baalbaki G, Thombs BD***, **Scleroderma Patient-centered Network (SPIN) Support Group Project Advisory Team**. Reasons for not participating in scleroderma support groups: a comparison of results from the North American and European Scleroderma Support Group Surveys. *Disabil Rehabil*. [IF=2.2]. [Link](#)

2020-2021

13. Kwakkenbos L, **Imran M**, McCall S, Mc Cord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DM, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, **Thombs BD***. CONSORT Extension for the Reporting of Randomised Controlled Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE): checklist with explanation and elaboration. *BMJ*. 2021;373:n857. [IF=30.2].
14. **Imran M**, Kwakkenbos L, McCall S, Mc Cord KA, Fröbert O, Hemkens LG, Zwarenstein M, Relton C, Rice DM, Langan SM, Benchimol EI, Thabane L, Campbell MK, Sampson M, Erlinge D, Verkooijen HM, Moher D, Boutron I, Ravaud P, Nicholl J, Uher R, Sauvé M, Fletcher J, Torgerson D, Gale C, Juszczak E, **Thombs BD***. Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for Trials Conducted Using Cohorts and Routinely Collected Data (CONSORT-ROUTINE). *BMJ Open*. 2021;049093. [IF=2.5].
15. Moore A, Traversy G, Reynolds D, Riva J, Theriault G, Wilson B, Subnath M, **Thombs BD***, **Canadian Task Force on Preventive Health Care**. Recommendations on screening for chlamydia and gonorrhea in primary care for individuals not known to be at high risk. *CMAJ* 2021;193:E549-E559. [IF=7.7]. [Link](#)
16. Torres TS, Luz PM, Marins LMS, Bezerra DRB, Almeida-Brasil CC, Veloso VG, Grinsztejn B, Harel D, **Thombs BD**. Cross-cultural adaptation of the Perceived Risk of HIV Scale in Brazilian Portuguese. *Health Qual Life Out*. 2021;19:117. [IF=2.3]. [Link](#)

17. Windle SB, Sequeira C, Filion KB, **Thombs BD**, Reynier P, Grad R, Ells C, Eisenberg MJ. Impaired driving and the legalization of recreational cannabis. *CMAJ*. 2021;193(14):E481-E485. [IF=7.7]. [Link](#)
18. **Lyubenova A, Neupane D, Levis B, Wu Y, Sun Y, He C, Krishnan A, Bhandari PM, Negeri Z, Imran M, Rice DB, Azar M**, Chiovitti MJ, Saadat N, Riehm KE, Boruff JT, Ioannidis JPA, Cuijpers P, Gilbody S, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Comeau L, Mitchell ND, Tonelli M, Vigod SN, Aceti F, Barnes J, Bavle AD, Beck CT, Bindt C, Boyce PM, Bunevicius A, Chaudron LH, Favez N, Figueiredo BFC, Garcia-Esteve L, Giardinelli L, Helle N, Howard LM, Kohlhoff J, Kusminskas L, Kozinszky Z, Lelli L, Leonardou AA, Meuti V, Nakić Radoš S, Navarro García P, Pawlby SJ, Quispel C, Robertson-Blackmore E, RoCHAT TJ, Sharp DJ, Siu BWM, Stein A, Stewart RC, Tadinac M, Tandon SD, Tendais I, Töreki A, Torres-Giménez A, Tran TD, Trevillion K, Turner K, Vega-Dienstmaier JM, Benedetti A, **Thombs BD***. Depression prevalence based on the EPDS compared to Structured Clinical Interview for DSM classification: systematic review and individual participant data meta-analysis. *Int J Methods Psychiatr Res*. 2021;30(1):e1860. [IF=2.3]. [Link](#)
19. Windle SB, Eisenberg MJ, Reynier P, Cabaussel J, **Thombs BD**, Grad R, Ells C, Sequeira C, Filion KB. The association between the legalization of recreational cannabis and fatal motor vehicle collisions in the United States: an ecologic study. *CMAJ Open*. [N/A]. 2021;9(1):E233-E241. [Link](#)
20. Harel D, **Levis B**, Ishihara M, **Levis AW**, Vigod SN, Howard LM, **Thombs BD***, Benedetti A, **DEPRESSION Screening Data (DEPRESSD) EPDS Collaboration**. Shortening the Edinburgh Postnatal Depression Scale (EPDS) using Optimal Test Assembly Methods: Development of the EPDS-Dep-5. *Acta Psychiatr Scand*. 2021;143(4):348-362. [IF=5.4]. [Link](#)
21. Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, Hopewell S, Hunt HA, Hyde CJ, Leflang MM, Macaskill P, McGrath TA, Moher D, Rietsma JB, Rutjes AWS, Takwoingi Y, Tonelli M, Whiting P, Willis BH, **Thombs BD***, Bossuyt P, McInnes MDF. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. *BMJ*. [IF=30.2]. 2021;372:n265. [Link](#)
22. **Gholizadeh S, Rice DB, Carboni-Jiménez A**, Kwakkenbos L, Boruff J, Malcarne VL, **Thombs BD***, Scleroderma Patient-centered Intervention Network (SPIN) Body Image Patient Advisory Team. Effects of cosmetic and other camouflage interventions on appearance-related and psychological outcomes among adults with visible differences: a systematic review. *BMJ Open*. 2021;11:e046634. [IF=2.5]. [Link](#)
23. Wennberg E, Lasry A, Windle SB, Filion KB, **Thombs BD**, Gore G, Fischer B, Eisenberg MJ. Non-medical cannabis use among Indigenous Canadians: A systematic review of prevalence and associated factors. *Int J Drug Policy*. 2021;90:103081. [IF=4.2]. [Link](#)
24. Pottie K, Magwood O, Rahman P, Concannon T, Alonso-Coello P, Jaramillo Garcia A, Santesso N, **Thombs BD**, Welch V, Wells GA, Saad A, Archibald D, Grad R, Moore A, Ximena Rojas M, Lorio A, Pinto N, Doull M, Morton R, Akl EA, Schünemann HJ, Tugwell P. Validating the “FACE” instrument using stakeholder perceptions of Feasibility, Acceptability, Cost, and Equity in guideline implementation. *J Clin Epidemiol*. 2021;131:133-140. [IF=5.0]. [Link](#)
25. **Wu Y, Levis B**, Ioannidis JPA, Benedetti A, **Thombs BD***, **DEPRESSD Collaboration**. Probability of major depression classification based on the SCID, CIDI and MINI diagnostic interviews: a synthesis of three individual participant data meta-analyses. *Psychother Psychosom*. 2021;90(1):28-40. [IF=14.9]. [Link](#)
26. Beck A, LeBlanc JC, Morissette K, Hamel C, Skidmore B, Colquhoun H, Eddy L, Moore A, Riva JJ, **Thombs BD**, Patten S, Bragg H, Colman I, Goldfield GS, Nicholls SG, Pajer K, Potter BK, Meeder R, Vasa P, Hutton B, Shea BJ, Graham E, Little J, Moher D, Stevens A. Screening for depression in children and adolescents: a protocol for a systematic review update. *Syst Rev*. 2021;10:24. [IF=2.5]
27. Pillay J, Riva JJ, Tessier LA, Colquhoun H, Lang E, Moore AE, **Thombs BD**, Wilson BJ, Tzenov A, Donnelly C, Émond M, Holroyd-Leduc J, Milligan J, Keto-Lambert D, Rahman S, Vandermeer B, Tricco AC, Straus SE, Thomas SM, Mitchelmore BR, Rolland-Harris E, Hartling L. Falls prevention interventions for older community-dwelling adults: protocol for systematic reviews on effectiveness and patient values and preferences. *Syst Rev*. 2021;10:18. [IF=2.5]. [Link](#)
28. Traversy G, Barnieh L, Akl E, Allen M, Brouwers M, Ganache I, Guyatt GH, Grundy Q, Kelsall D, Leng G, Moore A, Persaud N, Shunemann HJ, Straus S, **Thombs BD**, Rodin R, Tonelli C. Conflicts

of interest and health guidelines: practical guidance for developers. *CMAJ*.

2021;193(2):E49-E54. [IF=7.7]. [Link](#)

29. Gates A, Pillay J, Reynolds D, Stirling R, Traversy G, Korownyk C, Moore A, Thériault G, **Thombs BD**, Little J, Popadiuk C, van Niekirk D, Keto-Lambert D, Vandermeer B, Hartling L. Screening for cervical cancer: protocol for systematic reviews to inform Canadian recommendations. *Syst Rev*. 2021;10:2. [IF=2.5]. [Link](#)
30. Lawson DO, Puljak L, Pieper D, Schandelmaier S, Collins GS, Brignardello-Petersen R, Moher D, Tugwell P, Welch V, Samaan Z, **Thombs BD**, Nørskov AK, Jakobsen JC, Allison DB, Mayo-Wilson E, Young T, Chan AW, Ioannidis JPA, Guyatt G, Thabane L, Mbuagbaw L. Complete and transparent reporting of methodological studies in health research: a protocol for the development of the METHodological study Reporting Checklist (METRIC). *BMJ Open*. 2020;10:e040478. [IF=2.5]. [Link](#)
31. **Wu Y**, Kwakkenbos L, **Henry RS**, Carrier ME, **Gagarine M**, **Harb S**, Bourgeault A, Tao L, **Carboni-Jiménez A**, **Negeri Z**, Patten S, Bartlett SJ, Mouthon L, Varga J, Benedetti A, **Thombs BD***, SPIN Patient Advisors and **SPIN Investigators**. Factors associated with fears due to COVID-19: a Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Cohort study. *J Psychosom Res*. 2021;140:110314. [IF=2.9]. [Link](#)
32. Benedetti A, **Levis B**, Rücker G, Jones HE, Schumacher M, Ioannidis JPA, **Thombs BD***, **DEPRESSD Collaboration**. An empirical comparison of three methods for multiple cut-off diagnostic test meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) depression screening tool using published data versus individual level data. *Res Synth Methods*. 2020;11(6):833-848. [IF=5.3]. [Link](#)
33. **Thombs BD***, **Levis B**, **Lyubenova A**, **Neupane D**, **Negeri Z**, **Wu Y**, **Sun Y**, **He C**, Krishnan A, Vigod SN, **Bhandari PM**, Imran M, **Rice DB**, **Azar M**, Chiovitti MJ, Saadat N, Riehm KE, Boruff JT, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Comeau L, Mitchell ND, Tonelli M, Barnes J, Beck CT, Bindt C, Figueiredo BFC, Helle N, Howard LM, Kohlhoff J, Kozinszky Z, Leonardou AA, Nakić Radoš S, Quispel C, Rochat TJ, Stein A, Stewart RC, Tadinac M, Tandon SD, Tendais I, Töreki A, Tran TD, Trevillion K, Turner K, Vega-Dienstmaier JM, Benedetti A. Overestimation of postpartum depression prevalence based on a 5-item version of the EPDS: systematic review and individual participant data meta-analysis. *Can J Psychiatry*. 2020;65(12):835-844. [IF=3.3]. [Link](#)
34. **Cañedo-Ayala M**, **Rice DB**, **Levis AW**, **Chiovitti M**, **Thombs BD***. Balance of Group Sizes in Randomized Controlled Trials Published in APA Journals. *Health Psychol*. 2020;39(11):956-965. [IF=3.1]. [Link](#)
35. **Levis B**, **Negeri Z**, **Sun Y**, Benedetti A, **Thombs BD***, **DEPRESSD Collaboration**. Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: an individual participant data meta-analysis. *BMJ*. 2020;371:m4022. [IF=30.2]. [Link](#)
36. **Wu Y**, **Levis B**, **Riehm KE**, **Saadat N**, **Levis AW**, **Azar M**, **Rice DB**, Boruff J, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, Baron M, Bombardier CH, Butterworth P, Carter G, Chagas MH, Chan JCN, Cholera R, Conwell Y, de Man-van Ginkel JM, Fann JR, Fischer FH, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Harrison PA, Härter M, Hegerl U, Hides L, Hobfoll SE, Hudson M, Hyphantis T, Inagaki M, Jetté N, Khamseh ME, Kiely KM, Kwan Y, Lamers F, Liu S-I, Lotrakul M, Loureiro SR, Löwe B, McGuire A, Mohd-Sidik S, Munhoz TN, Muramatsu K, Osório FL, Patel V, Pence BW, Persoons P, Picardi A, Reuter K, Rooney AG, Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford L, Sung S, Tan PLL, Turner A, van Weert HC, White J, Whooley MA, Winkley K, Yamada M, Benedetti A, **Thombs BD***. Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. *Psychol Med*. 2020;50:1368-1380. [IF=8.4]. [Link](#)
37. **Wu Y**, Kwakkenbos L, **Henry RS**, Tao L, **Harb S**, Bourgeault A, Carrier ME, **Levis B**, **Sun Y**, **Bhandari PM**, **Carboni-Jiménez A**, **Gagarine M**, He C, Krishnan A, **Negeri Z**, **Neupane D**, Bartlett S, Benedetti A, **Thombs BD***, Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Investigators,¹² SPIN COVID-19 Patient Advisory Team. Validation of the COVID-19 Fears

- Questionnaires for Chronic Medical Conditions: a Scleroderma Patient-centered Intervention Network COVID-19 Cohort Study. *J Psychosom Res.* 2020;139:110271. [IF=2.9]. [Link](#)
38. Singh S, Windle SB, Filion KB, **Thombs BD**, O'Loughlin JL, Grad R, Eisenberg MJ. E-cigarettes and youth: Patterns of use, potential harms, and recommendations. *Prev Med.* 2020;133:106009. [IF=3.8]. [Link](#)
 39. Sommer SJ, Harel D, Kwakkenbos L, Carrier ME, Gholizadeh S, Gottesman K, Malcarne V, **Thombs BD***, **SPIN Investigators**. Assessing Differential Item Functioning for the Social Appearance Anxiety Scale A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *BMJ Open.* 2020;10:e037639. [IF=2.5]. [Link](#)
 40. Brehaut E, Neupane D, Levis B, Wu Y, Sun Y, Krishnan A, He C, Bhandari PM, Negeri Z, Riehm KE, Rice DB, Azar M, Yan XW, Imran M, Chiovitti MJ, Saadat N, Cuijpers P, Ioannidis JPA, Markham S, Patten SB, Ziegelstein R, Henry M, Ismail Z, Loiselle CG, Mitchell ND, Tonelli M, Boruff JT, Kloda LA, Beraldi A, Braeken APBM, Carter G, Clover K, Conroy RM, Cukor D, da Rocha e Silva CE, De Souza J, Downing MG, Feinstein A, Ferentinos PP, Fischer FH, Flint AJ, Fujimori M, Gallagher P, Goebel S, Jetté N, Julião M, Keller M, Kjærgaard M, Love AW, Löwe, B, Martin-Santos R, Michopoulos I, Navines R, O'Rourke SJ, Öztürk A, Pintor L, Ponsford JL, Rooney AG, Sánchez-González R, Schwarzbald ML, Sharpe M, Simard S, Singer S, Stone J, Tung K, Turner A, Walker, J, Walterfang M, White J, Benedetti A, **Thombs BD***. Depression prevalence using the HADS-D compared to SCID major depression classification: an individual participant data meta-analysis. *J Psychosom Res.* 2020;139:110256. [IF=2.9]. [Link](#)
 41. **Thombs BD***, Kwakkenbos L, Henry RS, Carrier ME, Patten S, Harb S, Bourgeault A, Tao L, Bartlett SJ, Mouthon L, Varga J, Benedetti A, SPIN Patient Advisors, SPIN Investigators. Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *J Psychosom Res.* 2020;139:110262. [IF=2.9]. [Link](#)
 42. Daste C, Abdoul H, Foissac F, Papelard A, Alami S, Kwakkenbos L, Carrier ME, Lefèvre-Colau M-M, **Thombs B**, Poiraudau S, Rannou F, Mouthon L, Nguyen C. Development of a new patient-reported outcome measure to assess activities and participation in people with systemic sclerosis: The Cochin 17-item Scleroderma Functional Scale. *Br J Dermatol.* 2020;183(4):710-718. [IF=7.0]. [Link](#)
 43. Luz PM, Torres TS, Almeida-Brasil CC, Marins LMS, Bezerra DRB, Veloso VG, Grinsztejn B, Harel D, **Thombs BD**. Translation and validation of the Short HIV Stigma Scale in Brazilian Portuguese. *Health Qual Life Out.* 2020;18:322 [IF=2.4]. [Link](#)
 44. Rice DB, Carboni-Jiménez A, Cañedo-Ayala M, Turner KA, Chiovitti M, Levis AW, **Thombs BD***. Demonstrated and perceived benefits and factors that influence the ability to establish and maintain services for informal caregivers of people with rare diseases: a scoping review. *The Patient - Patient-Centered Outcomes Research.* 2020;13(5):471-519. [IF=3.2]. [Link](#)
 45. Salameh JP, Bossuyt PM, McGrath TA, **Thombs BD***, Hyde CJ, Macaskill P, Deeks JJ, Leeflang M, Korevaar DA, Whiting P, Takwongi Y, Reitsma JB, Cohen JF, Frank RA, Hunt HA, Hooft L, Rutjes AWS, Willis BH, Gatsonis C, Levis B, Moher D, McInnes MDF. The Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy studies (PRISMA-DTA): Explanation and Elaboration. *BMJ.* 2020;370:m2632. [IF=30.2]. [Link](#)
 46. Rice DB, Cañedo-Ayala M, Carboni-Jiménez A, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, **Thombs BD***, Scleroderma Caregiver Advisory Team. Challenges and support service preferences of informal caregivers of people with systemic sclerosis: A cross-sectional survey. *Disabil Rehabil.* 2020;42(16):2304-2310. [IF=2.2]. [Link](#)
 47. Groulx S, Limburg H, Doull M, Klaranbach S, Singh H, Wilson B, **Thombs BD***, **Canadian Task Force on Preventive Health Care**. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease without alarm symptoms. *CMAJ.* 2020;192:E768-E777. [IF=7.7]. [Link](#)

2019-2020

48. Milette K, **Thombs BD***, Dewez S, Körner A, Peláez S. Scleroderma patient perspectives on social support from close social relationships. *Disabil Rehabil.* 2020;42(11):1588-1598. [IF=2.2]. [Link](#)

49. **Thombs BD***, Kwakkenbos L, Carrier, ME, Bourgeault A, Tao L, **Harb S**, **Gagarine M**, **Rice D**, Bustamante L, Ellis K, Duchek D, **Wu Y**, **Bhandari PM**, **Neupane D**, **Carboni-Jiménez A**, **Henry RS**, **Krishnan A**, **Sun Y**, **Levis B**, **He C**, **Turner KA**, Benedetti A, Culos-Reed N, El-Baalbaki G, Hebblethwaite S, Bartlett SJ, Dyas L, Patten S, Varga J, Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Patient Advisory Team, **SPIN Investigators**. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to reduce anxiety among at-risk scleroderma patients. *J Psychosom Res*. 2020;135:110132. [IF=2.9]. [Link](#)
50. **Levis B**, **Sun Y**, **He C**, **Wu Y**, **Krishnan A**, **Bhandari PM**, **Neupane D**, **Imran M**, **Brehaut E**, **Negeri Z**, Fischer FH, Benedetti A, **Thombs BD***, **Depression Screening Data (DEPRESSD) PHQ Collaboration**. Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis. *JAMA*. 2020;323(22):2290-2300. [IF=45.5]. [Link](#)
51. **Elder K**, **Turner KA**, Cosgrove L, Lexchin J, Shnier A, Moore A, Straus S, **Thombs BD***. Reporting of organizational financial conflicts of interest by producers of Canadian clinical practice guidelines: a cross-sectional study. *CMAJ*. 2020;192:E617-E625. [IF=7.7]. [Link](#)
52. **Levis B**, Benedetti A, Ioannidis JPA, Riehm KE, Saadat N, **Rice DB**, **Azar M**, Boruff J, Cuijpers P, Gilbody S, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Ayalon L, Baradaran HR, Beraldi A, Bombardier CH, Carter G, Chagas MH, Clover K, Conwell Y, Fann JR, Fischer FH, Greeno CG, Harrison PA, Ismail K, Jetté N, Khamseh ME, Kwan Y, Loureiro SR, Löwe B, Marsh L, McGuire A, Osório FL, Picardi A, Rooney AG, Sidebottom A, Tan PLL, Turner A, van Weert HC, Winkley K, Vöhringer PA, White J, **Thombs BD***. Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. *J Clin Epidemiol*. 2020;122:115-128. [IF=5.0]. [Link](#)
53. **Turner KA**, **Carboni-Jiménez A**, **Benea C**, **Elder K**, **Levis B**, Boruff J, Roseman M, Bero LA, Lexchin J, Turner EH, Benedetti A, **Thombs BD***. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. *BMJ Open*. 2020;10:e035633. [IF=2.5]. [Link](#)
54. **Azar M**, Benedetti A, Riehm KE, Imran M, Krishnan A, Chiovitti M, Sanchez T, Shrier I, **Thombs BD***. Individual Participant Data Meta-analyses (IPDMA) :Data contribution was associated with Trial Corresponding Author Country, Publication Year, and Journal Impact Factor. *J Clin Epidemiol*. 2020;124:16-23. [IF=5.0]. [Link](#)
55. **Carrier ME**, **Kwakkenbos L**, Nielson WR, **Fedoruk C**, Nielsen K, Milette K, Pope J, Frech T, **Gholizadeh S**, Hummers L, Johnson SR, Piotrowski P, **Jewett L**, Gordon J, Chung L, Bilsker D, **Turner KA**, **Cumin J**, Welling J, Fortune C, Leite C, Gottesman K, Sauve M, Rodriguez Reyna, TS, Hudson M, Larche M, van Breda W, Suarez Almazor ME, Bartlett SJ, Malcarne VL, Mayes MD, Boutron I, Mouthon L, Wigley F, **Thombs BD***, **SPIN Investigators**. The Scleroderma Patient-centered Intervention Network Self-management (SPIN-SELF) Program: Protocol for a Randomized Feasibility Trial. *JMIR Res Protoc*. 2020;9(4):e16799. [IF=N/A]. [Link](#)
56. **Coroiu A**, Moran C, Bergeron C, **Thombs BD**, Geller AC, Kingsland E, Korner A. Operationalization of skin self-examination in randomized controlled trials with individuals at increased risk for melanoma: a systematic review. *Patient Educ Couns*. 2020;103(5):1013-1026. [IF=2.6]. [Link](#)
57. **Benea C**, **Turner KA**, Roseman M, Bero LA, Lexchin J, Turner EH, **Thombs BD***. Reporting of conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017-2018 and 2009. *Syst Rev*. 2020;9:77. [IF=2.5]. [Link](#)
58. Eisenberg MJ, Habib B, Alcaraz M, **Thombs BD**, Filion KB. Bright light therapy for depressive symptoms in hospitalized cardiac patients: a randomized controlled pilot trial. *PLOS ONE*. 2020;15(3):e0230839. [IF=2.7]. [Link](#)
59. **He C**, **Levis B**, Riehm KE, Saadat N, **Levis AW**, **Azar M**, **Rice DB**, **Krishnan A**, **Wu Y**, **Sun Y**, **Imran M**, Boruff J, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, Baron M, Bombardier CH, Butterworth P, Carter G, Chagas MH, Chan JCN, Cholera R, Clover K, Conwell Y, de Man-van Ginkel JM, Fann JR, Fischer FH, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Harrison PA, Härter M, Hegerl U, Hides L, Hobfoll SE, Hudson M, Hyphantis T, Inagaki M, Ismail K, Jetté N, Khamseh ME,

- Kiely KM, Kwan Y, Lamers F, Liu S-I, Lotrakul M, Loureiro SR, Löwe B, Marsh L, McGuire A, Mohd-Sidik S, Munhoz TN, Muramatsu K, Osório FL, Patel V, Pence BW, Persoons P, Picardi A, Reuter K, Rooney AG, Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford L, Sung S, Tan PLL, Turner A, van Weert HC, White J, Whooley MA, Winkley K, Yamada M, **Thombs BD***, Benedetti A. The accuracy of the Patient Health Questionnaire-9 algorithm for screening to detect major depression: an individual participant data meta-analysis. *Psychother Psychosom*. 2020;89(1):25-37. [IF=14.9]. [Link](#)
60. **Thombs BD***, **Levis AW**, **Azar M**, Saadat N, Riehm KE, Sanchez T, Chiovitti MJ, **Rice DB**, **Levis B**, Fedoruk C, **Lyubenova A**, **López Malo Vázquez de Lara A**, Kloda LA, Benedetti A, Shrier I, Platt RW, Kimmelman J. Group sample sizes in nonregulated health care intervention trials described as randomized controlled trials were overly similar. *J Clin Epidemiol*. 2020;120:8-16. [IF=5.0]. [Link](#)
61. **Cañedo-Ayala M**, **Rice DB**, **Levis B**, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, **Thombs BD***, Scleroderma Caregiver Advisory Committee. Factors associated with symptoms of depression among informal caregivers of people with systemic sclerosis: a cross-sectional study. *Disabil Rehabil*. 2020;42(3):394-399. [IF=2.2]. [Link](#)
62. **Wu Y**, **Levis B**, Sun Y, Krishnan A, He C, Riehm KE, **Rice D**, **Azar M**, Yan XW, **Neupane D**, **Bhandari PM**, Imran M, Chiovitti MJ, Saadat N, Boruff JT, Cuijpers P, Gilbody S, McMillan D, Ioannidis J, Kloda LA, Patten S, Shrier I, Ziegelstein R, Henry M, Ismail Z, Loiselle C, Mitchell ND, Tonelli M, Al-Adawi S, Beraldi A, Braeken APBM, Büel-Drabe N, Buneviciu A, Carter G, Chen CK, Cheung G, Clover K, Conroy RM, Cukor D, da Rocha e Silva CE, Dabscheck E, Daray F, Douven E, Downing MG, Feinstein A, Ferentinos P, Fischer F, Flint A, Fujimori M, Gallagher P, Gandy M, Goebel S, Grassi L, Härter M, Jenewein J, Jette N, Julião M, Kim JM, Kim SW, Kjærgaard S, Köhler S, Loosman W, Löwe B, Martin-Santos R, Massardo L, Matsuoka Y, Mehnert A, Michopoulos I, Misery L, Navines R, O'Donnell M, Öztürk A, Peceliuniene J, Pérez L, Ponsford J, Quinn T, Reme SE, Reuter K, Rooney AG, Sánchez-González R, Schwarzbald ML, Senturk Cankorur V, Shaaban J, Sharpe L, Sharpe M, Simard S, Singer S, Stafford L, Stone J, Sultan S, Teixeira A, Tiringier I, Turner A, Walker J, Walterfang M, Wang LJ, White J, Wong D, Benedetti A, **Thombs BD***. Probability of major depression diagnostic classification based on the SCID, CIDI and MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale – Depression Subscale scores: an individual participant data meta-analysis of 73 primary studies. *J Psychosom Res*. 2020;129:109892. [IF=2.9]. [Link](#)
63. Grundy Q, Mayes C, Holloway K, Mazzarello S, **Thombs BD**, Bero L. Conflict of interest as ethical shorthand: understanding the range and nature of “non-financial conflict of interest” in biomedicine. *J Clin Epidemiol*. 2020;120:1-7. [IF=5.0]. [Link](#)
64. Lancione S, Wade K, Windle SB, Fillion KB, **Thombs BD**, Eisenberg MJ. Non-Medical cannabis in North America: an overview of regulatory approaches. *Public Health*. 2020;178:7-14. [IF=1.8]. [Link](#)
65. **Levis B**, McMillan D, Sun Y, He C, **Rice DB**, Krishnan A, **Wu Y**, **Azar M**, Sanchez TA, Chiovitti MJ, **Bhandari PM**, **Neupane D**, Saadat N, Riehm KE, Imran M, Boruff JT, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Comeau L, Mitchell ND, Tonelli M, Vigod SN, Aceti F, Alvarado R, Alvarado-Esquivel C, Bakare MO, Barnes J, Beck CT, Bindt C, Boyce PM, Bunevicius A, Couto TC, Chaudron LH, Correa H, de Figueiredo FP, Eapen V, Fernandes M, Figueiredo BFC, Fisher JRW, Garcia-Esteve L, Giardinelli L, Helle N, Howard LM, Khalifa DS, Kusminskas L, Kohlhoff J, Kozinszky Z, Lelli L, Leonardou AA, Lewis BA, Maes M, Meuti V, Nakić Radoš S, Navarro García P, Nishi D, Robertson-Blackmore E, RoCHAT TJ, Rowe HJ, Siu BWM, Skalkidou A, Stein A, Stewart RC, Su KP, Sundström-Poromaa I, Tadinac M, Tandon SD, Tendais I, Thiagayson P, Töreki A, Torres-Giménez A, Tran TD, Trevillion K, Turner K, Vega-Dienstmaier JM, Wynter K, Yonkers KA, Benedetti A, **Thombs BD***. Comparison of major depression diagnostic classification probability using the SCID, CIDI and MINI diagnostic interviews among women in pregnancy or postpartum: An individual participant data meta-analysis. *Int J Methods Psychiatr Res*. 2019;28:e1803. [IF=2.3]. [Link](#)
66. **Thombs BD***, **Aguila K**, Dyas L, Carrier ME, Fedoruk C, **Horwood L**, **Cañedo-Ayala M**, Sauvé M, **Kwakkenbos L**, Malcarne VL, El-Baalbaki G, Peláez S, Connolly K, Hudson M, Platt RW, SPIN-SSLED Support Group Advisory Team. Protocol for a partially nested randomized controlled trial to

evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader Education (SPIN-SSLED) Program. *Trials*. 2019;20:717. [IF=1.9]. [Link](#)

67. Becetti K, **Kwakkenbos L**, Carrier ME, Gordon J, Nguyen J, Mancuso C, Mouthon L, Nguyen C, Rannou F, Welling J, **Thombs BD***, Spiera R, **SPIN Investigators**. Physical or occupational therapy utilization in systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study. *J Rheumatol*. 2019;46(12):1605-1613. [IF=3.4]. [Link](#)
68. Birtwhistle R, Morissette K, Dickinson JA, Reynolds DL, Avey MT, Reyes Domingo F, Rodin R, **Thombs BD***, **Canadian Task Force on Preventive Health Care**. Recommendations on screening adults for asymptomatic thyroid dysfunction in primary care. *CMAJ*. 2019;191:E1274-1280. [IF=7.7]. [Link](#)
69. **Thombs BD***, Dyas L, Pépin M, Aquila K, Carrier ME, Tao L, **Harb S**, Malcarne VL, El-Baalbaki G, Peláez S, Sauvé M, Hudson M, Platt RW, SPIN-SSLED Patient Advisory Team. Scleroderma Patient-centered Intervention Network – Scleroderma Support group Leader Education (SPIN-SSLED) Program: Non-randomised feasibility trial. *BMJ Open*. 2019;9:e029935. [IF=2.5]. [Link](#)
70. **Kwakkenbos L**, Cumin J, Carrier ME, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Rannou R, Welling J, **Thombs BD***, **SPIN Investigators**. Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *BMJ Open*. 2019;9:e029542. [IF=2.5]. [Link](#)
71. Windle SB, Ware K, Filion KB, Gore G, Kimmelman J, **Thombs BD**, Eisenberg MJ. Potential harms from legalization of recreational cannabis use in Canada. *Can J Public Health*. 2019;110(2):222-226. [IF=1.6]. [Link](#)
72. Pépin M, **Kwakkenbos L**, Carrier ME, Peláez S, El-Baalbaki G, Malcarne VL, **Thombs BD***, Scleroderma Patient-centered Network (SPIN) Support Group Project Advisory Team. Reasons for attending support groups and organizational preferences: a replication study using the North American Scleroderma Support Group Survey. *J Scleroderma Relat Disord*. 2019;4(3):173-186. [IF=N/A]. [Link](#)
73. Tao L, Fedoruk C, **Turner KA**, Cumin J, Carrier ME, **Carboni-Jiménez A**, Pépin M, **Kwakkenbos L**, **Thombs BD***, SPIN Patient Advisory Board. The Scleroderma Research Topics Survey for patients and health care professionals: a Scleroderma Patient-centered Intervention Network (SPIN) project. *J Scleroderma Relat Disord*. 2019;4(3):165-172. [IF=N/A]. [Link](#)
74. **Milette K**, **Thombs BD***, Maiorino K, Nielson WR, Körner A, Peláez S. Challenges and strategies for coping with scleroderma: implications for a scleroderma-specific self-management program. *Disabil Rehabil*. 2019;41(21):2506-2515. [IF=2.2]. [Link](#)
75. Ioannidis JPA, **Thombs BD**. A user's guide to inflated and manipulated impact factors. *Eur J Clin Invest*. 2019;49:e13151. [IF=3.5]. [Link](#)
76. Gates M, Pillay J, Thériault G, Limburg H, Grad R, Klarenbach S, Korownyk C, Reynolds D, Riva J, **Thombs BD**, Kline G, Leslie WD, Courage S, Vandermeer B, Featherstone R, Hartling L. Screening to prevent fragility fractures among adults 40 years and older in primary care: protocol for a systematic review. *Syst Rev*. 2019;8:216. [IF=2.5] [Link](#)
77. **Thombs BD***, **Turner KA**, Shrier I. Defining and evaluating overdiagnosis in mental health: a meta-research review. *Psychother Psychosom*. 2019;88(4):193-202. [IF=14.9] [Link](#)

2018-2019

78. Moynihan R, Bero L, Hill S, Johansson M, Lexchin J, MacDonald H, Mintzes B, Pearson C, Stavdal A, Stegenga J, **Thombs BD**, Thornton H, Vandvik P, Wieseler B, Godlee F. Pathways to independence: towards producing and using trustworthy evidence. *BMJ*. 2019;367:l6576. [IF=27.6]. [Link](#)
79. **Delisle VC**, **Gumuchian ST**, El-Baalbaki G, Körner A, Malcarne VL, Peláez S, Carrier ME, Pépin M, **Thombs BD***, Scleroderma Support Group Project Advisory Team. Training and support needs of scleroderma support group facilitators: the North American Scleroderma Support Group Facilitators Survey. *Disabil Rehabil*. 2019;41(20):2477-2482. [IF=2.0]. [Link](#)
80. **Azar M**, Riehm K, Saadat N, Sanchez T, Chiovitti M, **Qi L**, **Rice DB**, **Levis B**, Fedoruk C, **Levis AW**, Kloda LA, Kimmelman J, Benedetti A, **Thombs BD***. Evaluation of journal registration policies

- and prospective registration of randomized clinical trials of nonregulated healthcare interventions. *JAMA Intern Med.* 2019;179(5):624-632. [IF=20.0]. [Link](#)
81. Bashir NY, Moore JE, Buckland D, Rodrigues M, Tonelli M, **Thombs BD**, Bell NR, Isaranuwatchai W, Peng T, Shilman DM, Straus SE. Are patient educational materials on cancer screening more effective when co-created with patients? A qualitative interview study and randomized controlled trial. *Curr Oncol.* 2019;26(2):124-136. [IF=2.0]. [Link](#)
 82. **Levis B**, Benedetti A, **Thombs BD***, **DEPRESSsion Screening Data (DEPRESSD) Collaboration**. The diagnostic accuracy of the Patient Health Questionnaire-9 (PHQ-9) for detecting major depression: an individual participant data meta-analysis. *BMJ.* 2019;365:l1476. [IF=23.6]. [Link](#)
 83. **Gumuchian ST**, **Delisle VC**, **Kwakkenbos L**, Pépin M, **Carrier ME**, Malcarne CL, Peláez S, El-Baalbaki G, **Thombs BD***, Scleroderma Support Group Project Advisory Team. Reasons for attending support groups and organizational preferences: the European Scleroderma Support Group Members Survey. *Disabil Rehabil.* 2019;41(8):974-982. [IF=2.0]. [Link](#)
 84. **Levis B**, Yan XW, **He C**, **Sun Y**, Benedetti A, **Thombs BD***. Comparison of depression prevalence estimates in meta-analyses based on screening tools and rating scales versus validated diagnostic interviews: a meta-research review. *BMC Med.* 2019;17:65. [IF=9.1]. [Link](#)
 85. Harel D, Mills SD, **Kwakkenbos L**, **Carrier ME**, Nielsen K, Portales A, Bartlett SJ, Malcarne VL, **Thombs BD***, **SPIN Investigators**. Shortening patient-reported outcome measures through Optimal Test Assembly: Application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. *BMJ Open.* 2019;9(2):e024010. [IF=2.4]. [Link](#)
 86. **Turner KA**, **Rice DB**, **Carboni-Jiménez A**, Boruff J, **Thombs BD***. Effects of training and support programs for leaders of illness-based support groups: commentary and updated evidence. *Syst Rev.* 2019;8:67. [IF=2.5]. [Link](#)
 87. **Rice DB**, **Thombs BD***. Support groups in scleroderma. *Current Rheumatol Rep.* 2019;21(4):9. [IF=3.1]. [Link](#)
 88. Salameh J-P, McInnes MDF, Moher D, **Thombs BD**, McGrath TA, Frank R, Sharifabadi AD, Kraaijpoel N, **Levis B**, Bossuyt PM. Completeness of reporting of systematic reviews of diagnostic test accuracy based on the PRISMA-DTA reporting guideline. *Clin Chem.* 2019;65(2):291-301. [IF=8.6]. [Link](#)
 89. Hamel C, Lang E, Morissette K, Beck A, Stevens A, Skidmore B, Colquhoun H, LeBlanc J, Moore A, Riva JJ, **Thombs BD**, Colman I, Grigoriadis S, Nicholls SG, Potter BK, Ritchie K, Robert J, Vasa P, Horner B, Patten S, Vigod S, Hutton B, Shea B, Shanmugasagaram S, Little J, Moher D. Screening for depression in women during pregnancy or the first-year postpartum and in the general adult population: a protocol for two systematic reviews to update a guideline of the Canadian Task Force on Preventive Health Care. *Syst Rev.* 2019;8:27. [IF=2.5]. [Link](#)
 90. Hersi M, Traversy G, **Thombs BD**, Beck A, Skidmore A, Groulx S, Lang E, Reynolds DL, Wilson B, Bernstein SL, Selby P, Johnson-Obaseki S, Manuel D, Pakhale S, Pesseau J, Courage S, Hutton B, Shea BJ, Welch V, Morrow M, Little J, Stevens A. Effectiveness of stop smoking interventions among adults: protocol for an overview of systematic reviews and an updated systematic review. *Syst Rev.* 2019;8:28. [IF=2.5]. [Link](#)
 91. Ruiz-Casares M, Lilley S, **Thombs BD**, Platt RW, Scott S, Isdijoso W, Hermanus E, Andrina M, Mayo N. Protocol for a cluster randomised controlled trial evaluating a parenting with home visitation program to prevent physical and emotional abuse of children in Indonesia: the Families First Program. *BMJ Open.* 2019;9(1):e021751. [IF=2.4]. [Link](#)
 92. Ishihara M, Harel D, **Levis B**, **Levis AW**, **Riehm KE**, **Saadat N**, **Azar M**, **Rice DB**, **Sanchez TA**, **Chiovitti MJ**, **Cuijpers P**, **Gilbody S**, **Ioannidis JPA**, **Kloda LA**, **McMillan D**, **Patten SB**, **Shrier I**, **Steele RJ**, **Ziegelstein RC**, **Arroll B**, **Baron M**, **Bombardier CH**, **Butterworth P**, **Carter G**, **Clover K**, **Conwell Y**, **Gjerdingen D**, **Goodyear-Smith F**, **Greeno CG**, **Hambridge J**, **Harrison PA**, **Hudson M**, **Ismail K**, **Jetté N**, **Kiely KM**, **Marsh L**, **McGuire A**, **Pence BW**, **Rooney AG**, **Sidebottom A**, **Simning A**, **Turner A**, **White J**, **Whooley MA**, **Winkley K**, **Benedetti A**, **Thombs BD***. Shortening self-report mental health symptom measures through optimal test assembly methods: development and validation of the Patient Health Questionnaire-4. *Depress Anxiety.* 2019;36(1):82-92. [IF=5.0]. [Link](#)
 93. **Gumuchian ST**, Peláez S, **Delisle VD**, **Carrier ME**, **Jewett LR**, El-Baalbaki G, Fortune C, Hudson M, Körner A, **Kwakkenbos L**, Bartlett SJ, **Thombs BD***. Understanding coping strategies among

people living with scleroderma: A focus group study. *Disabil Rehabil*. 2018;40(25):2012-3021. [IF=2.0]. [Link](#)

94. Pillay J, Moore A, Rahman P, Lewin G, Reynolds D, Riva J, Theriault G, **Thombs BD**, Wilson B, Robinson J, Burchell AN, Dillon J, Singh A, Wong T, Ramdyal A, Cadieux G, Featherstone R, Doull M, Traversy G, Courage D, MacGregor T, Johnson C, Vandermeer B, Hartling L. Screening for chlamydia and/or gonorrhea in primary health care: Protocol for systematic review. *Syst Rev*. 2018;7:248. [IF=N/A]. [Link](#)
95. Klarenbach S, Lewin G, Singh H, Thériault G, Tonelli M, Doull M, Courage S, Jaramillo Garcia A, Sims-Jones N, **Thombs BD***, **Canadian Task Force on Preventive Health Care**. Update of the *Canadian Task Force on Preventive Health Care's* recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk for breast cancer. *CMAJ*. 2018;190:E1441-E1451. [IF=6.2]. [Link](#)
96. Benedetti A, **Wu Y**, **Levis B**, Wilchesky M, Boruff J, Ioannidis JPA, Patten SB, Cuijpers P, Shrier I, Gilbody S, Ismail Z, McMillan D, Mitchell N, Ziegelstein RC, **Thombs BD***. Diagnostic accuracy of the Geriatric Depression Scale-30, Geriatric Depression Scale-15, Geriatric Depression Scale-5, and Geriatric Depression Scale-4 for detecting major depression: protocol for a systematic review and individual participant data meta-analysis. *BMJ Open*. 2018;8:e026598. [IF=2.4]. [Link](#)
97. **Kwakkenbos L**, Juszczak E, Hemkens LG, Sampson M, Fröbert O, Relton C, Gale C, Zwarenstein M, Langan SM, Moher D, Boutron I, Ravaud P, Campbell MK, McCord KA, van Staa TP, Thabane L, Uher R, Verkooijen HM, Benchimol EI, Erlinge D, Sauvé M, Torgerson D, **Thombs BD***. Protocol for the Development of a CONSORT Extension for RCTs Using Cohorts and Routinely Collected Health Data. *Res Integr Peer Rev*. 2018;3:9. [IF=N/A]. [Link](#)
98. Fox RS, **Kwakkenbos L**, **Carrier ME**, Mills SD, Gholizadeh S, **Jewett LR**, Roesch SC, Merz EL, Assassi S, Furst DE, Gottesman K, Mayes MD, **Thombs BD***, Malcarne VL, **SPIN Investigators**. Reliability and validity of three versions of the Brief Fear of Negative Evaluation Scale-II in patients with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study. *Arthritis Care Res*. 2018;70(11):1646-1652. [IF=3.3]. [Link](#)
99. **Kwakkenbos L**, Sanchez TA, **Turner KA**, Mouthon L, **Carrier ME**, Hudson M, van den Ende CHM, Schouffoer AA, Welling J, Sauvé M, **Thombs BD***, **SPIN Investigators**. The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network Cohort study. *Clin Exp Rheumatol*. 2018;36 Suppl 113(4):88-94. [IF=3.2]. [Link](#)
100. Mills SD, **Kwakkenbos L**, **Carrier ME**, Gholizadeh S, Fox RS, **Jewett LR**, Gottesman K, Roesch SC, **Thombs BD***, Malcarne VL, **SPIN Investigators**. Validation of the Social Appearance Anxiety Scale in patients with systemic sclerosis: A Scleroderma Patient-centered Intervention Network Cohort study. *Arthritis Care Res*. 2018;70(10):1557-1562. [IF=4.1]. [Link](#)
101. Dougherty DH, **Kwakkenbos L**, **Carrier ME**, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudau S, Sauvé M, Boire G, Bruns A, Chung L, Denton CD, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larche M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, **Thombs BD***, Mayes MD, **SPIN Investigators**. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: baseline clinical features and comparison to other large scleroderma cohorts. *Rheumatology*. 2018;57(9):1623-1631. [IF=5.2]. [Link](#)
102. **Kwakkenbos L**, Imran M, McCord KA, Sampson M, Fröbert O, Gale C, Hemkens LG, Langan SM, Moher D, Relton C, Zwarenstein M, Benchimol EI, Boutron I, Campbell MK, Erlinge D, Jawad S, Ravaud P, **Rice D**, Sauvé M, van Staa TP, Thabane L, Uher R, Verkooijen HM, Juszczak E, **Thombs BD***. Protocol for a scoping review to support development of a CONSORT extension for RCTs using cohorts and routinely collected health data. *BMJ Open*. 2018;8:e025266. [IF=2.4]. [Link](#)

2017-2018

103. **Azar M**, **Rice DB**, **Kwakkenbos L**, **Carrier ME**, Shrier I, Bartlett SJ, Hudson M, Mouthon L, Poiraudau S, van den Ende CHM, Johnson SR, Rodriguez Reyna TS, Schouffoer AA, Welling J, **Thombs BD***, **SPIN Investigators**. Exercise habits and factors associated with exercise in systemic

- sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *Disabil Rehabil.* 2018;40(17):1997-2003. [IF=2.0]. [Link](#)
104. Moore A, Courage S, Doull M, Grad R, Groulx S, Jaramillo Garcia A, Pottie K, Tonelli M, **Thombs BD***, **Canadian Task Force on Preventive Health Care**. Recommendations on screening for asymptomatic bacteriuria in pregnancy. *CMAJ.* 2018;190(27):E823-E830. [IF=6.2]. [Link](#)
 105. **Levis B**, Benedetti A, **Riehm KE**, **Saadat N**, **Levis AW**, **Azar M**, **Rice DB**, **Chiovitti MJ**, **Sanchez TA**, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, Baron M, Beraldi A, Bombardier CH, Butterworth P, Carter G, Chagas MH, Chan JCN, Cholera R, Chowdhary N, Clover K, Conwell Y, de Man-van Ginkel JM, Delgadillo J, Fann JR, Fischer FH, Fischler B, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Hambridge J, Harrison PA, Hegerl U, Hides L, Hobfoll SE, Hudson M, Hyphantis T, Inagaki M, Ismail K, Jetté N, Khamseh ME, Kiely KM, Lamers F, Liu S-I, Lotrakul M, Loureiro SR, Löwe B, March L, McGuire A, Sidik MS, Munhoz TN, Muramatsu K, Osório FL, Patel V, Pence BW, Persoons P, Picardi A, Rooney AG, Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford L, Sung S, Tan PLL, Turner A, van der Feltz-Cornelis CM, van Weert HC, Vöhringer PA, White J, Whooley MA, Winkley K, Yamada M, Zhang Y, **Thombs BD***. Probability of major depression classification using semi-structured versus fully structured diagnostic interviews. *Br J Psychiatry.* 2018;212(6):377-385. [IF=5.9]. [Link](#)
 106. Wilson BJ, Courage S, Dickinson J, Klarenbach S, Doull M, Jaramillo A, Sims-Jones N, **Thombs BD***, **Canadian Task Force on Preventive Health Care**. Screening for impaired visual acuity in community-dwelling adults age 65 years and older in primary care settings. *CMAJ.* 2018;190(19):E588-E594. [IF=6.2]. [Link](#)
 107. Cosgrove L, Karter JM, Vaswani A, **Thombs BD**. Unexamined assumptions and unintended consequences of routine screening for depression. *J Psychosom Res.* 2018;109:9-11. [IF=2.9]. [Link](#)
 108. Gholizadeh S, **Kwakkenbos L**, **Carrier ME**, Mills SD, Fox RS, **Jewett LR**, Gottesman K, Roesch S, **Thombs BD***, Malcarne VL, **SPIN Investigators**. Validation of the Social Anxiety Interaction Scale (SIAS-6) in systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *J Scleroderma Relat Disord.* 2018;3(1):98-105. [IF=N/A]. [Link](#)
 109. **Carrier ME**, **Kwakkenbos L**, Boutron I, Welling J, Sauvé M, van den Ende C, Schouffoer AA, Hudson M, **Thombs BD***, Mouthon L, **SPIN Investigators**. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): study protocol. *J Scleroderma Relat Disord.* 2018;3(1):91-97. [IF=N/A]. [Link](#)
 110. **Pal NE**, **Gumuchian ST**, **Delisle VC**, **Pépin M**, Malcarne VL, **Carrier ME**, **Kwakkenbos L**, Peláez S, El-Baalbaki G, **Thombs BD***, Scleroderma Support Group Project Advisory Team. Development and preliminary validation of the Scleroderma Support Group Leader Self-efficacy Scale. *J Scleroderma Relat Disord.* 2018;3(1):106-111. [IF=N/A]. [Link](#)
 111. Bell NR, Dickinson JA, Grad R, Singh H, Kasperavicius D, **Thombs BD***. Prevention in practice – understanding and communicating risk: measures of outcome and the magnitude of benefits and harms. *Can Fam Physician.* 2018;64(3):181-185. [IF=1.8]. [Link](#)
 112. **Jewett LR**, **Gumuchian ST**, **Rice DB**, **Kolorz F**, Harrison P, **Thombs BD***. Factors associated with negative observer responses towards individuals with visible differences: a scoping review. *Body Image.* 2018;25:103-132. [IF=1.8]. [Link](#)
 113. Merz EL, **Kwakkenbos L**, **Carrier ME**, Gholizadeh S, Mills SD, Fox RS, **Jewett LR**, Roesch SC, Williamson H, Harcourt D, Moss T, **Thombs BD***, Malcarne VL, **SPIN Investigators**. Comparison of factor structure and convergent validity of the Derriford Appearance Scale-24 - standard scoring versus treating “not applicable” responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *BMJ Open.* 2018;8:e018641. [IF=2.4]. [Link](#)
 114. **Rice DB**, **Cañedo-Ayala M**, **Turner KA**, **Gumuchian ST**, Malcarne VL, Hagedoorn M, **Thombs BD***, Scleroderma Caregiver Advisory Committee. Use of the nominal group technique to identify stakeholder priorities and inform survey development: an example with informal caregivers of people with scleroderma. *BMJ Open.* 2018;8:e019726. [IF=2.4]. [Link](#)
 115. **Coroiu A**, **Kwakkenbos L**, Moran C, **Thombs B**, Albani C, Bourkas S, Zenger M, Braehler E, Körner A. Structural validation of the Self-Compassion Scale with a German general population sample. *PLOS ONE.* 2018;13(2):e0190771. [IF=2.4]. [Link](#)

116. **Gumuchian ST, Delisle VC**, Peláez S, Malcarne VL, El-Baalbaki G, **Kwakkenbos L, Jewett LR**, Carrier ME, Pépin M, **Thombs BD***, Scleroderma Support Group Project Advisory Team. Reasons for not participating in scleroderma patient support groups: A cross-sectional study. *Arthritis Care Res.* 2018;70(2):275-283. [IF=4.1]. [Link](#)
117. McInnes MDF, Moher D, **Thombs BD**, McGrath TA, Bossuyt PM, the PRISMA-DTA Group. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. *JAMA.* 2018;319(4):388-396. [IF=47.74]. [Link](#)
118. **Thombs BD***, **Kwakkenbos L, Levis AW**, Benedetti A. Addressing overestimation of the prevalence of depression prevalence based on self-report screening questionnaires. *CMAJ.* 2018;190:E44-49. [IF = 6.2]. [Link](#)
119. **Roseman M**, Riehm KE, **Saadat N**, Kloda LA, Boruff J, Ickowicz A, Baltzer F, Katz LY, Patten SB, Rousseau C, **Thombs BD***. Depression screening and health outcomes in children and adolescents: a systematic review. *Can J Psychiatry.* 2017;62(12):813-817. [IF=3.6]. [Link](#)
120. Simoneau G, **Levis B**, Cuijpers P, Gilbody S, Ioannidis JPA, Patten SB, Shrier I, Bombardier CH, de Lima Osório F, Fann JR, Gjerdingen D, Lamers F, Lotrakul M, Löwe B, Shaaban J, Stafford L, van Weert HCPM, Whooley MA, Wittkamp KA, Yeung AS, **Thombs BD***, Benedetti A. A comparison of bivariate, multivariate random effects, and Poisson correlated gamma-frailty models to meta-analyze individual patient data of ordinal scale diagnostic tests. *Biometrical Journal.* 2017;59(6):1317-1338. [IF=1.1]. [Link](#)
121. Birtwhistle R, Bell N, **Thombs BD**, Grad R, Dickinson J. Periodic preventive health visits: a more appropriate approach to delivering preventive services: From the Canadian Task Force on Preventive Health Care. *Can Fam Physician.* 2017;63(11): 824-826. [IF=1.8]. [Link](#)
122. Moore A, Straus S, Kasperavicius D, Bell N, Dickinson J, Grad R, Singh H, Thériault G, **Thombs BD**, Colquhoun H. Knowledge translation tools in preventive health care. *Can Fam Physician.* 2017;63(11): 853-858. [IF=1.8]. [Link](#)
123. **Jewett LR, Kwakkenbos L**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Assessment of English-French differential item functioning of the Satisfaction with Appearance Scale (SWAP) in systemic sclerosis. *Body Image.* 2017;22:97-102. [IF=1.8]. [Link](#)
124. McGrath TA, Alabousi M, Skidmore B, Korevaar DA, Bossuyt PM, Moher D, **Thombs BD**, McInnes MDF. Recommendations for reporting of systematic reviews and meta-analyses of diagnostic test accuracy: a systematic review. *Syst Rev.* 2017;6:194. [IF=N/A]. [Link](#)
125. Clarke S, Ells C, **Thombs BD**, Clarke D. Defining elements of patient-centered care for therapeutic relationships: a literature review of common themes. *Eur J Pers Cent Healthc.* 2017;5(3):362-372. [IF=N/A] [Link](#)
126. Singh H, Holmes NM, Jaramillo Garcia A, Bell N, Dickinson JA, Lewin G, Tonelli M, Sims-Jones N, **Canadian Task Force on Preventive Health Care**. Recommendations on screening for abdominal aortic aneurysm in primary care. *CMAJ.* 2017;189(36):E1137-1145. [IF=6.2]. [Link](#)
127. Boitor M, Gélinas C, Richard-Lalonde M, **Thombs BD**. The effect of massage on acute postoperative pain of critically and acutely ill adults post-thoracic surgery: Systematic review and meta-analysis of randomized controlled trials. *Heart & Lung.* 2017;46(5):339-346. [IF=1.7]. [Link](#)
128. **Thombs BD***, **Saadat N, Riehm KE**, Karter JM, Vaswani A, Andrews BK, Simons P, Cosgrove L. Consistency and sources of divergence in recommendations on screening with questionnaires with presently experienced health problems or symptoms: a comparison of recommendations from the Canadian Task Force on Preventive Health Care, UK National Screening Committee, and US Preventive Services Task Force. *BMC Med.* 2017;15:150. [IF=9.1]. [Link](#)
129. **Kwakkenbos L, Thombs BD***, Khanna D, Carrier ME, Baron M, Furst D, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett S, **SPIN Investigators**. Validation of the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) in scleroderma and associations with clinical characteristics: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *Rheumatology.* 2017;56(8):1302-1311. [IF=5.2]. [Link](#)
130. **Thombs BD***, Ziegelstein RC. Primary care doctors should not screen their patients for depression. *Expert Rev Neurother.* 2017;17(7):645-647. [IF=3.7]. [Link](#)

2016-2017

131. **Levis B**, Benedetti A, **Levis AW**, Ioannidis JPA, Shrier I, Cuijpers P, Gilbody S, Kloda LA, McMillan D, Patten SB, Steele RJ, Ziegelstein RC, Bombardier CH, de Lima Osório F, Fann JR, Gjerdingen D, Lamers F, Lotrakul M, Loureiro SR, Löwe B, Shaaban J, Stafford L, van Weert HCPM, Whooley MA, Wittkamp KA, Yeung AS, **Thombs BD***. Selective cutoff reporting in studies of diagnostic test accuracy: A comparison of conventional and individual patient data meta-analyses of the Patient Health Questionnaire-9 depression screening tool. *Am J Epidemiol*. 2017;185(10):954-964. [IF=5.0]. [Link](#)
132. **Delisle VC**, **Gumuchian ST**, **Rice DB**, **Levis AW**, Kloda LA, Körner A, **Thombs BD***. Perceived benefits and factors that influence the ability to establish and maintain patient support groups in rare diseases: A scoping review. *The Patient - Patient-Centered Outcomes Research*. 2017;10(3):283-293. [IF=2.2]. [Link](#)
133. Grad R, **Thombs BD**, Bacchus M, Birthwhistle R, Klarenbach S, Singh H, Tonelli M, Dorais V, Holmes NM, Martin WK, Rodin R, Jaramillo Garcia A, Canadian Task Force on Preventive Health Care. Recommendations on Hepatitis C Screening for Adults. *CMAJ*. 2017;189(16):E594-604. [IF=6.7]. [Link](#)
134. **Thombs BD***, Jaramillo Garcia A, Reid D, Pottie K, Parkin PC, Morissette K, Tonelli M, Canadian Task Force on Preventive Health Care. Recommendations on behavioural interventions for prevention and treatment of cigarette smoking in school-aged children and youth. *CMAJ*. 2017;189(8):E310-316. [IF=6.7]. [Link](#)
135. **Coroiu A**, **Kwakkenbos L**, **Levis B**, Hudson M, Baron M, Cella D, **Thombs BD***, **Canadian Scleroderma Research Group**. Comparability of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores between cancer and systematic sclerosis patients: An assessment of differential item functioning. *J Scleroderma Relat Disord*. 2017;2(1):57-63. [IF=N/A] [Link](#)
136. **Levis B**, **Kwakkenbos L**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Sociodemographic and disease correlates of fatigue in systemic sclerosis: An updated analysis of 785 Canadian Scleroderma Research Group patients. *Clin Rheumatol*. 2017;36(2):373-379. [IF=2.6]. [Link](#)
137. **Thombs BD***, **Kwakkenbos L**, **Riehm KE**, **Saadat N**, **Fedoruk C**. Comparison of self-efficacy for managing chronic disease between patients with systemic sclerosis and other chronic conditions: systematic review. *Rheumatol Int*. 2017;37(2):281-292. [IF=1.7]. [Link](#)
138. **Jewett LR**, **Kwakkenbos L**, **Carrier ME**, Malcarne V, Harcourt D, Rumsey N, Mayes MD, Assassi S, Körner A, Fox RS, Gholizadeh S, Mills SD, Fortune C, **Thombs BD***, **SPIN Investigators**. Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. *Body Image*. 2017;20:99-106. [IF=2.1]. [Link](#)
139. **Roseman M**, **Saadat N**, **Riehm KE**, Kloda LA, Ickowicz A, Baltzer F, Katz LY, Patten SB, Rousseau C, Roy D, **Thombs BD***. Accuracy of depression screening tools to detect major depression in children and adolescents: A systematic review. *Can J Psychiatry*. 2016;61(12):746-757. [IF=3.0]. [Link](#)
140. **Rice DB**, Kloda LA, Shrier I, **Thombs BD***. Reporting quality in abstracts of meta-analyses of depression screening tool accuracy was deficient based on PRISMA for Abstracts *BMJ Open*. 2016;6:e012867. [IF=2.6]. [Link](#)
141. **Delisle VC**, **Gumuchian ST**, Kloda L, Boruff J, El-Baalbaki G, Körner A, Malcarne VL, **Thombs BD***, Scleroderma Support Group Project Advisory Team. The effect of support group peer-facilitator training programs to improve peer-facilitator and support group member outcomes: A systematic review. *BMJ Open*. 2016;6:e013325. [IF=2.6]. [Link](#)
142. **Levis AW**, Harel D, **Kwakkenbos L**, **Carrier ME**, Mouthon L, Poiraudau S, Bartlett SJ, Khanna D, Malcarne VL, Sauve M, Poole JL, Schouffoer AA, Steele RJ, van den Ende CHM, Welling J, **Thombs BD***, **SPIN Investigators**. Development and Validation of the Cochin Hand Function Scale – Short Form (CHFS-6) Using Optimal Test Assembly Methods: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *Arthritis Care Res*. 2016;68(11):1704-1713. [IF=3.2]. [Link](#)

143. Manea L, Hewitt C, North A, Plummer F, Richardson R, **Thombs BD**, Williams B, Gilbody S, McMillan D. Identifying depression with the PHQ-2: A diagnostic meta-analysis. *J Affect Disord*. 2016;203:382-395. [IF=3.6]. [Link](#)
144. **Jewett LR**, **Kwakkenbos L**, **Carrier ME**, Malcarne VL, Bartlett SJ, Furst DE, Gottesman D, Mayes MM, Assassi S, Harcourt D, Williamson H, Johnson SR, Körner A, Steen V, Fox RS, Gholizadeh S, Mills SD, Molnar JC, **Rice DB**, **Thombs BD***, **SPIN Investigators**. The association of race/ethnicity and sex with appearance concerns: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *Clin Exp Rheumatol*. 2016;34 Suppl 100(5):92-99. [IF=2.5]. [Link](#)
145. **Delisle VC**, **Gumuchian ST**, Peláez S, Malcarne VL, El-Baalbaki G, Körner A, Hudson M, Baron M, **Thombs BD***. Reasons for non-participation in scleroderma support groups. *Clin Exp Rheumatol*. 2016;34 Suppl 100(5):56-62. [IF=2.5]. [Link](#)
146. **Riehm KE**, **Kwakkenbos L**, **Carrier ME**, Bartlett SJ, Malcarne VL, Mouthon L, Nielson WR, Poirauda S, Nielsen K, Baron M, Frech T, Hudson M, Pope J, Sauve M, Suarez-Almazor ME, Wigley FM, **Thombs BD***, **SPIN Investigators**. Validity of the Self-Efficacy for Managing Chronic Disease (SEMCD) Scale in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. *Arthritis Care Res*. 2016;68(8):1195-1200. [IF=3.2]. [Link](#)
147. **Jewett LR**, Malcarne VL, Körner A, Kwakkenbos L, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley F, **Thombs BD***, **Canadian Scleroderma Research Group**. Development and validation of the Body Concealment Scale for Scleroderma (BCSS). *Arthritis Care Res*. 2016;68(8):1158-1165. [IF=3.2]. [Link](#)
148. **Levis B**, **Rice DB**, **Kwakkenbos L**, Steele R, Hagedoorn M, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Using marital status and continuous marital satisfaction ratings to predict depressive symptoms in married and unmarried women with systemic sclerosis: A Canadian Scleroderma Research Group study. *Arthritis Care & Res*. 2016;68(8):1143-1149. [IF=3.2]. [Link](#)
149. Lewin G, Morissette K, Dickinson J, Bell N, Bacchus M, Singh H, Tonelli M, Jaramillo Garcia A, **Canadian Task Force on Preventive Health Care**. Recommendations on screening for lung cancer. *CMAJ*. 2016;188(6):425-432. [IF=6.7]. [Link](#)
150. **Rice DB**, Kloda LA, Shrier I, **Thombs BD***. Reporting Completeness and Transparency of Meta-analyses of Depression Screening Tool Accuracy: A Comparison of Meta-analyses Published Before and After the PRISMA Statement. *J Psychosom Res*. 2016;87:57-69. [IF=2.8]. [Link](#)
151. **Rice DB**, Kloda LA, Levis B, Qi B, Kingsland E, **Thombs BD***. Are MEDLINE searches sufficient for systematic reviews of the diagnostic test accuracy of depression screening tools? A review of meta-analyses. *J Psychosom Res*. 2016;87:7-13. [IF=2.8]. [Link](#)

2015-2016

152. **Thombs BD***, **Rice DB**. Sample sizes and precision of estimates of sensitivity and specificity from primary studies on the diagnostic accuracy of depression screening tools: A survey of recently published studies. *Int J Methods Psychiatr Res*. 2016;25(2):145-152. [IF=2.9]. [Link](#)
153. Tonelli M, Parkin P, Leduc D, Brauer P, Pottie K, Dunfield L, Jaramillo A, Martin W, Connor-Gorber S, Ugnat A-M, **Thombs BD**, **Canadian Task Force on Preventive Health Care**. Recommendations on screening for developmental delay. *CMAJ*. 2016;188(8):579-587. [IF=6.7]. [Link](#)
154. **Rice DB**, Shrier I, Kloda LA, Benedetti A, **Thombs BD***. Methodological quality of meta-analyses of the diagnostic accuracy of depression screening tools was suboptimal based on AMSTAR. *J Psychosom Res*. 2016;84:84-92. [IF=2.8]. [Link](#)
155. **Coronado-Montoya S**, **Levis AW**, **Kwakkenbos L**, Steele R, Turner EH, **Thombs BD***. Reporting of positive results in randomized controlled trials of mindfulness-based mental health interventions. *PLOS ONE*. 2016;11(4):e0153220. [IF=3.1]. [Link](#)
156. Bacchus CM, Dunfield L, Connor Gorber S, Holmes NM, Birtwhistle R, Dickinson JA, Lewin G, Singh H, Klarenbach S, Mai V, Tonelli M, **Canadian Task Force on Preventive Health Care**. Recommendations on screening for colorectal cancer in primary care. *CMAJ*. 2016;188(5):340-348. [IF=6.7]. [Link](#)
157. **Thombs BD***, Benedetti A, Kloda LA, **Levis B**, **Azar M**, **Riehm KE**, **Saadat N**, Cuijpers P, Gilbody S, Ioannidis JPA, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, Loiselle CG, Henry M,

- Ismail Z, Mitchell N, Tonelli M. The Diagnostic Accuracy of the Hospital Anxiety and Depression Scale (HADS) for Detecting Major Depression: Protocol for a Systematic Review and Individual Patient Data Meta-analyses. *BMJ Open*. 2016; 6:e011913. [IF=2.6]. [Link](#)
158. **Gumuchian ST**, Peláez S, **Delisle VC**, Carrier ME, **Jewett LR**, El-Baalbaki G, Fortune C, Hudson M, Impens A, Körner A, Bilsker D, Persmann J, **Kwakkenbos L**, Bartlett SJ, **Thombs BD***. Exploring emotional distress among people living with scleroderma: A focus group study. *PLOS ONE*. 2016;11(3):e0152419. [IF=3.1]. [Link](#)
 159. Tonelli M, Connor Gorber S, Moore A, **Thombs BD**, **Canadian Task Force on Preventive Health Care**. Recommendations on routine screening pelvic examination: Canadian Task Force on Preventive Health Care adoption of the American College of Physicians guideline. *Can Fam Physician*. 2016;62(3):211-214. [IF=2.4]. [Link](#)
 160. **Rice DB**, **Thombs BD***. Inclusion of Currently Diagnosed or Treated Patients in Studies of Depression Screening Tool Accuracy: A Cross-sectional Analysis of Recently Published Primary Studies and Meta-Analyses. *PLOS ONE*. 2016;11(2):e0150067. [IF=3.1]. [Link](#)
 161. Pottie K, Rahal R, Birtwhistle R, **Thombs BD**, Singh H, Connor Gorber S, Dunfield L, Jaramillo A, Shane A, Bacchus M, Bell N, Tonelli M, **Canadian Task Force on Preventive Health Care**. Recommendations on screening for cognitive impairment in older adults. *CMAJ*. 2016;188(1):37-46. [IF=6.7]. [Link](#)
 162. Tolin DF, McKay D, Forman EM, Klonsky ED, **Thombs BD**, Empirically supported treatment: Recommendations for new models. *Clin Psychol Sci Pract*. 2015;22(4):317-337. [IF=2.1]. [Link](#)
 163. **Levis AW**, Leentjens A, Levenson J, Lumley M, **Thombs BD***. Comparison of self-citation by peer reviewers in a journal with single-blind peer review versus a journal with open peer review. *J Psychosom Res*. 2015;79(6):561-565. [IF=2.8]. [Link](#)
 164. **Azar M**, **Riehm KE**, McKay D, **Thombs BD***. Transparency of outcome reporting and trial registration of randomized controlled trials published in the Journal of Consulting and Clinical Psychology. *PLOS ONE*. 2015;10(11):e0142894. [IF=3.1]. [Link](#)
 165. Montoro R, **Thombs BD**, Igartua K. The association of bullying with suicide ideation, plan, and attempt among adolescents with GLB or unsure sexual identity, heterosexual identity with same-sex attraction or behavior, or heterosexual identity without same-sex attraction or behaviour. *Sante Ment Que*. 2015;40(3):55-75. [IF=N/A] [Link](#)
 166. **Thombs BD***, Benedetti A, Kloda LA, **Levis B**, **Riehm KE**, **Azar M**, Cuijpers P, Gilbody S, Ioannidis JPA, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, Tonelli M, Mitchell N, Comeau L, Schinazi J, Vigod S. The Diagnostic Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for Detecting Major Depression in Pregnant and Postnatal Women: Protocol for a Systematic Review and Individual Patient Data Meta-analyses. *BMJ Open*. 2015;5:e009742. [IF=2.6]. [Link](#)
 167. **Kwakkenbos L**, **Delisle VC**, Fox RS, Gholizadeh S, **Jewett LR**, **Levis B**, **Milette K**, Mills SD, Malcarne VL, **Thombs BD***. Psychosocial aspects of scleroderma. *Rheum Dis Clin N Am*. 2015;41(3):519-528. [IF=1.7]. [Link](#)
 168. Gariepy G, **Thombs BD**, Kestens Y, Kaufman JS, Blair A, Schmitz N. The neighborhood build environment and trajectories of major depression symptoms in adults: a latent class growth analysis. *PLOS ONE*. 2015;10(7):e0133603. [Impact Factor = 3.1]. [Link](#)
 169. Paris J, Bhat V, **Thombs BD**. Is adult ADHD being overdiagnosed? *Can J Psychiatry*. 2015;60(7):324-328. [IF=3.0]. [Link](#)
 170. **Kwakkenbos L**, Minton O, Stone PC, Alexander S, Baron M, Hudson M, **Thombs BD***, **Canadian Scleroderma Research Group**. Can the cancer-related fatigue case-definition criteria be applied to chronic medical illness? A comparison between women with breast cancer and systemic sclerosis. *J Rheum*. 2015;42(7):1156-1162. [IF=3.2]. [Link](#)

2014-2015

171. Parkin P, Connor Gorber S, Shaw E, Bell N, Jaramillo A, Tonelli M, Brauer P. **Canadian Task Force on Preventive Health Care**. Recommendations for growth monitoring, and prevention and management of overweight and obesity in children and youth in primary care. *CMAJ*. 2015;187(6):411-421. [IF=6.7]. [Link](#)

172. **Riehm KE, Azar M, Thombs BD***. Transparency of outcome reporting and trial registration of randomized controlled trials in top psychosomatic and behavioral health journals: A five-year follow-up. *J Psychosom Res.* 2015;75(1):1-12. [IF=2.7]. [Link](#)
173. **Thombs BD*, Jewett LR, Kwakkenbos L**, Hudson M, Baron M, **Canadian Scleroderma Research Group**. Major depression diagnoses among patients with systemic sclerosis: Baseline and one-month follow-up. *Arthritis Care Res.* 2015;67(3):411-416. [IF=4.7]. [Link](#)
174. **Thombs BD*, Levis AW, Razykov I, Syamchandra A**, Leentjens A, Levenson J, Lumley M. Potentially coercive self-citation via peer review: A cross sectional study. *J Psychosom Res.* 2015;78(1):7-11. [IF=2.7]. [Link](#)
175. Brauer P, Connor Gorber S, Shaw E, Singh H, Bell N, Shane AR, Jaramillo A, Tonelli M, **Canadian Task Force on Preventive Health Care**. Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care. *CMAJ.* 2015;187(3):184-195. [IF=6.0]. [Link](#)
176. **Delisle VC**, Hudson M, Baron M, **Thombs BD*, Canadian Scleroderma Research Group**. Sex and time to diagnosis of systemic sclerosis: An updated analysis of 1,129 patients from the Canadian Scleroderma Research Group Registry. *Clin Exp Rheumatol.* 2014;32(6 Suppl 86):S1-S14. [IF=3.0]. [Link](#)
177. Bell N, Connor Gorber S, Shane A, Joffres M, Harminder S, Dickinson J, Shaw E, Tonelli M, **Canadian Task Force on Preventive Health Care**. Recommendations on screening for prostate cancer with the prostate specific antigen (PSA) test. *CMAJ.* 2014;186(16):1225-1234. [IF=6.0]. [Link](#)
178. Willems LM, **Kwakkenbos L**, Leite C, **Thombs BD**, van den Hoogen FHJ, Maia A, Vliet Vlieland TPM, van den Ende CHM. Frequency and impact of disease symptoms experienced by patients with systemic sclerosis: a comparison across five European countries. *Clinical and Experimental Rheumatology.* 2014;32(Suppl 86):88-93. [IF=2.7]. [Link](#)
179. **Thombs BD***, Benedetti A, Kloda LA, **Levis B**, Nicolau I, Cuijpers P, Gilbody S, Ioannidis JPA, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC. The diagnostic accuracy of the Patient Health Questionnaire-2 (PHQ-2), Patient Health Questionnaire-8 (PHQ-8), and Patient Health Questionnaire-9 (PHQ-9) for detecting major depression: Protocol for a systematic review and individual patient data meta-analyses. *Syst Rev.* 2014;3:124. [IF=N/A]. [Link](#)
180. **Thombs BD*, Kwakkenbos L, Coronado-Montoya S**. Trial registration in rheumatology: The next step. *Arthritis Care Res.* 2014;66(10):1435-1437. [IF=4.7]. [Link](#)
181. Rousseau C, Beaugregard C, Daignault K, Petrakos H, **Thombs BD**, Steele R, Vasiliadis H-M, Hechtman L. A randomized-controlled trial of a classroom-based drama workshop program to improve mental health outcomes among immigrant and refugee youth in special classes. *PLOS ONE.* 2014;9:e104704. [IF=3.2]. [Link](#)
182. **Delisle VC, Kwakkenbos L**, Hudson M, Baron M, **Thombs BD*, Canadian Scleroderma Research Group**. A comparison of the measurement equivalence of English and French versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in systemic sclerosis. *PLOS ONE.* 2014;9:e102897. [IF=3.2]. [Link](#)

2013-2014

183. Wang J, **Thombs BD**, Schmid MR. The Swiss Health Literacy Survey: development and psychometric properties of a multi-dimensional instrument to assess competencies for health. *Health Expect.* 2014;17(3):396-417. [IF=2.9]. [Link](#)
184. **Kwakkenbos L**, Coyne JC, **Thombs BD***. Prevalence of posttraumatic stress disorder (PTSD) in women with breast cancer. *J Psychosom Res.* 2014;76(6):485-486. [IF=2.8]. [Link](#)
185. **Thombs BD***, Arthurs E, **Coronado-Montoya S, Roseman M, Delisle VC, Leavens A, Levis B**, Azoulay L, Smith C, Ciofani L, Coyne JC, Feeley N, Gilbody S, Schinazi J, Stewart DE, Zekowicz P. Depression screening and patient outcomes in pregnancy or postpartum: a systematic review. *J Psychosom Res.* 2014;76(6):443-446. [IF=2.8]. [Link](#)
186. **Kwakkenbos L**, Willems LM, Baron M, Hudson M, Cella D, van den Ende CHM, **Thombs BD*, Canadian Scleroderma Research Group**. The comparability of English, French and Dutch scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): An assessment of

differential item functioning in patients with systemic sclerosis. *PLOS ONE*. 2014;9(3):e91979. [IF=3.5]. [Link](#)

187. **Thombs BD***, Ziegelstein RC, **Roseman M**, Klotz LA, Ioannidis JPA. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: A systematic review. *BMC Med*. 2014;12(1):13. [IF=7.3]. [Link](#)
188. **Thombs BD***, Ziegelstein RC. Does depression screening improve depression outcomes in primary care settings? *BMJ*. 2014;348:g1253. [IF=16.4]. [Link](#)
189. **Razykov I**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: An updated analysis of 959 patients. *Rheumatology*. 2013;52(11):2056-2061. [IF=4.4]. [Link](#)
190. **Thombs BD***, Ziegelstein RC. Depression screening in patients with coronary heart disease: Does the evidence matter? *J Psychosom Res*. 2013;75(6):497-499. [IF=2.8]. [Link](#)
191. **Milette K** Hudson M, Körner A, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Sleep disturbances in systemic sclerosis: Evidence for the role of pain, pruritus, and gastrointestinal symptoms. *Rheumatology*. 2013;52(9):1715-1720. [IF=4.4]. [Link](#)
192. **Kwakkenbos L**, **Jewett LR**, Baron M, Bartlett SJ, Furst D, Gottesman K, Khanna D, Malcarne VL, Mayes MD, Mouthon L, Poiraudou S, Sauve M, Nielson WR, Poole JL, Assassi S, Boutron I, Ellis C, van den Ende CHM, Hudson M, Impens A, Körner A, Leite C, Costa Maia A, Mendelson C, Pope J, Steele RJ, Suarez-Almazor ME, Ahmed S, **Coronado-Montoya S**, **Delisle VC**, Gholizadeh S, Jang Y, **Levis B**, **Milette K**, Mills SD, **Razykov I**, Sobel RM, **Thombs BD***. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomized controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation intervention trials in a rare disease context. *BMJ Open*. 2013;3:e003563. [IF=2.1]. [Link](#)
193. **Meijer A**, **Roseman M**, **Delisle VC**, **Milette K**, **Levis B**, **Syamchandra A**, Stefanek ME, Ziegelstein RC, Stewart DE, de Jonge P, Coyne JC, **Thombs BD***. Effects of screening for psychological distress on patient outcomes in cancer? A systematic review. *J Psychosom Res*. 2013;75(1):1-17. [IF=2.8]. [Link](#)

2012-2013

194. **Razykov I**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. The utility of the PHQ-9 to assess suicide risk in patients with systemic sclerosis. *Arthritis Care Res*. 2013;65(5):753-758. [IF=3.7]. [Link](#)
195. **Jewett LR**, **Razykov I**, Hudson M, Baron M, **Thombs BD***. Lifetime, 12-month, and 30-day prevalence of major depressive disorder among patients with systemic sclerosis. *Rheumatology*. 2013;52(4):669-675. [IF=4.2]. [Link](#)
196. Körner A, Drapeau M, **Thombs BD**, Rosberger Z, Wang B, Khanna M, Spatz A, Coroiu A, Garland R, Batist G. Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care. *BMC Dermatology*. 2013;3. [IF=N/A]. [Link](#)
197. **Kwakkenbos L**, Arthurs E, van den Hoogen FHJ, Hudson M, van Lankveld WGJM, Baron M, van den Ende CHM, **Thombs BD***, **Canadian Scleroderma Research Group**. Cross-language measurement equivalence of the Center for Epidemiologic Studies Depression (CES-D) Scale in systemic sclerosis: A comparison of Canadian and Dutch patients. *PLOS ONE*. 2013;8(1):e53923. [IF=3.7]. [Link](#)
198. **Thombs BD***, **Roseman M**, Coyne JC, de Jonge P, **Delisle VC**, **Arthurs E**, **Levis B**, Ziegelstein R. Does Evidence Support the American Heart Association's Recommendation to Screen Patients for Depression in Cardiovascular Care? An Updated Systematic Review. *PLOS ONE*. 2013;8(1):e52654. [IF=3.7]. [Link](#)
199. **Canadian Task Force on Preventive Health Care**. Dickinson J, Tsakonas E, Conner Gorber S, Lewin G, Shaw E, Singh H, Joffres M, Birtwhistle R, Tonelli M, Mai V, McLachlin M. Recommendations on screening for cervical cancer. *CMAJ*. 2013;185(1):35-45. [IF=6.5]. [Link](#)
200. **Levis B**, Burri A, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Comparison of rates of sexual activity and dysfunction between women with systemic sclerosis and women from a population sample. *PLOS ONE*. 2012;7(12):e52129. [IF=3.7]. [Link](#)

201. Arthurs E, Steele R, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Are scores on the English and French versions of the PHQ-9 comparable? An assessment of differential item functioning. *PLOS ONE*. 2012;7(12):e52028. [IF=3.7]. [Link](#)
202. **Delisle V**, Abbey SE, Beck AT, Dobson KS, Dozois DJA, Grace SL, Stewart DE, Ziegelstein RC, **Thombs BD***. The influence of somatic symptoms on Beck Depression Inventory scores in hospitalized post-myocardial infarction patients. *Can J Psychiatry*. 2012;57(12):752-758. [IF=2.5]. [Link](#)
203. Harel D, **Thombs BD***, Hudson M, Baron M, Steele R, **Canadian Scleroderma Research Group**. Measuring fatigue in systemic sclerosis: A comparison of the SF-36 Vitality subscale and FACIT fatigue scale. *Rheumatology*. 2012;51(12):2177-2185. [IF=4.2]. [Link](#)
204. **Thombs BD***, **Roseman M**, Kloda LA. Depression screening and mental health outcomes in children and adolescents: A systematic review protocol. *Systematic Reviews*. 2012;1:58. [IF=N/A]. [Link](#)
205. **Thombs BD***, **Razykov I**. Inappropriate self-citation via peer review: A simple solution. *CMAJ*. 2012;184(16):1864. [IF=6.5]. [Link](#)
206. Sjonnesen K, Berzins S, Fiest K, Bulloch AGM, Metz LM, **Thombs BD**, Patten SB. Evaluation of the PHQ-9 as an assessment instrument for symptoms of depression in multiple sclerosis patients. *Postgrad Med*. 2012;124(5):69-77. [IF=2.0]. [Link](#)
207. **Delisle VC**, Arthurs E, Abbey SE, Grace SL, Stewart DE, Steele R, Ziegelstein R, **Thombs BD***. Somatic Symptom Reporting on the Beck Depression Inventory Among Post-Myocardial Infarction Patients: In-hospital Versus Follow-up Assessments. *J Psychosom Res*. 2012;73(5):356-361. [IF=3.3]. [Link](#)
208. Wathen CN, MacGregor JCD, Hammerton J, Coben JH, Herrman H, Stewart DE, MacMillan HL, **PreVAiL Research Network**. Priorities for research in child maltreatment, intimate partner violence and resilience to violence exposures: results of an international Delphi consensus development process. *BMC Public Health*. 2012;12:684. [IF=2.1]. [Link](#)
209. **Roseman M**, Turner EH, Lexchin J, Coyne JC, Bero LA, **Thombs BD***. Reporting of conflict of interest from drug trials in Cochrane reviews: A cross-sectional study. *BMJ*. 2012;345:e5155. [IF=17.2]. [Link](#)
210. Leavens A, Patten S, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Influence of somatic symptoms on PHQ-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. *Arthritis Care Res*. 2012;64(8):1195-1201. [IF=3.7]. [Link](#)
211. **Delisle VC**, Beck AT, Ziegelstein RC, **Thombs BD***. Symptoms of heart disease or its treatment may increase Beck Depression Inventory scores in hospitalized post-myocardial infarction patients. *J Psychosom Res*. 2012;73(3):157-162. [IF=3.3]. [Link](#)
212. **Razykov I**, Ziegelstein RC, Whooley MA, **Thombs BD***. The PHQ-9 versus the PHQ-8 – Is Item 9 useful for assessing suicide risk in coronary artery disease patients? Data from the Heart and Soul Study. *J Psychosom Res*. 2012;73(3):163-168. [IF=3.3]. [Link](#)
213. Bassel M, Hudson M, Baron M, Taillefer SS, Mouthon L, Poiraudreau S, Poole JL, **Thombs BD***. Physical and occupational therapy referral and use among systemic sclerosis patients with impaired hand function: Results from a Canadian national survey. *Clin Exp Rheumatol*. 2012;30(4):574-577. [IF=2.7]. [Link](#)
214. **Nath Y**, Paris J, **Thombs BD**, Kirmayer LJ. Prevalence and social determinants of suicidal behaviours among college youth in India. *Int J Soc Psychiatry*. 2012;58(4):393-399. [IF=1.5]. [Link](#)
215. **Newton E**, **Thombs BD***, Groleau D. The experience of emotional distress among women with scleroderma. *Qual Health Res*. 2012;22(9):1195-1206 [IF=2.2]. [Link](#)

2011-2012

216. **Thombs BD***, **Jewett LR**, Assassi S, Baron M, Bartlett S, Costa Maia A, El-Baalbaki G, Furst D, Gottesman K, Haythornthwaite JA, Hudson M, Impens A, Korner A, Leite C, Mayes MD, Malcarne VL, Motivala SJ, Mouthon L, Nielson WR, Plante D, Poiraudreau S, Poole JL, Pope J, Sauve M, Steele RJ, Suarez-Almazor ME, Taillefer S, van den Ende C, Arthurs E, Bassel M, **Delisle V**, **Milette K**, Leavens A, **Razykov I**, Khanna D. New directions for patient-centered care in

- scleroderma: The Scleroderma Patient-centered Intervention Network (SPIN). *Clin Exp Rheumatol*. 2012;30(Suppl. 71):S23-S29. [IF=2.1]. [Link](#)
217. **Thombs BD***, Ziegelstein RC. When prevention is a bad idea: Problems with the DECARD trial and the premise behind it. *J Psychosom Res*. 2012;72(5):333-335. [IF=3.3]. [Link](#)
 218. **Jewett LR**, Hudson M, Baron M, Malcarne V, **Thombs BD***, **Canadian Scleroderma Research Group**. Sociodemographic and disease correlates of body image distress among patients with systemic sclerosis. *PLOS ONE*. 2012;7(3):e33281. [IF=4.1]. [Link](#)
 219. **Thombs BD***, Coyne JC, Cuijpers P, de Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, Patten SB, Turner EH, Ziegelstein RC. Rethinking recommendations for depression screening in primary care. *CMAJ*. 2012;184(4):413-418. [IF=8.2]. [Link](#)
 220. **Levis B**, Hudson M, **Knafo R**, Baron M, Nielson WR, Hill M, **Thombs BD***, **Canadian Scleroderma Research Group**. Sexual activity and impairment among women with systemic sclerosis. *Arthritis Care Res*. 2012;64(3):340-350. [IF=4.9]. [Link](#)
 221. **Delisle V**, Beck AT, Dobson KS, Dozois DJA, **Thombs BD***. Revisiting gender differences in somatic symptoms of depression: Much ado about nothing? *PLOS ONE*. 2012;7(2):d32490. [IF=4.1]. [Link](#)
 222. **Adeponle A**, **Thombs BD**, Groleau D, Jarvis EG, Kirmayer LJ. Use of the cultural formulation to resolve uncertainty in the diagnosis of psychosis among ethnocultural minority and immigrant patients. *Psychiatr Serv*. 2012;63(2):147-153. [IF=2.4]. [Link](#)
 223. **El-Baalbaki G**, **Lober J**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. A comparison of the McGill Pain Questionnaire and single-item pain measures in systemic sclerosis. *J Rheumatol*. 2011;38(2):2581-2587. [IF=3.7]. [Link](#)
 224. **Meijer A**, **Roseman M**, **Milette K**, Coyne JC, Stefanek M, Ziegelstein RC, **Arthurs E**, **Leavens A**, Palmer SC, Stewart DE, De Jonge P, **Thombs BD***. Depression screening and patient outcomes in cancer: A systematic review. *PLOS ONE*. 2011; 6(11): e27181. [IF=4.1]. [Link](#)
 225. Czarny MJ, **Arthurs E**, Coffee D-F, Smith C, Ziegelstein RC, **Thombs BD***. The prevalence of antidepressant prescription or use in patients with acute coronary syndrome: A systematic review. *PLOS ONE* 2011;6(11): e27671. [IF=4.1]. [Link](#)
 226. **Thombs BD***, Körner A. Is there evidence that depression screening benefits patients with chronic medical illness? Should physicians routinely screen for depression in the absence of evidence? *Der Nervenarzt*. 2011;82(11):1469-1475. [IF=0.7]. [Link](#)
 227. Magyar-Russell G, **Thombs BD**, Cai JX, Baveja T, Kuhl E, Singh PP, Barroso MMB, **Arthurs E**, **Roseman M**, Amin N, Marine J, Ziegelstein RC. Prevalence of anxiety and depression in patients with implantable cardioverter defibrillators: A systematic review of the literature. *J Psychosom Res*. 2011;71(4):223-231. [IF=3.3]. [Link](#)
 228. Pottie K, Greenaway C, Feightner J, Welch V, Greenaway C, Swinkels H, Rashid M, Narasiah L, Kirmayer L, Ueffing E, MacDonald N, Hassan G, McNally C, Kahn K, Burhmann R, Dunn S, Dominic A, McCarthy AE, Gagnon A, Rousseau C, Tugwell P and the **Canadian Collaboration for Immigrant and Refugee Health (listed author)**. Review: Evidence-based clinical guidelines for immigrants and refugees. *CMAJ*. 2011;183:E824-E925. [IF=8.2]. [Link](#)
 229. Hassan G, **Thombs BD**, Rousseau C, Kirmayer LJ, Feightner J, Ueffing E, Pottie K. Child Maltreatment: Evidence-based clinical guidelines for immigrants and refugees. *CMAJ*. 2011;183:E824-E925, Appendix 12. [IF=8.2]. [Link](#)
 230. Hassan G, **Thombs BD**, Rousseau C, Kirmayer LJ, Feightner J, Ueffing E, Pottie K. Intimate Partner Violence: Evidence-based clinical guidelines for immigrants and refugees. *CMAJ*. 183:E824-E925, Appendix 13. [IF=8.2]. [Link](#)
 231. Rousseau C, Pottie K, **Thombs BD**, Munoz M, Jurcik T. Post Traumatic Stress Disorder: Evidence-based clinical guidelines for immigrants and refugees. *CMAJ*. 2011;183:E824-E925, Appendix 11. [IF=8.2]. [Link](#)
 232. **Thombs BD***, **Arthurs E**, **El-Baalbaki G**, **Meijer A**, Ziegelstein RC, Steele RJ. Risk of bias from inclusion of patients who already have diagnosis of or are undergoing treatment for depression in diagnostic accuracy studies of screening tools for depression: systematic review. *BMJ*. 2011;343:d4825. [IF=14.1]. [Link](#)

2010-2011

233. Roest A, **Thombs BD**, Grace SL, Stewart DE, Abbey SE, de Jonge P. Somatic/affective, but not cognitive/affective symptoms, of depression after acute coronary syndrome are associated with 12-month all-cause mortality. *J Affect Disord*. 2011;131(1-3):158-163. [IF=3.7]. [Link](#)
234. **Knafo R**, Haythornthwaite JA, Heinberg L, Wigley F, **Thombs BD***. The association of body image distress and pain with sexual impairment in women with systemic sclerosis. *Rheumatol*. 2011;50(6):1125-1130. [IF=4.2]. [Link](#)
235. **Meijer A**, Conradi HJ, Bos E, **Thombs BD**, van Melle J, de Jonge P. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. *Gen Hosp Psychiatry*. 2011;33(3):203-216. [IF=2.8]. [Link](#)
236. Rousseau C, Hassan G, Moreau N, **Thombs BD**. The perception of discrimination and its association with mental health in newly arrived immigrants before and after 9/11. *Am J of Public Health*. 2011;101(5):909-915. [IF=3.9]. [Link](#)
237. **Milette K**, **Razykov I**, Pope J, Hudson M, Baron M, **Thombs BD***. Clinical correlates of sleep problems in systemic sclerosis. *Rheumatol*. 2011;50(5):921-925. [IF=4.2] [Link](#)
238. **Bassel M**, Hudson M, Taillefer S, **Schieur O**, Baron M, **Thombs BD***. Frequency and impact of symptoms experienced by patients with systemic sclerosis: Results from a Canadian national survey. *Rheumatol*. 2011;50(4):762-767. [IF=4.2]. [Link](#)
239. Zuidersma M, **Thombs BD**, de Jonge P. Onset and recurrence of depression as a predictor for worsened cardiovascular prognosis in depressed ACS patients: a systematic review. *Psychother Psychosom*. 2011;80(4):227-237. [IF=6.0]. [Link](#)
240. **Roseman M**, **Milette K**, Bero LA, Lexchin J, Turner E, Coyne JC, **Thombs BD***. Reporting of conflicts of interest in meta-analyses of pharmacological treatments. *JAMA*. 2011;305(10):1008-1017. [IF=30.0]. [Link](#)
241. **Milette K**, **Roseman M**, **Thombs BD***. Transparency of outcome reporting and trial registration of randomized controlled trials in psychosomatic and behavioural health research: A systematic review. *J Psychosom Res*. 2011;70(3):205-217. [IF=2.8]. [Link](#)
242. De Jonge P, Conradi HJ, **Thombs BD**, Rosmalen JGM, Burger H, Ormel J. Prevention of false positive findings in observational studies: Registration will not work But replication might. *J Epidemiol Community Health*. 2011;65(2):95-96. [IF=3.0]. [Link](#)
243. Lawrence JW, Rosenberg L, Rimmer RB, **Thombs BD**, Fauerbach JA. Measuring perceived stigmatization and social comfort among pediatric burn survivors. *Rehabil Psychol*. 2010;55(4):360-371. [IF=1.7]. [Link](#)
244. **Jewett LR**, Hudson M, Haythornthwaite JA, Heinberg L, Wigley F, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Development and validation of the Brief-Satisfaction with Appearance Scale (Brief-SWAP) for systemic sclerosis. *Arthritis Care Res*. 2010;62(12):1779-1786. [IF=4.7]. [Link](#)
245. Hudson M, Impens A, Baron M, **Thombs BD**, Walker JG, Steele R, **Canadian Scleroderma Research Group**. Discordance between patient and physician assessments of disease severity in systemic sclerosis. *J Rheumatol*. 2010;37(11):2307-2312. [IF=3.6]. [Link](#)
246. **El-Baalbaki G**, **Razykov I**, Hudson M, **Bassel M**, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. The association of pruritus with quality of life and disability in systemic sclerosis. *Arthritis Care Res*. 2010;62(10):1489-1495. [IF=4.7]. [Link](#)
247. Eze-Nliam CM, **Thombs BD**, Lima BB, Smith CG, Ziegelstein RC. The association of depression with adherence to antihypertensive medications: A systematic review. *J Hypertens*. 2010;28(9):1785-1795. [IF=4.0]. [Link](#)
248. **Thombs BD***, van Lankveld W, **Bassel M**, Baron M, Buzza R, Haslam S, Haythornthwaite JA, Hudson M, **Jewett LR**, **Knafo R**, Kwakkenbos L, Malcarne V, **Milette K**, Motivala S, **Newton EG**, Nielson W, Pacy M, **Razykov I**, **Schieur O**, Worron-Sauve M, Taillefer S. Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. *Arthritis Care Res*. 2010;62(8):1181-1189. [IF=4.7]. [Link](#)

249. **Thombs BD***, Ziegelstein RC, de Jonge P, Grace SL, Pilote L, Dozois DJA, Beck AT, **Fuss S**, Stewart DE, Ormel J, Dobson KS, Abbey SE. Somatic symptom overlap in Beck Depression Inventory-II Scores following myocardial infarction. *Br J Psychiatry*. 2010;197(1):61-66. [IF=5.9]. [Link](#)

2009-2010

250. Bhar SS, **Thombs BD**, Pignotti M, **Bassel M**, **Jewett LR**, Coyne JC, Beck AT. Is long term psychodynamic psychotherapy more efficacious than shorter term therapies? Review of the evidence. *Psychother Psychosom*. 2010;79(4):208-216. [IF=5.4]. [Links](#)
251. **Thombs BD***, **Adeponle AB**, Kirmayer LJ, Morgan JF. A Brief Scale for Assessing Hospital Doctors' Attitudes Toward Collaborative Care for Mental Health (DACC-MH). *Can J Psychiatry*. 2010;55(4):264-267. [IF=2.2]. [Link](#)
252. **Milette K**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: Internal consistency reliability, convergent validity, and clinical correlates. *Rheumatology*. 2010;49(4):789-796. [IF=4.2]. [Link](#)
253. Coyne JC, **Thombs BD**, Hagedoorn M. Ain't necessarily so: Review and critique of recent meta-analyses of behavioral medicine interventions in *Health Psychology*. *Health Psychol*. 2010;29(2):107-116. [IF=3.5]. [Link](#)
254. **Schieir O**, **Thombs BD***, Hudson M, Boivin JF, Steele R, Bernatsky S, Hanley J, Baron M, **Canadian Scleroderma Research Group**. Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. *Arthritis Care Res*. 2010;62(3):409-417. [IF=4.2]. [Link](#)
255. **Zhao Y**, Montoro R, Igartua K, **Thombs BD***. Risk for suicide ideation and attempt among adolescents reporting "unsure" sexual identity or heterosexual identity plus same-sex attraction or behavior: Forgotten groups? *J Am Acad Child Adolesc Psychiatry*. 2010;49(2):104-113. [IF=5.0]. [Link](#)
256. Parakh K, Bhat U, **Thombs BD**, Fauerbach JA, Bush DE, Ziegelstein RC. Self-Assessed Physical Health Predicts Ten-Year Mortality after Myocardial Infarction. *J Cardiopulm Rehabil Prev*. 2010;30(1):35-39. [IF=1.6]. [Link](#)
257. Stefanek M, Palmer SC, **Thombs BD**, Coyne JC. Finding what is not there: Unwarranted claims of an effect of psychosocial intervention on recurrence and survival. *Cancer*. 2009;115(24):5612-5616. [IF=5.4]. [Link](#)
258. **Razykov I**, **Thombs BD***, Hudson M, **Bassel M**, Baron M, **Canadian Scleroderma Research Group**. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. *Arthritis Care Res*. 2009;61(12):1765-1770. [IF=4.2]. [Link](#)
259. Igartua K, **Thombs BD**, Burgos G, Montoro R. Concordance and discrepancy in sexual identity, attraction, and behaviour among adolescents. *J Adolesc Health*. 2009;45(6):602-608. [IF=3.3]. [Link](#)
260. Hudson M, Steele R, Lu Y, **Thombs BD**, **Schieir O**, Baron M, **Canadian Scleroderma Research Group**. Work disability in systemic sclerosis. *J Rheumatol*. 2009;36(11):2481-2486. [IF=3.9]. [Link](#)
261. **Thombs BD***, Bernstein DP, Lobbestael J, Arntz A. A validation study of the Dutch Childhood Trauma Questionnaire – Short Form: Factor structure, reliability, and known-groups validity. *Child Abuse Negl*. 2009;33(8):518-523. [IF=2.3]. [Link](#)
262. **Thombs BD***, **Jewett LR**, **Knafo R**, Coyne JC, Ziegelstein RC. Learning from history: A commentary on the AHA Scientific Advisory on depression screening. *Am Heart J*. 2009;158(4):503-505. [IF=4.4]. [Link](#)
263. **Knafo R**, **Thombs BD***, **Jewett LR**, Hudson M, Wigley F, Haythornthwaite JA. (Not) talking about sex. A systematic comparison of sexual impairment in women with systemic sclerosis and other chronic disease samples. *Rheumatology*. 2009;48(10):1300-1303. [IF=4.2]. [Link](#)
264. Ziegelstein RC, **Thombs BD**, Coyne JC, de Jonge P. Routine screening for depression in patients with coronary heart disease: Never mind. *J Am Coll Cardiol*. 2009;54(10):886-890. [IF=12.5]. [Link](#)
265. Hudson M, **Thombs BD**, Steele R, Panopalis P, **Newton E**, Baron M, **Canadian Scleroderma Research Group**. Health-related quality of life in systemic sclerosis: A systematic review. *Arthritis Care Res*. 2009;61(8):1112-1120. [IF=4.2]. [Link](#)

266. **Thombs BD***, Hudson M, Bassel M, Taillefer SS, Baron M, **Canadian Scleroderma Research Group**. Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis. *Arthritis Care Res*. 2009;61(7):966-973. [IF=4.2]. [Link](#)

2008-2009

267. Hudson M, Steele R, Lu Y, **Thombs BD**, Panopalis P, Baron M, **Canadian Scleroderma Research Group**. Clinical correlates of self-reported physical health status in systemic sclerosis. *J Rheumatol*. 2009;36(6):1226-1229. [IF=3.3]. [Link](#)
268. **Ruiz-Casares M**, **Thombs BD***, Rousseau C. The association of single and double orphanhood with symptoms of depression among children and adolescents in Namibia. *Eur Child Adolesc Psychiatry*. 2009;18(6):369-376. [IF=1.8]. [Link](#)
269. Hudson M, **Thombs BD**, Steele R, Panopalis P, **Newton E**, Baron M, **Canadian Scleroderma Research Group**. Quality of life in systemic sclerosis compared to the general population and patients with other chronic conditions. *J Rheumatol*. 2009;36(4):768-772. [IF=3.3]. [Link](#)
270. Coyne JC, **Thombs BD**, Stefanek M, Palmer SC. Time to let go of the illusion that psychotherapy extends the survival of cancer patients: A reply to Kraemer and colleagues. *Psychol Bull*. 2009;135(2):179-182. [IF=12.6]. [Link](#)
271. **Schieir O**, **Thombs BD***, Berkson L, Couture F, Fitzcharles MA, Gagné M, Garfield B, Gutkowski A, Hudson M, Kang H, Kapusta M, Ligier S, Mathieu J-P, Ménard H, Starr M, Stein M, Zummer M, Baron M. Symptoms of depression predict trajectory of pain among patients with early inflammatory arthritis: A path analysis approach to assessing pain. *J Rheumatol*. 2009;36(2):231-239. [IF=3.3]. [Link](#)
272. Hudson M, **Thombs BD**, Baron M, **Canadian Scleroderma Research Group**. Time to diagnosis in systemic sclerosis: Is gender a factor? *Arthritis Care Res*. 2009;61(2):274-278. [IF=6.8]. [Link](#)
273. **Adeponle AB**, **Thombs BD***, Adekan ML, Kirmayer LJ. Family participation in treatment and post-discharge appointment and medication adherence at a Nigerian psychiatric hospital. *Br J Psychiatry*. 2009;194(1):86-87. [IF=5.1]. [Link](#)
274. **Thombs BD***, Ziegelstein RC, Whooley MA. Optimizing detection of major depression among patients with coronary artery disease using the Patient Health Questionnaire: Data from the Heart and Soul Study. *J Gen Intern Med*. 2008;23(12):2014-2017. [IF=2.7]. [Link](#)
275. **Thombs BD***, Ziegelstein RC, Stewart DE, Abbey SE, Parakh K, Grace SL. Physical Health Status Assessed During Hospitalization for Acute Coronary Syndrome Predicts Mortality 12 Months Later. *J Psychosom Res*. 2008;65(6):587-593. [IF=2.5]. [Link](#)
276. **Thombs BD***, de Jonge P, Coyne JC, Whooley MA, Frasure-Smith N, Mitchell AJ, Zuidersma M, Eze-Nliam C, Bezerra B, Smith CG, Soderlund K, Ziegelstein RC. Depression screening and patient outcomes in cardiovascular care: A systematic review. *JAMA*. 2008;300(18):2161-2171. [IF=31.7]. [Link](#)
277. Parakh K, **Thombs BD**, Bhat U, Fauerbach JA, Bush DE, Ziegelstein RC. Long-term significance of Killip class and left ventricular systolic dysfunction. *Am J Med*. 2008;121(11):1015-1018. [IF=5.1]. [Link](#)
278. **Thombs BD***, Bassel M, McGuire L, Smith MT, Hudson M, Haythornthwaite JA. Fatigue in systemic sclerosis: A systematic comparison with other chronic illnesses. *Rheumatology*. 2008;47(10):1559-1563. [IF=4.1]. [Link](#)
279. **Thombs BD***, Ziegelstein RC, Stewart DE, Abbey SE, Parakh K, Grace SL. Usefulness of a single-item general self-rated health question to predict mortality 12 months after an acute coronary syndrome. *Eur J Cardiovasc Prev Rehabil*. 2008;15(4):479-481. [IF=2.4]. [Link](#)
280. **Thombs BD***, Ziegelstein RC, Beck CA, Pilote L. A general factor model for the Beck Depression Inventory – II: Validation in a sample of patients hospitalized with acute myocardial infarction. *J Psychosom Res*. 2008;65(2):115-121. [IF=2.5]. [Link](#)
281. **Thombs BD***, Ziegelstein RC, Parakh K, Stewart DE, Abbey SE, Grace SL. Probit structural equation regression model: General depressive symptoms predicted post-myocardial infarction mortality after controlling for somatic symptoms of depression. *J Clin Epidemiol*. 2008;61(8):832-839. [IF=2.9]. [Link](#)

2007-2008

282. Kirmayer LJ, **Thombs BD**, Jurcik T, Jarvis GE, Guzder J. Use of the DSM-IV cultural formulation on a cultural consultation service. *Psychiatr Serv*. 2008;59(6):683-686. [IF=2.1]. [Link](#)
283. Baron M, Sutton E, Hudson M, **Thombs BD**, Markland J, Pope J, Robinson D, Jones N, Docherty P, Abu-Hakima M, LeClercq S, Smith D, Mathieu J-P. The relationship of dyspnea to function and quality of life in systemic sclerosis. *Ann Rheum Dis*. 2008;67(5):644-650. [IF=6.4]. [Link](#)
284. **Thombs BD***, Hudson M, Taillefer SS, Baron M, **Canadian Scleroderma Research Group**. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. *Arthritis Care Res*. 2008;59(4):504-509. [IF=7.7]. [Link](#)
285. Parakh K, **Thombs BD**, Fauerbach JA, Bush DE, Ziegelstein RC. Effect of depression on late (8 years) mortality after myocardial infarction. *Am J Cardiol*. 2008;101(5):602-606. [IF=3.6]. [Link](#)
286. **Thombs BD***, Hudson M, **Schieir O**, Taillefer SS, Baron M, **Canadian Scleroderma Research Group**. Reliability and validity of the Center for Epidemiological Studies Depression Scale in patients with systemic sclerosis. *Arthritis Care Res*. 2008;59(3):438-443. [IF=7.7]. [Link](#)
287. **Thombs BD***, **Fuss S**, Hudson M, **Schieir O**, Taillefer SS, Fogel J, Ford DE, Baron M, **Canadian Scleroderma Research Group**. High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. *Arthritis Care Res*. 2008;59(3):431-437. [IF=7.7]. [Link](#)
288. **Thombs BD***. Patient and injury characteristics, mortality risk, and length of stay related to child abuse by burning: Evidence from a national sample of 15,802 pediatric admissions. *Ann Surg*. 2008;247(3):519-523. [IF=7.4]. [Link](#)
289. Hudson M, **Thombs BD**, Steele R, Watte R, Taillefer S, Baron M, **Canadian Scleroderma Research Group**. Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disease Assessment Schedule II. *Arthritis Care Res*. 2008;59(2):279-284. [IF=7.7]. [Link](#)
290. **Thombs BD***, Notes LD, Magyar-Russell G, Lawrence JW, Bresnick MG, Fauerbach JA. Body image satisfaction in burn survivors: From survival to socialization. *J Psychosom Res*. 2008;64(2):205-212. [IF=1.9]. [Link](#)
291. **Thombs BD***, Bresnick MG. Mortality risk and length of stay associated with self-inflicted burn injury: Evidence from a national sample of 30,382 adult patients. *Crit Care Med*. 2008;36(1):118-125. [IF=6.3]. [Link](#)
292. **Thombs BD***, Ziegelstein RC, Stewart DE, Abbey SE, Parakh K, Grace SL. Usefulness of persistent symptoms of depression to predict physical health status 12 months after an acute coronary syndrome. *Am J Cardiol*. 2008;101(1):15-19. [IF=3.6]. [Link](#)
293. Edwards RR, Magyar-Russell G, **Thombs B**, Smith MT, Holavanahalli R, Patterson DR, Blakeney P, Lezotte D, Haythornthwaite JA, Fauerbach JA. Acute pain at discharge from hospitalization is a prospective predictor of long-term suicidal ideation after burn injury. *Arch Phys Med Rehabil*. 2007;88(12 Supplement 2):S36-42. [IF=1.8]. [Link](#)
294. **Thombs BD***, Miller SD, Ziegelstein RC. On pot, potomania, and (couch) potatoes: The link between habits and mood. *J Psychosom Res*. 2007;63(5):459-462. [IF=1.9]. [Link](#)
295. **Thombs BD***, Lewis C, Bernstein DP, Medrano MA, Hatch JP. An evaluation of the measurement invariance of the Childhood Trauma Questionnaire – Short Form across gender and race in a sample of drug abusing adults. *J Psychosom Res*. 2007;63(4):391-398. [IF=1.9]. [Link](#)

2006-2007

296. **Thombs BD***, Taillefer SS, Hudson M, Baron M. Depression in patients with scleroderma. A systematic review of the evidence. *Arthritis Care Res*. 2007;57(6):1089-1097. [IF=7.8]. [Link](#)
297. Price LA, **Thombs BD**, Chen CL, Milner SM. Liver disease in burn injury: Evidence from a national sample of 31,338 adult patients. *J Burns Wounds*. 2007;7(June 12):e1. [IF=N/A]. [Link](#)
298. **Thombs BD***. Use of the Beck Depression Inventory for assessing depression in patients hospitalized with burn injuries: Disentangling symptoms of depressed mood from injury and treatment factors. *Burns*. 2007;33(5):547-553. [IF=1.1]. [Link](#)

299. Ziegelstein RC, Meuchel J, Kim TJ, Latif M, Alvarez W, Dasgupta N, **Thombs BD**. Selective serotonin reuptake inhibitors in hospitalized acute coronary syndrome patients. *Am J Med*. 2007;120(6):525-530. [IF=4.5]. [Link](#)
300. **Thombs BD***, Bresnick MG, Magyar-Russell G. Who attempts suicide by burning? An analysis of age patterns of mortality by self-inflicted burning in the United States. *Gen Hosp Psychiatry*. 2007;29(3):244-250. [IF=2.5]. [Link](#)
301. **Thombs BD***, Magyar-Russell G, Bass EB, Stewart KJ, Tsilidis KK, Bush DE, Fauerbach JA, McCann UD, Ziegelstein RC. Performance characteristics of depression screening instruments in survivors of acute myocardial infarction: A review of the evidence. *Psychosomatics*. 2007;48(3):185-194. [IF=2.0]. [Link](#)
302. **Thombs BD***, Singh VA, Milner SM. The effect of pre-existing medical comorbidities on mortality and length of hospital stay in acute burn injury: Evidence from a national sample of 31,338 adult patients. *Ann Surg*. 2007;245(4):629-634. [IF=7.7]. [Link](#)
303. **Thombs BD***, Bennett W, Ziegelstein RC, Bernstein DP, Scher CD, Forde DR. Cultural sensitivity in screening adults for a history of childhood abuse: Evidence from a community sample. *J Gen Intern Med*. 2007;22(3):368-373. [IF=3.0]. [Link](#)
304. **Thombs BD***, Bresnick MG, Magyar-Russell G, Lawrence JW, McCann UD, Fauerbach JA. Symptoms of depression predict change in physical health after burn injury. *Burns*. 2007;33(3):292-298. [IF=1.1]. [Link](#)
305. **Thombs BD***, Bernstein DP, Ziegelstein RC, Bennett W, Walker EA. A brief 2-item screener for detecting a history of physical or sexual abuse in childhood. *Gen Hosp Psychiatry*. 2007;29(1):8-13. [IF=2.5]. [Link](#)
306. **Thombs BD***, Haines J, Bresnick MG, Magyar-Russell G, Fauerbach JA, Spence RJ. Depression in burn reconstruction patients: Symptom prevalence and association with body image dissatisfaction and physical function. *Gen Hosp Psychiatry*. 2007;29(1):14-20. [IF=2.5]. [Link](#)
307. Brummett BR, Wade JC, Ponterotto JG, **Thombs BD**, Lewis C. Psychological well-being and a multicultural personality disposition. *J Couns Dev*. 2007;85(1):73-81. [IF=0.6]. [Link](#)
308. **Thombs BD***, Bernstein DP, Ziegelstein RC, Scher CD, Forde DR, Walker EA, Stein MB. An evaluation of screening questions for childhood abuse in two community samples: Implications for clinical practice. *Arch Intern Med*. 2006;166(18):2020-2026. [IF=7.9]. [Link](#)
309. **Thombs BD***, Bresnick MG, Magyar-Russell. Depression in survivors of burn injury: A systematic review. *Gen Hosp Psychiatry*. 2006;28(6):494-502. [IF=2.5]. [Link](#)
310. Lawrence JW, Fauerbach JA, **Thombs BD**. Frequency and correlates of depression symptoms among long-term adult burn survivors. *Rehabil Psychology*. 2006;51(4):306-313. [IF=0.9]. [Link](#)

2005-2006

311. **Thombs BD***, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE, Ziegelstein RC. Prevalence of depression in survivors of acute myocardial infarction: A review of the evidence. *J Gen Intern Med*. 2006;21(1):30-38. [IF=3.0]. [Link](#)
312. **Thombs BD***, Singh VA, Milner SM. Children under 4 years are at greater risk of mortality following acute burn injury: Evidence from a national sample of 12,902 pediatric admissions. *Shock*. 2006;26(4):348-352. [IF=3.1]. [Link](#)
313. Esselman PC, **Thombs BD**, Fauerbach JA, Magyar-Russell G. Burn rehabilitation: State of the science. *Am J Phys Med Rehabil*. 2006;85(4):383-413. [IF=1.1]. [Link](#)
314. Lawrence JW, Fauerbach JA, Heinberg LJ, Doctor M, **Thombs BD**. The reliability and validity of the Perceived Stigmatization Questionnaire (PSQ) and the Social Comfort Questionnaire (SCQ) among an adult burn survivor sample. *Psychol Assess*. 2006;18(1):106-111. [IF=2.6]. [Link](#)
315. Lawrence JW, Fauerbach JA, **Thombs BD**. A test of the moderating role of importance of appearance in relation between perceived scar severity and body-esteem among adult burn survivors. *Body Image*. 2006;3(2):101-111. [IF = N/A]. [Link](#)
316. Fauerbach JA, Bush DE, **Thombs BD**, McCann UD, Fogel J, Ziegelstein RC. Depression following acute myocardial infarction: a prospective relationship with ongoing health and function. *Psychosomatics*. 2005; 46(4):355-361. [IF=2.3]. [Link](#)

2004-2005

317. McCann UD, Fauerbach JA, **Thombs BD**. Anxiety and cardiac disease. *Prim Psychiatry*. 2005;12(5):47-50. [IF=N/A]. [Link](#)
318. **Thombs BD***, Fauerbach JA, McCann UD. Posttraumatic stress disorders following injury: Assessment and treatment. *Prim Psychiatry*. 2005;12(5):51-55. [IF=N/A]. [Link](#)
319. Ziegelstein RC, Kim SY, Kao D, Fauerbach JA, **Thombs BD**, McCann U, Colburn J, Bush DE. Can doctors and nurses recognize depression in patients hospitalized with an acute myocardial infarction in the absence of formal screening? *Psychosom Med*. 2005;67(3):393-7. [IF=3.4]. [Link](#)

H.3.3. Peer-Reviewed Technical Reports Produced for Government Agencies

1. Bush DE, Ziegelstein RC, Patel UV, **Thombs BD**, Ford DE, Fauerbach JA, et al. Evidence report on post-myocardial infarction depression. Agency for Healthcare Research and Quality Evidence Report/Technology Assessment. (Prepared by the Johns Hopkins Evidence-based Practice Center, Baltimore, MD). 2005. [Link](#)
2. Esselman PC, **Thombs BD**, Fauerbach JA, Magyar-Russell, G, Price MC. State of the science in rehabilitation from burn injury. National Institute on Disability and Rehabilitation Research White Paper. 2005.

H.3.4. Other Reports

1. Taillefer SS, Bernstein J, **Schieir O**, Buzza R, Hudson M, Baron M, **Thombs BD**, Scleroderma Society of Canada, Canadian Scleroderma Research Group. Canadian scleroderma patient survey of health concerns and research priorities: An initiative of the Scleroderma Society of Canada and the Canadian Scleroderma Research Group. 2010.

H.3.5. Invited Editorials, Commentaries

1. Ziegelstein RC, **Rice DB**, **Thombs BD**. Routine depression screening in patients with cardiovascular disease: time to reconsider the AHA Science Advisory. *J Am Coll Cardiol*. Under review.
2. Ziegelstein RC, **Thombs BD**. This cat has only eight lives. *Eur J Clin Invest*. In press.
3. Moore A, Strauss S, Lexchin J, **Thombs BD***. Financial conflict of interest among clinical practice guideline-producing organizations. *Brit J Gen Pract*. 2020;70(700):530-531.
4. **Thombs BD**, **Bonardi O**, **Rice DB**, Boruff JT, Azar M, **He C**, Markham S, **Sun Y**, **Wu Y**, Krishnan A, Thombs-Vite I, Benedetti A. Curating evidence on mental health during COVID-19: a living systematic review. *J Psychosom Res*. 2020;133:110113. [IF=3.3]. [Link](#)
5. **Thombs BD***, Straus SE, Moore AE, **Canadian Task Force on Preventive Health Care**. Update on Task Force terminology and outreach activities: advancing guideline usability for the Canadian primary care context. *Can Fam Physician*. 2019;65(1):12-13. [IF=1.9]. [Link](#)
6. **Thombs BD***, **Levis B**, **Rice DB**, **Wu Y**, Benedetti A. Reducing waste and increasing the usability of psychiatry research: the family of EQUATOR reporting guidelines and one of its newest members – the PRISMA-DTA statement. *Can J Psychiatry*. 2018;63(8):509-512. [IF=3.0]. [Link](#)
7. **Thombs BD***, Lewin G, Tonelli M. Implementing preventive healthcare recommendations in family medicine practice: introduction to a series from the Canadian Task Force on Preventive Health Care. *Can Fam Physician*. 2017;63(7):504-505. [IF=1.9]. [Link](#)
8. Ellis C, **Thombs BD**. Ethically managing incidental findings. *CMAJ*. 2014;186(9):655-656. [IF=6.5]. [Link](#)
9. **Thombs BD***, Stewart DE. Depression screening in pregnancy and postpartum: Who needs evidence? *J Psychosom Res*. 2014;76(6):492-493. [IF=3.3]. [Link](#)
10. **Thombs BD***, Ziegelstein RC. Depression screening in primary care: Why the Canadian Task Force on Preventive Health Care did the right thing. *Can J Psychiatry*. 2013;58(12):692-696. [IF=2.5]. [Link](#)
11. **Thombs BD***, Coyne JC. Moving forward by moving back: Re-assessing guidelines for cancer distress screening. *J Psychosom Res*. 2013;75(1):20-22. [IF=3.3]. [Link](#)

12. **Thombs BD***. Quantitative – other: A depression screening tool finds that 54% of acute cardiac patients are at risk of depression: use of the tool improves documentation and referral. *Evid Based Nurs* 2013;16(2):47-48. [IF=N/A]. [Link](#)
13. Ziegelstein RC, **Thombs BD**. Coping with Rising Health Care Costs. *JAMA Intern Med*. 2012;172(21):1684-1685. [IF=11.5]. [Link](#)
14. Ziegelstein RC, **Thombs BD**. Is routine screening a parachute for heart disease patients with depression? *J Psychosom Res*. 2011;71(1):3-5. [IF=2.8]. [Link](#)
15. **Thombs BD***, Ziegelstein RC. Back to the future in style: Psychosomatic research in cardiovascular disease. *J Psychosom Res*. 2009;67(1):1-3. [IF=2.5]. [Link](#)
16. Ziegelstein RC, **Thombs BD**. The brain and the heart: The twain meet. *Eur Heart J*. 2005;26(24):2607-8. [IF=7.3]. [Link](#)
17. **Thombs BD***, Fauerbach JA. A cross-cultural study of perceived stress among parents of children with large burn injuries: a comment on Rose et al. *J Burn Care Rehabil*. 2005;26(5):444-445. [IF=1.1]. [Link](#)

H.3.6. Letters to the Editor and Replies

1. **Wu Y, Negeri Z**, Benedetti A, **Thombs BD***. Prevalence of depressive symptoms in patients with systemic sclerosis. *Arch Rheumatol*. 2020;35(3):458-459. [Link](#)
2. Klarenbach SW, Moore AE, **Thombs BD***, Canadian Task Force on Preventive Health Care. The authors respond to: "Revamp governance of Canadian Task Force on Preventive Health Care". *CMAJ*. 2020;192(6):E146-E147. [IF=6.9]. [Link](#)
3. **Thombs BD***, Ziegelstein RC. Cardiac outcomes after treatment for depression in patients with acute coronary syndrome. *JAMA*. 2018;320(20):2151. [IF=47.7]. [Link](#)
4. Verkooijen HM, Couwenberg A, May A, **Thombs BD**, **Kwakkenbos L**, Zwarenstein M. Don't forget about the 'R' in cmRCT; Reply to Groenwold and van Smeden. *J Clin Epidemiol*. 2019;106:143-144. [IF=4.2] [Link](#)
5. Kasperavicius D, Bell N, Grad R, Dickinson J, Moore A, Singh H, **Thombs BD**, Wilson B. CTFPHC response to Dr. Dermer's letter to the CFP Editor. *Can Fam Physician*. 2017;63(11):828-830. [Link](#)
6. **Levis B**, Benedetti A, **Thombs BD***. Three authors reply. *Am J Epidemiol*. 2017;186(7):895. [IF=5.2]. [Link](#)
7. Braillon A, Fonseca Das Neves J, **Thombs BD**. Dépression résistante ou résistance à la thérapie cognitive et comportementale? [Resistant depression or resistance to cognitive behavioral therapy?] *Presse Med*. 2016;45(10):954. [IF=1.1]. [Link](#)
8. **Levis B, Azar M, Thombs BD***. Resident physicians with depression or depressive symptoms. *JAMA*. 2016;315(21):2347. [IF=35.3]. [Link](#)
9. **Thombs BD***, Hudson M. No Evidence for Depression Screening in Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. *J Rheum*. 2016;43(5):992. [IF=3.2] [Link](#)
10. Paris J, Bhat V, **Thombs B**. Adult attention-deficit hyperactivity disorder is being overdiagnosed. *Can J Psychiatry*. 2016;61(1):62. [IF=2.5]. [Link](#)
11. **Thombs BD***. Routine depression screening for patients with diabetes. *JAMA*. 2014;312(22):2411. [IF=35.3]. [Link](#)
12. **Thombs BD***, Stewart DE. Depression screening in pregnancy and postpartum: How close are we? *J Psychosom Res*. 2014;77(3):244-245. [IF=2.7]. [Link](#)
13. **Thombs BD***, Ziegelstein RC. Patient engagement programs and treatment of depression. *JAMA*. 2014;311(11):1158-1159. [IF=30.0]. [Link](#)
14. **Thombs BD***, **Razykov I**, Hudson M, Baron M. The utility of the PHQ-9 to assess suicide risk in patients with systemic sclerosis - Reply. *Arthritis Care Res*. 2014;66(3):497-498. [IF=3.7]. [Link](#)
15. **Thombs BD***, Ells C, Black L. Patient Reported Outcome Alert Monitoring. *JAMA*. 2014;311(4):420. [Link](#)
16. **Thombs BD***, Ziegelstein RC. Evidence Does Matter - and Evidence Does Not Support the National Heart Foundation of Australia's Consensus Statement on Depression Screening. *J Psychosom Res*. 2014;76(2):173-174. [IF=3.3]. [Link](#)

17. **Coronado-Montoya S, Kwakkenbos L, Levis B, Thombs BD***. Reassessing the clinical utility of the Patient Health Questionnaire (PHQ-9) for depression screening in prenatal women: A commentary on Sidebottom et al. *Arch Womens Ment Health*. 2013;16(3):253-254. [IF=2.0]. [Link](#)
18. **Thombs BD***. Clarification of the REMIT trial protocol. *Am Heart J*. 2012;164(5):e15. [IF=4.5]. [Link](#)
19. **Thombs BD***. No Evidence for Depression Screening in Cardiovascular Care Settings: A Comment on CANMAT Task Force Recommendations. *Ann Clin Psychiatry*. 2012;24(4):319-322. [IF=1.5]. [Link](#)
20. Hudson M, **Thombs BD**, Steele R, Baron M. Patient-reported outcome measures in systemic sclerosis: Comment on the article by Hinchcliff et al. *Arthritis Care Res*. 2012;64(6):942-943. [IF=4.7]. [Link](#)
21. **Razykov I, Levis B, Thombs BD***. Screening for depression and risk of suicide in patients with arthritis: Comment on the article by Tektonidou et al. *Arthritis Care Res*. 2012;64(4):623. [IF=4.7]. [Link](#)
22. **Thombs BD***. Postpartum depression screening: a comment on Leung et al. *J Public Health*. 2012;34(1):162-163. [IF=1.9]. [Link](#)
23. **Thombs BD***, Coyne JC, Cuijpers P, de Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, Patten SB, Turner EH, Ziegelstein RC. Rethinking the article by Thombs and colleagues – the authors respond. *CMAJ*. 2012;184(4):438-439. [IF=9.0]. [Link](#)
24. **Delisle VC, Arthurs E, Ziegelstein RC, Thombs BD***. A Meta-Analysis of Selective Serotonin Reuptake Inhibitors in Acute Coronary Syndrome: Cause for Concern. *J Psychopharmacol*. 2011;25(12):1730-1731. [IF=3.6]. [Link](#)
25. **Arthurs E, Leavens A, Levis B, Thombs BD***. Are couple-oriented interventions effective across chronic illnesses? A commentary on Martire et al. *Ann Behav Med*. 2011;42(1):134-135. [IF=3.2]. [Link](#)
26. **Leavens A, Arthurs E, Thombs BD***. Should postpartum depression screening policies be re-evaluated? A commentary on Kozhimannil et al. *Health Aff*. 2011;30(6):1216. [IF=3.8]. [Link](#)
27. **Thombs BD*, Jewett LR, Bassel M**. Is there room for criticism of studies of psychodynamic psychotherapy? *Am Psychol*. 2011;66(2):148-149. [IF=6.0]. [Link](#)
28. Coyne JC, Hagedoorn M, **Thombs BD**. Most Published and Unpublished Dissertations Should Be Excluded from Meta-Analyses: Comment on Moyer et al. *Psychooncology*. 2011;20(2):224-225. [IF=2.9]. [Link](#)
29. **Zhao Y**, Montoro R, Igartua K, **Thombs BD***. Sexual orientation and suicide: A comment on Renaud et al. *Can J Psychiatry*. 2010;55(11):746-747. [IF=2.5]. [Link](#)
30. Palmer SC, Stefanek ME, **Thombs BD**, Coyne JC. Psychological intervention and survival: Wishing does not make it so. *Clin Cancer Res*. 2010;16(21):5364-5365. [IF=7.3]. [Link](#)
31. **Milette K, El-Baalbaki G, Thombs BD***. Letter to the Editor: Intimacy and psychological distress among couples coping with head and neck or lung cancer. *Psychooncology*. 2010;19(11):1235-1236. [IF=2.9]. [Link](#)
32. **El-Baalbaki G, Arthurs E, Levis B, Thombs BD***. Effects of befriending on depressive symptoms and distress: A precautionary note on promising findings. *Br J Psychiatry*. 2010;197(3):247. [IF=5.9]. [Link](#)
33. **Thombs BD*, Roseman M, Arthurs E**. Prenatal and postpartum depression in fathers and mothers. *JAMA*. 2010;304(9):961. [IF=30.0]. [Link](#)
34. **Thombs BD***. Traumatic brain injury and major depressive disorder. *JAMA*. 2010;304(8):857. [IF=30.0]. [Link](#)
35. **Knafo R, Jewett LR, Bassel M, Thombs BD***. Sexual function in women with systemic sclerosis: A comment on Schouffoer et al. *Arthritis Care Res*. 2010;62(8):1200. [IF=4.7]. [Link](#)
36. **Razykov I, Newton EG, Lober J, Thombs BD***. Daily SMS reminders for asthma treatment adherence: A comment on Strandbygaard et al. *Respir Med*. 2010;104(8):1234-1235. [IF=2.5]. [Link](#)
37. **Jewett LR, Newton E, Smith S, Thombs BD***. Time to Abandon Small-Sample Cohort Research in Health Psychology? *Health Psychol*. 2010;29(4):339-340. [IF=4.0]. [Link](#)
38. **Roseman M, Milette K, Zhao Y, Thombs BD***. Is Optimism Associated with Physical Health? A Commentary on Rasmussen et al. *Ann Behav Med*. 2010;37(3):204-206. [IF=3.2]. [Link](#)

39. **Adeponle AB, Thombs BD***. Depression in hospitalized and stable heart failure patients in an urban Nigerian teaching hospital: A cautionary comment. *Gen Hosp Psychiatry*. 2010;32(2):e1-e2. [IF=2.7]. [Link](#)
40. Ziegelstein RC, **Thombs BD**, de Jonge P, Coyne JC. No laughing matter – reply. *J Am Coll Cardiol*. 2010;55(8):836-837. [IF=12.5]. [Link](#)
41. **Schieir O, Milette K, Adeponle A, Thombs BD***. The effectiveness of tai chi for chronic musculoskeletal pain conditions: Is the evidence ready for meta-analysis? Comment on the article by Hall et al. *Arthritis Care Res*. 2010;62(1):139-140. [IF=4.2]. [Link](#)
42. **Knafo R, Zhao Y, Newton E, Thombs BD***. In reference to *Sexual Problems After Total or Partial Laryngectomy*. *Laryngoscope*. 2009;119(8):1667-1668. [IF=2.0]. [Links](#)
43. **Newton E, Jewett LR, Thombs BD***. Childhood psychosocial stressors and adult onset arthritis: A comment on Von Korff et al. *Pain*. 2009;144(3):340-344. [IF=5.4]. [Link](#)
44. **Thombs BD*, Schieir O, Knafo R**, Ziegelstein RC. Timing may be important, but methodology is everything: A commentary on Parker et al. *Biol Psychiatry*. 2009;66(3):e1-e2. [IF=8.9]. [Link](#)
45. **Thombs BD***, Coyne JC. Should alternative diagnostic criteria be used to assess major depression severity among patients with cancer? A comment on Akechi et al. *Gen Hosp Psychiatry*. 2009;31(4):397-398. [IF=2.7]. [Link](#)
46. Coyne JC, **Thombs BD**, Mitchell AJ. Monahan et al.: PHQ-9 and PHQ-2 in Western Kenya. *J Gen Intern Med*. 2009;24(7):890. [IF=2.7]. [Link](#)
47. **Thombs BD*, Adeponle AB**, Kirmayer LJ, Rousseau C, Ziegelstein RC. More antidepressants for African Americans with coronary heart disease? Maybe – maybe not. *Am Heart J*. 2009;157(5):e33. [IF=4.3]. [Link](#)
48. **Thombs BD***, de Jonge P, Ziegelstein RC. Screening for depression in patients with coronary heart disease – reply. *JAMA*. 2009;301(13):1338. [IF=31.7]. [Link](#)
49. Coyne JC, **Thombs BD**, Hagedoorn M. A meta-analysis of psychosocial interventions for cancer patients gone awry. *Ann Behav Med*. 2009;37(1):94-96. [IF=3.2]. [Link](#)
50. **Thombs BD*, Bassel M, Jewett LR**. Analyzing effectiveness of long-term psychodynamic psychotherapy. *JAMA*. 2009;301(9):930. [IF=31.7]. [Link](#)
51. **Thombs BD***. Do more predictors improve mortality risk estimates among burn patients? Comment on McGwin et al. *Burns*. 2009;35(2):303-304. [IF=1.6]. [Link](#)
52. **Thombs BD***, Hudson M. Problems using aggregate scores of the Medical Outcomes Study 36-item Short Form Health Survey in knee and hip osteoarthritis: Possible solutions. *Osteoarthritis Cartilage*. 2008;16(11):1431-1432. [IF=4.1]. [Link](#)
53. Coyne JC, **Thombs BD**. Was it shown that "close relationships and emotional processing predict decreased mortality in women with breast cancer?" A critique of Weihs et al. (2008). *Psychosom Med*. 2008;70(6):737-738. [IF=3.5]. [Link](#)
54. Eze-Nliam CM, **Thombs BD**, Bezerra Lima B, Smith CG, Ziegelstein RC. Depression and adherence to antihypertensive therapy. *Am J Hypertens*. 2008;21(7):724-725. [IF=3.1]. [Link](#)
55. **Thombs BD***, Ziegelstein RC. Diabetes, depression, and death: A randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT): Response to Bogner et al. *Diabetes Care*. 2008;31(6):e54. [IF=7.9]. [Link](#)
56. **Thombs BD***, Ziegelstein RC. The effect of a primary care practice-based depression intervention on mortality in older adults: Replication needed. *Ann Intern Med*. 2008;148(3):244-245. [IF=15.5]. [Link](#)
57. **Thombs BD***. Perceived social support predicts outcomes following myocardial infarction: A call for screening? *Health Psychol*. 2008;27(1):1. [IF=3.0]. [Link](#)
58. **Thombs BD***, Ziegelstein RC. Retrospective screening of patients for age of initial diagnosis of coronary artery disease: Shouldn't we just ask? *J Cardiovasc Nurs*. 2008;23(1):79-81. [IF=N/A]. [Link](#)
59. **Thombs BD***, Parakh K, Ziegelstein RC. Throw the window out the door. *J Am Coll Cardiol*. 2007;50(15):1519-1520. [IF=11.1]. [Link](#)
60. Hudson M, **Thombs B**, Baron M. Are the SF-36 physical and mental component scores useful measures in patients with systemic sclerosis? *Arthritis & Rheumatism (Arthritis Care & Research)*. 2007;57(7):1339. [IF=7.7]. [Link](#)

61. Parakh K, Bush DE, Ziegelstein RC, **Thombs BD**, Fauerbach JA. Mortality and adherence to pharmacotherapy after acute myocardial infarction. *JAMA*. 2007;297(17):1877. [IF=23.2]. [Link](#)
62. Ziegelstein RC, **Thombs BD**, Parakh K, Stewart DE, Abbey SE, Grace SL. The Brain and the heart: Independent or interactive. *J Am Coll Cardiol*. 2007;49(17):1824. [IF=9.7]. [Link](#)
63. **Thombs BD***, Bresnick MG, Magyar-Russell G, Kim TJ. Early treatment of acute stress symptoms in pediatric burn patients with imipramine and fluoxetine: Commentary on Tcheung et al. *Pediatr Crit Care Med*. 2006;7(5):498. [IF=N/A]. [Link](#)
64. **Thombs BD***, Grace SL, Ziegelstein RC. Do symptom dimensions of depression following myocardial infarction relate differently to physical health indicators and cardiac prognosis? *Am J Psychiatry*. 2006;163(7):1295-1296. [IF=8.3]. [Link](#)
65. Ziegelstein RC, **Thombs BD**. The heart, the brain, and the Kounis syndrome: reply. *Eur Heart J*. 2006;27(6):757-758. [IF=7.3]. [Link](#)

H.3.7. Book Reviews

1. **Thombs BD***. Review of the book *Culture and children's intelligence: Cross-cultural analysis of the WISC-III*. J. Georgas, L. G. Weiss, F. J. R. van de Vijver, & D. H. Saklofske (Eds.). *Transcult Psychiatry*. 2008;45(4):708-711. [IF=N/A]. [Link](#)

H.3.8. Book Chapters

1. Gholizadeh S, Fox RS, Mills SD, Jewett LR, **Thombs BD**, Malcarne VL. Body image distress in scleroderma. In Allanore Y, Denton CP, Kuwana M Chung L, Shah A, Varga J (eds.). *Scleroderma: From pathogenesis to comprehensive management*, 3rd ed. Chicago: Springer. In press.
2. **Thombs BD***, Kwakkenbos L. Psychosocial issues and care for patients with systemic sclerosis. In Allanore Y, Denton CP, Kuwana M Chung L, Shah A, Varga J (eds.). *Scleroderma: From pathogenesis to comprehensive management*, 3rd ed. Chicago: Springer. In press.
3. Gholizadeh S, Fox RS, Mills SD, **Jewett LR**, **Thombs BD**, Malcarne VL. Coping with the disfigurement of scleroderma: Facial, skin, and hand changes. In Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M (eds.). *Scleroderma: From pathogenesis to comprehensive management*, 2nd ed. Chicago: Springer. 2017. [Link](#)
4. **Jewett LR**, **Kwakkenbos L**, **Thombs BD***. Psychosocial issues and care for patients with systemic sclerosis. In Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M (eds.). *Scleroderma: From pathogenesis to comprehensive management*, 2nd ed. Chicago: Springer. 2017. [Link](#)
5. **Kwakkenbos L**, **Thombs BD***. Non-drug approaches to treating Raynaud's phenomenon. In Wigley FM, Herrick A, Flavahan A (eds.). *Raynaud's phenomenon*. Chicago: Springer. 2014. [Link](#)
6. **Jewett LR**, Haythornthwaite J, **Thombs BD***. Psychosocial issues and care for patients with scleroderma. In Varga J, Denton CP, Wigley FM (eds.). *Scleroderma: From pathogenesis to comprehensive management*. Chicago: Springer. 2012.
7. **Jewett LR**, Hudson M, **Thombs BD***. A 38-year-old woman with elevated muscle enzymes, Raynaud's phenomenon and positive anti-topoisomerase I antibody: Is she depressed? In Silver RM, Denton CP (eds.), *Case studies in systemic sclerosis*. Chicago: Springer. 2011. [Link](#)
8. **Thombs BD***, Ziegelstein RC. Screening in cardiovascular care. In Mitchell AJ, Coyne JC (eds.), *Screening for depression in clinical practice: A practical guide for detection and diagnosis of mood disorders in primary & secondary care*, Oxford, UK: Oxford University Press. 2009. [Link](#)
9. Chen EC, **Thombs BD**, Costa C. Building connection through diversity in group counseling: A dialogical perspective. In Pope-Davis DB, Coleman HLK, Liu WM, Toporek RL (eds.), *Handbook of multicultural competencies in counseling and psychology*, Thousand Oaks, CA: Sage. 2003. [Link](#)

H.3.9. Professional or Cultural Journals

1. 2020 SPIN Recap Article. *Scleroderma Canada Newsletter*. Scleroderma Canada. Winter 2020.
2. 2020 SPIN Recap Article. *The Scleroderma Reporter*. Scleroderma Society of Ontario. Winter 2020.
3. Nouveau programme de formation du SPIN pour les animateurs de groupes de soutien pour la sclérodémie /New SPIN Training Program for Scleroderma Support Group Leaders. *Le Bulletin*, Sclérodémie Québec, Spring-Summer 2019.
4. Neues SPIN-Trainingsprogramm für Leiterinnen von Sklerodermie-Selbsthilfegruppen. *Scleroderma Liga e.V. Website News*, Scleroderma Liga e.V. March 3, 2019. [Link](#)

5. Online program on the way for people with rare autoimmune disease. *JGH News*, Jewish General Hospital Newspaper. January 2019. [Link](#)
6. Fedoruk C, Carrier ME, **Kwakkenbos L**, **Thombs BD***. The Scleroderma Patient-centered Intervention Network (SPIN): an innovative cohort-based initiative for scleroderma. *Journal of the Canadian Rheumatology Association*. 2019;29(1):14-15. [Link](#)
7. SPIN – Initiative zur Entwicklung von Unterstützungsprogrammen für Sklerodermie. *Scleroderma Liga e.V. Website News*, Scleroderma Liga e.V. December 14, 2018. [Link](#)
8. Le SPIN-SHARE à la Conférence nationale sur la sclérodémie: Lancement de programmes de soutien axés sur les patients sclérodermiques/The SPIN-SHARE at the National Scleroderma Conference: Moving forward with patient-centred support programs. *Le Bulletin*, Sclérodémie Québec, Fall-Winter 2018.
9. SPIN-SHARE at the National Scleroderma Conference: Moving Forward with Patient-centered Support Programs. *Scleroderma Canada Newsletter*, Scleroderma Canada. Winter 2018. [Link](#)
10. SPIN launches online platform to provide self-management tools. *Lady Davis Institute Research Newsletter*, the Lady Davis Institute for Medical Research. November 2018. [Link](#)
11. Scleroderma Patient-centered Intervention Network (SPIN): An International Patient-researcher Partnership. *IMHA on the move!* The Institute of Musculoskeletal Health and Arthritis, Canadian Institutes of Health Research, October 2018.
12. Carrier ME, **Kwakkenbos L**, **Thombs BD***. Le projet SPIN-SHARE: Accessibilité gratuite aux programmes de soutien en ligne du RIPS/The SPIN-SHARE project: Making SPIN's online support programs accessible for free. *Le Bulletin*, Sclérodémie Québec, Spring-Summer 2018.
13. **Rice DB**, **Jiménez-Carboni A**, **Cañedo-Ayala M**, **Thombs BD***. Une étude du RIPS pour soutenir les aidant(e)s naturel(le)s/The Experience of Informal Caregivers: SPIN-CARE Supporting Caregivers. *Le Bulletin*, Sclérodémie Québec. Winter 2017.
14. **Thombs BD***, **Kwakkenbos L**, Carrier ME. SPIN and Scleroderma Canada Leading the Way! *Scleroderma Canada Newsletter*, Scleroderma Canada. Winter 2017/2018.
15. **Thombs BD***, **Kwakkenbos L**, Carrier ME. Le RIPS a le vent dans les voiles. *Le Bulletin*, Sclérodémie Québec. March 2017
16. Carrier ME, **Kwakkenbos L**, **Thombs BD***. Help others to live better with scleroderma. *The Scleroderma Reporter*. Scleroderma Society of Ontario. Spring/Summer 2015.
17. Carrier ME, **Kwakkenbos L**. Introducing the Scleroderma Patient-centered Intervention Network (SPIN) Co-Director and Coordinator. *The Scleroderma Reporter*. Scleroderma Society of Ontario. Spring/Summer 2015 (supervised trainee contribution).
18. **Gumuchian S**, **Delisle VC**, **Thombs BD***. Illuminating the support group experience: Helping leaders get the support they need. *The Scleroderma Reporter*. Scleroderma Society of Ontario. Spring/Summer 2015.
19. **Thombs BD***. Towards better care for scleroderma: An update from the Scleroderma Patient-centered Intervention Network. *The Scleroderma Connection*, Scleroderma Society of Canada. Fall 2014.
20. **Thombs BD***. Screening for postpartum depression is premature and possibly harmful. *New York Times, Room for Debate*. June 19, 2014. [Link](#)
21. **SPIN Research Group***, Coping with Stress, *The Scleroderma Connection*, Scleroderma Society of Canada, Spring 2013. [Link](#)
22. The Scleroderma Patient-centered Intervention Network (SPIN), *Scleroderma Association of Manitoba*. February 2013.
23. **Milette K**. An update on SPIN's online self-management program. *Scleroderma Voice*. Scleroderma Foundation. Summer 2013 (supervised trainee contribution).
24. **Milette K**. An update on SPIN's online self-management program. *The Scleroderma Connection*. Scleroderma Society of Canada. Winter 2013 (supervised trainee contribution). [Link](#)
25. **Milette K**. An update on SPIN's online self-management program. *Scleroderma Association of British Columbia*. Spring 2013 (supervised trainee contribution).
26. The Scleroderma Patient-centered Intervention Network (SPIN), *Scleroderma Manitoba*. Fall 2013.
27. International Collaboration Working to Improve the Lives of Those Living with Scleroderma, *Scleroderma Voice*. Fall 2013.

28. **Jewett LR**. Scleroderma Patient-centered Intervention Network (SPIN). *Sclerodata*. Scleroderma Association of British Columbia. Summer 2012 (supervised trainee contribution).
29. **Jewett LR**. Scleroderma Patient-centered Intervention Network (SPIN). *The Researcher – The Canadian Scleroderma Research Group Newsletter*. Canadian Scleroderma Research Group. Fall-Winter 2011 (supervised trainee contribution).
30. **Thombs BD***. Scleroderma Patient-centered Intervention Network (SPIN). *The Scleroderma Report*. Scleroderma Society of Ontario. Fall 2011-Winter 2012.
31. **Levis B**. Sexual functioning in women with scleroderma: the taboo report. *Sclerodata*. Scleroderma Association of British Columbia. Autumn 2011 (supervised trainee contribution).
32. **Jewett LR**. Getting under the skin: A look at body image in scleroderma. *Canadian Scleroderma a News*. Scleroderma Society of Canada. May 2010 (supervised student contribution).
33. **Schieir O**. The scleroderma pain puzzle: Putting the pieces together. *Canadian Scleroderma News*. Scleroderma Society of Canada. February 2010 (supervised student contribution).
34. **Bassel M**. The experience of fatigue: Sick and tired of being sick and tired? *Canadian Scleroderma News*. Scleroderma Society of Canada. February 2010 (supervised student contribution).
35. **Newton E**. Scleroderma and sadness: The inside scoop. *Canadian Scleroderma News*. Scleroderma Society of Canada. November 2009 (supervised student contribution).
36. **Thombs BD***. Fatigue in scleroderma: A new Canadian Scleroderma Research Group study. *Canadian Scleroderma News*. Scleroderma Society of Canada. May 2008.
37. Neel M, **Thombs BD**, Fauerbach JA. Coping with real, remembered and imagined stress III: Cognitive methods. *Burn Support News. Issue II*. Grand Rapids, MI: The Phoenix Society, Inc. 2005.
38. **Thombs BD***. What do culturally sensitive psychological practices mean? *Network for Multicultural Training in Psychology Newsletter*, 2003.

H.3.10. Peer-Reviewed Oral Conference Presentations, Symposia

1. **Wu Y, Levis B, Ioannidis JPA, Benedetti A, Thombs BD*, DEPRESSion Screening Data (DEPRESSD) Collaboration**. Major depression classification based on different diagnostic interviews: a synthesis of individual participant data meta-analyses. *Methods for Evaluation of medical prediction Models, Tests and Biomarkers (MEMTAB) Conference*. Leuven, Belgium. December 2020 (presented via videoconference due to COVID-19). *Diagnostic and Prognostic Research*. 2021;5(Suppl 1):8.
2. **Levis B, Bhandari PM, Neupane D, Thombs BD*, Benedetti A, DEPRESSion Screening Data (DEPRESSD) PHQ Collaboration**. Bias in diagnostic accuracy estimates due to data-driven cutoff selection: a simulation study. *Methods for Evaluation of medical prediction Models, Tests and Biomarkers (MEMTAB) Conference*. Leuven, Belgium. December 2020 (presented via videoconference due to COVID-19). *Diagnostic and Prognostic Research*. 2021;5(Suppl 1):23.
3. **Levis B, Sun Y, He C, Wu Y, Krishnan A, Bhandari PM, Neupane D, Imran M, Brehaut E, Negeri ZF, Fischer FH, Benedetti A, Thombs BD***, and the DEPRESSD PHQ Collaboration. Screening for depression with the Patient Health Questionnaire-2 (PHQ-2) alone and in combination with the PHQ-9: individual participant data meta-analysis. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
4. **Levis B, Negeri Z, Sun Y, Benedetti A, Thombs BD***, and the DEPRESSD EPDS Collaboration. Screening for depression in pregnant and postpartum women: an individual participant data meta-analysis of the Edinburgh Postnatal Depression Scale. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
5. **Levis B, Dehtiarova Y, Sun Y, Wu Y, Benedetti A, Thombs BD***, and the DEPRESSD PHQ Collaboration. *depressionscreening100.com/phq*: a practice-based perspective to using the Patient Health Questionnaire-9 to screen for depression. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
6. **Negeri ZF, Levis B, Wu Y, Thombs BD***, Benedetti A, and the DEPRESSD PHQ Collaboration. Latent class models for individual participant data meta-analyses of diagnostic test accuracy studies with imperfect reference standards. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).

7. **Azar M**, Benedetti A, **Riehm KE**, Imran M, Krishnan A, **Chiovitti M**, Sanchez T, Shrier I, **Thombs BD***. Characteristics of Meta-analyses and Included Trials Associated with Data Contribution to Individual Participant Data Meta-Analyses of Randomized Controlled Trials. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
8. **Negeri ZF**, **Levis B**, **Wu Y**, **Thombs BD***, Benedetti A. and the **DEPRESSED PHQ Collaboration**. Latent class models for individual participant data meta-analyses of diagnostic test accuracy studies with imperfect reference standards. *2020 Joint Statistical Meetings*. Philadelphia, Pennsylvania, USA. August 2020 (presented via videoconference due to COVID-19).
9. **Levis B**, Benedetti A, **Thombs BD***, **DEPRESSION Screening Data (DEPRESSD) PHQ Collaboration**. Using the Patient Health Questionnaire-9 to screen for major depression: an individual participant data meta-analysis. *Primary Care Mental Health Conference 2020*. University of York, Heslington, UK. May 2020. (not presented due to COVID-19).
10. **Carboni-Jiménez A**, **Rice DB**, **Cañedo-Ayala M**, **Thombs BD***. The experience of informal caregivers of persons with systemic sclerosis: a SPIN-CARE study. In **Rice DB** (Chair). Patient-centered Interdisciplinary Research in a Rare Disease Context: The Scleroderma Patient-centered Intervention Network (SPIN) (Symposium). *2020 Interdisciplinary Conference in Psychology*, Ottawa, Ontario, Canada. May 2020 (presented via videoconference due to COVID-19).
11. **Harb S**, Peláez S, **Carrier ME**, Kwakkenbos L, Bartlett SJ, Hudson M, Mouthon L, Sauvé M, Welling J, **Thombs BD***, Shrier I, Scleroderma Patient-centered Intervention Network (SPIN) – Physical Activity Enhancement Patient Advisory Team, **SPIN Investigators**. Physical activity barriers and facilitators in scleroderma: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. In **Rice DB** (Chair). Patient-centered Interdisciplinary Research in a Rare Disease Context: The Scleroderma Patient-centered Intervention Network (SPIN) (Symposium). *2020 Interdisciplinary Conference in Psychology*, Ottawa, Ontario, Canada. May 2020 (presented via videoconference due to COVID-19).
12. **Thombs BD***, Dyas L, Pépin M, **Aguila K**, **Carrier ME**, **Tao L**, **Harb S**, Malcarne VL, El-Baalbaki G, Peláez S, Sauve M, Hudson M, Platt RW, SPIN-SSLED Patient Advisory Team. Patients supporting patients: The SPIN – Scleroderma Support group Leader Education (SPIN-SSLED) Program. In **Rice DB** (Chair). Patient-centered Interdisciplinary Research in a Rare Disease Context: The Scleroderma Patient-centered Intervention Network (SPIN) (Symposium). *2020 Interdisciplinary Conference in Psychology*, Ottawa, Ontario, Canada. May 2020 (presented via videoconference due to COVID-19).
13. **Neupane D**, **Levis B**, **Bhandari PM**, **Thombs BD***, Benedetti A, **DEPRESSION Screening Data (DEPRESSD) Collaboration**. Selective cutoff reporting in diagnostic accuracy studies of the PHQ-9 and EPDS depression screening tools. In **Wu Y** (Chair). Addressing challenges in evaluating depression screening tool accuracy via individual participant data meta-analysis (Symposium). *9th Interdisciplinary Conference in Psychology*. Ottawa, Canada. May 2020 (presented via videoconference due to COVID-19).
14. **Bhandari PM**, **Levis B**, **Neupane D**, Patten SB, Shrier I, **Thombs BD***, Benedetti A, **DEPRESSION Screening Data (DEPRESSD) EPDS Collaboration**. Bias in accuracy estimates from data-driven optimal cutoff selection: simulation study using EPDS IPDMA dataset. In **Wu Y** (Chair). Addressing challenges in evaluating depression screening tool accuracy via individual participant data meta-analysis (Symposium). *9th Interdisciplinary Conference in Psychology*. Ottawa, Canada. May 2020 (presented via videoconference due to COVID-19).
15. **Brehaut E**, **Neupane D**, **Bhandari PM**, **Levis B**, **Wu Y**, Benedetti A, **Thombs BD***, **DEPRESSION Screening Data (DEPRESSD) HADS Collaboration**. Prevalence using the HADS Depression Subscale compared to SCID classification: individual participant data meta-Analysis. In **Wu Y** (Chair). Addressing challenges in evaluating depression screening tool accuracy via individual participant data meta-analysis (Symposium). *9th Interdisciplinary Conference in Psychology*. Ottawa, Canada. May 2020 (presented via videoconference due to COVID-19).
16. **Wu Y**, **Levis B**, Ioannidis JPA, Benedetti A, **Thombs BD**, **DEPRESSION Screening Data (DEPRESSD) Collaboration**. Major depression classification based on different diagnostic interviews: a synthesis of individual participant data meta-analyses. In **Wu Y** (Chair). Addressing challenges in evaluating depression screening tool accuracy via individual participant data meta-

analysis (Symposium). 9th *Interdisciplinary Conference in Psychology*. Ottawa, Canada. May 2020 (presented via videoconference due to COVID-19).

17. **Negeri ZF, Levis B, Benedetti A, Thombs BD*, DEPRESSsion Screening Data (DEPRESSD) PHQ Collaboration.** Accuracy of the PHQ-9 for screening to detect major depression: systematic review and meta-analysis of individual participant data. In **Wu Y** (Chair). Addressing challenges in evaluating depression screening tool accuracy via individual participant data meta-analysis (Symposium). 9th *Interdisciplinary Conference in Psychology*. Ottawa, Canada. May 2020 (presented via videoconference due to COVID-19).
18. **Bhandari PM, Levis B, Neupane D**, Patten SB, Shrier I, **Thombs BD***, Benedetti A, and the **DEPRESSsion Screening Data (DEPRESSD) EPDS Collaboration.** Bias in diagnostic accuracy estimates due to data-driven cutoff selection: simulation study using individual participant data from 49 studies on the diagnostic accuracy of the Edinburgh Postnatal Depression Scale. In **Levis B** (Chair). Use of individual participant data meta-analysis to address challenges in evaluating depression screening tool accuracy (Symposium). 81st *Canadian Psychological Association Annual Convention*. Montreal, Quebec, Canada. May 2020 (presented virtually due to COVID-19).
19. **Neupane D, Levis B, Bhandari PM, Thombs BD***, Benedetti A, and the **DEPRESSsion Screening Data (DEPRESSD) EPDS and PHQ-9 Collaboration.** Selective cutoff reporting in studies of the accuracy of the PHQ-9 and EPDS depression screening tools: comparison of results based on published cutoffs versus all cutoffs using individual participant data meta-analysis. In **Levis B** (Chair). Use of individual participant data meta-analysis to address challenges in evaluating depression screening tool accuracy (Symposium). 81st *Canadian Psychological Association Annual Convention*. Montreal, Quebec, Canada. May 2020 (presented virtually due to COVID-19).
20. **Wu Y, Levis B**, Ioannidis JPA, Benedetti A, **Thombs BD***, and the **DEPRESSsion Screening Data (DEPRESSD) Collaboration.** Major depression classification based on the SCID, CIDI and MINI diagnostic interviews: a meta-analysis of individual participant data meta-analyses. In **Levis B** (Chair). Use of individual participant data meta-analysis to address challenges in evaluating depression screening tool accuracy (Symposium). 81st *Canadian Psychological Association Annual Convention*. Montreal, Quebec, Canada. May 2020 (presented virtually due to COVID-19).
21. Birtwhistle R, Morissette K, Dickinson JA, Reynolds DL, Avey MT, Domingo FR, Rodin R, Moore A, Riva J, **Thombs BD***. Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care. *Alberta College of Family Physicians Family Medicine Summit*. Banff, Alberta, Canada, March 2020 (not presented due to COVID-19).
22. Groulx S, Limburg H, Doull M, Klarenbach S, Singh H, Wilson B, Lang E, Moore A, **Thombs BD***. Canadian Task Force recommendations on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease (GERD) without alarm symptoms. *Alberta College of Family Physicians Family Medicine Summit*. Banff, Alberta, Canada, March 2020 (not presented due to COVID-19).
23. Kwakkenbos L, Carrier ME, **Turner K**, Tao L, Aquila K, **Carboni-Jimenez A**, **Cañedo-Ayala M**, **Harb S**, Welling J, Sauve M, van den Ende C, Schouffoer A, Hudson M, Nguyen C, Boutron I, Rannou F, **Thombs BD***, Mouthon L, and the **SPIN Investigators.** Randomized controlled trial of an internet-based exercise program to improve hand function in patients with scleroderma: a Scleroderma Patient- centered Intervention Network (SPIN) study. 6th *Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020.
24. Relton C, Nickolls B, Zwarenstein M, Hemken L, Uher R, Frobert O, Fibert P, **Imran M**, **Kwakkenbos L**, **Thombs BD***. Review of use of the Trials within Cohorts (TwICs) design approach. 5th *International Clinical Trials Methodology Conference*. Brighton, UK. October 6-9, 2019.
25. **Levis B**, Benedetti A, Rücker G, Jones HE, **Thombs BD***, and the **DEPRESSD Collaboration.** An empirical comparison of methods for meta-analysis of diagnostic accuracy when studies selectively report cutoffs. 40th *Annual Conference of the International Society for Clinical Biostatistics*. Leuven, Belgium. July 2019.
26. **Levis B**. From 0 to 18,158: A journey in individual participant data meta-analysis. *Early Career Biostatisticians' Day of the 2019 International Society for Clinical Biostatistics*. Leuven, Belgium. July 2019.

27. **Harb S**, Cumin J, **Rice DB**, Peláez S, **Thombs BD***, Shrier I, SPIN-PACE Patient Advisory Team. Identifying barriers and facilitators to physical activity for people with scleroderma: A nominal group technique study. *50th Laurentian Conference of Rheumatology*, Estérel, Quebec, Canada, May 2019.
28. **Kwakkenbos L**, Tao L, **Carboni-Jiménez A**, **Turner KA**, **Aguila K**, Boruff J, Ahmed S, **Thombs BD***. Perceived barriers and facilitators of using synchronous telerehabilitation of physical and occupational therapy in musculoskeletal disorders: A scoping review. *The 9th Annual Edith Strauss Interactive Day*. Montreal, Quebec, Canada. April 2019.
29. **Levis B**, Rücker G, Jones HE, **Thombs BD***, Benedetti A, and the **DEPRESSD Collaboration**. Estimating diagnostic accuracy when primary studies selectively report cutoffs: Individual participant data meta-analysis versus three methods for analyzing published data. *2018 Cochrane Colloquium*. Edinburgh, Scotland. September 2018.
30. **Levis B**, Yan XW, He C, Benedetti A, **Thombs BD***. Overestimation of depression prevalence in meta-analyses via the inclusion of primary studies that assessed depression using screening tools or rating scales rather than validated diagnostic interviews. *Preventing Overdiagnosis*. Copenhagen, Denmark. August 2018.
31. **Turner KA**, Shrier I, **Thombs BD***. Defining overdiagnosis of mental health disorders: Secondary analysis of an overdiagnosis scoping review. *Preventing Overdiagnosis*. Copenhagen, Denmark. August 2018.
32. **Levis B**, Rücker G, Jones HE, **Thombs BD***, Benedetti A, and the **DEPRESSD Research Group**. Estimating diagnostic test accuracy in the context of incomplete reporting across cutoff thresholds: A comparison of conventional meta-analysis of published data, two modelling approaches using published data, and individual participant data meta-analysis. *Methods for Evaluating Medical Tests and Biomarkers (MEMTAB) Conference*. Utrecht, Netherlands. July 2018.
33. **Turner KA**, **Kwakkenbos L**, **Sanchez T**, **Carrier ME**, Mouthon L, Hudson M, Van den Ende C, Schouffoer A, Welling J, Sauvé M, **Thombs BD***. The association of sociodemographic and disease variables with hand function in systemic sclerosis. *Canadian Dermatology Association 93rd Annual Conference*, Montreal, Canada, June 2018.
34. Relton C, Zwarenstein M, **Thombs BD**, **Kwakkenbos L**, Fröbert O, Juszczak E, Thomas K. Rethinking the architecture of pragmatic trials: A review of trials within both researcher-generated and routine healthcare data structures. *39th Annual Meeting of the Society for Clinical Trials*. Portland, Oregon, USA. May 2018.
35. Harel D, Ishihara M, **Levis B**, **Thombs BD***. Optimal methods for shortening patient-reported outcome measures. *12th International Conference on Health Policy Statistics*. Charleston, South Carolina, USA. January 2018.
36. Bell N, Dickinson J, Grad R, **Thombs BD**. Better decision making with patients on the harms and benefits of screening. *Family Medicine Forum 2017*. Montreal, Quebec, Canada. November 2017.
37. **Azar M**, Benedetti A, Shrier I, **Chiovitti M**, **Sanchez T**, **Levis B**, **Thombs BD***. Trial and meta-analysis characteristics associated with data contribution in individual patient data meta-analyses of randomized controlled trials. *Preventing Overdiagnosis 2017*. Quebec City, Quebec, Canada. August 2017.
38. **Levis B**, Benedetti A, **Riehm KE**, **Saadat N**, **Levis AW**, **Azar M**, **Rice DB**, **Chiovitti M**, **Thombs BD***, and the **DEPRESSD Research Group**. Overdiagnosis of major depression based on lay-administered fully structured diagnostic interviews. *Preventing Overdiagnosis 2017*. Quebec City, Quebec, Canada. August 2017.
39. **Levis B**, Benedetti A, **Riehm KE**, **Saadat N**, **Levis AW**, **Azar M**, **Rice DB**, **Chiovitti M**, **Thombs BD***, and the **DEPRESSD Research Group**. Underestimation of depression screening tool sensitivity when using lay-administered fully structured diagnostic interviews as the reference standard: an individual patient data meta-analysis. *Cochrane Canada Symposium*. Hamilton, Ontario, Canada. May 2017.
40. **Kwakkenbos L**, **Thombs BD***. Novel approaches for pragmatic evaluations and dissemination of E-health interventions: The Scleroderma Patient-centered Intervention Network. *5th Association for Researchers in Psychology and Health Conference*, Leiden, The Netherlands. February 2017.
41. **Thombs BD***, **Saadat N**, **Riehm K**, Vaswani A, Andrews B, Simmons P, Cosgrove L. There is not

evidence that “screening” with self-report questionnaires for presently experienced health problems and symptoms improves health: A review of randomized controlled trials included in major screening guidelines and recommendations. *Preventing Overdiagnosis 2016*, Barcelona, Spain. September 2016.

42. **Azar M**, **Riehm K**, **Saadat N**, **Fedoruk C**, Kimmelman J, **Levis B**, **Levis AW**, **Rice DB**, Kloda LA, **Thombs BD***. Transparency of outcome reporting and trial registration of randomized controlled trials of non-regulated health interventions. *Preventing Overdiagnosis 2016*, Barcelona, Spain. September 2016.
43. **Levis AW**, Harel D, **Kwakkenbos L**, **Thombs BD***. Using optimal test assembly methods for shortening patient-reported outcome measures: development and validation of the Cochin Hand Function Scale-6. *Statistical Society of Canada Annual Meeting* St. Catharines, Ontario, Canada. May 2016.
44. **Kwakkenbos L**, **Thombs BD***, Bartlett SJ, **Carrier ME**, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D, **SPIN investigators**. The PROMIS-29 in systemic sclerosis: Associations with clinical characteristics in the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, San Francisco, California, USA. November 2015.
45. Gholizadeh S, Mills SD, Fox RS, **Jewett L**, **Carrier ME**, **Kwakkenbos L**, Gottesman K, Roesch SC, **Thombs BD***, Malcarne VL, **SPIN Investigators**. A psychometric analysis of the Social Interaction Anxiety Scale (SIAS-6) in systemic sclerosis: Preliminary results from the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, San Francisco, California, USA, November 2015.
46. **Levis B**, Benedetti A, **Thombs BD***. Selective cutoff reporting in diagnostic test accuracy studies of depression screening tools: Comparing traditional meta-analysis to individual patient data meta-analysis. *2015 Cochrane Colloquium*. Vienna, Austria. October 2015.
47. **Levis B**, Benedetti A, **Thombs BD***. Selective cutoff reporting in studies of diagnostic test accuracy of depression screening tools: Comparing traditional meta-analysis to individual patient data meta-analysis. *Preventing Overdiagnosis 2015*, Bethesda, Maryland, USA. September 2015.
48. Harel D, Steele RJ, **Thombs BD**, Hudson M, Baron M, **Canadian Scleroderma Research Group**. A weighted summed score for the Center for Epidemiologic Studies - Depression Scale in systemic sclerosis. *Joint Statistical Meetings*, Seattle, Washington, USA. August 2015.
49. **Kwakkenbos L**, Minton O, Stone PC, Alexander S, Baron M, Hudson M, **Thombs BD***. Identifying clinically significant fatigue in rheumatic diseases: a case-definition approach. *European League Against Rheumatism Congress 2015*, Rome, Italy. June 2015.
50. **Levis B**, Benedetti A, **Levis AW**, **Thombs BD***. Comparing traditional meta-analysis to individual patient data meta-analysis to assess the diagnostic accuracy of the Patient Health Questionnaire-9. In Thombs BD (Chair), Improving evidence-based psychological services by identifying and reducing reporting biases (Symposium). *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada. June 2015.
51. **Levis AW**, Kelley GA, **Thombs BD***. Assessing reporting bias in trials of exercise interventions for pain management in rheumatic diseases: An application of the test for excess significance. In Thombs BD (Chair), Improving evidence-based psychological services by identifying and reducing reporting biases (Symposium). *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada. June 2015.
52. **Rice DB**, **Thombs BD***. Sample size specification and population appropriateness in depression screening accuracy studies. In Thombs BD (Chair), Improving evidence-based psychological services by identifying and reducing reporting biases (Symposium). *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada. June 2015.
53. **Riehm K**, **Azar M**, **Thombs BD***. Outcome reporting and trial registration in top behavioral health journals. In Thombs BD (Chair), Improving evidence-based psychological services by identifying and reducing reporting biases (Symposium). *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada. June 2015.
54. **Kwakkenbos L**, **Thombs BD***, Bartlett S, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D,

SPIN Investigators. The PROMIS-29 in systemic sclerosis: associations with clinical characteristics. *PROMIS Health Organization Inaugural Conference*, Philadelphia, Pennsylvania, USA. May 2015.

55. Bartlett SJ, Carrier ME, Correia H, **Kwakkenbos L**, **Thombs BD***, **SPIN Investigators**. PROMIS-29 en français: coordinating translation efforts in Canada and France for a universal approach. *PROMIS Health Organization Inaugural Conference*, Philadelphia, Pennsylvania, USA. May 2015.
56. **Jewett LR**, **Delisle VC**, Mendelson C, Malcarne VL, Hudson M, **Thombs BD***. Visible differences from medical illness: body image concerns in scleroderma. In symposium (Malcarne VL, discussant): Overcoming barriers to developing, testing, and disseminating interventions for body image distress in a rare disease context: the Scleroderma Patient-centered Intervention Network (SPIN). *Appearance Matters 6*, Bristol, UK. July 2014.
57. Welling J, **Thombs BD***. Patient organizations in the Scleroderma Patient-centered Intervention Network (SPIN): Partner, expert and advocate. In symposium (Malcarne VL, discussant): Overcoming barriers to developing, testing, and disseminating interventions for body image distress in a rare disease context: the Scleroderma Patient-centered Intervention Network (SPIN). *Appearance Matters 6*, Bristol, UK. July 2014.
58. **Kwakkenbos L**, **Thombs BD***. Leveraging an innovative trial design for pragmatic evaluations of psychological interventions: the cohort multiple randomized controlled trial (cmRCT) design. In symposium (Malcarne VL, discussant): Overcoming barriers to developing, testing, and disseminating interventions for body image distress in a rare disease context: the Scleroderma Patient-centered Intervention Network (SPIN). *Appearance Matters 6*, Bristol, UK. July 2014.
59. **Coronado-Montoya S**, **Levis AW**, **Kwakkenbos L**, Steele R, Turner EH, **Thombs BD***. Application of the excess significance bias test in randomized controlled trials of mindfulness-based mental health interventions. *Lady Davis Institute of Medical Research 2014 Annual Retreat*, Montreal, Quebec, Canada. May 2014.
60. **Thombs BD***, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JPA. Re-Analysis of the United States Preventive Services Task Force Systematic Review on Screening for Depression in Primary Care. *Preventing Overdiagnosis International Conference*, Dartmouth University, Hanover, New Hampshire, USA. September 2013.
61. **Razykov I**, **Thombs BD***. The Utility of the PHQ-9 to Assess Suicide Risk in Medical Patients. *2013 World Congress on Suicide – International Academy for Suicide Research*, Montreal, Quebec, Canada, June 2013.
62. **Delisle V**, Abbey S, Beck A, Dobson KS, Dozois DJA, Grace S, Stewart D, Ziegelstein R, **Thombs BD***. The influence of somatic symptoms on Beck Depression Inventory scores in hospitalized post-myocardial infarction patients. In Thombs BD (Chair), Psychological measurement in hospital and health centers (Symposium). *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada. June 2013.
63. **Jewett L**, Hudson M, Heinberg L, Wigley F, Haythornthwaite J, Baron M, **Thombs BD***. Assessing visible differences from medical illness: Development and validation of a body image avoidance questionnaire for people living with scleroderma. In Thombs BD (Chair), Psychological measurement in hospital and health centers (Symposium). *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada. June 2013.
64. **Kwakkenbos L**, Arthurs E, van den Hoogen F, Hudson M, van Lankveld W, Baron M, van den Ende C, **Thombs BD***. Cross-language measurement equivalence of the Center for Epidemiologic Studies Depression (CES-D) scale in systemic sclerosis: A comparison of Canadian and Dutch patients. In Thombs BD (Chair), Psychological measurement in hospital and health centers (Symposium). *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada. June 2013.
65. **Razykov I**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. The utility of the Patient Health Questionnaire-9 to assess suicide risk in medical patients. In Thombs BD (Chair), Psychological measurement in hospital and health centers (Symposium). *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada. June 2013.
66. **Kwakkenbos L**, **Thombs BD***. Novel approaches for evaluating psychological interventions: The cohort multiple randomized controlled trial (cmRCT) design. Theory Review. *2013 Canadian*

Psychological Association Convention, Quebec City, Quebec, Canada, June 2013.

67. **Levis B, Thombs BD***. Individual patient-data meta-analysis to overcome shortcomings in traditional meta-analysis of screening test accuracy. Theory Review. *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada, June 2013.
68. **Razykov I**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. The utility of the Patient Health Questionnaire-9 to assess suicide risk in patients with systemic sclerosis. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Washington, DC, USA, November 2012.
69. **Jewett LR**, Hudson M, Baron M, Malcarne V, **Thombs BD***, **Canadian Scleroderma Research Group**. Acquired disfigurement from medical illness: Correlates of body image distress among people with scleroderma. *Appearance Matters 5*, Bristol, UK, July 2012.
70. **Levis B**, Hudson M, Knafo R, Baron M, Nielson W, Hill M, **Thombs BD***. Frequency and impact of symptoms experienced by patients with systemic sclerosis: Sexual activity and impairment among women with systemic sclerosis. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Chicago, Illinois, USA, November 2011.
71. **Thombs BD***, **Arthurs E**, **El-Baalbaki G**, **Meijer A**, Ziegelstein R, Steele R. Forecasting yesterday's weather: The risk of spectrum bias from the inclusion of already diagnosed/treated patients in studies of depression screening tools. *19th Cochrane Colloquium*, Madrid, Spain. October 2011.
72. **Delisle VC**, Beck AT, Dobson KS, Dozois DJA, **Thombs BD***. Revisiting differences in somatic symptoms of depression among men and women: Much ado about nothing? *National Student Conference of the Canadian Society of Epidemiology and Biostatistics*, Montreal, Quebec, Canada. June 2011.
73. **Thombs BD***, **Arthurs E** (presenter), **El-Baalbaki G**, **Meijer A**, Ziegelstein R, Steele R. Risk of bias from the inclusion of already diagnosed or treated patients in diagnostic accuracy studies of depression screening tools. *National Student Conference of the Canadian Society of Epidemiology and Biostatistics*, Montreal, Quebec, Canada. June 2011.
74. **Arthurs E**, Hudson M, Baron M, **Thombs BD***. Are French and English versions of the PHQ-9 comparable? An assessment of differential item functioning. *National Student Conference of the Canadian Society of Epidemiology and Biostatistics*, Montreal, Quebec, Canada. June 2011.
75. **Arthurs E**, Hudson M, Baron M, **Thombs BD***. Are French and English versions of the PHQ-9 comparable? An assessment of differential item functioning. In Thombs BD (Chair), Myths and measures: Mental health assessment in medical settings (Symposium). *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
76. **Leavens A**, Patten S, Hudson M, Baron M, **Thombs BD***. Are self-report depression scales biased in medical settings? Somatic symptoms reported on the PHQ-9 by patients with scleroderma compared to a general population sample. In Thombs BD (Chair), Myths and measures: Mental health assessment in medical settings (Symposium). *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
77. **Delisle V**, Dozois DJA, Dobson KS, Beck AT, **Thombs BD***. Revisiting the role of somatic symptoms among depressed women and men: Much ado about nothing? In Thombs BD (Chair), Myths and measures: Mental health assessment in medical settings (Symposium). *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
78. **Razykov I**, Hudson M, Baron M, **Thombs BD***. Screening for suicidal ideation and intent in medical patients: Is the PHQ-9 the answer? In Thombs BD (Chair), Myths and measures: Mental health assessment in medical settings (Symposium). *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
79. **Milette K**, **Thombs BD***. Moving research into practice: Why trial registration and outcome reporting standards matter. Theory Review. *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada, June 2011.
80. **El-Baalbaki G**, Lober J, Hudson M, Baron M, **Thombs BD***. Measuring pain in systemic sclerosis: The Short-Form McGill Pain Questionnaire or a single-item measure of pain. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Atlanta, Georgia, USA, November 2010.

81. Bassel M, Hudson M, Taillefer S, Schieir O, Baron M, **Thombs BD***. Frequency and impact of symptoms experienced by patients with systemic sclerosis: Results from a Canadian national survey. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Atlanta, Georgia, USA, November 2010.
82. Jewett LR, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Sociodemographic and disease correlates of body image in systemic sclerosis. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Atlanta, Georgia, USA, November 2010.
83. Jewett LR, Hudson M, Haythornthwaite JA, Heinberg L, Wigley F, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Development and validation of the Brief-Satisfaction with Appearance Scale (Brief-SWAP) for systemic sclerosis. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Atlanta, Georgia, USA, November 2010.
84. Delisle V, Dozois DJA, Dobson KS, Beck AT, **Thombs BD***. Do women really report more somatic symptoms of depression than men? *Innovations in Gender, Sex, and Health Research, Canadian Institutes of Health Research – Institute of Gender and Health*, Toronto, Ontario, Canada, November 2010.
85. **Thombs BD***. Should we expect that screening for depression will benefit patients? In **BD Thombs** (Chair). Current controversies in the definition, identification, and care of depression. *Canadian Psychiatric Association Annual Conference*, Toronto, Ontario, Canada, September 2010.
86. Roseman M, Milette K, Bero L, Coyne JC, Lexchin J, Turner E, **Thombs BD***. Hidden conflicts of interest in meta-analyses of pharmacological treatments. *First Annual Lady Davis Institute of Medical Research Scientific Retreat*, Montreal, Quebec, Canada, May 2010.
87. Jewett LR, **Thombs BD***. Psychological health and well-being in scleroderma: What can we do to help? *41st Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2010.
88. Razykov I, **Thombs BD***. Psychological health and well-being in scleroderma: What are the most pressing issues? *41st Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2010.
89. Roseman M, Milette K, Bero L, Coyne JC, Lexchin J, Turner E, **Thombs BD***. Hidden conflicts of interest in meta-analyses of pharmacological treatments. *8th Annual Canadian Cochrane Symposium*, Ottawa, Ontario, Canada, May 2010.
90. Adeponle AB, Groleau D, **Thombs BD**, Kirmayer LJ. Use of cultural consultation to resolve uncertainty in the diagnosis of psychosis in immigrant patients. *Society for the Study of Psychiatry and Culture, 2010 Annual Conference*, Montreal, Quebec, Canada, April-May 2010.
91. Jewett LR, **Thombs BD***, Hudson M, Heinberg L, Wigley F, Haythornthwaite JA. Measuring body image avoidance in patients with systemic sclerosis. *American College of Rheumatology, 2009 Scientific Meeting*, Philadelphia, Pennsylvania, USA, October 2009.
92. Newton E, Schnitzer M, Steele R, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. The longitudinal trajectory of depressive symptoms in systemic sclerosis. *American College of Rheumatology, 2009 Scientific Meeting*, Philadelphia, Pennsylvania, USA, October 2009.
93. Knafo R, **Thombs BD***. Female sexual dysfunction in scleroderma: Too important to ignore. In Thombs BD (Chair), Clinical psychology in medical settings: Does one size fit all? (Symposium). *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada, June 2009.
94. Bassel M, **Thombs BD***. The great equalizer: How self-report depression questionnaires disproportionately inflate prevalence estimates. In Thombs BD (Chair), Clinical psychology in medical settings: Does one size fit all? (Symposium). *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada, June 2009.
95. Newton E, **Thombs BD***. A longitudinal analysis of depressive symptoms and treatment among patients with scleroderma. In Thombs BD (Chair), Clinical psychology in medical settings: Does one size fit all? (Symposium). *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada, June 2009.
96. Jewett L, **Thombs BD***. Validity and reliability of the Body Image Avoidance Questionnaire for Acquired Disfigurement (BIAQ-AD). In Thombs BD (Chair), Clinical psychology in medical settings:

Does one size fit all? (Symposium). *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada, June 2009.

97. **Thombs BD***. Does size matter? A review of effect sizes. Theory Review. *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada, June 2009.
98. **Thombs BD***. Should we screen for depression in specialty medical settings? A review of screening basics. Theory Review. *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada, June 2009.
99. **Knafo R, Thombs BD***, Jewett L, Hudson M, Wigley F, Haythornthwaite JA. The impact of systemic sclerosis on female sexual function: A systematic comparison study. *McGill University Department of Psychiatry Student Research Day*, Montreal, Quebec, Canada, May 2009.
100. Bassel M, **Thombs BD***, Hudson M, Taillefer SS, Baron M, **Canadian Scleroderma Research Group**. Sociodemographic, disease, and symptom correlates of fatigue in scleroderma. *40th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2009.
101. **Newton E, Thombs BD***, Hudson M, Steele R, Schnitzer M, Taillefer S, Baron M, **Canadian Scleroderma Research Group**. The longitudinal trajectory of depressive symptoms in systemic sclerosis. *40th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2009.
102. **Schieir O, Thombs BD***, Hudson M, Boivin JF, Steele R, Bernatsky S, Hanley J, Baron M, **Canadian Scleroderma Research Group**. Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. *40th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2009.
103. **Razykov I, Thombs BD***, Hudson M, Bassel M, Baron M, **Canadian Scleroderma Research Group**. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. *40th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2009.
104. **Jewett LR, Thombs BD***, Hudson M, Heinberg L, Wigley F, Haythornthwaite J. Development of body image avoidance measures for patients with scleroderma. *40th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2009.
105. **Knafo R, Thombs BD***, **Jewett LR**, Hudson M, Wigley F, Haythornthwaite J. A systematic comparison of sexual impairment in women with systemic sclerosis and other chronic disease samples. *40th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2009.
106. Coyne JC, **Thombs BD**, Hagedoorn M. Meta-analyses to establish the effectiveness of psychosocial interventions in health psychology: Is the literature ready? *Society of Behavioral Medicine, 30th Annual Meeting & Scientific Sessions*, Montreal, Quebec, Canada, April 2009.
107. **Schieir O, Thombs BD***, Hudson M, Boivin JF, Hanley J, Taillefer S, **Canadian Scleroderma Research Group**, Baron M. Pain in systemic sclerosis: Examining clinical correlates of pain in patients with systemic sclerosis. *Department of Epidemiology, Biostatistics, and Occupational Health Research Day*, McGill University, Montreal, Quebec, Canada, April 2008.
108. **Thombs BD***, Whooley MA, Ziegelstein RC. Identifying and addressing barriers to screening for depression in cardiovascular care. In Ziegelstein RC (Chair), Why don't cardiologists care (about depression and anxiety)? – Identifying and overcoming barriers. (Symposium). *American Psychosomatic Society, 66th Annual Scientific Conference*, Baltimore, Maryland, USA, March 2008.
109. Montoro R, **Thombs BD**, Burgos G, Igartua K. Suicide and harassment based on being perceived as gay: Results from the Quebec Youth Risk Behaviour Survey. *7th Congress of the International Society for Adolescent Psychiatry and Psychology*, Montreal, Quebec, Canada, July 2007.
110. **Thombs BD***. Cross-cultural measurement in clinical psychology: Methodological and practical considerations. In Ryder AG (Chair), Research at the intersection of clinical and cultural psychology: The study of mental health in context, part I. (Symposium). *Canadian Psychological Association, 2007 Annual Convention*, Ottawa Ontario, Canada, June 2007.
111. **Schieir O, Thombs BD***, Couture F, Fitzcharles MA, Gagne M, Garfield B, Gutkowski A, Kang H, Kapusta M, Ligier S, Mathieu JP, Menard H, Starr M, Stein M, Zummer M, Baron M. Baseline depression predicts depression and pain at 6 month when controlling for objective disease severity; *38th Laurentian Conference of Rheumatology*, Mont Tremblant Quebec, Canada, May 2007.

112. **Thombs BD***, Singh VA, Milner SM. Increased risk of mortality in burn injury related to medical comorbidities: Evidence from the National Burn Repository. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S74.
113. Singh VA, **Thombs BD**, Milner SM. Increased risk of mortality in burn injury among children under four years old: Evidence from the National Burn Repository. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S61.
114. **Thombs BD***, Singh VA, Milner SM. Female gender as a risk factor for mortality from burn injury: Evidence from the National Burn Repository. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S104.
115. Lawrence JW, Rosenberg L, **Thombs BD**, Fauerbach JA. Comparing parent and child perceptions of stigmatizing behavior. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S67.
116. Lawrence JW, Rosenberg L, **Thombs BD**, Fauerbach JA. Comparing the body-esteem of adolescent and young adult burn survivors to a nonburned control group. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S120.
117. **Thombs BD***, Lattyak RM, Magyar-Russell G, Lawrence JW, Fauerbach JA. Screening for symptoms of acute stress in patients with burn injury: An evaluation of the Stanford Acute Stress Reaction Questionnaire. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S89.
118. Magyar-Russell GM, Bresnick MG, DeLateur BJ, Fauerbach JA, Ober MS, **Thombs BD**, Notes LD. The impact of psychological factors on adherence to a therapeutic exercise program among burn survivors. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S103.
119. **Thombs BD***, Bresnick MG, Lawrence JW, McCann UD, Magyar-Russell G, Fauerbach JA. Depression in burn injury: Prevalence, persistence, comorbidity with PTSD, and association with functional outcome. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S85.
120. Lawrence JW, Rosenberg L, **Thombs BD**, Fauerbach JA. Measuring perceived stigmatization among pediatric burn survivors. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S88.
121. Fauerbach JA, Lezotte D, Holavanahalli R, Wiechman S, Engrav L, Kowalske K, B. DeLateur, MD, **Thombs BD**, Milner S, Patterson DR. Defining and tracking impairment after burn injury. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S101.
122. McKibben JB, Magyar-Russell G, Fauerbach JA, **Thombs BD**, Lawrence JW. Predicting post traumatic stress disorder from acute stress disorder in burn injured patients: A longitudinal study. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S104.
123. Fauerbach JA, Lezotte D, Engrav L, Kowalske K, DeLateur BJ, Holavanahalli R, Magyar-Russell GM, McKibben J, **Thombs BD**, Patterson DR. Measuring post-burn participation in home, work and social roles. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S102.
124. Fauerbach JA, **Thombs BD**, Lezotte D, Holavanahalli R, Wiechman S, Engrav L, Kowalske K, DeLateur BJ, Magyar-Russell GM, Patterson Dr. Early predictors of long term psychological distress. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S76.
125. Fauerbach JA, Heltshe S, Lezotte D, Holavanahalli R, Magyar-Russell GM, McKibben J, **Thombs BD**, Kowalske K, Patterson DR, deLateur BJ. Early predictors of long-term participation in society following burn injury. Proc Amer Burn Assoc, 38th Annual Meeting, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res.* 2006;27(2 Suppl):S64.
126. Notes LD, Magyar-Russell G, Lawrence JW, Fauerbach JA, **Thombs BD**. Body image satisfaction in burn survivors: Transition from the hospital to the community. *Mid-Atlantic Burn Association, 28th Annual Meeting*, Princeton New Jersey, USA, November 2005.

127. Lattyak RM, Bresnick MG, Notes LD, Magyar-Russell G, Fauerbach JA, **Thombs BD***. A systematic review of posttraumatic stress disorders after burn injury: Implications for assessment and treatment. *Mid-Atlantic Burn Association, 28th Annual Meeting*, Princeton New Jersey, USA, November 2005.
128. Bresnick MG, Lattyak RM, Notes LD, Magyar-Russell G, Fauerbach JA, **Thombs BD***. A systematic review of depression after burn injury: Implications for assessment and treatment. *Mid-Atlantic Burn Association, 28th Annual Meeting*, Princeton New Jersey, USA, November 2005.
129. Ullrich PM, Wiechman SA, Fauerbach JA, Kowalske KJ, Blakeney P, Engrav LH, Esselman PC, Lezotte DC, **Thombs BD**, Patterson DR. Course of distress over two-years among patients followed at NIDRR Burn Model System sites. Proc Amer Burn Assoc, 37th Annual Meeting, Chicago Illinois, USA, April 2005. *J Burn Care Res.* 2005;26(2 Suppl):S115.
130. Lawrence JW, Fauerbach JA, **Thombs BD**. Burn severity and importance of appearance: Testing the competence x importance model of body-esteem. Proc Amer Burn Assoc, 37th Annual Meeting, Chicago Illinois, USA, April 2005. *J Burn Care Res.* 2005;26(2 Suppl):S115.
131. **Thombs BD***, Fauerbach JA, Lawrence JW, Wiechman SA, Patterson DR, Kowalske KJ, Blakeney P, Rose MW. Body image satisfaction in burn survivors: Natural history across periods of wound healing, maximal scar activity, and approaching scar maturity. Proc Amer Burn Assoc, 37th Annual Meeting, Chicago Illinois, USA, April 2005. *J Burn Care Res.* 2005;26(2 Suppl):S56.
132. **Thombs BD***. Psychological assessment in patients with acute burn injuries. *Mid-Atlantic Burn Association, 27th Annual Meeting*, Baltimore Maryland, USA, December 2004.
133. **Thombs BD***. The diverse therapy group: How valid is consensual validation? *American Psychological Association, 2002 Annual Convention*, Chicago Illinois, USA, August 2002.
134. **Thombs BD***. Building connection through feedback in the diverse counseling group: The group leader as participant-observer. In Trammel RL & Chen EC (Co-Chairs), Working with diverse populations in groups: Competencies, issues, and challenges (Symposium). *American Psychological Association, 2001 Annual Convention*, San Francisco California, USA, August 2001.

H.3.11. Peer-Reviewed Poster Presentations

1. **Østbø N**, Yakes Jimenez E, **Harb S**, Bourgeault A, Carrier ME, **Thombs BD***, SPIN - Diet and Nutrition Education Patient Advisory Team. Nutrition information resources used by people with scleroderma and perceived advantages and disadvantages: a nominal group technique study. 2021 *Canadian Rheumatology Association Annual Scientific Meeting*. Online. February 2021.
2. **Harb S**, Peláez S, Carrier ME, Kwakkenbos L, Bartlett SJ, Hudson M, Mouthon L, Sauvé M, Welling J, Shrier I, **Thombs BD***, SPIN – Physical Activity Enhancement Patient Advisory Team, **SPIN Investigators**. Barriers and facilitators to physical activity for people with scleroderma: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. 2020 *Canadian Rheumatology Association Annual Scientific Meeting*. Online. February 2020
3. **Tao L**, **Carboni-Jiménez A**, **Turner K**, **Østbø N**, Aquila K, Boruff J, Krishnan A, Ahmed S, **Thombs BD***, Kwakkenbos L. Perceived barriers and facilitators of using synchronous telerehabilitation of physical and occupational therapy in musculoskeletal disorders: a scoping review. 2021 *Canadian Rheumatology Association Annual Scientific Meeting*. Online. February 2021.
4. **Wu Y**, Kwakkenbos L, **Henry RS**, Carrier ME, **Gagarine M**, **Harb S**, Bourgeault A, **Tao L**, **Carboni-Jiménez A**, **Negeri Z**, Patten SB, Bartlett SJ, Mouthon L, Varga J, Benedetti A, **Thombs BD***, **SPIN Investigators**. Factors associated with fears due to COVID-19: a Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 Cohort study. 2021 *Canadian Rheumatology Association Annual Scientific Meeting*. Online. February 2021.
5. **Neupane D**, **Levis B**, **Bhandari PM**, **Thombs BD***, Benedetti A, **DEPRESSion Screening Data (DEPRESSD) Collaboration**. Selective cutoff reporting in diagnostic accuracy studies of the PHQ-9 and EPDS depression screening tools. *Methods for Evaluation of medical prediction Models, Tests and Biomarkers (MENTAB) Conference*. Leuven, Belgium. December 2020 (presented virtually). *Diagnostic and Prognostic Research.* 2021;5(Suppl 1):53.
6. Leclair V, **Thombs BD**, Wang M, Vinet E, Albert A, Hudson M. Patient-reported outcomes in early autoimmune inflammatory myopathies. *American College of Rheumatology Convergence 2020*. November 2020 (presented virtually).

7. **Turner KA, Carboni-Jiménez A, Benea C, Elder K, Levis B**, Boruff J, Roseman M, Bero LA, Lexchin J, Turner EH, Benedetti A, **Thombs BD***. Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
8. **Negeri ZF, Levis B**, Benedetti A, **Thombs BD***, and the DEPRESSD PHQ Collaboration. Accuracy of the PHQ-9 for screening to detect major depression: an updated systematic review and meta-analysis of individual participant data. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
9. **Neupane D, Levis B, Bhandari PM, Thombs BD***, Benedetti A, DEPRESSD Collaboration. Selective cutoff reporting in depression screening accuracy studies: a comparison of meta-analysis of published cutoffs only versus all cutoffs. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
10. **Wu Y, Levis B**, Ioannidis JPA, Benedetti A, **Thombs BD***, and the DEPRESSD Collaboration. Probability of major depression classification based on different diagnostic interviews: a synthesis of individual participant data meta-analyses. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
11. **Wu Y, Levis B**, Benedetti A, **Thombs BD***, and the DEPRESSD HADS Collaboration. Accuracy of the Hospital Anxiety and Depression Scale – Depression subscale (HADS-D) for detecting major depression: individual participant data meta-analysis. *27th Cochrane Colloquium*. Toronto, Ontario, Canada. October 2020 (not presented due to COVID-19).
12. **Carboni-Jiménez A, Rice DB, Cañedo-Ayala M, Levis B, Imran M, Chiovitti M, Thombs BD***. Caregiving intensity and perceived burden among informal caregivers of persons with systemic sclerosis compared to other chronic medical conditions: A systematic review. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
13. **Carrier ME**, Kwakkenbos L, Nielson WR, **Fedoruk C**, Nielsen K, **Milette K**, Pope J, Frech T, Gholizadeh S, Hummers L, Johnson SR, Piotrowski P, Jewett L, Gordon J, Chung L, Bilsker D, Turner K, Cumin J, Welling J, Fortune C, Leite C, Gottesman K, Sauve M, Rodriguez Reyna TS, Hudson M, Larche M, van Breda W, Suarez-Almazor ME, Bartlett SJ, Malcarne VL, Mayes MD, Boutron I, Mouthon L, Wigley F, **Thombs BD***, **SPIN Investigators**. Randomized Feasibility Trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
14. **Fedoruk C**, Kwakkenbos L, **Carrier ME**, **Rice DB**, **Turner KA**, **Cañedo-Ayala M**, **Carboni-Jiménez A**, **Tao L**, **Harb S**, **Gholizadeh S**, **Aguila K**, **Thombs BD***. The Scleroderma Patient-centered Intervention Network (SPIN): Engaging patients in rheumatology research. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
15. **Harb S**, **Cumin J**, **Rice DB**, Peláez S, Hudson M, Bartlett SJ, Roren A, Furst DE, Frech TM, Nguyen C, Nielson WR, **Thombs BD***, Shrier I, SPIN-PACE Patient Advisory Team. Identifying barriers and facilitators to physical activity for people with scleroderma: A nominal group technique study. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
16. **Harb S**, Peláez S, **Thombs BD***, Shrier I, SPIN-PACE Patient Advisory Team. Use of a cohort-based survey to identify important barriers and facilitators to physical activity for people with scleroderma: A Scleroderma Patient-centered Intervention Network Cohort study protocol. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
17. Kwakkenbos L, **Carboni-Jiménez A**, **Carrier ME**, **Pépin M**, Peláez S, Malcarne VL, El-Baalbaki G, **Thombs BD***, Scleroderma Support Group Project Advisory Team. Reasons for not participating in scleroderma patient support groups: a comparison of results from the North American and European Scleroderma Support Group Surveys. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
18. Kwakkenbos L, Hudson M, Schraven L, Thonen-Velthuisen J, **Thombs BD***. Development and evaluation of a patient decision aid for autologous hematopoietic stem cell transplantation in

systemic sclerosis. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).

19. Meier A, **Gholizadeh S**, Ataseven B, Roesch S, **Carrier ME**, Kwakkenbos L, **Thombs BD***, Malcarne VL. The relationship of patient sociodemographic and scleroderma disease characteristics with social interaction anxiety: A Scleroderma Patient-centered Intervention Network Cohort study. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
20. Sommer SJ, Harel D, Mills S, Kwakkenbos L, **Carrier ME**, **Gholizadeh S**, Portales A, Nielson K, Bartlett S, Malcarne V, **Thombs BD***. Investigating differential item functioning on the Social Appearance Anxiety Scale for French- and English-speaking patients: A Scleroderma Patient-centered Intervention Network Cohort study. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
21. **Tao L**, Kwakkenbos L, **Carboni-Jiménez A**, **Turner KA**, **Aguila K**, Boruff J, Ahmed S, **Thombs BD***. Perceived barriers and facilitators of using synchronous telerehabilitation of physical and occupational therapy in musculoskeletal disorders: A scoping review. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
22. **Thombs BD***, Dyas L, **Pépin M**, **Razykov I**, **Aguila K**, **Carrier ME**, **Tao L**, Malcarne V, El-Baalbaki G, Platt R, Hudson M, Sauve M, Connolly K, Scleroderma Support Group Advisory Team. Feasibility trial of the Scleroderma Patient-centered Intervention Network Support Group Leader Education (SPIN-SSLED) Program. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
23. Wojeck RK, Kwakkenbos L, **Carrier ME**, Bailey DE, Knisely MR, Somers TJ, Bartlett SJ, Pope J, Nielson WR, Nielson K, **Thombs BD***, Silva SG, **SPIN Investigators**. Trajectories of pain in systemic sclerosis. *6th Systemic Sclerosis World Congress*. Prague, Czech Republic, March 2020 (not presented due to COVID-19).
24. Burnett L, Einarson K, Rashid S, **Thombs BD**, Moore A, Morissette K, Rodin R, Straus SE. Integrating knowledge user perspectives into evidence-based clinical practice guideline development and implementation. *12th Annual Conference on the Science of Dissemination & Implementation in Health*. Arlington, Virginia, USA. December 2019.
25. **Thombs BD***, **Kwakkenbos L**, **Carrier ME**, **Rice DB**, **Fedoruk C**, **Turner K**, **Cañedo-Ayala M**, **Carboni-Jiménez A**, **Tao L**, **Harb S**, **Gholizadeh S**, **Aguila K**, Sauve M, **SPIN Investigators**. Addressing challenges to patient-centered care in a rare disease context: the Scleroderma Patient-centered Intervention Network (SPIN). *The 2019 Scleroderma Foundation Patient Education Conference*. Chicago, Illinois, USA. July 2019.
26. **Fedoruk C**, **Kwakkenbos L**, **Carrier ME**, **Rice DB**, **Turner K**, **Cañedo-Ayala M**, **Carboni-Jiménez A**, **Tao L**, **Harb S**, **Gholizadeh S**, **Aguila K**, **Thombs BD***. The Scleroderma Patient-centered Intervention Network (SPIN): Engaging patients in rheumatology research. *The 2019 Scleroderma Foundation Patient Education Conference*. Chicago, Illinois, USA. July 2019.
27. **Imran M**, **Kwakkenbos L**, McCord KA, Sampson M, Fröbert O, Gale C, Hemkens LG, Langan SM, Moher D, Relton C, Zwarenstein M, Benchimol EI, Boutron I, Campbell MK, Erlinge D, Jawad S, Ravaud P, **Rice D**, Sauvé M, van Staa TP, Thabane L, Uher R, Verkooijen HM, Juszczak E, **Thombs BD**. Development of a CONSORT extension for RCTs using cohorts and routinely collected health data. *Trials Using Cohorts and Routinely Collected Health Data: International Symposium on their Efficacy and Analysis*. London, UK. May 15, 2019.
28. **Fedoruk C**, **Kwakkenbos L**, **Carrier ME**, **Rice DB**, **Turner KA**, **Cañedo-Ayala M**, **Carboni-Jiménez A**, **Tao L**, **Harb S**, **Gholizadeh S**, **Aguila K**, **Thombs BD***. The Scleroderma Patient-centered Intervention Network (SPIN): Engaging patients in rheumatology research. *50th Laurentian Conference of Rheumatology*, Estérel, Quebec, Canada. May 2019.
29. **Turner KA**, **Kwakkenbos L**, **Cumin J**, **Carrier ME**, Boutron I, Bartlett SJ, Malcarne V, Mouthon L, Nielson WR, Welling J, **Thombs BD***. Factors influencing patient-reported willingness to participate in an online self-care intervention: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *50th Laurentian Conference of Rheumatology*, Estérel, Quebec, Canada. May 2019.

30. **Turner KA**, Shrier I, **Thombs BD***. Defining and evaluating overdiagnosis in mental health: a cross-sectional study. *31st Association for Psychological Science Annual Convention*, Washington, D.C., USA. May 2019.
31. **Kwakkenbos L**, Carrier ME, Boutron I, Welling J, Sauve M, van den Ende C, Schouffoer AA, Hudson M, Nguyen C, Rannou F, **Thombs BD***, Mouthon L, **SPIN Investigators**. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND). *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
32. **Carboni-Jiménez A**, **Rice DB**, Chiovitti M, **Cañedo-Ayala M**, **Thombs BD***. Caregiving intensity and perceived burden among informal caregivers of persons with systemic sclerosis compared to other chronic medical conditions. *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
33. **Rice DB**, **Cañedo-Ayala M**, **Carboni-Jiménez A**, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, **Thombs BD***, Caregiver Advisory Committee. Challenges and service preferences of informal caregivers of people with systemic sclerosis. *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
34. **Gholizadeh S**, **Kwakkenbos L**, Carrier ME, Mills SD, Fox RS, Gottesman K, Roesch SR, **Thombs BD***, Malcarne VL. Latent profile analysis-derived typologies of systemic sclerosis patients using body image indicators: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
35. **Harb S**, Cumin J, **Rice DB**, Peláez S, **Thombs BD***, Shrier I. Use of the nominal group technique to identify barriers and facilitators to physical activity for people with scleroderma. *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
36. Tao L, Cumin J, **Turner KA**, Carrier ME, Fedoruk C, **Carboni-Jiménez A**, Pépin M, **Kwakkenbos L**, **Thombs BD***. The Scleroderma Research Topics Survey for patients and health care professionals: A Scleroderma Patient-centered Intervention Network (SPIN) project. *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
37. Fedoruk C, **Kwakkenbos L**, Carrier ME, **Rice DB**, **Turner KA**, **Cañedo-Ayala M**, **Carboni-Jiménez A**, Tao L, **Harb S**, **Gholizadeh S**, Aguila K, **Thombs BD***. The Scleroderma Patient-centered Intervention Network (SPIN): engaging patients in rheumatology research. *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
38. **Turner KA**, **Kwakkenbos L**, Cumin J, Carrier ME, Boutron I, Bartlett SJ, Malcarne V, Mouthon L, Nielson WR, Welling J, **Thombs BD***. Factors influencing patient-reported willingness to participate in an online self-care intervention: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
39. **Thombs BD***, Dyas L, Pépin M, **Razykov I**, Aguila K, Carrier ME, Malcarne V, El-Baalbaki G, Platt R, Hudson M, Sauve M, Connolly K, Scleroderma Support Group Advisory Team. Feasibility trial of the Scleroderma Patient-centered Intervention Network Support Group Leader Education (SPIN-SSLED) Program. *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March 2019.
40. **Thombs BD***, **Kwakkenbos L**, Carrier ME, **Rice DB**, Fedoruk C, **Turner K**, **Cañedo-Ayala M**, **Carboni-Jiménez A**, Tao L, **Harb S**, **Gholizadeh S**, Aguila K, Sauve M, **SPIN Investigators**. Addressing Challenges to Patient-centered Care in a Rare Disease Context: The Scleroderma Patient-centered Intervention Network (SPIN). *2019 Canadian Rheumatology Association Annual Scientific Meeting*. Montreal, Quebec, Canada. February-March, 2019.
41. **Gholizadeh S**, **Kwakkenbos L**, Carrier ME, Mills SD, Fox RS, **Jewett LR**, Gottesman K, Roesch SC, **Thombs BD***, Malcarne VL. Identifying distinct subgroups of systemic sclerosis patients using body image indicators. *18th National Scleroderma Conference*. Calgary, Alberta, Canada. September 2018.

42. **Cañedo-Ayala M, Rice DB, Levis B, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, Thombs BD***, Caregiver Advisory Committee. Caregiver, care recipient, and caregiving factors associated with symptoms of depression among informal caregivers of people living with systemic sclerosis. *18th National Scleroderma Conference*. Calgary, Alberta, Canada. September 2018.
43. **Rice DB, Cañedo-Ayala M, Carboni-Jiménez A, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, Thombs BD***, Caregiver Advisory Committee. Challenges and support service preferences of informal caregivers of people with systemic sclerosis: a cross-sectional survey. *18th National Scleroderma Conference*. Calgary, Alberta, Canada. September 2018.
44. **Turner KA, Kwakkenbos L, Sanchez T, Carrier ME, Mouthon L, Hudson M, Van den Ende C, Schouffoer A, Welling J, Sauvé M, Thombs BD***. The association of sociodemographic and disease variables with hand function in systemic sclerosis. *18th National Scleroderma Conference*. Calgary, Alberta, Canada. September 2018.
45. **Carboni-Jiménez A, Rice DB, Thombs BD***. Caregiving intensity and perceived burden among caregivers of persons with systemic sclerosis compared to other chronic medical conditions. *18th National Scleroderma Conference*. Calgary, Alberta, Canada. September 2018.
46. **Turner KA, Shrier I, Thombs BD***. Defining overdiagnosis of mental health disorders: Secondary analysis of an overdiagnosis scoping review. *Too Much Medicine Symposium*, Helsinki, Finland. August 2018.
47. **Levis B, Yan XW, He C, Benedetti A, Thombs BD***. Overestimation of depression prevalence in meta analyses via the inclusion of primary studies that assessed depression using screening tools or rating scales rather than validated diagnostic interviews. *Too Much Medicine Symposium*, Helsinki, Finland. August 2018.
48. Lang E, Kasperavicius D, Buckland D, Scoleri L, Moore JA, **Thombs BD***, Strauss S. Decision support and knowledge translation tools to highlight the benefits and downstream harms of screening: Resources from the Canadian Task Force for Preventive Healthcare. *Too Much Medicine Symposium*, Helsinki, Finland. August 2018.
49. **Levis B, Benedetti A, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Chiovitti MJ, Sanchez TA, Thombs BD***, DEPRESSD Research Group. Are semi-structured and fully structured diagnostic interviews equivalent reference standards for major depression? An individual participant data meta-analysis comparing diagnoses across diagnostic interviews. *Methods for Evaluating Medical Tests and Biomarkers (MENTAB) Conference*. Utrecht, Netherlands. July 2018.
50. **Levis B, Benedetti A, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Chiovitti MJ, Sanchez TA, Thombs BD***, DEPRESSD Research Group. Diagnostic accuracy of the PHQ-9 depression screening tool compared to semi-structured versus fully structured diagnostic interviews: an individual participant data meta-analysis comparing reference standards. *Methods for Evaluating Medical Tests and Biomarkers (MENTAB) Conference*. Utrecht, Netherlands. July 2018.
51. **Cañedo-Ayala M, Rice DB, Levis B, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, Thombs BD***, Caregiver Advisory Committee. Caregiver Advisory Committee. Caregiver, care recipient, and caregiving factors associated with symptoms of depression among informal caregivers of people living with systemic sclerosis. *5th Annual Skin Research Group of Canada Conference*, Montreal, Quebec, Canada, June 2018.
52. **Carboni-Jiménez A, Rice DB, Thombs BD***. Caregiving intensity and perceived burden among informal caregivers of persons with systemic sclerosis compared to other chronic medical conditions. *5th Annual Skin Research Group of Canada Conference*, Montreal, Quebec, Canada, June 2018.
53. **Turner KA, Kwakkenbos L, Sanchez T, Carrier ME, Mouthon L, Hudson M, Van den Ende C, Schouffoer A, Welling J, Sauvé M, Thombs BD***. The Association of sociodemographic and disease variables with hand function in systemic sclerosis. *5th Annual Skin Research Group of Canada Conference*, Montreal, Quebec, Canada, June 2018.
54. **Pépin M, Kwakkenbos L, Pelaez S, Carrier ME, Malcarne VL, El-Baalbaki G, Thombs BD***. Reasons for attending support groups and organizational preferences: the North American Support Group Survey. *5th Annual Skin Research Group of Canada Conference*, Montreal, Quebec, Canada, June 2018.

55. **Cañedo-Ayala M, Rice DB, Levis B, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, Thombs BD***, Caregiver Advisory Committee. Caregiver, care recipient, and caregiving factors associated with symptoms of depression among informal caregivers of people living with systemic sclerosis. *49th Laurentian Conference of Rheumatology*, Estérel, Quebec, Canada, May 2018.
56. **Carboni-Jiménez A, Rice DB, Thombs BD***. Caregiving Intensity and Perceived Burden Among Caregivers of Persons with Systemic Sclerosis Compared to Other Chronic Medical Conditions. *49th Laurentian Conference of Rheumatology*, Estérel, Quebec, Canada, May 2018.
57. **Cañedo-Ayala M, Rice DB, Levis B, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, Thombs BD***, Caregiver Advisory Committee. Caregiver, Care Recipient, and Caregiving Factors Associated with Symptoms of Depression among Informal Caregivers of People Living with Systemic Sclerosis. *International Congress of Applied Psychology*, Montreal, Quebec, Canada. June 2018.
58. **Carboni Jiménez A, Rice DB, Thombs BD***. Examining Caregiver Intensity and Perceived Burden of Informal Caregivers to Persons with Chronic Medical Conditions: A Systematic Review. *International Congress of Applied Psychology*, Montreal, Quebec, Canada. June 2018.
59. Becetti K, Gordon JK, Nguyen J, Mancuso C, **Kwakkenbos L, Carrier ME, Thombs BD***, Spiera RF, **SPIN Investigators**. Rates and Predictors of Physical Therapy and Occupational Therapy Utilization in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.
60. Becetti K, Gordon JK, Nguyen J, Mancuso C, **Kwakkenbos L, Carrier ME, Thombs BD***, Spiera RF, **SPIN Investigators**. Mental Health Care in Systemic Sclerosis; Rates of Utilization and Associated Factors in the Scleroderma Patient-centered Intervention Network Cohort. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.
61. **Kwakkenbos L, Carrier ME, Boutron I, Welling J, Sauve M, van den Ende CHM, Schouffoer AA, Hudson M, Thombs BD***, Mouthon L, **SPIN Investigators**. Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND). *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.
62. **Kwakkenbos L, Dougherty DH, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Sauvé M, Thombs BD***, Mayes MD, **SPIN Investigators**. The Scleroderma Patient-Centered Intervention Network (SPIN) Cohort: baseline clinical features and comparison to other large scleroderma cohorts. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.
63. **Kwakkenbos L, Cumin J, Carrier ME, Boutron I, Bartlett SJ, Malcarne V, Mouthon L, Nielson WR, Welling J, Thombs BD***. Factors Influencing Patient-reported Willingness to Participate in an Online Self-care Intervention: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.
64. **Pépin M, Kwakkenbos L, Pelaez S, Carrier ME, Malcarne V, Gumuchian ST, Delisle VC, El-Baalbaki G, Thombs BD***. Reasons for attending support groups and organizational preferences: The North American Support Group Survey. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.
65. **Turner KA, Kwakkenbos L, Sanchez T, Carrier ME, Mouthon L, Hudson M, Van den Ende C, Schouffoer A, Welling J, Sauvé M, Thombs BD***. The Association of Sociodemographic and Disease Variables with Hand Function in Systemic Sclerosis. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018..
66. **Rice DB, Cañedo-Ayala M, Gumuchian ST, Hagedoorn M, Malcarne V, Thombs BD***, Caregiver Advisory Committee. (2016). Focus Group Discussions to Inform the Development of Services for Informal Caregivers of Patients with Scleroderma. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.
67. **Rice DB, Cañedo-Ayala M, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, Thombs BD***, Caregiver Advisory Committee. Challenges and Service Preferences of Informal Caregivers of People with Systemic Sclerosis. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.
68. **Cañedo-Ayala M, Rice DB, Levis B, Carrier ME, Cumin J, Malcarne V, Hagedoorn M, Thombs BD***, Caregiver Advisory Committee. Caregiver, Care Recipient, and Caregiving Factors Associated

with Symptoms of Depression among Informal Caregivers of People Living with Systemic Sclerosis. *5th Systemic Sclerosis World Congress*, Bordeaux, France, February 2018.

69. Gholizadeh S, **Kwakkenbos L**, Carrier ME, Mills SD, Fox RS, **Jewett L**, Gottesman K, Roesch SC, **Thombs BD***, Malcarne VL, **SPIN Investigators**. Latent profile analysis-derived typologies of systemic sclerosis patients using body image indicators: A Scleroderma Patient-Centered Intervention Network (SPIN) cohort study. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, San Diego, California, USA. November 2017.
70. Merz EL, **Kwakkenbos L**, Carrier ME, Gholizadeh S, Mills SD, Fox RS, **Jewett LR**, Williamson H, Harcourt D, Assassi S, Furst DE, Gottesman K, Mayes MD, Moss T, **Thombs BD***, Malcarne VL, **SPIN Investigators**. Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating “not applicable” responses as missing data: A Scleroderma Patient-Centered Intervention Network cohort study. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, San Diego, California, USA. November 2017.
71. **Azar M**, Riehm KE, Saadat N, Sanchez T, Chiovitti M, **Qi L**, **Rice DB**, **Levis B**, Fedoruk C, **Levis AW**, Kloda LA, Kimmelman J, Benedetti A, **Thombs BD***. Journal Policies and Registration of Randomized Controlled Trials of Non-Regulated Healthcare Interventions: A Cross-sectional Study. *Global Evidence Summit*. Cape Town, South Africa. September 2017
72. **Levis B**, Benedetti A, Riehm KE, Saadat N, **Levis AW**, **Azar M**, **Rice DB**, Chiovitti M, **Thombs BD***, and the **DEPRESSD Research Group**. Are clinician-administered semi-structured interviews and lay-administered fully structured interviews equivalent gold standards for major depression? An individual patient data meta-analysis. *Global Evidence Summit*. Cape Town, South Africa. September 2017
73. **Levis B**, Benedetti A, Riehm KE, Saadat N, **Levis AW**, **Azar M**, **Rice DB**, Chiovitti M, **Thombs BD***, and the **DEPRESSD Research Group**. Underestimation of depression screening tool sensitivity when using lay-administered fully structured diagnostic interviews as the reference standard. *Global Evidence Summit*. Cape Town, South Africa. September 2017
74. **Cañedo-Ayala M**, **Rice D**, **Gumuchian S**, **Thombs BD***. Informal caregivers for scleroderma focus groups. *125th American Psychological Association Annual Convention*, Washington, DC, USA. August 2017.
75. **Cañedo-Ayala M**, **Rice D**, **Gumuchian S**, **Thombs BD***. Informal caregivers for scleroderma focus groups. *2017 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2017.
76. **Azar M**, Riehm KE, Saadat N, Sanchez T, Chiovitti M, **Qi L**, **Rice D**, **Levis B**, Fedoruk C, **Levis AW**, Kloda LA, Kimmelman J, Benedetti A, **Thombs BD***. Journal Policies and Registration of Randomized Controlled Trials of Non-Regulated Healthcare Interventions: A Cross-sectional Study. *Society for Epidemiologic Research 50th Annual Meeting*. Seattle, Washington, USA. June 2017.
77. **Levis B**, Benedetti A, Riehm KE, Saadat N, **Levis AW**, **Azar M**, **Rice DB**, **Thombs BD***, and the **DEPRESSD Research Group**. An Individual Patient Data (IPD) meta-analysis on the diagnostic test accuracy of the Patient Health Questionnaire-9 (PHQ-9) depression screening tool. *Society for Epidemiologic Research 50th Annual Meeting*. Seattle, Washington, USA. June 2017.
78. **Levis B**, Benedetti A, Riehm KE, Saadat N, **Levis AW**, **Azar M**, **Rice DB**, Chiovitti M, **Thombs BD***, and the **DEPRESSD Research Group**. Diagnostic interviews for major depression: A comparison of diagnoses made using semi-structured vs. fully-structured administration methods. *Society for Epidemiologic Research 50th Annual Meeting*. Seattle, Washington, USA. June 2017.
79. Pal NP, **Gumuchian ST**, **Delisle VC**, **Thombs BD***. The Scleroderma Support Group Leader Survey. *2017 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2017.
80. **Gumuchian ST**, **Delisle VC**, Malcarne VL, El-Baalbaki G, Pelaez S, **Jewett LR**, **Kwakkenbos L**, **Thombs BD***, Scleroderma Support Group Team. The Scleroderma Support Group Non-Attendees Survey: A cross-sectional Study. *2017 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2017.
81. **Rice D**, **Cañedo-Ayala M**, **Gumuchian ST**, **Thombs BD***. Informal caregivers for scleroderma

- focus groups. *48th Laurentian Conference of Rheumatology*, Estérel, Quebec, May 2017.
82. **Gumuchian ST**, Peláez S, **Delisle VC**, **Jewett LR**, El-Baalbaki G, Fortune C, Hudson M, Körner A, **Kwakkenbos L**, Bartlett SJ, **Thombs BD***. Exploring coping strategies among people living with scleroderma through focus groups: A Scleroderma Patient-centered Intervention Network Study. *48th Laurentian Conference of Rheumatology*, Estérel, Quebec, May 2017.
 83. **Coroiu A**, Moran C, Kingsland E, **Thombs BD**, Körner A. Skin self-examination (SSE) assessment in randomized controlled trials with individuals at increased risk for melanoma. *38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*, San Diego, CA, USA. May 2017.
 84. Harel D, **Levis AW**, **Kwakkenbos L**, **Thombs BD**. Using optimal test assembly methods to shorten patient-reported outcome measures. *International Biometric Society, Eastern North American Region 2017 Spring Meeting*, Washington, DC, USA. March 2017.
 85. **Coroiu A**, Moran C, **Rice D**, Kingsland E, **Thombs BD**, Körner A. The effect of psycho-educational interventions on health outcomes in individuals at increased risk for melanoma: A systematic review of randomized controlled trials. *World Congress of Skin Cancers*, Vienna, Austria. December 2016.
 86. Becetti K, Gordon JK, Nguyen J, Mancuso C, **Kwakkenbos L**, **Carrier ME**, **Thombs BD***, Spiera RF, **SPIN Investigators**. Rates and predictors of physical therapy and occupational therapy utilization in systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Washington, DC, USA. November 2016.
 87. Becetti K, Gordon JK, Nguyen J, Mancuso C, **Kwakkenbos L**, **Carrier ME**, **Thombs BD***, Spiera RF, **SPIN Investigators**. Mental health care in systemic sclerosis: rates of utilization and associated factors in the Scleroderma Patient-centered Intervention Network Cohort. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Washington, DC, USA. November 2016.
 88. **Azar M**, **Rice DB**, **Kwakkenbos L**, **Carrier ME**, Shrier I, Bartlett SJ, Hudson M, Mouthon L, Poiraudéau S, van den Ende CHM, Johnson SR, Rodriguez Reyna TS, Schouffoer AA, Welling J, **Thombs BD***, **SPIN investigators**. Exercise habits and factors associated with exercise in systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Washington, DC, USA. November 2016.
 89. **Jewett LR**, **Kwakkenbos L**, Malcarne VL, **Carrier ME**, **Thombs BD***, **SPIN Investigators**. Confirmatory factor analysis and assessment of differential item functioning of the Satisfaction with Appearance Scale in systemic sclerosis: a comparison across sex, race/ethnicity and disease subtype. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Washington, DC, USA. November 2016.
 90. **Coroiu A**, **Kwakkenbos A**, **Levis B**, Hudson M, Baron M, Cella D, **Thombs BD***, **Canadian Scleroderma Research Group**. The comparability of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores between cancer and systemic sclerosis: An assessment of differential item functioning. *International Society for Quality of Life Research Conference*, Copenhagen, Denmark. October 2016.
 91. Becetti K, Gordon JK, Nguyen J, Mancuso C, **Kwakkenbos L**, **Carrier ME**, **Thombs BD***, Spiera RF, **SPIN Investigators**. Mental Health Care in Systemic Sclerosis: Rates of Utilization and Associated Factors in the Scleroderma Patient-centered Intervention Network Cohort. *17th Annual National Scleroderma Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
 92. Becetti K, Gordon JK, Nguyen J, Mancuso C, **Kwakkenbos L**, **Carrier ME**, **Thombs BD***, Spiera RF, **SPIN Investigators**. Rates and Predictors of Physical Therapy and Occupational Therapy Utilization in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. *17th Annual National Scleroderma Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
 93. **Milette K**, Pelaez S, **Delisle V**, **Thombs BD***. The role of social support in coping with scleroderma: Preliminary results from a focus group study. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
 94. **Milette K**, Pelaez S, Nielson W, Khanna D, **Thombs BD***. Coping with scleroderma: A focus group

study. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.

95. **Rice DB, Thombs BD***. Focus group discussions to inform the development of services for informal caregivers of patients with scleroderma. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
96. **Pépin MR, Delisle VC, Gumuchian ST**, Malcarne VL, El-Baalbaki G, Pelaez S, **Thombs BD***, Scleroderma Support Group Team. The Scleroderma Support Group European Survey: Understanding people's experiences with scleroderma support groups. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
97. **Gumuchian ST, Delisle VC**, Peláez S, **Carrier ME, Jewett LR**, El-Baalbaki G, **Kwakkenbos L**, Bartlett SJ, **Thombs BD***. Exploring the sources of emotional distress and management strategies among people living with scleroderma through focus groups: A Scleroderma Patient-centered Intervention Network Study. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.
98. **Gumuchian ST, Delisle VC**, Malcarne VL, El-Baalbaki G, Pelaez S, **Jewett LR, Kwakkenbos L, Thombs BD***, Scleroderma Support Group Team. The Scleroderma Support Group Non-Attendees Survey: A Cross-sectional Study. *2016 Scleroderma National Conference, Scleroderma Society of Canada*, Montreal, Quebec, Canada. September 2016.\
99. **Jewett LR, Kwakkenbos L, Carrier ME**, Malcarne VL, Bartlett SJ, Furst DE, Gottesman K, Mayes MD, Assassi S, Harcourt D, Williamson H, Johnson SR, Körner A, Steen V, Fox RS, Gholizadeh S, Mills SD, **Rice DB, Thombs BD, SPIN Investigators**. Examination of the Association of Sex and Race/Ethnicity with Appearance Concerns: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *17th Annual National Scleroderma Conference, Scleroderma Society of Canada*. Montreal, Quebec, Canada. September 17, 2016.
100. **Delisle VC, Gumuchian ST**, Malcarne VL, El-Baalbaki G, Pelaez S, **Thombs, BD***. The Scleroderma Support Group Survey: Understanding people's experiences with scleroderma support groups. *Scleroderma Foundation Annual Patient Conference*. New Orleans, Louisiana, USA. July 2016.
101. **Carrier ME, Kwakkenbos L, Thombs BD*, SPIN Investigators**. An international collaboration to collect data and develop online interventions for scleroderma patients: an update from the Scleroderma Patient-centered Intervention Network (SPIN). *Scleroderma Foundation Annual Patient Conference*. New Orleans, Louisiana, USA. July 2016.
102. **Kwakkenbos L**, Bartlett S, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D, **Thombs BD*, SPIN Investigators**. Measuring quality of life in scleroderma using the PROMIS-29 measure: evidence from the Scleroderma Patient-centered Intervention Network (SPIN). *Scleroderma Foundation Annual Patient Conference*. New Orleans, Louisiana, USA. July 2016.
103. **Jewett LR**, Malcarne VL, **Kwakkenbos L**, Harcourt D, Rumsey N, Körner A, Steele RJ, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, **Thombs BD*, Canadian Scleroderma Research Group**. Development and validation of the Body Concealment Scale for Scleroderma (BCSS). *Scleroderma Foundation Annual Patient Conference*. New Orleans, Louisiana, USA. July, 2016.
104. **Jewett LR, Kwakkenbos L, Carrier ME**, Malcarne VL, Bartlett SJ, Furst DE, Gottesman K, Mayes MD, Assassi S, Harcourt D, Williamson H, Johnson SR, Körner A, Steen V, Fox RS, Gholizadeh S, Mills SD, **Rice DB, Thombs BD*, SPIN Investigators**. Examination of the association of sex and race/ethnicity with appearance concerns: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. *Scleroderma Foundation Annual Patient Conference*. New Orleans, Louisiana, USA. July, 2016.
105. **Levis B**, Benedetti A, **Levis AW**, Ioannidis JPA, Shrier I, Cuijpers P, Gilbody S, Kloda LA, McMillan D, Patten SB, Steele RJ, Ziegelstein RC, Bombardier CH, de Lima Osório F, Fann JR, Gjerdingen D, Lamers F, Lotrakul M, Loureiro SR, Löwe B, Shaaban J, Stafford L, van Weert HCPM, Whooley MA, Williams LS, Wittkamp KA, Yeung AS, **Thombs BD***. Selective Cutoff Reporting in Studies of Diagnostic Test Accuracy: A Comparison of Conventional and Individual Patient Data Meta-Analyses of the Patient Health Questionnaire-9 Depression Screening Tool. In: *Methods for Evaluating Medical Tests and Biomarkers*, Birmingham, UK, 19–20 July 2016. Diagnostic and

Prognostic Research 2017, 1(Suppl 1):7.

106. **Kwakkenbos L**, Dooley B, Brandão MP, Frisen A, Fitzgerald A, Kling J, Rodgers R, Silva A, Diedrichs P, Jarrett C, **Thombs BD**, **Jewett LR**, Harcourt D, Rumsey N. Systematic review to develop a core set of body image measures: a study of the COST Appearance Matters network. *Appearance Matters* 7, London, UK. June 2016.
107. **Jewett LR**, **Kwakkenbos L**, **Carrier ME**, Malcarne VL, Bartlett SJ, Furst DE, Gottesman K, Mayes MD, Assassi S, Harcourt D, Williamson H, Johnson SR, Körner A, Steen V, Fox RS, Gholizadeh S, Mills SD, Molnar JC, Rice DB, **Thombs BD***, **SPIN Investigators**. Examination of the Association of Sex and Race/Ethnicity with Appearance Concerns: A Scleroderma Patient-centered Intervention Network (SPIN) Study. *Appearance Matters* 7, London, UK. June 2016.
108. **Jewett LR**, **Kwakkenbos L**, **Carrier ME**, Malcarne VL, Steele RJ, Gottesman K, **Thombs BD***, and the **SPIN Investigators**. Confirmatory Factor Analysis and Assessment of Differential Item Functioning of the Satisfaction with Appearance Scale (SWAP) in Systemic Sclerosis: A Comparison across Sex, Race/Ethnicity, and Disease Subtype. *Appearance Matters* 7, London, UK. June 2016.
109. **Jewett LR**, Malcarne VL, **Kwakkenbos L**, Harcourt D, Rumsey N, Körner A, Steele RJ, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, **Thombs BD***, **Canadian Scleroderma Research Group (CSRG)**. Development and Validation of the Body Concealment Scale For Scleroderma (BCSS). *Appearance Matters* 7, London, England. June 2016.
110. **Levis B**, **Rice DB**, **Kwakkenbos L**, Steele R, Hagedoorn M, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. The role of marital satisfaction in emotional distress among women with systemic sclerosis: A comparison of continuous vs. dichotomous measurements of marital satisfaction. *2016 Epidemiology Congress of the Americas*. Miami, Florida, USA. June 2016.
111. **Azar M**, **Riehm KE**, McKay D, **Thombs BD***. Transparency of outcome reporting and trial registration of randomized controlled trials published in the Journal of Consulting and Clinical Psychology. *2016 Epidemiology Congress of the Americas*. Miami, Florida, USA. June 2016.
112. **Gumuchian ST**, **Delisle VC**, Malcarne VL, El-Balbaki G, Pelaez S, **Jewett LR**, **Kwakkenbos L**, **Thombs BD***, The Scleroderma Support Group Team. The Scleroderma Support Group Non-Attendees Survey: A Cross-sectional Study. *47th Laurentian Conference of Rheumatology*, l'Estérel, Quebec, Canada, May 2016.
113. **Azar M**, **Rice D**, **Kwakkenbos L**, **Carrier ME**, Shrier I, Hudson M, **Thombs BD***, **SPIN investigators**. Exercise Habits and Associated Factors in Scleroderma: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *47th Laurentian Conference of Rheumatology*, l'Estérel, Quebec, Canada, May 2016.
114. **Coroiu A**, Donovan A, Karapetian A, Kingsland E, **Thombs BD**, Körner A. The effect of psycho-educational interventions on health outcomes in individuals at increased risk for melanoma: A systematic review of randomized controlled trials. *2016 International Behavioural Trials Network (IBTN) Conference*. Montreal, Quebec, Canada. May 2016.
115. **Azar M**, **Rice D**, **Kwakkenbos L**, **Carrier ME**, Shrier I, Hudson M, **Thombs BD***, **SPIN Investigators**. Exercise Habits and Associated Factors in Scleroderma: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
116. **Carrier ME**, **Kwakkenbos L**, **Thombs BD***, **SPIN Investigators**. An International Collaboration to Collect Data and Develop Online Interventions for Scleroderma Patients and an Update from the Scleroderma Patient-centered Intervention Network (SPIN). *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
117. **Delisle VC**, **Gumuchian ST**, Malcarne VL, El-Balbaki G, Pelaez S, **Thombs BD***. The Scleroderma Support Group Team. The Scleroderma Support Group Survey: Understanding People's Experiences with Scleroderma Support Groups. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
118. **Delisle VC**, **Jewett LR**, Malcarne VL, Hudson M, **Thombs BD***. The Experience of Being Diagnosed and Living with Scleroderma: Improving Communication Between Patients and Health Care Professionals. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
119. Gholizadeh S, Mills SD, Fox RS, **Jewett LR**, **Carrier ME**, Kwakkenbos L, Gottesman K, Roesch SC,

- Thombs BD***, Malcarne VL, **SPIN Investigators**. A Psychometric Analysis of the Social Interaction Anxiety Scale (SIAS-6) in Systemic Sclerosis: Results from the Scleroderma Patient-centered Intervention Network Cohort. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
120. **Gumuchian ST**, **Delisle VC**, Peláez S, **Carrier ME**, **Jewett L**, El-Baalbaki G, **Kwakkenbos L**, **Thombs BD***, Bartlett SJ. Exploring the Sources of Emotional Distress and Management Strategies among People Living with Scleroderma through Focus Groups: A Scleroderma Patient-centered Intervention Network Study. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
 121. **Jewett LR**, **Delisle VC**, Malcarne VL, Peláez S, Hudson M, **Thombs BD***. The Experience of Living with Visible Differences from Scleroderma. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
 122. **Jewett LR**, Malcarne VL, **Kwakkenbos L**, Harcourt D, Rumsey N, Körner A, Steele RJ, Hudson M, Baron M, Haythornthwaite JA, Heinberg L, Wigley FM, **Thombs BD***, **Canadian Scleroderma Research Group (CSRG)**. Development and Validation of the Body Concealment Scale For Scleroderma (BCSS). *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
 123. **Kwakkenbos L**, **Thombs BD***, Bartlett SJ, **Carrier ME**, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D, **SPIN Investigators**. Associations of Clinical Disease Characteristics with PROMIS-29 Domains: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
 124. **Kwakkenbos L**, **Thombs BD***, Bartlett SJ, **Carrier ME**, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D, **SPIN Investigators**. Construct Validity of the PROMIS-29 in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
 125. **Levis B**, **Kwakkenbos L**, Hudson M, Baron M, **Thombs BD***. Fatigue in Scleroderma: A Canadian Scleroderma Research Group Study Investigating Sociodemographic and Disease Correlates. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
 126. Mills SD, Gholizadeh S, Fox RS, **Jewett LR**, **Carrier ME**, **Kwakkenbos L**, Gottesman K, Roesch SC, **Thombs BD***, Malcarne VL, **SPIN Investigators**. Psychometric Properties of the Social Appearance Anxiety Scale in Patients with Limited and Diffuse Systemic Sclerosis: Analysis from the Scleroderma Patient-centered Intervention Network Cohort. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
 127. **Rice D**, **Kwakkenbos L**, Steele R, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Characteristics of Patients with Clinically Significant Fatigue in Scleroderma. *4th Systemic Sclerosis World Congress*, Lisbon. Portugal. February 2016.
 128. **Riehm KE**, **Kwakkenbos L**, **Carrier ME**, Nielson W, Nielsen K, **Thombs BD***, **SPIN Investigators**. Can the Self-Efficacy to Manage Chronic Disease Scale Be Used to Evaluate Self-Efficacy in Patients with Systemic Sclerosis? A Scleroderma Patient-Centered Intervention Network Cohort Study. *4th Systemic Sclerosis World Congress*, Lisbon, Portugal. February 2016.
 129. **Kwakkenbos L**, **Thombs BD***, Bartlett SJ, **Carrier ME**, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D, **SPIN investigators**. Construct Validity of the PROMIS-29 in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, San Francisco, California, USA. November 2015.
 130. Mills SD, Gholizadeh S, Fox RS, **Jewett LR**, **Carrier ME**, **Kwakkenbos L**, Gottesman K, Roesch SC, **Thombs BD***, Malcarne VL, **SPIN Investigators**. Psychometric Properties of the Social Appearance Anxiety Scale in Patients with Limited and Diffuse Systemic Sclerosis: Analysis from the Scleroderma Patient-centered Intervention Network Cohort. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, San Francisco, California, USA. November 2015.
 131. **Coroiu A**, **Kwakkenbos L**, **Thombs BD**, Korner A. The Self-Compassion Scale (SCS): Confirmatory factor analysis with a general population sample. 49th Annual Convention of the Association of Behavioral and Cognitive Therapies, Chicago, Illinois, USA. November 2015.
 132. **Azar M**, **Rice D**, Hudson M, **Kwakkenbos L**, **Thombs BD***, **SPIN Investigators**. Exercise Habits

and its Associated Factors in Scleroderma. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.

133. Carrier ME, Kwakkenbos L, Thombs BD*, **SPIN investigators**. An international collaboration to collect data and develop online interventions for scleroderma patients: the Scleroderma Patient-centered Intervention Network (SPIN). *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
134. Delisle VC, Gumuchian ST, Malcarne V, Hudson M, **Thombs BD***. The Scleroderma Support Group Survey: Understanding people's experiences with scleroderma support groups. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
135. Delisle VC, Jewett L, Malcarne V, Hudson M, **Thombs BD***, **Canadian Scleroderma Research Group**. The experience of being diagnosed and living with scleroderma: improving communication between patients and health care professionals. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
136. Gumuchian S, Delisle V, Razykov I, Carrier ME, El-Baalbaki G, Kwakkenbos L, **Thombs BD***, Bartlett SJ. Using focus group discussions to develop an online resource to help individuals with scleroderma manage emotional distress. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
137. Jewett LR, Delisle VC, Peláez S, Malcarne VL, Hudson M, **Thombs BD***. The experience of living with visible differences from a rare and unpredictable disease: Body image in scleroderma. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
138. Kwakkenbos L, **Thombs BD***, Bartlett S, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D, **SPIN investigators**. Measuring quality of life in scleroderma using the PROMIS-29 measure: evidence from the Scleroderma Patient-centered Intervention Network (SPIN). *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
139. Levis B, Kwakkenbos L, Coronado-Montoya S, Hudson M, Baron M, **Thombs BD***. Sociodemographic and Disease Variables Associated with Fatigue in Systemic Sclerosis. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
140. Milette K, Nielson W, Khanna D, **Thombs BD***. Learning from personal experiences of people coping with and managing scleroderma. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
141. Rice D, Kwakkenbos L, Steele R, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Characteristics of patients with clinically significant fatigue in scleroderma. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
142. Riehm KE, Kwakkenbos L, Carrier ME, Nielson W, Nielsen K, **Thombs BD***, **SPIN Investigators**. Can the Self-Efficacy to Manage Chronic Disease Scale be used to evaluate self-efficacy in patients with systemic sclerosis? A psychometric analysis in the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort. *2015 Scleroderma National Conference, Scleroderma Society of Canada*, Hamilton, Ontario, Canada. September 2015.
143. Jewett LR, Delisle VC, Malcarne VL, Hudson M, **Thombs BD***. Living with visible differences from a rare disease: Body image in scleroderma. *123rd American Psychological Association Convention*, Toronto, Ontario, Canada, August 2015.
144. Levis B, Benedetti A, Levis AW, **Thombs BD***. Selective cutoff reporting in studies of diagnostic accuracy of depression screening tools. *123rd American Psychological Association Convention*, Toronto, Ontario, Canada, August 2015.
145. Rice DB, **Thombs BD***. Sample Size Specification and Population Appropriateness in Depression Screening Accuracy Studies. *123rd American Psychological Association Convention*, Toronto, Ontario, Canada, August 2015.
146. Kwakkenbos L, **Thombs BD***, Bartlett S, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D, **SPIN investigators**. Construct validity of the PROMIS-29 in systemic sclerosis: preliminary results from the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. *European League*

Against Rheumatism Congress 2015, Rome, Italy. June 2015.

147. **Levis AW**, Kelley GA, **Thombs BD***. Assessing reporting bias in trials of exercise interventions for pain management in rheumatic diseases: An application of the test for excess significance. *European League Against Rheumatism Congress 2015*, Rome, Italy. June 2015.
148. **Levis B**, Benedetti A, **Levis AW**, **Thombs BD***. Selective cutoff reporting in studies of diagnostic test accuracy of depression screening tools: Comparing traditional meta-analysis to individual patient data meta-analysis. *Society for Epidemiologic Research 48th Annual Meeting*. Denver, Colorado, USA. June 2015.
149. **Rice DB**, **Thombs BD***. Sample Size Specification and Population Appropriateness in Depression Screening Accuracy Studies. *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada, June 2015.
150. **Levis B**, Benedetti A, **Levis AW**, **Thombs BD***. Selective reporting in studies of diagnostic test accuracy: Comparing traditional meta-analysis to individual patient data meta-analysis to assess the diagnostic accuracy of the Patient Health Questionnaire-9. *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada, June 2015.
151. **Gumuchian S**, **Delisle V**, **Razykov I**, Carrier ME, El-Baalbaki G, **Kwakkenbos L**, **Thombs BD***, Bartlett S. Focus groups to inform the development of a scleroderma emotional distress internet-based tool. *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada, June 2015.
152. **Delisle VC**, **Jewett LR**, Malcarne VL, Hudson M, **Thombs BD***. The experience of being diagnosed and living with scleroderma. Improving communication between patients and health care professionals. *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada, June 2015.
153. **Jewett LR**, **Delisle VC**, Malcarne VL, Hudson M, **Thombs BD***. The experience of living with visible differences from a rare and unpredictable disease: Body image in scleroderma. *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada, June 2015.
154. **Coroiu A**, **Kwakkenbos L**, **Thombs BD**, Körner A. Preliminary evaluation of a 7-item melanoma knowledge questionnaire. *2015 Canadian Psychological Association Convention*, Ottawa, Ontario, Canada, June 2015.
155. **Kwakkenbos L**, **Thombs BD***, Bartlett S, Hudson M, Mouthon L, Malcarne V, Sauve M, Khanna D, **SPIN Investigators**. Construct validity of the PROMIS-29 in systemic sclerosis: preliminary results from the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. *PROMIS Health Organization Inaugural Conference*, Philadelphia, Pennsylvania, USA. May 2015.
156. **Levis B**, **Kwakkenbos L**, **Coronado-Montoya S**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Sociodemographic and disease correlates of fatigue in systemic sclerosis. *46th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2015.
157. **Rice D**, **Kwakkenbos L**, Steele R, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Demographic and disease correlates of clinically significant fatigue in systemic sclerosis: Preliminary evidence using case-definition criteria. *46th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada. May 2015.
158. **Gumuchian S**, **Delisle V**, **Razykov I**, Carrier, ME, El-Baalbaki G, **Kwakkenbos L**, **Thombs BD***, Bartlett SJ. Focus groups to inform the development of a scleroderma emotional distress coping tool. *46th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2015.
159. **Kwakkenbos L**, **Thombs BD***. Novel approaches for pragmatic evaluations and dissemination of E-health interventions: the Scleroderma Patient-centered Intervention Network. *4th Association for Researchers in Psychology and Health Conference*, Ghent, Belgium, February 2015.
160. **Kwakkenbos L**, Minton O, Stone PC, Alexander S, Baron M, Hudson M, **Thombs BD***. Case-definition criteria for identifying patients with clinically significant fatigue in chronic medical illness. *4th Association for Researchers in Psychology and Health Conference*, Ghent, Belgium, February 2015.
161. Mills SD, Fox RS, Gholizadeh S, Roesch SC, Baron M, Hudson M, Steele R, **Thombs BD**, Malcarne VL. Trajectories of disability over time among patients with systemic sclerosis. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*,

Boston, MA, USA, November 2014.

162. **Kwakkenbos L, Thombs BD***. Overcoming barriers to developing, testing, and disseminating psychosocial and rehabilitation interventions in a rare disease context: the Scleroderma Patient-centered Intervention Network (SPIN). *International Conference on Rare Disease and Orphan Drugs (ICORD) Annual Meeting*, Ede, The Netherlands. October 2014.
163. **Kwakkenbos L, Jewett LR, Thombs BD***. Overcoming barriers to developing, testing, and disseminating psychosocial and rehabilitation interventions in a rare disease context: the Scleroderma Patient-centered Intervention Network (SPIN). *International Society for Research on Internet Interventions (ISRII) 7th Scientific Meeting*, Valencia, Spain, October 2014.
164. **Thombs BD***. The Scleroderma Patient-centered Intervention Network (SPIN) for conducting large-scale international trials of non-pharmacological interventions in scleroderma: A way ahead for lupus? *Lupus 2014*, Quebec City, Quebec, Canada, September 2014.
165. **Milette K, Mendelson C, Khanna D, Nielson W, Thombs***. The SPIN self-management program for scleroderma: Learning from personal experiences (preliminary analysis). *122nd American Psychological Association Convention*, Washington, DC, USA, August 2014.
166. **Levis B, Razykov I, Kwakkenbos L, Hudson M, Baron M, Hagedoorn M, Thombs BD*, Canadian Scleroderma Research Group**. The role of marital satisfaction in emotional distress among women with scleroderma. *45th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2014.
167. **Kwakkenbos L, Jewett LR, Thombs BD*, SPIN Investigators**. An international collaboration to conduct large-scale trials of non-pharmacological interventions in scleroderma: the Scleroderma Patient-centered Intervention Network (SPIN). *45th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2014.
168. **Kwakkenbos L, Willems LM, Baron M, Hudson M, van den Ende CHM, Thombs BD*, Canadian Scleroderma Research Group**. Can scores from English, French and Dutch versions of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) be pooled? An assessment of differential item functioning in patients with systemic sclerosis. *45th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, May 2014.
169. **Coronado-Montoya S, Levis AW, Kwakkenbos L, Steele RJ, Turner EH, Thombs BD***. Application of the excess significance bias test in randomized controlled trials of mindfulness-based mental health interventions: a cross-sectional study. *Cochrane Canada 11th Annual Symposium*, Ottawa, Ontario, Canada, April 2014.
170. **Malcarne VL, Mayes MD, Assassi S, Fox RS, Gholizadeh S, Gottesman K, Harcourt D, Kwakkenbos L, Jewett LR, Mendelson C, Mills SD, Rumsey N, Strohauser T, Williamson H, Thombs BD***. Developing an Intervention for Body Image Distress in Systemic Sclerosis: An Update from the Scleroderma Patient-centered Intervention Network (SPIN). *3rd Systemic Sclerosis World Congress*, Rome, Italy, February 2014.
171. **Kwakkenbos L, Jewett LR, Thombs BD***. An international collaboration to conduct large-scale trials of non-pharmacological interventions in scleroderma: the Scleroderma Patient-centered Intervention Network (SPIN). *3rd Systemic Sclerosis World Congress*, Rome, Italy, February 2014.
172. **Kwakkenbos L, Willems LM, Baron M, Hudson M, van den Ende CHM, Thombs BD*, Canadian Scleroderma Research Group**. Can scores from English, French and Dutch versions of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) be pooled? An assessment of differential item functioning in patients with systemic sclerosis. *3rd Systemic Sclerosis World Congress*, Rome, Italy, February 2014.
173. **Coronado-Montoya S, Kwakkenbos L, Thombs BD***. Assessing publication bias in systematic reviews and meta-analyses in the context of small n trials: application of a capture-recapture method. *21st Cochrane Colloquium*, Quebec City, Quebec, Canada, September 2013.
174. **Levis B, Thombs BD***. The DEPREssion Screening Data (DEPRESSD) Registry: A protocol for a registry to support individual patient data meta-analyses of the diagnostic accuracy of depression screening tools. *21st Cochrane Colloquium*, Quebec City, Quebec, Canada, September 2013.
175. **Levis B, Thombs BD***. Addressing bias in estimates of diagnostic accuracy of depression screening tools: A data registry for individual patient data meta-analyses. *Preventing Overdiagnosis International Conference*, Dartmouth University, Hanover, New Hampshire, USA, September 2013.

176. **Razykov I, Delisle VC**, El-Baalbaki G, **Kwakkenbos L, Thombs BD***, Bartlett SJ. Developing an Internet-based intervention for coping with emotions and stress in scleroderma: A qualitative study. *Scleroderma Society of Canada 15th Annual Scleroderma Conference*, Hamilton, Ontario, Canada, September 2013.
177. **Milette K**, Mendelson C, Khanna D, Nielson W, **Thombs BD***. The SPIN self-management program for scleroderma: Learning from personal experiences (a preliminary look). *Scleroderma Society of Canada 15th Annual Scleroderma Conference*, Hamilton, Ontario, Canada, September 2013.
178. Willems LM, **Kwakkenbos L**, Leite C, **Thombs BD**, van den Hoogen FHJ, Maia A, van den Ende CHM. Frequency and impact of disease symptoms experienced by patients with systemic sclerosis: a comparison among five European countries. *European League Against Rheumatism 2013 – Annual European Congress of Rheumatology*. Madrid, Spain, June 2013.
179. **Coronado-Montoya S, Kwakkenbos L, Thombs BD***. Risk of bias in systematic reviews and meta-analyses of psychological interventions due to missing trial data: The case of mindfulness-based therapies. *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada, June 2013.
180. **Levis B**, Burri A, Hudson M, Baron M, **Thombs BD***. **Canadian Scleroderma Research Group**. Comparison of sexual activity and sexual impairment rates between women with systemic sclerosis and women from a general population sample. *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada, June 2013.
181. **Milette K**, Hudson M, Körner A, Baron M, **Thombs BD***. **Canadian Scleroderma Research Group**. Sleep disturbances in systemic sclerosis: Evidence for the role of gastrointestinal symptoms, pain, and pruritus. *2013 Canadian Psychological Association Convention*, Quebec City, Quebec, Canada, June 2013.
182. **Jewett LR, Razykov I**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Prevalence of current, 12-month, and lifetime depressive disorder among patients with systemic sclerosis. *44th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, April 2013.
183. **Delisle VC**, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Gender and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian Scleroderma Group Registry. *44th Laurentian Conference of Rheumatology*, Mont Tremblant, Quebec, Canada, April 2013.
184. **Levis B**, Burri A, Hudson M, Baron M, **Thombs BD***, **Canadian Scleroderma Research Group**. Sexual activity and sexual functioning among women with systemic sclerosis compared to women from a population sample. *American College of Rheumatology/Association for Rheumatology Health Professionals Annual Scientific Meeting*, Washington, DC, USA, November 2012.
185. Racine M, **Thombs BD**, Hudson M, Baron M, Nielson WR, **Canadian Scleroderma Research Group**. Clinical correlates of pain versus itch in scleroderma: An exploratory study. *14th World Congress on Pain, International Association for the Study of Pain*, Milan, Italy, August 2012.
186. **Milette K, Thombs B***, Hudson M, Baron M. Sleep Disturbances in Scleroderma: Evidence for the Role of Pain and Gastrointestinal Symptoms *120th Annual Convention of the American Psychological Association*, Orlando, Florida, USA, August 2012.
187. **Roseman M**, Bero L, Coyne JC, Lexchin J, Turner E, **Thombs BD***. Reporting of conflicts of interest in Cochrane reviews of trials of pharmacological treatments. *19th Cochrane Colloquium*, Madrid, Spain, October 2011.
188. **Delisle VC**, Abbey S, Beck A, Dobson K, Dozois D, Grace S, Stewart D, Ziegelstein R, **Thombs B***. The influence of somatic symptoms on Beck Depression Inventory scores in patients hospitalized with an acute coronary syndrome. *119th Annual Convention of the American Psychological Association*, Washington D.C., USA, August 2011.
189. **Jewett L**, Hudson M, Baron M, **Thombs B***. Acquired disfigurement from medical illness: Modeling correlates of body image distress among people with scleroderma. *119th Annual Convention of the American Psychological Association*, Washington D.C., USA, August 2011.
190. **Milette K, Roseman M, Thombs B***. Transparency of outcome reporting and trial registration of randomized controlled trials in top behavioural health journals: A systematic review. *119th Annual Convention of the American Psychological Association*, Washington D.C., USA, August 2011.

191. **Milette K, Razykov I**, Pope J, Hudson M, Motivala S, Baron M, **Thombs B***. Clinical correlates of sleep problems in systemic sclerosis: The prominent role of pain. *119th Annual Convention of the American Psychological Association*, Washington D.C., USA, August 2011.
192. **Arthurs E**, Hudson M, Baron M, **Thombs BD***. Are French and English versions of the PHQ-9 comparable? An assessment of differential item functioning. *3rd North American Congress of Epidemiology*, Montreal, Quebec, Canada. June 2011.
193. **Thombs BD***, **Arthurs E** (presenter), **El-Baalbaki G, Meijer A**, Ziegelstein RC, Steele R. Risk of Bias from the Inclusion of Already Diagnosed or Treated Patients in Diagnostic Accuracy Studies of Depression Screening Tools. *3rd North American Congress of Epidemiology*, Montreal, Quebec, Canada. June 2011.
194. **Razykov I**, Hudson M, Baron M, **Thombs BD***. Screening for suicide in medical patients: Is the PHQ-9 the Answer? *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
195. **Arthurs E**, Hudson M, Baron M, **Thombs BD***. Are French and English versions of the PHQ-9 comparable? An assessment of differential item functioning. *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
196. **Jewett LR**, Hudson M, Baron M, **Thombs BD***. Sociodemographic and disease-related predictors of body image distress among people with scleroderma: Examining acquired disfigurement from a chronic disease. *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
197. **Milette K, Roseman M, Thombs BD***. Transparency of outcome reporting and trial registration of randomized controlled trials in top psychosomatic and behavioural health journals: A systematic review. *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
198. **Zhao Y**, Montoro R, Igartua K, **Thombs BD***. Who identifies as gay, lesbian, or bisexual among adolescents with same-sex attraction/fantasy or behaviour? *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
199. **Delisle VC**, Beck AT, Dobson KS, Dozois DJA, **Thombs BD***. Do women really report more somatic symptoms than men? *2011 Canadian Psychological Association Convention*, Toronto, Ontario, Canada. June 2011.
200. **Delisle VC**, Abbey SE, Beck AT, Dobson KS, Dozois DJA, Grace SL, Stewart DE, Ziegelstein RC, **Thombs BD***. The influence of somatic symptoms on BDI versus BDI-II scores in patients hospitalized following myocardial infarction. *National Student Conference of the Canadian Society of Epidemiology and Biostatistics*, Montreal, Quebec, Canada. June 2011.
201. **Levis B**, Hudson M, **Knafo R**, Baron M, **Thombs BD***, Nielson WR, Hill M, **Canadian Scleroderma Research Group**. Sexual activity and impairment among female scleroderma patients. *Laurentian Conference of Rheumatology*. Mont-Tremblant, Quebec, Canada. May 2011.
202. **Razykov I**, Hudson M, Baron M, **Thombs B***. Development and validation of a pruritus measure in patients with systemic sclerosis. *Canadian Rheumatology Association Annual Meeting*, Cancun, Mexico, February 2011.
203. **Roseman M, Milette K**, Bero L, Coyne JC, Lexchin J, Turner E, **Thombs BD***. Hidden conflicts of interest in meta-analyses of pharmacological treatments. *Joint Colloquium of the Cochrane & Campbell Collaborations*, Keystone, Colorado, USA, October 2010.
204. **Milette K, Roseman M, Thombs BD***. Transparency of outcome reporting in behavioral health research: A systematic review. *XXVIII European Conference on Psychosomatic Research*. Innsbruck, Austria, June 2010.
205. **Milette K, Roseman M, Thombs BD***. Transparency of outcome reporting in behavioral health research: A systematic review. *8th Annual Canadian Cochrane Symposium*, Ottawa, Ontario, Canada, May 2010.
206. **Razykov I, Thombs BD***, Hudson M, Bassel M, Baron M. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. *Canadian Rheumatology Association, 2010 Conference*, Quebec City, Quebec, Canada, February 2010.

207. **Knafo R, Thombs BD***, Wigley F, Haythornthwaite JA. Clinical correlates of sexual impairment in women with systemic sclerosis. *Canadian Rheumatology Association, 2010 Conference*, Quebec City, Quebec, Canada, February 2010.
208. **Jewett LR, Thombs BD***, Hudson M, Heinberg L, Wigley F, Haythornthwaite JA. Measuring body image avoidance in patients with systemic sclerosis. *Canadian Rheumatology Association, 2010 Conference*, Quebec City, Quebec, Canada, February 2010.
209. **Newton E**, Schnitzer M, Steele R, Hudson M, Baron M, **Thombs BD*, Canadian Scleroderma Research Group**. The longitudinal trajectory of depressive symptoms in systemic sclerosis. *Canadian Rheumatology Association, 2010 Conference*, Quebec City, Quebec, Canada, February 2010.
210. **Knafo R, Thombs BD***, Hudson M, Wigley F, Haythornthwaite JA. Clinical correlates of sexual impairment in women with systemic sclerosis. *American College of Rheumatology, 2009 Scientific Meeting*, Philadelphia, Pennsylvania, USA, October 2009.
211. **Zhao Y, Thombs BD***, Montoro R, Igartua K. Risk of mental health problems among non-heterosexual identified adolescents: What about adolescents who are unsure of their sexual identity? *2009 Canadian Psychological Association Convention*, Montreal, Quebec, Canada, June 2009.
212. Magyar-Russell G, Cai JX, **Thombs BD**, Bavja T, Singh PP, Kuhl E, Amin N, Marine J, Ziegelstein RC. Prevalence of anxiety and depression in patients with implantable cardioverter defibrillators: A systematic review of the literature. *American Psychosomatic Society, 67th Annual Scientific Meeting*, Chicago, Illinois, USA, March 2009.
213. **Schieir O, Thombs BD***, Bernatsky S, Hudson M, Boivin J-F, Hanley J, Taillefer S, **Canadian Scleroderma Research Group**, Baron M. Pain is associated with higher physician use in patients with systemic sclerosis. *American College of Rheumatology, 2008 Scientific Meeting*, San Francisco, California, USA, October 2008.
214. **Schieir O, Thombs BD***, Hudson M, Bernatsky S, Boivin J-F, Hanley J, **Canadian Scleroderma Research Group**, Baron M. Clinical signs and symptoms associated with global pain among patients with limited and diffuse scleroderma. *American College of Rheumatology, 2008 Scientific Meeting*, San Francisco, California, USA, October 2008.
215. **Schieir O, Thombs BD***, Hudson M, Boivin JF, Hanley J, Taillefer S, **Canadian Scleroderma Research Group**, Baron M. "Where does it hurt? Patient characteristics and clinical signs & symptoms associated with global pain in SSc. *2nd Annual Scientific Meeting of the Canadian Scleroderma Research Group*, Ottawa, Ontario, Canada, September 2008.
216. **Adeponle AB, Thombs BD***, Adelekan ML, Kirmayer LJ. Family participation in treatment and post-discharge appointment and medication adherence at a Nigerian psychiatric hospital. *Society for the Study of Psychiatry and Culture, 2008 Conference*, San Diego, California, USA, June 2008.
217. **Thombs BD***, Hudson M, Taillefer S, **Canadian Scleroderma Research Group**, Baron M. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. *Canadian Rheumatology Association, 2008 Annual Meeting*, Mont Tremblant, Quebec, Canada, March 2008.
218. **Thombs BD***, **Bassel M**, Hudson M, Taillefer S, **Canadian Scleroderma Research Group**, Baron M. Sociodemographic and clinical correlates of fatigue in patients with systemic sclerosis: Evidence from 482 Canadian Scleroderma Research Group Registry patients. *Canadian Rheumatology Association, 2008 Annual Meeting*, Mont Tremblant, Quebec, Canada, March 2008.
219. **Schieir O, Thombs BD***, Hudson M, Taillefer S, **Canadian Scleroderma Research Group**, Baron M. Socio-demographic and clinical correlates of pain in patients with systemic sclerosis. *Canadian Rheumatology Association, 2008 Annual Meeting*, Mont Tremblant, Quebec, Canada, March 2008.
220. Hudson M, **Thombs BD**, Fritzler M, Bernstein J, **Canadian Scleroderma Research Group**, Baron M. Gender differences in antibody expression in systemic sclerosis. *Canadian Rheumatology Association, 2008 Annual Meeting*, Mont Tremblant, Quebec, Canada, March 2008.
221. Hudson M, **Thombs BD**, Steele R, Panopalis P, **Newton E**, **Canadian Scleroderma Research Group**, Baron M. Quality of life in systemic sclerosis compared to the general population and patients with other chronic conditions. *Canadian Rheumatology Association, 2008 Annual Meeting*, Mont Tremblant, Quebec, Canada, March 2008.

222. Bhat U, Parakh K, **Thombs BD**, Fauerbach JA, Bush DE, Ziegelstein RC. Baseline physical function is an independent predictor of long-term mortality after myocardial infarction: A ten-year study. *American Heart Association, 2007 Scientific Sessions*, Orlando, Florida, USA, November 2007.
223. **Hudson M, Thombs BD, Canadian Scleroderma Research Group**, Baron M. Time to diagnosis in systemic sclerosis: Is gender a factor? *American College of Rheumatology, 2007 Scientific Meeting*, Boston, Massachusetts, USA, November 2007.
224. **Thombs BD***, Hudson M, Taillefer SS, **Canadian Scleroderma Research Group**, Baron M. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. *American College of Rheumatology, 2007 Scientific Meeting*, Boston, Massachusetts, USA, November 2007.
225. **Thombs BD***, Ziegelstein RC, Stewart DE, Abbey SE, Grace SL. Both depression and self-rated physical health during hospitalization for an acute coronary syndrome predict mortality one year later. 15th European Congress of Psychiatry, Madrid, Spain, March 2007. *Eur Psychiatry*. 2007;22(1 Suppl):S249.
226. **Thombs BD***, Ziegelstein RC, Stewart DE, Abbey SE, Grace SL. Depression during hospitalization for an acute coronary syndrome predicts physical function one year later. 15th European Congress of Psychiatry, Madrid, Spain, March 2007. *Eur Psychiatry*. 2007;22(1 Suppl):S249.
227. **Thombs BD***, Ziegelstein RC, Stewart DE, Abbey SE, Grace SL. Comorbid anxiety and depression during hospitalization for an acute coronary syndrome increase risk of mortality one year later. 15th European Congress of Psychiatry, Madrid, Spain, March 2007. *Eur Psychiatry*. 2007;22(1 Suppl):S290.
228. Bresnick MG, **Thombs BD***. Self-Inflicted burn injury: Patient characteristics, mortality and length of hospital stay in a national sample of 30,382 adult patients. *Amer Burn Assoc, 39th Annual Meeting*, San Diego, California, USA, April 2007.
229. **Thombs BD***, Price LA, Milner SM. Liver Disease in burn injury: Evidence from a national sample of 30,382 adult patients. *Amer Burn Assoc, 39th Annual Meeting*, San Diego, California, USA, April 2007.
230. Spence RJ, **Thombs BD**, Haines J. Burns below the knee. An indication for hospitalization. *Amer Burn Assoc, 39th Annual Meeting*, San Diego, California, USA, April 2007.
231. Cockrell GY, **Thombs BD**. Assessing demographics and outcomes related to catastrophic skin diseases: Shortcomings in extant data collection methods. *Proc Amer Burn Assoc, 38th Annual Meeting*, Las Vegas, Nevada, USA, April 2006. *J Burn Care Res*. 2006;27(2 Suppl):S156.
232. Alvarez W, Ziegelstein RC, Meuchel J, **Thombs BD**, Latif M, Dasgupta N. (October, 2005). SSRI use in acute coronary syndromes: Effect on major adverse cardiac events and bleeding complications. American College of Clinical Pharmacy 2005 Annual Meeting, San Francisco California, USA, October 2005. *Pharmacotherapy*. 2005;25:1444.
233. **Ortega A, Torres L, DiMaggio A, Strong W, Hanson K, Thombs BD***. Body appearance satisfaction in female college students: Comparing graduates of coeducational and single-sex high schools across ethnicity. *Eastern Psychological Association, 2003 Annual Meeting*, Baltimore Maryland, USA, March 2003. [Mentored undergraduate course project].

I. MEDIA COVERAGE (Selected, including coverage of trainees)

I.1. International

- Fatigue, Raynaud's top physical activity barriers for patients with scleroderma. *Healio Rheumatology*, February 25, 2021 (interview with supervised student). [Link](#)
- Study: pandemic increases anxiety, but not depression, in scleroderma patients. *Scleroderma News*, October 6, 2020. [Link](#)
- Screening for depression: the long and short of it (Ann Robinson's research reviews). *The BMJ Opinion*, June 19, 2020. [Link](#)
- PHQ-2 screening followed by PHQ-9 may provide accurate depression detection, Joe Gramigna, *Healio Psychiatry*, June 17, 2020. [Link](#)

- Many Canadian medical societies fail to disclose industry funding in their clinical guidelines, Ed Silverman, **STAT News – Pharmalot**, June 9, 2020. [Link](#)
- PHQ-9 overestimates depression prevalence, Terri D'Arrigo, **Psychiatric News (American Psychiatric Association)**, June 4, 2020. [Link](#)
- New independent study finds Cochrane's transparency over reporting financial conflicts of interest is leading the way. **Cochrane Collaboration News**, May 21, 2020. [Link](#)
- PHQ-9 "substantially overestimates depression prevalence." Peter Simons, **Mad in America**, March 23, 2020. [Link](#)
- Sarah Markham: screening tools for depression offer value when combined with an informed shared decision process, **The BMJ Opinion**, April 9, 2019. [Link](#)
- Mener forskerne overvurderer hvor mange som er deprimerede: Spørreskjema finner flere deprimerede enn det fagfolkene gjør. Det kan gi et skjevt bilde av verden [Researchers overestimate how many people are depressed: Questionnaires identify more people with depression than professionals. It can give a biased picture]. **Forskning.no [Online news established by Research Council of Norway]**. January 17, 2018. [Link](#)
- Self-report screening questionnaires overestimate prevalence of depression. **Healio Psychiatric Annals**, January 17, 2018. [Link](#)
- Is mindfulness meditation good for kids? Here's what the science actually says. Brian Resnick, **Vox**, May 22, 2017. [Link](#)
- Is the United States Preventive Services Task Force still a voice of caution? Jeanne Lenzer, **BMJ**, 2017;356:j743. [Link](#)
- Depression lowest in women with systemic sclerosis who are happily married, study says. Ines Martins, **Scleroderma News**, August 30, 2016. [Link](#)
- Lower scores for depressive symptoms found among married vs unmarried women with systemic sclerosis. **Healio Rheumatology**, August 25, 2016. [Link](#)
- Depression screening inaccurate for children, teens, researchers say. Stephen Feller, **United Press International**, August 2, 2016. [Link](#)
- Is mindfulness meditation overhyped? Scientists may be exaggerating how good it is for us, Ed Cara, **Medical Daily**, April 25, 2016. [Link](#)
- Is mindfulness overrated? Melissa Dahl, **New York Mag**, April 24, 2016. [Link](#)
- A new study suggest mindfulness isn't quite as miraculous as we've been led to believe, Olivia Goldhill, **Quartz**, April 24, 2016. [Link](#)
- Power of positive thinking skews mindfulness studies, Anna Nowogrodzki, **Nature News, Scientific American**, April 21, 2016. [Link](#)
- We don't really know how effective mindfulness therapies are, researchers say, Susan Perry, **MINNPOST**, April 19, 2016. [Link](#)
- The marketing of mindfulness and why that matters, Alan Cassels, **Health News Review**, April 12, 2016. [Link](#)
- Don't screen all kids for developmental delays, Canadians say. Andrew M. Seaman, **Reuters**, March 30, 2016. [Link](#)
- Missing in action: Did US journalists miss a huge opportunity to critically examine mental health screening? Alan Cassels, **Health News Review**, February 3, 2016. [Link](#)
- A seal of approval for clinical treatments, **Association for Psychological Science Observer**, July/August 2015. [Link](#)
- 2013 ACR/ARHP Annual Meeting: health professionals in the spotlight, **The Rheumatologist**, January 2014. [Link](#)
- International collaboration working to improve the lives of those living with scleroderma, **Scleroderma Voice** (The member magazine of the Scleroderma Foundation), Fall 2013.
- Depression screening in patients with cardiac disease, **BMJ Evidence-based Nursing Podcasts**, April 15, 2013. [Link](#)
- Is big pharma getting too much flak? **Reuters, Baltimore Sun, Chicago Tribune**, September 18, 2012. [Link](#)
- In Session with Brett D. Thombs, PhD: Is screening for depression in primary care actually beneficial? **Psychiatry Weekly**, Volume 6, Number 27, November 28, 2011.

- It's time to rebuild the evidence base: With medical science so contaminated by conflicts of interest, what evidence can we trust? Ray Moynihan, *BMJ*, 2011;342:d3004. [Link](#)
- Pooled trials drowning in conflict-of-interest oversights, Nazlie Latefi, *Nature Medicine*, 2011;17:400-401. [Link](#)
- Radio broadcast interview: (Suicide risk among lesbian, gay, bisexual and transgender youth). *Voice of America*, April 20, 2011.
- Suicide risk may be lower for gays, lesbians in 'supportive' areas, *Los Angeles Times*, April 18, 2011. [Link](#)
- Bias creeps into meta-studies: US medical journal, *Agence France Press*, March 8, 2011.
- Influential research misses financial conflicts, *Reuters*, *Hartford Courant*, *Chicago Tribune*, March 8, 2011
- Major drug review research fails to disclose funding sources, *Health Day News Report*, *U.S. News & World Report*, *Bloomberg Businessweek*, *MSN Health*, March 8, 2011. [Link](#)
- Scientists Often Ignore Financial Conflicts When Reviewing Drugs, Study Finds, *AOL Health*, March 9, 2011.
- Gay, lesbian, bisexual higher suicide risk, *United Press International*, February 8, 2010. [Link](#)
- Will treating depression treat heart disease? *Wall Street Journal*, September 8, 2009. [Link](#)
- Researchers debate universal depression screening in cardiac patients, *American Psychiatry News*, February, 2009.
- Depression and cardiovascular disease: A need for increased awareness, *Journal Watch Cardiology*, 2008:3-3. [Link](#)
- Call for depression screening of heart patients is premature, *The Johns Hopkins University Gazette*, Baltimore, Maryland, USA, December 15, 2008. [Link](#)
- Depressionen und Infarktrisiko: Das herz im griff der seele [Depression and risk of infarct: The heart in the hands of the soul], *Frankfurter Allgemeine Zeitung*, Germany, December 10, 2008. [Link](#)
- CVD depression screening set to stay in QOF despite new evidence, *Pulse*, United Kingdom, November 17, 2008. [Link](#)
- American Heart Association urges screening cardiac patients for depression, *Baltimore Sun*, Baltimore, Maryland, USA, November 17, 2008.
- A heart-and-mind link; In cardiac cases, depression can hurt recovery. Now there's a push for screening, *Los Angeles Times*, Los Angeles, California, USA, November 17, 2008. [Link](#)
- Test burdensome: Cardiologists may ignore depression, *Arab Times*, Kuwait, November 13, 2008.
- Routine depression screening, *The Times*, Malta, November 13, 2008.
- Depression and heart link questioned, *United Press International*, November 13, 2008.
- Screening heart patients for depression doesn't help, says study, *Asian News International*, November 12, 2008.
- Depressed? Your cardiologist might not ask, *Reuters*, November 12, 2008. [Link](#)
- Screening heart patients for depression not effective: McGill, Johns Hopkins study; American Heart Association call for routine screening 'premature,' scientists say, *Ascribe News*, November 11, 2008.
- Study questions screening heart attack patients for depression: International experts say there isn't enough evidence to prove its value, *ABC News*, November 11, 2008. [Link](#)
- Study questions screening heart attack patients for depression, *Washington Post*, Washington, DC, November 11, 2008.
- Persistent depression after heart trouble harmful, *Reuters*, February 5, 2008. [Link](#)
- Increased depression help needed for burns patients, *Expert Review of Dermatology*, 2(1), February, 2007.
- Burn patients need more help coping with depression, *Health Behavior News Service*, January 15, 2007.
- Many burn patients experience depression, *United Press International*, January 11, 2007.

I.2. National/Local

- Radio talk show (10 minute segment): (SPIN-CHAT Trial). *CJAD 800*, Montreal (with Tara Schwartz). April 25, 2021. [Link](#)

- Radio talk show (15 minute segment): (Mental health in COVID-19 based on living systematic review). **630 CHED**, Edmonton, and **770 CHQR**, Calgary (with Daryl McIntyre). March 31, 2021.
- 'There's a lot of resilience': Why mental health is holding up to COVID-19 better than expected. **National Post**. Tristin Hopper. March 29, 2021. [Link](#)
- Après les mesures sanitaires s'enchaînent les SOS en santé mentale [Mental health SOS following public health measures]. **Radio-Canada**. March 18, 2021. [Link](#)
- Shock therapy: curfew to curtail COVID-19 spread might just worsen public mental health, morale. Sharon Kirkey. **National Post**. January 9, 2021. [Link](#)
- Expert advice on how to tackle resolutions for 2021. Chloe Rose Stuart-Ulin. **CBC**. December 31, 2020. [Link](#)
- Majority of Quebecers believe first wave of COVID-19 pandemic is over, survey finds. Morgan Lowrie, **Canadian Press (published in Globe and Mail, L'actualité, other outlets)**, June 19, 2020. [Link](#)
- New wave of McGill research projects supported by MI4 fund. **McGill Alumni Magazine**, May 22, 2020. [Link](#)
- University of Alberta phd student develops AI to identify depression. **Globe and Mail**, August 18, 2019. [Link](#)
- Why mindfulness may be right for you: For dealing with stress, this meditative practice can make a difference – and that's only one of its benefits. **Good Times Magazine**, January/February 2018.
- Radio talk show (10 minute segment): (Addressing overestimation of the prevalence of depression prevalence based on self-report screening questionnaires). **Global News – News Talk 770**, Calgary, Alberta, January 16, 2018.
- Studies overestimate prevalence of depression, article shows. **The Globe and Mail**, January 15, 2018. [Link](#)
- La prevalence de la depression serait surestimée: Un article remet en cause l'usage des questionnaires d'auto-évaluation par les cliniciens et les chercheurs. **Le Devoir**, January 15, 2018. [Link](#)
- Television and radio interview (10 minute segment): (Canadian Task Force on Preventive Health Care statement on annual checkup). **CBC Daybreak**. November 17, 2017.
- Le bilan de santé annuel est inutile : Une nouvelle étude démontre que les médecins devraient consacrer leur temps à soigner les malades plutôt qu'à examiner les bien-portants. **Le Devoir**, November 15, 2017. [Link](#)
- Radio talk show (10 minute segments): (Recommendations on behavioural interventions for the prevention and treatment of cigarette smoking among school-aged children and youth). **CBC Radio Syndication (11 live interviews)**. March 1, 2017.
- Radio talk show (10 minute segment): (Recommendations on behavioural interventions for the prevention and treatment of cigarette smoking among school-aged children and youth). **Jim Harrison Show, CHNL Radio**, Kamloops, British Columbia, March 1, 2017.
- Doctors advised to talk to young Canadians about smoking (article and podcast). **Radio Canada International**, March 1, 2017. [Link](#)
- Doctors have role to play in preventing kids and teens from smoking: Task Force. **Canadian Press (appeared in print and online versions of Globe and Mail, Toronto Star, other Canadian news outlets)**. February 27-28, 2017. [Link](#)
- Recommendations on behavioural interventions for the prevention and treatment of cigarette smoking among school-aged children and youth. **CMAJ Podcast**, February 27, 2017. [Link](#)
- Inaccurate depression screening tools used for children and adolescents. Cait Martin Newnham, **SickNotWeak (sicknotweak.com)**. Canada. August 11, 2016. [Link](#)
- Radio talk show (15 minute segment): (Accuracy of depression screening tools to detect major depression in children and adolescents: A systematic review). **The Ryan Jespersen Show, 630 CHED**, Edmonton, Alberta, August 8, 2016.
- Depression screening tests for children unreliable, study says: Doctors in Canada and the U.S. are increasingly using short questionnaires to identify depression in pediatric patients. **Toronto Star**, August 5, 2016. [Link](#)
- Mindfulness is trendy, but that doesn't mean it's easy. **Chatelaine**, August, 2016 (online July 13, 2016). [Link](#)
- Adults overdiagnosed, overprescribed for ADD/ADHD? **CJAD News**, August 1, 2015.

- Explosion de diagnostics du TDAH chez l'adulte, **Le Devoir**, July 25, 2015. [Link](#)
- Radio talk show (10 minute segment): (Is adult ADHD being overdiagnosed?). **The Ed Hand Show, 1310 News**, Ottawa, Ontario, July 27, 2015.
- Radio talk show (20 minute segment): (Is adult ADHD being overdiagnosed?). **Kingkade & Breakenridge Show, News Talk 770**, Calgary, Alberta, July 28, 2015.
- Emerging Stars, **McGill Headway**, Spring 2015. [Link](#)
- Television Interview: Doctors and obesity: Encouraging weight loss has little benefit, new Canadian guidelines acknowledge, **CBC News: The National**, January 26, 2015. [Link](#)
- Outstanding emerging researchers get new Principal's Prize, **McGill Reporter**, May 27, 2014. [Link](#)
- Fuzziness in funding, **McGill News**, Fall/Winter 2012. [Link](#)
- Impossible de se fier aux revues systématiques sur les médicaments, déclarent des chercheurs québécois, **L'actualité médicale**, October 10, 2012.
- 'Critical information' from drug trials kept from doctors and patients: study, **Montreal Gazette**, August 22, 2012.
- Santé mentale des jeunes: le fédéral finance trois projets de recherche, **Profession Santé**, February 15, 2012.
- Patients cancéreux: le dépistage de la dépression causerait plus de tort que de bien, **Profession Santé**, November 15, 2011.
- Radio talk show (15 minute segment): (Rethinking recommendations for depression screening in primary care). **The Rutherford Show**. Airs on multiple stations across Alberta, Canada, September 16, 2011.
- Radio talk show (30 minute segment): (Risk of bias from inclusion of patients who already have diagnosis of or are undergoing treatment for depression in diagnostic accuracy studies of screening tools for depression: systematic review). **The Rutherford Show**. Airs on multiple stations across Alberta, Canada, August 22, 2011.
- Radio talk show (30 minute segment): (Risk of bias from inclusion of patients who already have diagnosis of or are undergoing treatment for depression in diagnostic accuracy studies of screening tools for depression: systematic review). **Tommy Schnurmacher Show, CJAD Radio**, Montreal, Quebec, August 19, 2011.
- Des tests peu fiables pour dépister la dépression. **Le Devoir** (front page), August 19, 2011. [Link](#)
- Radio broadcast interview: (Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments). **HealthBeat, CJAD Radio**, Montreal, Quebec, March 13, 2011.
- Médicaments – Qui finance les essais cliniques? Les liens entre les chercheurs et l'industrie pharmaceutique sont rarement relevés dans les publications médicales. **Le Devoir**, March 9, 2011. [Link](#)
- Sponsorship biases keep MDs in the dark: Conflicts of interest between researchers, pharmaceutical firms not fully disclosed, **Vancouver Sun**, March 9, 2011. [Link](#)
- Medical studies affected by funding, study finds, **Montreal Gazette**, March 9, 2011. [Link](#)
- Hidden hand can influence doctor's decisions: Researcher-drug company links may lead to conflict of interest, **Victoria Times Colonist**, March 9, 2011.
- Undisclosed funding sources raise issue of bias in medical studies: Report, **Vancouver Province, Edmonton Journal, Regina Leader-Post, Saskatoon StarPhoenix, Windsor Star, Ottawa Citizen, Calgary Herald**, March 9, 2011.
- Les études sur les médicaments devraient mentionner leur source de financement, **La Presse Canadienne**, March 9, 2011.
- Medical journals still publishing studies that fail to reveal funding: study, **Globe and Mail**, March 10, 2011.
- The investigation of conflicts of interest, **McGill Daily**, April 4, 2011. [Link](#)
- Radio broadcast interview: (Sexual orientation and risk of suicide ideation and attempt). **Health on Earth, CKUT**, Montreal, Quebec, May 11, 2010.
- The Award for Excellence in Psychological or Clinical Research, **Pulse**, Jewish General Hospital, Montreal, Quebec, Winter 2011.
- Sexual identity and teen suicide: A deeper look at a groundbreaking McGill study on the connections between the two, **The McGill Daily**, Montreal, Quebec, April 2, 2010. [Link](#)
- Suicide risk in gay and lesbian teens: Self-identity is critical say researchers, **JGH News**, Jewish General Hospital, Montreal, Quebec, Spring 2010.

- Radio news: (Sexual orientation and risk of suicide ideation and attempt). **Radio Canada International**, February 16, 2010.
- Gay teenagers more likely to think about suicide: study, **National Post**, **Vancouver Sun**, February 11, 2010.
- Gay teens' suicide risk higher: Montreal study; Homophobia to blame, McGill researchers say, **Montreal Gazette** (front page), February 12, 2010. [Link](#)
- La perception de l'identité sexuelle favorise les idées suicidaires, **La Presse Canadienne**, February 5, 2010. [Link](#)
- Vivre mieux avec la sclérodémie, **Découvrir: La Revue de la Recherche de L'ACFAS**, 2009; Mars-Avril: 14-15.
- Evidence lacking for mass screening of heart patients for depression: study; Basic questions from cardiologists would find that about a third of patients screen positive for depression according to researcher, **The Times – Transcript**, Moncton, New Brunswick, Canada, November 15, 2008.
- Screening all heart patients for depression not seen as especially useful, says study, **Prince George Citizen**, Prince George, British Columbia, Canada, November 13, 2008.
- Screening little benefit for patients, **Nanaimo Daily News**, Nanaimo, British Columbia, November 12, 2008.
- Depression test too imprecise, **Leader Post**, Regina, Saskatchewan, November 12, 2008.
- Depression screening little benefit for heart patients, **Alberni Valley Times**, Port Alberni, British Columbia, November 12, 2008.
- No evidence heart patients need to be screened for depression: study, **National Post**, Don Mills, Ontario, November 12, 2008.
- Depression screening does not help heart patients: Researcher, **Vancouver Sun**, Vancouver, BC, November 12, 2008.
- No reason to screen all heart patients for depression, **The Canadian Press**, November 12, 2008.
- Depression tests are inexact tools: study, **Montreal Gazette**, Montreal, QC, November 12, 2008. [Link](#)
- Radio broadcast interview: (Depression screening in cardiovascular care). **The World at Six**, Canadian Broadcasting Corporation, November 12, 2008.

I.3. Coverage of Research in Books for the Lay Public

- Cassels A. *Seeking sickness: Medical screening and the misguided hunt for disease*. Greystone Books, 2012, pp. 81-83. [Link](#)

J. CREATIVE OUTPUTS – KNOWLEDGE TRANSLATION

J.1. Patient-oriented Disease Management in a Rare Disease Context

J.1.1 Online Patient Disease Management Programs

The Scleroderma Patient-centered Intervention Network (SPIN) designs, tests, and then publicly disseminates free-of-charge online evidence-based programs to support successful patient disease management. The programs are designed to be easy to navigate and engaging, with creative animations, videos, and visuals to provide entertaining educational segments on key topics. Each program has sections to help users develop and maintain a personalized program for disease management, including goal-setting strategies with examples, progress tracking, sharing goals and progress with friends and family, and patient videos of their experiences.

Two online programs have been finalized:

1. SPIN-HAND is a hand exercise program designed to prevent or reduce functional impairment due to hand involvement from scleroderma. The core program consists of 4 modules that address specific aspects of hand function, including (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and

Strength (2 exercises). Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.

SPIN-HAND is currently available to the public: <https://tools.spinsclero.com/>

2. SPIN-SELF is a general scleroderma self-management program designed to increase disease-management self-efficacy. It includes modules on (1) Coping with Pain; (2) Skin Care, Finger Ulcers and Raynaud's; (3) Sleep Problems; (4) Fatigue; (5) Gastrointestinal Symptoms; (6) Itch; (7) Managing Emotions and Stress; (8) Coping with Appearance Changes; and (9) Effective Communication with Healthcare Providers.

SPIN-SELF is expected to be available publicly in 2021.

J.1.2. Support Group Leader Training Program Manual and Trainer Guide

The Scleroderma Patient-centered Intervention Network – Scleroderma Support Group Leader Education Program (SPIN-SSLED; www.spinsclero.com/projects/ssled), which is currently undergoing testing, is the only program of its kind in any disease in the world. To guide the SPIN-SSLED Program, Dr. Thombs' team developed a Participant Program Manual and Instructor Program Manual with a comprehensive curriculum for each training session. Following Dr. Thombs' recently launched CIHR-funded trial of the program, he will publish these manuals online under a Creative Commons Attribution-NonCommercial-ShareAlike copyright so that the program can be adapted and used for people with other diseases.

1. The Scleroderma Support Group Leader Education (SPIN-SSLED) Program: Participant's Program Manual. <https://www.dropbox.com/s/pbpuuzsnw64qedf/SPIN-SSLED%20Participant%20Manual%202019-05-21.pdf?dl=0>
2. The Scleroderma Support Group Leader Education (SPIN-SSLED) Program: Instructor's Program Manual. <https://www.dropbox.com/s/by7lo96rvts8ych/SPIN-SSLED%20Instructor%20Manual%202019-05-21.pdf?dl=0>

J.1.3. Scleroderma Patient-centered Intervention Network (SPIN) Knowledge Translation (KT) Tools

SPIN regularly generates infographics to provide patient-friendly and easily understood research summaries to its 1,600+ followers on Facebook, 500+ followers on Twitter, and via its webpage (<https://spinsclero.com>). See infographics webpage for examples in English (<https://spinsclero.com/en/news-media/infographics>) and French (<https://spinsclero.com/fr/nouvelles-medias/infographiques>).

J.1.4. Patient Webinars

- COVID-19 and Vaccines Patient Webinar. Hosted by Scleroderma Canada and the Scleroderma Patient-centered Intervention Network. February 11, 2021, 100 attendees. Primary organizer and moderator.
- Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program Patient Webinar Series (13 webinars). February to June, 2021, approximately 40 attendees per session. Primary organizer and moderator.
- Scleroderma and COVID-19: A Conversation with the Experts. Videoconference forum hosted by the Scleroderma Patient-centered Intervention Network, in partnership with Scleroderma Canada, the Scleroderma Society of Ontario, the Scleroderma Foundation, and the Scleroderma Research Foundation, March 21, 2020, 210 attendees. Primary organizer and moderator.

J.2. Depression Screening in Medical Settings

Dr. Thombs' DEPRESSD Project Team creates KT tools to facilitate interpretation and implementation of results from its meta-analyses for health care providers who may not fully understand complex test accuracy results in published studies. There are currently four examples available online, which are highlighted in corresponding meta-analysis articles by Dr. Thombs' collaboration.

1. Using the PHQ-9 to Screen for Depression: A Practice-based Perspective. <http://depressionscreening100.com/phq/>. Interactive knowledge translation tool to help health care providers implement research findings from **Levis B** et al., *BMJ*, 2019, updated for **Negeri Z** et al, under review.
2. Using the PHQ-2 Alone and in Combination with the PHQ-9 to Screen for Depression: A Practice-based Perspective. <http://depressionscreening100.com/phq-2/>. Interactive knowledge translation tool to help health care providers implement research findings from **Levis B** et al., *JAMA*, 2020.
3. Using the EPDS to Screen for Depression in Pregnancy and Postpartum: A Practice-based Perspective. <http://depressionscreening100.com/phq-2/>. Interactive knowledge translation tool to help health care providers implement research findings from **Levis B** et al., *BMJ*, 2020.
4. Using the HADS-D to Screen for Depression: A Practice-based Perspective. <http://depressionscreening100.com/phq-2/>. Interactive knowledge translation tool to help health care providers implement research findings from **Wu Y** et al., under review.

J.3. Canadian Task Force on Preventive Health Care KT Tools

For each of its guidelines, the Task Force creates a series of KT tools aimed to facilitate understanding and usability of its recommendations on prevention activities in Canadian primary care, including screening interventions. In 2018 alone, the Task Force disseminated just under 20,000 copies of its KT tools through website downloads and distribution at conferences and other venues, and there were more than 50,000 visits to Task Force Knowledge Translation Tool web pages. KT tools for all Task Force guidelines can be accessed on the Task Force website (<https://canadiantaskforce.ca/tools-resources/>).